Document:

TherapeuticsMD, Inc. 10-Q 

 

Exhibit
10.1

 

CERTAIN
IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM
TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.

 

Execution
Version

 

FINANCING
AGREEMENT

 

dated
as of April 24, 2019

 

among

 

THERAPEUTICSMD,
INC.

as the Borrower,

 

CERTAIN
SUBSIDIARIES OF BORROWER

as Guarantors,

 

VARIOUS
LENDERS FROM TIME TO TIME PARTY HERETO,

 

AND

 

TPG
SPECIALTY LENDING, INC.,

as Administrative Agent

 

     

     

    

 

TABLE
OF CONTENTS

 

	 	Page
	 	 
	Article
    I DEFINITIONS AND INTERPRETATION	1
	Section 1.1   	Definitions	1
	Section 1.2   	Accounting and Other Terms	30
	Section 1.3   	Interpretation, etc.	31
	Section 1.4   	Time References	32
	 	 	 
	Article
    II LOANS	32
	Section 2.1   	Term Loans	32
	Section 2.2   	Use of Proceeds	34
	Section 2.3   	Evidence of Debt; Register; Lenders’ Books and
Records; Notes	34
	Section 2.4   	Interest	35
	Section 2.5   	Conversion/Continuation	36
	Section 2.6   	Default Interest	36
	Section 2.7   	Fees	37
	Section 2.8   	Repayment of Term Loans	37
	Section 2.9   	Voluntary Prepayments and Commitment Reductions	37
	Section 2.10   	Mandatory Prepayments	38
	Section 2.11   	Application of Prepayments	39
	Section 2.12   	General Provisions Regarding Payments	40
	Section 2.13   	Ratable Sharing	42
	Section 2.14   	Increased Costs; Capital Adequacy	42
	Section 2.15   	Taxes; Withholding, etc.	43
	Section 2.16   	Obligation to Mitigate	46
	Section 2.17   	Defaulting Lenders	47
	Section 2.18   	Removal or Replacement of a Lender	47
	Section 2.19   	Making or Maintaining LIBOR Rate Loans	48
	 	 	 
	Article
    III CONDITIONS PRECEDENT	50
	Section 3.1   	Closing Date	50
	Section 3.2   	Conditions to Each Credit Extension	53
	 	 	 
	Article
    IV REPRESENTATIONS AND WARRANTIES	54
	Section 4.1   	Organization; Requisite Power and Authority; Qualification	54
	Section 4.2   	Capital Stock and Ownership	54
	Section 4.3   	Due Authorization	55
	Section 4.4   	No Conflict	55
	Section 4.5   	Governmental Consents	55
	Section 4.6   	Binding Obligation	55
	Section 4.7   	Historical Financial Statements	55
	Section 4.8   	[Reserved]	55
	Section 4.9   	No Material Adverse Effect	56
	Section 4.10   	Adverse Proceedings, etc.	56
	Section 4.11   	Payment of Taxes	56
	Section 4.12   	Properties, Title	56
	Section 4.13   	Environmental Matters	56

 

    - i - 

     

    

 

	Section 4.14   	No Defaults	57
	Section 4.15   	Material Contracts	57
	Section 4.16   	Governmental Regulation	57
	Section 4.17   	Margin Stock	57
	Section 4.18   	Employee Benefit Plans	57
	Section 4.19   	Certain Fees	58
	Section 4.20   	Solvency	58
	Section 4.21   	[Reserved]	58
	Section 4.22   	Compliance with Statutes, etc.	58
	Section 4.23   	Intellectual Property	58
	Section 4.24   	Insurance	59
	Section 4.25   	Common Enterprise	59
	Section 4.26   	Permits, Etc.	59
	Section 4.27   	Bank Accounts and Securities Accounts	59
	Section 4.28   	Security Interests	59
	Section 4.29   	PATRIOT ACT and FCPA	60
	Section 4.30   	Managerial Assistance and Related Persons	60
	Section 4.31   	Disclosure	60
	Section 4.32   	Use of Proceeds	61
	Section 4.33   	Regulatory Compliance	61
	Section 4.34   	Government Contracts	62
	Section 4.35   	Health Care Regulatory Laws	62
	 	 	 
	Article
    V AFFIRMATIVE COVENANTS	64
	Section 5.1   	Financial Statements and Other Reports	64
	Section 5.2   	Existence	68
	Section 5.3   	Payment of Taxes and Claims	68
	Section 5.4   	Maintenance of Properties	68
	Section 5.5   	Insurance	69
	Section 5.6  	Books and Records; Inspections	69
	Section 5.7   	Lenders Meetings and Conference Calls	70
	Section 5.8   	Compliance with Laws	70
	Section 5.9   	Environmental	70
	Section 5.10   	Subsidiaries	71
	Section 5.11   	Further Assurances	71
	Section 5.12   	Control Agreements	71
	Section 5.13   	Post-Closing Matters	72
	 	 	 
	Article
    VI NEGATIVE COVENANTS	72
	Section 6.1   	Indebtedness	72
	Section 6.2   	Liens	72
	Section 6.3   	Material Contracts	72
	Section 6.4   	No Further Negative Pledges	72
	Section 6.5   	Restricted Junior Payments	72
	Section 6.6   	Restrictions on Subsidiary Distributions	73
	Section 6.7   	Investments	73
	Section 6.8   	Financial Covenants	73
	Section 6.9   	Fundamental Changes; Disposition of Assets; Acquisitions	74
	Section 6.10   	Disposal of Subsidiary Interests	75
	Section 6.11   	Sales and Lease Backs	75
	Section 6.12   	Transactions with Shareholders and Affiliates	75

 

    - ii - 

     

    

 

	Section 6.13   	Conduct of Business	76
	Section 6.14   	Changes to Certain Agreements and Organizational Documents	76
	Section 6.15   	Accounting Methods	76
	Section 6.16   	Deposit Accounts	76
	Section 6.17   	Prepayments of Certain Indebtedness	76
	Section 6.18   	Anti-Terrorism Laws	76
	Section 6.19   	Anti-Corruption Laws	77
	Section 6.20   	Real Property	77
	 	 	 
	Article
    VII GUARANTY	77
	Section 7.1   	Guaranty of the Obligations	77
	Section 7.2   	Contribution by Guarantors	77
	Section 7.3   	Payment by Guarantors	77
	Section 7.4   	Liability of Guarantors Absolute	78
	Section 7.5   	Waivers by Guarantors	79
	Section 7.6   	Guarantors’ Rights of Subrogation, Contribution,
etc.	80
	Section 7.7   	Subordination of Other Obligations	80
	Section 7.8   	Continuing Guaranty	81
	Section 7.9   	Authority of Guarantors or Company	81
	Section 7.10   	Financial Condition of Company	81
	Section 7.11   	Bankruptcy, etc.	81
	Section 7.12   	Discharge of Guaranty Upon Sale of Guarantor	82
	 	 	 
	Article
    VIII EVENTS OF DEFAULT	82
	Section 8.1   	Events of Default	82
	Section 8.2   	Remedies	84
	Section 8.3   	Rights Not Exclusive	85
	 	 	 
	Article
    IX ADMINISTRATIVE AGENT	85
	Section 9.1   	Appointment of Administrative Agent	85
	Section 9.2   	Powers and Duties	85
	Section 9.3   	General Immunity	85
	Section 9.4   	Administrative Agent Entitled to Act as Lender	86
	Section 9.5   	Lenders’ Representations, Warranties and Acknowledgment	87
	Section 9.6   	Right to Indemnity	87
	Section 9.7   	Successor Administrative Agent	88
	Section 9.8   	Collateral Documents and Guaranty	89
	Section 9.9   	Agency for Perfection	89
	Section 9.10   	Reports and Other Information; Confidentiality; Disclaimers	90
	Section 9.11   	Protective Advances	91
	 	 	 
	Article
    X MISCELLANEOUS	91
	Section 10.1   	Notices	91
	Section 10.2   	Expenses	92
	Section 10.3   	Indemnity	93
	Section 10.4   	Set-Off	93
	Section 10.5   	Amendments and Waivers	94
	Section 10.6   	Successors and Assigns; Participations	95
	Section 10.7   	Independence of Covenants	97
	Section 10.8   	Survival of Representations, Warranties and Agreements	98
	Section 10.9   	No Waiver; Remedies Cumulative	98

 

    - iii - 

     

    

 

	Section 10.10   	Marshalling; Payments Set Aside	98
	Section 10.11   	Severability	98
	Section 10.12   	Obligations Several; Independent Nature of Lenders’
Rights	98
	Section 10.13   	Headings	98
	Section 10.14   	APPLICABLE LAW	99
	Section 10.15   	CONSENT TO JURISDICTION	99
	Section 10.16   	WAIVER OF JURY TRIAL	99
	Section 10.17   	Confidentiality	100
	Section 10.18   	Usury Savings Clause	101
	Section 10.19   	Counterparts	101
	Section 10.20   	Effectiveness	101
	Section 10.21   	PATRIOT Act Notice	102

 

    - iv - 

     

    

 

	APPENDICES:	A-1	Initial
    Term Loan Commitments
	 	A-2	Delayed
    Draw A-1 Term Loan Commitments
	 	A-3	Delayed
    Draw A-2 Term Loan Commitments
	 	B	Notice
    Addresses
	 	 
	SCHEDULES:	 
	 	4.1	Jurisdictions
    of Organization and Qualification
	 	4.2	Capital
    Stock and Ownership
	 	4.12	Real
    Property
	 	4.13	Environmental
    Matters
	 	4.15	Material
    Contracts
	 	4.23(b)-(c)	Intellectual
    Property
	 	4.24	Insurance
	 	4.27	Bank
    Accounts and Securities Accounts
	 	4.34	Government
    Contracts
	 	5.13	Certain
    Post Closing Matters
	 	6.1	Certain
    Indebtedness
	 	6.2	Certain
    Liens
	 	6.6	Certain
    Loans and Advances to Employees
	 	6.7	Certain
    Investments
	 	6.12	Certain
    Affiliate Transactions
	 	 	 
	EXHIBITS:	A-1	Funding
    Notice
	 	A-2	Conversion/Continuation
    Notice
	 	B	Compliance
    Certificate
	 	C	Assignment
    Agreement
	 	D	Certificate
    Regarding Non-Bank Status
	 	E	Closing
    Date Certificate
	 	F	Solvency
    Certificate

 

    - v - 

     

    

 

FINANCING
AGREEMENT

 

This
FINANCING AGREEMENT, dated as of April 24, 2019, is entered into by and among THERAPEUTICSMD, INC., a Nevada Corporation (“Company”
or “Borrower”), and certain Subsidiaries of Borrower, as Guarantors, the Lenders from time to time party hereto
and TPG SPECIALTY LENDING, INC., a Delaware corporation (“TSL”), as administrative agent for the Lenders (in
such capacity, “Administrative Agent”).

 

W
I T N E S E T H:

 

WHEREAS,
capitalized terms used in these Recitals shall have the respective meanings set forth for such terms in Section 1.1 hereof;

 

WHEREAS,
Lenders have agreed to extend to Company (a) an initial term loan in an aggregate principal amount not exceeding $200,000,000
and (b) delayed draw term loans in an aggregate principal amount not exceeding $100,000,000, in each case the proceeds of which
will be used as described in Section 2.2;

 

WHEREAS,
Company has agreed to secure all of its Obligations by granting to Administrative Agent, for the benefit of Secured Parties, a
first priority Lien on all of its assets (except as otherwise set forth in the Collateral Documents), including a pledge of all
of the Capital Stock of each of its Subsidiaries; and

 

WHEREAS,
Guarantors have agreed to guarantee the obligations of Company hereunder and to secure their respective Obligations by granting
to Administrative Agent, for the benefit of Secured Parties, a first priority Lien on all of their respective assets (except as
otherwise set forth in the Collateral Documents), including a pledge of all of the Capital Stock of each of their respective Subsidiaries.

 

NOW,
THEREFORE, in consideration of the premises and the agreements, provisions and covenants herein contained, the parties hereto
agree as follows:

 

Article
I

DEFINITIONS AND INTERPRETATION

 

Section
1.1        Definitions. The following terms
used herein, including in the preamble, recitals, exhibits and schedules hereto, shall have the following
meanings:

 

“Adjusted
LIBOR Rate” means, for any Interest Rate Determination Date with respect to an Interest Period for a LIBOR Rate Loan,
the greater of (a) the rate per annum obtained by dividing (i) (A) the rate per annum equal to the Intercontinental Exchange Benchmark
Administration Ltd. (or such other Person that takes over the administration of such rate) LIBOR Rate (“ICE LIBOR”),
as published by a nationally recognized service such as the Dow Jones Market Service (Telerate), Reuters or Bloomberg (or such
other commercially available source providing quotations of ICE LIBOR as may be reasonably designated by the Administrative Agent
from time to time), or a comparable or successor rate used generally in the market for syndicated commercial loans that has been
reasonably approved by the Administrative Agent in consultation with the Borrower (such rate, the “Alternate Benchmark
Rate”), at approximately 11:00 a.m., London time on the Interest Rate Determination Date, for Dollar deposits (for delivery
on the first day of such Interest Period) with a term equivalent to such Interest Period or (B) if such rate is not available
at such time for any reason, the rate per annum determined by the Administrative Agent to be the rate at which deposits in Dollars
for delivery on the first day of such Interest Period in same day funds in the approximate amount of the LIBOR Rate Loan being
made, continued or converted and with a term equivalent to such Interest Period would be offered to major banks in the London
interbank eurodollar market at their request at approximately 11:00 a.m. (London time) on the Interest Rate Determination Date,
by (ii) an amount equal to (A) one, minus (B) the Applicable Reserve Requirement, and (b) 2.70% per annum. Any such determination
of LIBOR shall be conclusive absent manifest error.

 

     - 1 -

     

    

 

“Administrative
Agent” has the meaning specified in the preamble hereto.

 

“Administrative
Agent’s Account” means an account at a bank designated by Administrative Agent from time to time by written
notice to Borrower in accordance with Section 10.1(a) as the account into which the Loan Parties shall make all payments
to Administrative Agent under this Agreement and the other Loan Documents.

 

“Adverse
Proceeding” means any action, suit, proceeding (whether administrative, judicial or otherwise), governmental
investigation or arbitration (whether or not purportedly on behalf of Borrower or any of its Subsidiaries) at law or in equity,
or before or by any Governmental Authority, domestic or foreign (including any Environmental Claims) or other regulatory body
or any mediator or arbitrator, whether pending or, to the knowledge of Borrower or any of its Subsidiaries, threatened in writing
against Borrower or any of its Subsidiaries or any property of Borrower or any of its Subsidiaries.

 

“Affected
Lender” has the meaning specified in Section 2.19(b).

 

“Affected
Loans” has the meaning specified in Section 2.19(b).

 

“Affiliate”
means, as applied to any Person, any other Person directly or indirectly controlling (including any member of the senior management
group of such Person), controlled by, or under common control with, that Person. For the purposes of this definition, “control”
(including, with correlative meanings, the terms “controlling,” “controlled by” and “under common
control with”), as applied to any Person, means the possession, directly or indirectly, of the power (a) to vote 10% or
more of the securities having ordinary voting power for the election of directors of such Person, or (b) to direct or cause the
direction of the management and policies of that Person, whether through the ownership of voting securities or by contract or
otherwise. Notwithstanding anything herein to the contrary, in no event shall Administrative Agent or any Lender or any of their
Affiliates or Related Funds be considered an “Affiliate” of any Loan Party.

 

“Aggregate
Amounts Due” has the meaning specified in Section 2.13.

 

“Aggregate
Payments” has the meaning specified in Section 7.2.

 

“Agreement”
means this Financing Agreement and any annexes, exhibits and schedules attached hereto as it may be amended, supplemented or otherwise
modified from time to time in accordance with and subject to the terms and conditions of this Agreement.

 

“Alternate
Benchmark Rate” has the meaning set forth in the definition of Adjusted LIBOR Rate.

 

“Annovera”
means (a) the ANNOVERA (segesterone acetate/ethinyl estradiol vaginal system) product approved for commercialization in the U.S.
as of the Closing Date and (b) any other vaginal system being developed or commercialized by the Company (or any Affiliate thereof
that is controlled by the Company), or any of its licensees or sub-licensees (now or in the future) (in the case of such licensees
or sub-licensees, solely with respect to development or commercialization pursuant to agreements with the Company or any of its
Subsidiaries) that contains segesterone acetate and/or ethinyl estradiol (and in the case of clause (a) and clause (b) above,
including any of their respective derivatives, polymorphs, isomers, prodrugs, metabolites, esters, salts and other forms, formulations,
and methods of delivery thereof), commercialized by the Company (or any Affiliate thereof that is controlled by the Company),
or any of its licensees or sub-licensees (now or in the future) (in the case of such licensees or sub-licensees, solely with respect
to development or commercialization pursuant to agreements with the Company or any of its Subsidiaries) in any country of the
world under any brand name for any indication.

 

     - 2 -

     

    

 

“Annovera
Agreement” means that certain License Agreement, dated July 30, 2018, between Company and The Population Council, Inc.,
as amended from time to time in accordance with the terms hereof.

 

“Annovera
Patents” means the U.S. and foreign patents and pending patent applications owned or in-licensed by Company or any of
its Subsidiaries, now or in the future, that relate to, or otherwise may be useful in connection with, the research, development,
manufacture, use, or sale of Annovera.

 

“Anti-Corruption
Laws” means all Requirements of Law concerning or relating to bribery or corruption, including, without limitation,
the United States Foreign Corrupt Practices Act of 1977, as amended, and the anti-bribery and anti-corruption laws and regulations
of those jurisdictions in which the Loan Parties do business.

 

“Anti-Terrorism
Laws” means any Requirement of Law relating to terrorism or money laundering, including, without limitation,
(a) the Money Laundering Control Act of 1986 (i.e., 18 U.S.C. §§ 1956 and 1957), (b) the Currency and Foreign
Transactions Reporting Act (31 U.S.C. §§ 5311-5330 and 12 U.S.C. §§ 1818(s), 1820(b) and 1951-1959) (the “Bank
Secrecy Act”), (c) the USA Patriot Act, (d) the laws, regulations and Executive Orders administered by the United
States Department of the Treasury’s Office of Foreign Assets Control (“OFAC”),
(e) the Comprehensive Iran Sanctions, Accountability, and Divestment Act of 2010 and implementing regulations by the United States
Department of the Treasury, (f) any law prohibiting or directed against terrorist activities or the financing of terrorist activities
(e.g., 18 U.S.C. §§ 2339A and 2339B), or (g) any similar laws enacted in the United States or any other jurisdictions
in which the parties to this Agreement operate, as any of the foregoing laws may from time to time be amended, renewed, extended,
or replaced and all other present and future legal requirements of any Governmental Authority governing, addressing, relating
to, or attempting to eliminate, terrorist acts and acts of war and any regulations promulgated pursuant thereto.

 

“Applicable
Margin” means (a) with respect to a Term Loan that is a LIBOR Rate Loan, 7.75% and (b) with respect to a Term Loan that
is a Base Rate Loan, 6.75%.

 

“Applicable
Reserve Requirement” means, at any time, for any LIBOR Rate Loan, the maximum rate, expressed as a decimal, at which
reserves (including, without limitation, any basic marginal, special, supplemental, emergency or other reserves) are required
to be maintained with respect thereto against “Eurocurrency liabilities” (as such term is defined in Regulation D)
under regulations issued from time to time by the Board of Governors of the Federal Reserve System or other applicable banking
regulator having appropriate jurisdiction. Without limiting the effect of the foregoing, the Applicable Reserve Requirement shall
reflect any other reserves required to be maintained by such member banks with respect to (a) any category of liabilities which
includes deposits by reference to which the applicable Adjusted LIBOR Rate or any other interest rate of a Loan is to be determined,
or (b) any category of extensions of credit or other assets which include LIBOR Rate Loans. A LIBOR Rate Loan shall be deemed
to constitute Eurocurrency liabilities and as such shall be deemed subject to reserve requirements without benefits of credit
for proration, exceptions or offsets that may be available from time to time to the applicable Lender. The rate of interest on
LIBOR Rate Loans shall be adjusted automatically on and as of the effective date of any change in the Applicable Reserve Requirement.

 

     - 3 -

     

    

 

“Application
Event” means the (a) occurrence of an Event of Default and (b) the election by Administrative Agent or the Required
Lenders during the continuance of such Event of Default to require that payments and proceeds of Collateral be applied pursuant
to Section 2.12(f).

 

“Asset
Sale” means a sale, lease or sub lease (as lessor or sublessor), sale and leaseback, assignment, conveyance,
transfer, license or sublicense (including a Permitted Product Transaction) or other disposition to (other than to a Loan Party),
or any exchange of property with, any Person, in one transaction or a series of transactions, of all or any part of any Loan Party’s
businesses, assets or properties of any kind, whether real, personal, or mixed and whether tangible or intangible, whether now
owned or hereafter acquired, including, without limitation, the Capital Stock of any Loan Party. For purposes of clarification,
“Asset Sale” shall include (a) the sale or other disposition for value of any contracts, (b) any disposition of property
through a “plan of division” under the Delaware Limited Liability Company Act or any comparable transaction under
any similar law, (c) the early termination or modification of any contract resulting in the receipt by any Loan Party of a cash
payment or other consideration in exchange for such event, (d) any sale of accounts (or any rights thereto (including, without
limitation, any rights to any residual payment stream with respect thereto)) by any Loan Party or Subsidiary of Borrower and (e)
any royalty monetization transaction with respect to licenses or sublicenses of the intellectual property owned or controlled
by the Company or any of its Subsidiaries, including but not limited to sales of royalty streams, royalty bonds and other royalty
financings, synthetic royalty and revenue interest transactions and hybrid monetization transactions.

 

Notwithstanding
the foregoing, none of the following items will be deemed to be an Asset Sale:

 

		(i)	an
                                         issuance of Capital Stock by a Subsidiary of the Company to the Company or to another
                                         Loan Party;

 

		(ii)	use
                                         or transfer of Cash or Cash Equivalents in a manner that is not prohibited by the terms
                                         of this Agreement or the other Loan Documents;

 

		(iii)	the
                                         licensing or sublicensing of patents, trademarks, know-how or other intellectual property
                                         or general intangibles related thereto (in each case, other than a Permitted Product
                                         Transaction) in the ordinary course of business which do not materially interfere with
                                         the ordinary conduct of the business of the Company or any of its Subsidiaries (provided
                                         that any exclusive license of patents that effectively constitutes a transfer of
                                         the related patent shall be deemed to be an Asset Sale); and

 

		(iv)	the
                                         lease, assignment or sublease of any real or personal property (other than a Permitted
                                         Product Transaction) in the ordinary course of business which do not materially interfere
                                         with the ordinary conduct of the business of the Company or any of its Subsidiaries.

 

“Assignment
Agreement” means an Assignment and Assumption Agreement substantially in the form of Exhibit C.

 

“Assignment
Letter” means that certain Assignment Side Letter, dated as of the date hereof, among Borrower, Administrative Agent
and Lenders.

 

“Authorized
Officer” means, as applied to any Person, any individual holding the position of chairman of the board (if an
officer), chief executive officer, president or one of its vice presidents (or the equivalent thereof), and such Person’s
chief financial officer or treasurer or other substantially comparable title.

 

     - 4 -

     

    

 

“Bankruptcy
Code” means Title 11 of the United States Code entitled “Bankruptcy,” as now and hereafter in effect,
or any successor statute.

 

“Base
Rate” means, for any day, a rate per annum equal to the greatest of (a) the Prime Rate in effect on such day, (b) the
Federal Funds Effective Rate in effect on such day plus 1⁄2 of 1%, (c) the Adjusted LIBOR Rate (which rate shall be
calculated based upon an Interest Period of three months and to be determined on a daily basis) plus 1%, and (d) 5.20%
per annum. Any change in the Prime Rate, the Federal Funds Effective Rate or the Adjusted LIBOR Rate shall be effective on the
effective day of such change in the Prime Rate, the Federal Funds Effective Rate or the Adjusted LIBOR Rate, respectively.

 

“Base
Rate Loan” means a Loan bearing interest at a rate determined by reference to the Base Rate.

 

“Beneficiary”
means Administrative Agent and each Lender.

 

“Bijuva”
means (a) the BIJUVA (estradiol and progesterone) product approved for commercialization in the U.S. as of the Closing Date, and
(b) any other product being developed or commercialized for the treatment of vasomotor symptoms by the Company (or any Affiliate
thereof that is controlled by the Company), or any of its licensees or sub-licensees (now or in the future) (in the case of such
licensees or sub-licensees, solely with respect to development or commercialization pursuant to agreements with the Company or
any of its Subsidiaries) that contains estradiol and progesterone (and in the case of clause (a) and clause (b) above, including
any of their respective derivatives, polymorphs, isomers, prodrugs, metabolites, esters, salts and other forms, formulations,
and methods of delivery thereof), commercialized in any country of the world under any brand name.

 

“Bijuva
Patents” means the U.S. and foreign patents and pending patent applications owned or in-licensed by Company or any of
its Subsidiaries, now or in the future, that relate to, or otherwise may be useful in connection with, the research, development,
manufacture, use, or sale of Bijuva..

 

“Blocked
Person” means any Person:

 

(a)       that
is publicly identified (i) on the most current list of “Specially Designated Nationals and Blocked Persons” published
by OFAC or resides, is organized or chartered, or has a place of business in a country or territory subject to OFAC sanctions
or embargo program or (ii) as prohibited from doing business with the United States under the International Emergency Economic
Powers Act, the Trading With the Enemy Act, or any other Anti-Terrorism Law;

 

(b)       that
is owned or controlled by, or that owns or controls, or that is acting for or on behalf of, any Person described in clause (a)
above;

 

(c)       which
any Lender is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law; and

 

(d)       that
is affiliated or associated with a Person described in clauses (a), (b) or (c) above.

 

“Board
of Directors” means, (a) with respect to any corporation, the board of directors of the corporation or any committee
thereof duly authorized to act on behalf of such board, (b) with respect to a partnership, the board of directors of the general
partner of the partnership, (c) with respect to a limited liability company, the managing member or members or any controlling
committee or board of directors of such company or the sole member or the managing member thereof, and (d) with respect to any
other Person, the board or committee of such Person serving a similar function.

 

     - 5 -

     

    

 

“Borrower”
has the meaning specified in the preamble hereto.

 

“Business
Day” means (a) any day excluding Saturday, Sunday and any day which is a legal holiday under the laws of the State of
New York or is a day on which banking institutions located in either such state are authorized or required by law or other governmental
action to close, and (b) with respect to all notices, determinations, fundings and payments in connection with the Adjusted LIBOR
Rate or any LIBOR Rate Loans, the term “Business Day” shall mean any day which is a Business Day described in clause
(a) and which is also a day for trading by and between banks in Dollar deposits in the London interbank market.

 

“Capital
Lease” means, as applied to any Person, any lease of any property (whether real, personal or mixed) by that Person
(a) as lessee that, in conformity with GAAP as in effect on December 31, 2018, is or should be accounted for as a capital lease
on the balance sheet of that Person or (b) as lessee which is a transaction of a type commonly known as a “synthetic lease”
(i.e., a transaction that is treated as an operating lease for accounting purposes but with respect to which payments of rent
are intended to be treated as payments of principal and interest on a loan for federal income Tax purposes).

 

“Capital
Stock” means any and all shares, equity interests, economic participations or other equivalents (however designated)
of capital stock of a corporation, any and all equivalent ownership interests in a Person (other than a corporation), including,
without limitation, partnership interests and membership interests, and any and all warrants, rights or options to purchase or
other written arrangements or rights to acquire any of the foregoing.

 

“Cash”
means money, currency or a credit balance in any demand or Deposit Account.

 

“Cash
Equivalents” means, as at any date of determination, (a) marketable securities (i) issued or directly and unconditionally
guaranteed as to interest and principal by the United States Government, or (ii) issued by any agency of the United States the
obligations of which are backed by the full faith and credit of the United States, in each case maturing within one year after
such date; (b) marketable direct obligations issued by any state of the United States of America or any political subdivision
of any such state or any public instrumentality thereof, in each case maturing within one year after such date and having, at
the time of the acquisition thereof, a rating of at least A 1 from S&P or at least P 1 from Moody’s; (c) commercial
paper maturing no more than one year from the date of creation thereof and having, at the time of the acquisition thereof, a rating
of at least A 1 from S&P or at least P 1 from Moody’s; (d) certificates of deposit or bankers’ acceptances maturing
within one year after such date and issued or accepted by any Lender or by any commercial bank organized under the laws of the
United States of America or any state thereof or the District of Columbia that (i) is at least “adequately capitalized”
(as defined in the regulations of its primary Federal banking regulator), and (ii) has Tier 1 capital (as defined in such regulations)
of not less than $100,000,000; and (e) shares of any money market mutual fund that (i) has substantially all of its assets invested
continuously in the types of investments referred to in clauses (a) and (b) above, (ii) has net assets of not less
than $500,000,000, and (iii) has the highest rating obtainable from either S&P or Moody’s.

 

“Certificate
Regarding Non-Bank Status” means a certificate substantially in the form of Exhibit D.

 

“Change
of Control” means, at any time, any of the following occurrences:

 

(a)       any
Person or “group” (within the meaning of Rules 13d 3 and 13d 5 under the Exchange Act) (i) shall have acquired beneficial
ownership of 50.1% or more on a fully diluted basis of the voting interest in the Capital Stock of Borrower or (ii) shall have
obtained the power (whether or not exercised) to elect a majority of the members of the Board of Directors (or similar governing
body) of Borrower;

 

     - 6 -

     

    

 

(b)       except
pursuant to a transaction permitted by this Agreement, Borrower shall cease to beneficially own and control, directly or indirectly,
100% on a fully diluted basis of the economic and voting interest in the Capital Stock of each Loan Party;

 

(c)       the
majority of the seats (other than vacant seats) on the Board of Directors (or similar governing body) of Borrower cease to be
occupied by Persons who either (i) were members of the Board of Directors of Borrower on the Closing Date, or (ii) were nominated
for election by the Board of Directors of Borrower, a majority of whom were directors on the Closing Date or whose election or
nomination for election was previously approved by a majority of such directors; or

 

(d)       any
“change of control” or similar event shall occur under, and as defined in or set forth in the documents evidencing
or governing, (i) the Capital Stock of Borrower if, as a result of such change of control or similar event, Borrower is required
to make a payment of $5,000,000 or more or (ii) any Indebtedness in an individual principal amount of $5,000,000 or more owed
by Borrower or any of its Subsidiaries.

 

“Closing
Date” means the date on which the Initial Term Loans are made, which is April 24, 2019.

 

“Closing
Date Certificate” means a Closing Date Certificate substantially in the form of Exhibit E.

 

“Collateral”
means, collectively, all of the real, personal and mixed property (including Capital Stock to the extent permitted under any Loan
Document) and all interests therein and proceeds thereof now owned or hereafter acquired by any Person upon which a Lien is granted
or purported to be granted by such Person pursuant to the Collateral Documents as security for the Obligations.

 

“Collateral
Access Agreement” means a collateral access agreement in form and substance reasonably satisfactory to Administrative
Agent.

 

“Collateral
Documents” means the Pledge and Security Agreement, the Mortgages, the Collateral Access Agreements, if any,
any Control Agreement, and all other instruments, documents and agreements delivered by any Loan Party pursuant to this Agreement
or any of the other Loan Documents in order to grant to Administrative Agent, for the benefit of Secured Parties, a Lien on any
real, personal or mixed property of that Loan Party as security for the Obligations, in each case, as such Collateral Documents
may be amended or otherwise modified from time to time, in accordance with and subject to the terms and conditions hereof and
thereof.

 

“Commitment”
means the Term Loan Commitment.

 

“Commodity
Exchange Act” means the Commodity Exchange Act (7 U.S.C. § 1 et seq.), as amended from time to time, and
any successor statute.

 

“Company”
has the meaning specified in the preamble hereto.

 

“Compliance
Certificate” means a Compliance Certificate substantially in the form of Exhibit B.

 

“Connection
Income Taxes” means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that
are franchise Taxes or branch profits Taxes.

 

     - 7 -

     

    

 

“Contractual
Obligation” means, as applied to any Person, any provision of any Security issued by that Person or of any indenture,
mortgage, deed of trust, contract, license, undertaking, agreement or other instrument to which that Person is a party or by which
it or any of its properties is bound or to which it or any of its properties is subject.

 

“Control
Agreement” means a control agreement, in form and substance reasonably satisfactory to Administrative Agent,
executed and delivered by Borrower or a Guarantor Subsidiary, Administrative Agent, and the applicable securities intermediary
(with respect to a Securities Account) or bank (with respect to a Deposit Account).

 

“Conversion/Continuation
Date” means the effective date of a continuation or conversion, as the case may be, as set forth in the applicable Conversion/Continuation
Notice.

 

“Conversion/Continuation
Notice” means a Conversion/Continuation Notice substantially in the form of Exhibit A-2.

 

“Controlled
Investment Affiliate” means, as to any Person, any other Person that (a) directly or indirectly, is in control of, is
controlled by, or is under common control with, such Person and (b) is organized by such Person primarily for the purpose of making
equity or debt investments in one or more companies. For purposes of this definition, “control” of a Person means
the power, directly or indirectly, to direct or cause the direction of the management and policies of such Person whether by contract
or otherwise.

 

“Credit
Date” means the date of a Credit Extension.

 

“Credit
Extension” means the making of a Loan.

 

“Debtor
Relief Law” means the Bankruptcy Code and any other liquidation, conservatorship, bankruptcy, assignment for
the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief law of
the United States or other applicable jurisdiction from time to time in effect.

 

“Declined
Proceeds” means the amount of Net Proceeds received in connection with a Waivable Mandatory Prepayment for which
a Lender has elected to waive its right to prepayment in accordance with Section 2.11(b).

 

“Default”
means a condition or event that, after notice or lapse of time or both, would constitute an Event of Default.

 

“Default
Excess” means, with respect to any Defaulting Lender, the excess, if any, of such Defaulting Lender’s Pro
Rata Share of the aggregate outstanding principal amount of Term Loans of all Lenders (calculated as if all Defaulting Lenders
(other than such Defaulting Lender) had funded all of their respective Defaulted Loans) over the aggregate outstanding principal
amount of all Term Loans of such Defaulting Lender.

 

“Default
Period” means, with respect to any Defaulting Lender, the period commencing on the date of the applicable Funding
Default or violation of Section 9.5(c), as applicable, and ending on the earliest of the following dates: (a) the date
on which all Commitments are cancelled or terminated and/or the Obligations are declared or become immediately due and payable,
in each case, in accordance with and subject to the terms and conditions of this Agreement, (b) the date on which (i) the Default
Excess with respect to such Defaulting Lender shall have been reduced to zero (whether by the funding by such Defaulting Lender
of any Defaulted Loans of such Defaulting Lender or by the non pro rata application of any voluntary or mandatory prepayments
of the Loans in accordance with and subject to the terms and conditions of Section 2.9 or Section 2.10 or by a combination
thereof), and (ii) such Defaulting Lender shall have delivered to Company and Administrative Agent a written reaffirmation of
its intention to honor its obligations hereunder with respect to its Commitments, (c) the date on which Company, Administrative
Agent and Required Lenders waive all Funding Defaults of such Defaulting Lender in writing and (d) if such Defaulting Lender is
a Defaulting Lender solely due to a violation of Section 9.5(c), the date on which Administrative Agent shall have waived
all violations of Section 9.5(c) by such Defaulting Lender in writing.

 

     - 8 -

     

    

 

“Defaulted
Loan” has the meaning specified in Section 2.17.

 

“Defaulting
Lender” has the meaning specified in Section 2.17.

 

“Default
Rate” means any interest payable pursuant to Section 2.6.

 

“Delayed
Draw A-1 Term Loan” means the Term Loan funded after the Closing Date pursuant
to Section 2.1(a)(ii).

 

“Delayed
Draw A-1 Term Loan Commitment” means the commitment of a Lender to make or
otherwise fund the Delayed Draw Term Loan and “Delayed Draw A-1 Term Loan Commitments” means such commitments of all
such Lenders in the aggregate. The amount of each Lender’s Delayed Draw A-1 Term Loan Commitment, if any, is set forth on
Appendix A-3 or in the applicable Assignment Agreement, subject to any adjustment or reduction pursuant to the terms and
conditions hereof. The aggregate amount of the Delayed Draw A-1 Term Loan Commitments as of the Closing Date is $50,000,000.

 

“Delayed
Draw A-2 Term Loan” means the Term Loan funded after the Closing Date pursuant
to Section 2.1(a)(iii).

 

“Delayed
Draw A-2 Term Loan Commitment” means the commitment of a Lender to make or
otherwise fund the Delayed Draw Term Loan and “Delayed Draw A-2 Term Loan Commitments” means such commitments of all
such Lenders in the aggregate. The amount of each Lender’s Delayed Draw A-2 Term Loan Commitment, if any, is set forth on
Appendix A-4 or in the applicable Assignment Agreement, subject to any adjustment or reduction pursuant to the terms and
conditions hereof. The aggregate amount of the Delayed Draw A-2 Term Loan Commitments as of the Closing Date is $50,000,000.

 

“Delayed
Draw Term Loan” means, collectively, the Delayed Draw A-1 Term Loan and the
Delayed Draw A-2 Term Loan.

 

“Delayed
Draw Term Loan Commitment” means, collectively, the Delayed Draw A-1 Term Loan
Commitment and the Delayed Draw A-2 Term Loan Commitment.

 

“Delayed
Draw Term Loan Commitment Period” means the time period commencing on the Closing Date through and including the Delayed
Draw Term Loan Commitment Termination Date.

 

“Delayed
Draw Commitment Termination Date” means the earliest to occur of (a) the date the Term Loan Commitments are permanently
reduced to zero in accordance with and pursuant to Section 2.12(b) or 2.13, (b) the date of the termination of the
Term Loan Commitments in accordance with and pursuant to Section 8.1, (c) solely in the case of the Delayed Draw A-1 Term
Loan Commitment, January 23, 2020 (or such later date as may be consented to by the Required Lenders in their sole discretion)
and (d) solely in the case of the Delayed Draw A-2 Term Loan Commitment, March 31, 2020 (or such later date as may be consented
to by the Required Lenders in their sole discretion).

 

     - 9 -

     

    

 

“Deposit
Account” means a demand, time, savings, passbook or like account with a bank, savings and loan association, credit
union or like organization, other than an account evidenced by a negotiable certificate of deposit.

 

“Disputes”
has the meaning set forth in Section 4.23(d).

 

“Disqualified
Capital Stock” means any Capital Stock that, by its terms (or by the terms of any security or other Capital Stock
into which it is convertible or for which it is exchangeable), or upon the happening of any event or condition, (a) matures or
is mandatorily redeemable, pursuant to a sinking fund obligation or otherwise, (b) is redeemable at the option of the holder thereof,
in whole or in part, (c) provides for the scheduled payments of dividends or distributions in cash, or (d) is convertible into
or exchangeable for (i) Indebtedness or (ii) any other Capital Stock that would constitute Disqualified Capital Stock, in each
case of clauses (a) through (d), prior to the date that is 91 days after the Term Loan Maturity Date.

 

“Disqualified
Institution” means (a) any Person designated by Borrower as a “Disqualified Institution” by written notice
delivered to Administrative Agent prior to the Closing Date and consented to by Administrative Agent and the named Affiliates
of each such Person which are clearly identifiable as such on the basis of each such Affiliate’s name, (b) those Persons
that are competitors of any Loan Party or any Subsidiary thereof, and its named Affiliates, in each case to the extent identified
by Borrower to Administrative Agent in writing prior to the Closing Date and consented to by the Administrative Agent, and the
named Affiliates of each such Person which are clearly identifiable as such on the basis of such Affiliate’s name or (c)
any other Person as Borrower and Administrative Agent shall mutually agree after the Closing Date; provided, that (x) the
Persons described in clause (b) above shall not include any Person that is engaged in making, purchasing, holding or otherwise
investing in commercial loans and similar extensions of credit in the ordinary course of business and (y) “Disqualified
Institution” shall exclude any Person that Borrower has designated as no longer being a “Disqualified Institution”
by written notice delivered to Administrative Agent from time to time.

 

“Dollars”
and the sign “$” mean the lawful money of the United States of America.

 

“Eligible
Assignee” means (a) any Lender, any Affiliate of any Lender and any Related Fund (any two or more Related Funds
being treated as a single Eligible Assignee for all purposes hereof), (b) any commercial bank, insurance company, investment or
mutual fund or other entity that is an “accredited investor” (as defined
in Regulation D under the Securities Act) and which other entity extends credit or buys loans as one of its or its Affiliates’
businesses, and (c) any other Person (other than a natural Person); provided, (i) neither Borrower nor any Affiliate of
Borrower shall, in any event, be an Eligible Assignee, (ii) no Person owning or controlling any trade debt or Indebtedness of
any Loan Party (other than the Obligations) or any Capital Stock of any Loan Party (in each case, unless approved by Administrative
Agent) shall, in any event, be an Eligible Assignee and (iii) no Disqualified Institution shall be an Eligible Assignee so long
as no Event of Default has occurred and is continuing.

 

“Employee
Benefit Plan” means any “employee benefit plan” as defined in Section 3(3) of ERISA which is or was sponsored,
maintained or contributed to by, or required to be contributed by, Borrower, any of its Subsidiaries or any of their respective
ERISA Affiliates.

 

“Environmental
Claim” means any complaint, summons, citation, investigation, notice, directive, notice of violation, order, claim,
demand, action, litigation, judicial or administrative proceeding, judgment, letter or other communication from any Governmental
Authority or any other Person, involving (a) any actual or alleged violation of any Environmental Law; (b) any Hazardous Material
or any actual or alleged Hazardous Materials Activity; (c) injury to the environment, natural resource, any Person (including
wrongful death) or property (real or personal) in connection with Hazardous Materials or actual or alleged violations of Environmental
Laws; or (d) actual or alleged Releases or threatened Releases of Hazardous Materials either (i) on, at or migrating from any
assets, properties or businesses currently or formerly owned or operated by any Loan Party or any of its Subsidiaries or any predecessor
in interest, (ii) from adjoining properties or businesses, or (iii) onto any facilities which received Hazardous Materials generated
by any Loan Party or any of its Subsidiaries or any predecessor in interest.

 

     - 10 -

     

    

 

“Environmental
Laws” means any and all current or future foreign or domestic, federal or state (or any subdivision of either of them),
statutes, ordinances, orders, rules, regulations, judgments, decrees, permits, licenses or binding determinations of any Governmental
Authorizations, or any other requirements of Governmental Authorities relating to (a) the manufacture, generation, use, storage,
transportation, treatment, disposal or Release of Hazardous Materials; or (b) occupational safety and health, industrial hygiene,
land use or the protection of the environment, human, plant or animal health or welfare.

 

“Environmental
Liabilities and Costs” means all liabilities, monetary obligations, losses (including monies paid in settlement), damages,
punitive damages, natural resources damages, consequential damages, treble damages, costs and expenses (including all reasonable
fees, disbursements and expenses of counsel, experts and consultants and costs of investigations and feasibility studies), fines,
penalties, sanctions and interest incurred in connection with any Remedial Action, any Environmental Claim, or any other claim
or demand by any Governmental Authority or any Person that relates to any actual or alleged violation of Environmental Laws, actual
or alleged exposure or threatened exposure to Hazardous Materials, or any actual or alleged Release or threatened Release of Hazardous
Materials.

 

“Environmental
Lien” means any Lien in favor of any Governmental Authority for Environmental Liabilities and Costs.

 

“Equity
Issuance” means, without duplication, either (a) the sale or issuance by Borrower of any shares of its Capital Stock
or (b) the receipt by Borrower of any cash capital contributions in respect of Capital Stock of the Borrower.

 

“ERISA”
means the Employee Retirement Income Security Act of 1974, as amended from time to time, and any successor thereto.

 

“ERISA
Affiliate” means, as applied to any Person, (a) any corporation which is a member of a controlled group of corporations
within the meaning of Section 414(b) of the Internal Revenue Code of which that Person is a member; (b) any trade or business
(whether or not incorporated) which is a member of a group of trades or businesses under common control within the meaning of
Section 414(c) of the Internal Revenue Code of which that Person is a member; and (c) any member of an affiliated service group
within the meaning of Section 414(m) or (o) of the Internal Revenue Code of which that Person, any corporation described in clause
(a) above or any trade or business described in clause (b) above is a member.

 

“ERISA
Event” means (a) a “reportable event” within the meaning of Section 4043 of ERISA and the regulations issued
thereunder with respect to any Pension Plan (excluding those for which the provision for thirty day notice to the PBGC has been
waived by regulation); (b) the failure to meet the minimum funding standard of Section 412 of the Internal Revenue Code with respect
to any Pension Plan (whether or not waived in accordance with Section 412(d) of the Internal Revenue Code) or the failure to make
by its due date a required installment under Section 412(m) of the Internal Revenue Code with respect to any Pension Plan or the
failure to make any required contribution to a Multiemployer Plan; (c) the provision by the administrator of any Pension Plan
pursuant to Section 4041(a)(2) of ERISA of a notice of intent to terminate such plan in a distress termination described in Section
4041(c) of ERISA; (d) [reserved]; (e) the institution by the PBGC of proceedings to terminate any Pension Plan, or the occurrence
of any event or condition which might constitute grounds under ERISA for the termination of, or the appointment of a trustee to
administer, any Pension Plan; (f) the imposition of liability on Borrower, any of its Subsidiaries or any of their respective
ERISA Affiliates pursuant to Section 4062(e) or 4069 of ERISA or by reason of the application of Section 4212(c) of ERISA; (g)
the withdrawal of Borrower, any of its Subsidiaries or any of their respective ERISA Affiliates in a complete or partial withdrawal
(within the meaning of Sections 4203 and 4205 of ERISA) from any Multiemployer Plan if there is any potential liability therefor,
or the receipt by Borrower, any of its Subsidiaries or any of their respective ERISA Affiliates of notice from any Multiemployer
Plan that it is in insolvency pursuant to Section 4245 of ERISA, or that it intends to terminate or has terminated under Section
4041A or 4042 of ERISA; (h) [reserved]; (i) the assertion of a material claim (other than routine claims for benefits) against
any Employee Benefit Plan other than a Multiemployer Plan or the assets thereof, or against Borrower, any of its Subsidiaries
or any of their respective ERISA Affiliates in connection with any Employee Benefit Plan; (j) receipt from the Internal Revenue
Service of notice of the failure of any Pension Plan (or any other Employee Benefit Plan intended to be qualified under Section
401(a) of the Internal Revenue Code) to qualify under Section 401(a) of the Internal Revenue Code, or the failure of any trust
forming part of any Pension Plan to qualify for exemption from taxation under Section 501(a) of the Internal Revenue Code; or
(k) the imposition of a Lien pursuant to Section 401(a)(29) or 412(n) of the Internal Revenue Code or pursuant to ERISA with respect
to any Pension Plan.

 

     - 11 -

     

    

 

“Event
of Default” means each of the conditions or events set forth in Section 8.1.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended from time to time, and any successor statute.

 

“Excluded
Account” means (i) Deposit Accounts and Securities Accounts the balance of which consists exclusively of (a)
withheld income Taxes and federal, state or local employment Taxes in such amounts as are required to be paid to the Internal
Revenue Service or state or local government agencies within the following two months with respect to employees of the Company
or any of its Subsidiaries, and (b) any payroll accounts, health care reimbursement accounts and employee benefits accounts, including
any accounts containing amounts required to be paid over to an employee benefit plan pursuant to DOL Reg. Sec. 2510.3-102 on behalf
of or for the benefit of employees of the Company or any of its Subsidiaries, (ii) all segregated Deposit Accounts constituting
(and the balance of which consists solely of funds set aside in connection with) tax accounts, fiduciary accounts and trust accounts
and (iii) any Deposit Accounts and Securities Accounts, amounts on deposit in which do not exceed $100,000 individually or $500,000
in the aggregate at any one time or (iv) any Deposit Accounts that contain accounts receivable arising from any Governmental Payor
where Administrative Agent may not under applicable Law obtain a security interest in or lien on such Deposit Account receiving
the proceeds of such accounts receivable; provided, that amounts in such Deposit Account referred to in this subclause
(iv) are automatically transferred on each Business Day into a Deposit Account that is not an Excluded Account.

 

“Excluded
Taxes” has the meaning specified in Section 2.15(b).

 

“Existing
Indebtedness” means Indebtedness and other obligations outstanding under that certain Credit and Security Agreement,
dated as of May 1, 2018, between the Loan Parties, MidCap Financial Trust, as agent, and the lenders from time to time party thereto,
as amended prior to the Closing Date.

 

“Extraordinary
Receipts” means any cash received by Borrower or any of its Subsidiaries not in the ordinary course of business (and
not consisting of proceeds described in Section 2.10(a) or (b) hereof), including, without limitation, (a) foreign,
United States, state or local Tax refunds, (b) pension plan reversions, (c) judgments, proceeds of settlements or other consideration
of any kind in connection with any cause of action (including, without limitation, infringement proceeds, breach of contract claims,
damages (including treble damages), settlement amounts and other payments) received by Company from any of its existing or future
licensees under any license or settlement agreement or recovered by Company, in each case, pursuant to any enforcement of any
of the Product Patents or any license agreement relating thereto against third parties), and (d) condemnation awards (and payments
in lieu thereof), (e) indemnity payments not received in the ordinary course of business, and (f) any purchase price adjustment
received in connection with any purchase agreement entered into in connection with the acquisition by a Loan Party of (i) any
Capital Stock of another Person or (ii) all or substantially all of the assets of another Person.

 

     - 12 -

     

    

 

“Facility
Fee” has the meaning set forth in the Fee Letter.

 

“Fair
Share” has the meaning specified in Section 7.2.

 

“FASB
ASC” means the Accounting Standards Codification of the Financial Accounting Standards Board.

 

“FATCA”
means Sections 1471 through 1474 of the Internal Revenue Code, in effect as of the date of this Agreement (or any amended or successor
version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or
official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Internal Revenue Code and
any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention
among Governmental Authorities and implementing such Sections of the Internal Revenue Code.

 

“FDA”
means the U.S. Food and Drug Administration or any successor thereto.

 

“FDA
Laws” means all applicable statutes, rules, regulations, standards, guidelines, policies and orders and Requirements
of Law administered, implemented, enforced or issued by FDA or any comparable Governmental Authority.

 

“Federal
Funds Effective Rate” means for any day, the rate per annum (expressed, as a decimal, rounded upwards, if necessary,
to the next higher 1/100 of 1%) equal to the weighted average of the rates on overnight Federal funds transactions with members
of the Federal Reserve System arranged by Federal funds brokers on such day, as published by the Federal Reserve Bank of New York
on the Business Day next succeeding such day; provided, if such day is not a Business Day, the Federal Funds Rate for such
day shall be such rate on such transactions on the next preceding Business Day as so published on the next succeeding Business
Day.

 

“Federal
Healthcare Program Laws” means collectively, federal Medicare or federal or state Medicaid statutes, Sections
1128, 1128A, 1128B, 1128C or 1877 of the SSA (42 U.S.C. §§ 1320a-7, 1320a-7a, 1320a-7b, 1320a-7c and 1395nn), the federal
TRICARE statute (10 U.S.C. § 1071 et seq.), the civil False Claims Act of 1863 (31 U.S.C. § 3729 et seq.), criminal
false claims statutes (e.g., 18 U.S.C. §§ 287 and 1001), the Program Fraud Civil Remedies Act of 1986 (31 U.S.C. §
3801 et seq.), HIPAA, or related regulations or other Requirements of Law that directly or indirectly govern the health care industry,
programs of Governmental Authorities related to healthcare, health care professionals or other health care participants, or relationships
among health care providers, suppliers, distributors, manufacturers and patients, and the pricing, sale and reimbursement of health
care items or services.

 

“Fee
Letter” means the letter agreement, dated as of the Closing Date, between Company and Administrative Agent, as amended,
amended and restated, supplemented or otherwise modified from time to time in accordance with and subject to the terms and conditions
hereof and thereof.

 

     - 13 -

     

    

 

“Financial
Officer Certification” means, with respect to the financial statements for which such certification is required,
the certification of the chief financial officer of Borrower that such financial statements fairly present, in all material respects,
the financial condition of Borrower and its Subsidiaries as at the dates indicated and the results of their operations and their
cash flows for the periods indicated, subject to changes resulting from audit and normal year-end adjustments.

 

“Fiscal
Quarter” means a fiscal quarter of any Fiscal Year.

 

“Fiscal
Year” means the fiscal year of Borrower and its Subsidiaries ending on December 31 of each calendar year.

 

“Flood
Hazard Property” means any real property subject to a mortgage in favor of Administrative Agent, for the benefit of
the Secured Parties, and located in an area designated by the Federal Emergency Management Agency as having special flood or mud
slide hazards.

 

“Flow
of Funds Agreement” means that certain Flow of Funds Agreement, dated as of the Closing Date, executed by each Loan
Party, the Administrative Agent, each Lender and any other person party thereto, in form and substance reasonably satisfactory
to the Administrative Agent, in connection with the disbursement of Loan proceeds in accordance with Section 2.2.

 

“Foreign
Official” means any officer or employee of a non-U.S. government or any department, agency, or instrumentality
thereof, or of a public international organization, or any person acting in an official capacity for or on behalf of any such
government or department, agency, or instrumentality, or for or on behalf of any such public international organization.

 

“Funding
Default” has the meaning specified in Section 2.17.

 

“Funding
Notice” means a notice substantially in the form of Exhibit A-1.

 

“GAAP”
means, subject to the limitations on the application thereof set forth in Section 1.2, United States generally accepted
accounting principles in effect as of the date of determination thereof.

 

“Governmental
Authority” means any federal, state, municipal, national or other government, governmental department, commission,
board, bureau, court, agency or instrumentality or political subdivision thereof or any entity or officer exercising executive,
legislative, judicial, regulatory or administrative functions of or pertaining to any government or any court, in each case whether
associated with a state of the United States, the United States, or a foreign entity or government.

 

“Governmental
Authorization” means any permit, license, authorization, plan, directive, consent order or consent decree of
or from any Governmental Authority.

 

“Governmental
Payor” means Medicare, Medicaid, TRICARE, CHAMPVA, any state health plan adopted pursuant to Title XIX of the Social
Security Act, any other state or federal health care program and any other Governmental Authority which maintains a payment or
reimbursement program, and in which any Loan Party or Subsidiary thereof directly participates.

 

“Grantor”
has the meaning specified in the Pledge and Security Agreement.

 

“Guaranteed
Obligations” has the meaning specified in Section 7.1.

 

     - 14 -

     

    

 

“Guarantor”
means, subject to Section 5.10, each Subsidiary of Borrower and each other Person which guarantees, pursuant to Article
VII or otherwise, all or any part of the Obligations.

 

“Guarantor
Subsidiary” means each Guarantor.

 

“Guaranty”
means (a) the guaranty of each Guarantor set forth in Article VII and (b) each other guaranty, in form and substance reasonably
satisfactory to Administrative Agent, made by any other Guarantor for the benefit of the Secured Parties guaranteeing all or part
of the Obligations.

 

“Hazardous
Materials” means, regardless of amount or quantity, (a) any element, compound or chemical that is defined, listed or
otherwise classified as a contaminant, pollutant, toxic pollutant, toxic or hazardous substance, extremely hazardous substance
or chemical, hazardous waste, special waste, or solid waste under Environmental Laws or that is likely to cause immediately, or
at some future time, harm to or have an adverse effect on, the environment or risk to human health or safety, including, without
limitation, any pollutant, contaminant, waste, hazardous waste, toxic substance or dangerous good which is defined or identified
in any Environmental Law and which is present in the environment in such quantity or state that it contravenes any Environmental
Law; (b) petroleum and its refined products; (c) polychlorinated biphenyls; (d) any substance exhibiting a hazardous waste characteristic,
including, without limitation, corrosivity, ignitability, toxicity or reactivity as well as any radioactive or explosive materials;
(e) any raw materials, building components (including, without limitation, asbestos-containing materials) and manufactured products
containing hazardous substances listed or classified as such under Environmental Laws; and (f) any substance or materials that
are otherwise regulated under Environmental Law.

 

“Hazardous
Materials Activity” means any past, current, proposed or threatened activity, event or occurrence involving any Hazardous
Materials, including the use, manufacture, possession, storage, holding, presence, existence, location, Release, threatened Release,
discharge, placement, generation, transportation, processing, construction, treatment, abatement, removal, remediation, disposal,
disposition or handling of any Hazardous Materials, and any corrective action or response action with respect to any of the foregoing.

 

“Highest
Lawful Rate” means the maximum lawful interest rate, if any, that at any time or from time to time may be contracted
for, charged, or received under the laws applicable to any Lender which are presently in effect or, to the extent allowed by law,
under such applicable laws which may hereafter be in effect and which allow a higher maximum non-usurious interest rate than applicable
laws now allow.

 

“HIPAA”
means the Health Insurance Portability and Accountability Act of 1996, the Health Information Technology for Economic and Clinical
Health Act (Title XIII of the American Recovery and Reinvestment Act of 2009), and other state or local laws regulating the privacy
and/or security of patient-identifying health care information, including with respect to notification of breach of privacy or
security of such information,

 

“Historical
Financial Statements” means as of the Closing Date, (a) the audited consolidated financial statements of Borrower
and its Subsidiaries, for the Fiscal Year ended December 31, 2018 consisting of consolidated balance sheets and the related consolidated
statements of income, stockholders’ equity and cash flows for such Fiscal Year, and (b) the internally prepared, unaudited
consolidated financial statements of Borrower and its Subsidiaries for each fiscal month ended January 31, 2019, February 28,
2019 and March 31, 2019, consisting of a consolidated balance sheet and the related consolidated statements of income and cash
flows for such fiscal month, in the case of clauses (a) and (b), certified by the chief financial officer of Borrower
that they fairly present, in all material respects, the financial condition of Borrower and its Subsidiaries as at the dates indicated
and the results of their operations and their cash flows for the periods indicated, subject, if applicable, to changes resulting
from audit and normal year-end adjustments.

 

    - 15 -

    

    

 

“Imvexxy”
means (a) the IMVEXXY (estradiol vaginal inserts) product approved for commercialization in the U.S. as of the Closing Date, and
(b) any other vaginal product being developed or commercialized for the treatment of vaginal atrophy by the Company (or any Affiliate
thereof that is controlled by the Company), or any of its licensees or sub-licensees (now or in the future) (in the case of such
licensees or sub-licensees, solely with respect to development or commercialization pursuant to agreements with the Company or
any of its Subsidiaries) that contains estradiol as the sole active ingredient (and in the case of clause (a) and clause (b) above,
including any of their respective derivatives, polymorphs, isomers, prodrugs, metabolites, esters, salts and other forms, formulations,
and methods of delivery thereof), commercialized in any country of the world under any brand name.

 

“Imvexxy
Patents” means the U.S. and foreign patents and pending patent applications owned or in-licensed by Company or any of
its Subsidiaries, now or in the future, that relate to, or otherwise may be useful in connection with, the research, development,
manufacture, use, or sale of Imvexxy..

 

“Increased
Cost Lenders” has the meaning specified in Section 2.18.

 

“Indebtedness”
means, as applied to any Person, without duplication, (a) all indebtedness for borrowed money; (b) that portion of obligations
with respect to Capital Leases that is properly classified as a liability on a balance sheet in conformity with GAAP as in effect
on December 31, 2018; (c) all obligations of such Person evidenced by notes, bonds or similar instruments or upon which interest
payments are customarily paid and all obligations in respect of notes payable and drafts accepted representing extensions of credit
whether or not representing obligations for borrowed money; (d) any obligation owed for all or any part of the deferred purchase
price of property or services, including any earn-outs or other deferred payment obligations in connection with an acquisition
(excluding (i) trade payables incurred in the ordinary course of business and repayable in accordance with customary trade terms
and (ii) accruals for payroll and other liabilities accrued in the ordinary course of business), in each case, if such obligation
or earn-outs are classified as a liability on the balance sheet of such Person in accordance with GAAP; (e) all obligations created
or arising under any conditional sale or other title retention agreement with respect to property acquired by such Person; (f)
all indebtedness secured by any Lien on any property or asset owned or held by that Person regardless of whether the indebtedness
secured thereby shall have been assumed by that Person or is non-recourse to the credit of that Person; (g) the face amount of
any letter of credit or letter of guaranty issued, bankers’ acceptances facilities, surety bonds and similar credit transactions
issued for the account of that Person or as to which that Person is otherwise liable for reimbursement of drawings; (h) the direct
or indirect guaranty, endorsement (otherwise than for collection or deposit in the ordinary course of business), co-making, discounting
with recourse or sale with recourse by such Person of the obligation of another; (i) any guarantee of such Person the primary
purpose or intent of which is to provide assurance to an obligee that the obligation of the obligor thereof will be paid or discharged;
(j) any liability of such Person for an obligation of another through any agreement (contingent or otherwise) (i) to purchase,
repurchase or otherwise acquire such obligation or any security therefor, or to provide funds for the payment or discharge of
such obligation (whether in the form of loans, advances, stock purchases, or capital contributions or otherwise) or (ii) to maintain
the solvency or any balance sheet item, level of income or financial condition of another if, in the case of any agreement described
under subclauses (i) or (ii) of this clause (j), the primary purpose or intent thereof is as described in
clause (i) above; and (k) all obligations of such Person in respect of any exchange traded or over the counter derivative
transaction, including, without limitation, any Interest Rate Agreement, whether entered into for hedging or speculative purposes
and (l) Disqualified Capital Stock. The Indebtedness of any Person shall include the Indebtedness of any partnership or joint
venture in which such Person is a general partner or joint venturer, unless such Indebtedness is expressly non-recourse to such
Person.

 

    - 16 -

    

    

 

“Indemnified
Liabilities” means, collectively, any and all liabilities (including Environmental Liabilities and Costs), obligations,
losses, damages (including natural resource damages), penalties, claims (including Environmental Claims), costs (including the
costs of any investigation, study, sampling, testing, abatement, cleanup, removal, remediation or other response action necessary
to remove, remediate, clean up or abate any Hazardous Materials Activity), expenses and disbursements of any kind or nature whatsoever
(including the reasonable and documented out-of-pocket fees and disbursements of counsel for Indemnitees in connection with any
investigative, administrative or judicial proceeding commenced or threatened by any Person, whether or not any such Indemnitee
shall be designated as a party or a potential party thereto, and any fees or expenses incurred by Indemnitees in enforcing this
indemnity), whether direct, indirect or consequential and whether based on any federal, state or foreign laws, statutes, rules
or regulations (including securities and commercial laws, statutes, rules or regulations and Environmental Laws), on common law
or equitable cause or on contract or otherwise, that may be imposed on, incurred by, or asserted in writing against any such Indemnitee,
in any manner relating to or arising out of (a) this Agreement or the other Loan Documents or the transactions contemplated hereby
or thereby (including the Lenders’ agreement to make Credit Extensions or the use or intended use of the proceeds thereof,
or any enforcement of any of the Loan Documents (including any sale of, collection from, or other realization upon any of the
Collateral or the enforcement of the Guaranty)); (b) the statements contained in the proposal letter delivered by any Lender to
Company prior to the Closing Date with respect to the transactions contemplated by this Agreement; or (c) any Environmental Claim
or any Hazardous Materials Activity relating to or arising from, directly or indirectly, any past or present activity, operation,
land ownership, or practice of Borrower or any of its Subsidiaries.

 

“Indemnified
Taxes” means (a) Taxes (other than Excluded Taxes) imposed on or with respect to any payment made by or on account
of any obligation of any Loan Party under any Loan Document and (b) to the extent not otherwise described in clause (a), Other
Taxes.

 

“Indemnitee”
has the meaning specified in Section 10.3.

 

“Indemnitee
Agent Party” has the meaning specified in Section 9.6.

 

“Initial
Term Loan” means the Term Loan funded on the Closing Date pursuant to Section
2.1(a)(i).

 

“Initial
Term Loan Commitment” means the commitment of a Lender to make or otherwise
fund the Initial Term Loan and “Initial Term Loan Commitments” means such commitments of all such Lenders in the aggregate.
The amount of each Lender’s Initial Term Loan Commitment, if any, is set forth on Appendix A-1 or in the applicable
Assignment Agreement, subject to any adjustment or reduction pursuant to the terms and conditions hereof. The aggregate amount
of the Initial Term Loan Commitments as of the Closing Date is $200,000,000.

 

“Insolvency
Proceeding” means any proceeding commenced by or against any Person under any provision of any Debtor Relief
Law.

 

“Intercompany
Subordination Agreement” means that certain Intercompany Subordination Agreement, dated as of the date hereof,
made by the Loan Parties and their Subsidiaries in favor of Administrative Agent for the benefit of the Secured Parties in form
and substance satisfactory to Administrative Agent.

 

“Interest
Payment Date” means (a) with respect to any Base Rate Loan, the last Business Day of each Fiscal Quarter, commencing
on the first such date to occur after the Closing Date; (b) with respect to any LIBOR Rate Loan, (i) the last Business Day of
each Fiscal Quarter, commencing on the first such date to occur after the Closing Date and (ii) the last day of each Interest
Period applicable to such Loan; and (c) with respect to each Loan, the final maturity date of the Loans (whether by scheduled
maturity, acceleration or otherwise).

 

    - 17 -

    

    

 

“Interest
Period” means, in connection with a LIBOR Rate Loan, an interest period of three months (a) initially, commencing on
the Credit Date or Conversion/Continuation Date thereof, as the case may be; and (b) thereafter, commencing on the day on which
the immediately preceding Interest Period expires; provided, (i) if an Interest Period would otherwise expire on a day
that is not a Business Day, such Interest Period shall expire on the next succeeding Business Day unless no further Business Day
occurs in such month, in which case such Interest Period shall expire on the immediately preceding Business Day; (ii) any Interest
Period that begins on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day
in the calendar month at the end of such Interest Period) shall, subject to clauses (b)(iii) and (b)(iv) of this
definition, end on the last Business Day of a calendar month; and (iii) no Interest Period with respect to any portion of any
Term Loan shall extend beyond Term Loan Maturity Date.

 

“Interest
Rate Agreement” means any interest rate swap agreement, interest rate cap agreement, interest rate collar agreement,
interest rate hedging agreement or other similar agreement or arrangement, each of which is (a) for the purpose of hedging the
interest rate exposure associated with Borrower’s and its Subsidiaries’ operations, (b) approved by Administrative
Agent, and (c) not for speculative purposes.

 

“Interest
Rate Determination Date” means, with respect to any Interest Period, the date that is two Business Days prior to the
first day of such Interest Period.

 

“Internal
Revenue Code” means the Internal Revenue Code of 1986, as amended to the date hereof and from time to time hereafter,
and any successor statute.

 

“Investment”
means (a) any direct or indirect purchase or other acquisition by Borrower or any of its Subsidiaries of, or of a beneficial interest
in, any of the securities or Capital Stock or all or substantially all of the assets of any other Person (or of any division or
business line of such other Person); (b) any direct or indirect redemption, retirement, purchase or other acquisition for value,
by any Subsidiary of Borrower from any Person, of any Capital Stock of such Person; (c) any direct or indirect loan, advance or
capital contributions by Borrower or any of its Subsidiaries to any other Person, including all indebtedness and accounts receivable
from that other Person that are not current assets or did not arise from sales to that other Person in the ordinary course of
business; and (d) any direct or indirect Guarantee of any obligations of any other Person. The amount of any Investment shall
be the original cost of such Investment plus the cost of all additions thereto, without any adjustments for increases or decreases
in value, or write ups, write downs or write offs with respect to such Investment.

 

“Joint
Venture” means a joint venture, partnership or other similar arrangement, whether in corporate, partnership or
other legal form; provided, in no event shall any corporate Subsidiary of any Person be considered to be a Joint Venture
to which such Person is a party.

 

“Lender”
means each lender listed on the signature pages hereto as a Lender, and any other Person that becomes a party hereto in accordance
with and subject to the terms and conditions hereof pursuant to an Assignment Agreement other than any Person that ceases to be
a party hereto pursuant to any Assignment Agreement.

 

“Liabilities”
means all claims, actions, suits, judgments, damages, losses, liability, obligations, responsibilities, fines, penalties, sanctions,
costs, fees, Taxes, commissions, charges, disbursements and expenses, in each case of any kind or nature (including interest accrued
thereon or as a result thereto and fees, charges and disbursements of financial, legal and other advisors and consultants), whether
joint or several, whether or not indirect, contingent, consequential, actual, punitive, treble or otherwise.

 

    - 18 -

    

    

 

“LIBOR
Rate Loan” means a Loan bearing interest at a rate determined by reference to the Adjusted LIBOR Rate.

 

“Lien”
means (a) any lien, mortgage, pledge, assignment, hypothec, deed of trust, security interest, charge or encumbrance of any kind
(including any agreement to give any of the foregoing, any conditional sale or other title retention agreement, and any lease
in the nature thereof) and any option, trust or other preferential arrangement having the practical effect of any of the foregoing,
and (b) in the case of securities or Capital Stock, any purchase option, call or similar right of a third party with respect to
such securities or Capital Stock.

 

“Loan”
means any Term Loan.

 

“Loan
Account” means an account maintained hereunder by Administrative Agent on its books of account at the Payment
Office, and with respect to Company, in which it will be charged with the Term Loan made to, and all other Obligations incurred
by the Loan Parties.

 

“Loan
Document” means any of this Agreement, the Notes, if any, the Collateral Documents, the Fee Letter, the Flow
of Funds Agreement, any Guaranty, the Intercompany Subordination Agreement, and all other material documents, instruments or agreements
executed and delivered by a Loan Party for the benefit of Administrative Agent or any Lender in connection herewith.

 

“Loan
Party” means Company or any Guarantor.

 

“Loan
Party Partner” has the meaning set forth in Section 4.33(a).

 

“Margin
Stock” has the meaning specified in Regulation U of the Board of Governors of the Federal Reserve System as in
effect from time to time.

 

“Material
Adverse Effect” means a material adverse effect on (a) the business operations, properties, assets, condition
(financial or otherwise) or liabilities of Borrower and its Subsidiaries taken as a whole; (b) the ability of any Loan Party to
fully and timely perform its obligations under any Loan Document to which it is a party; (c) the legality, validity, binding effect,
or enforceability against a Loan Party of a Loan Document to which it is a party; (d) the Collateral or the validity, perfection
or priority of Administrative Agent’s Liens on the Collateral except as expressly permitted in the Collateral Documents;
(e) the rights, remedies and benefits available to, or conferred upon, Administrative Agent and any Lender or any other Secured
Party under any Loan Document; (f) any Product; and (g) the Product Patents for a particular Product (taken as a whole); or (h)
any Registration by the FDA.

 

“Material
Contract” means any contract or other written arrangement to which Borrower or any of its Subsidiaries is a party
(other than the Loan Documents), now or in the future, for which breach, non-performance, cancellation or failure to renew would
reasonably be expected to have a Material Adverse Effect, which, as of the Closing Date, are those contracts and arrangements
listed on Schedule 4.15.

 

“Material
Regulatory Liabilities” means (a)(i) any Liabilities arising from the violation of FDA Laws, Public Health Laws,
Federal Health Care Program Laws, and other applicable comparable Requirements of Law, or the terms, conditions of or requirements
applicable to any Registrations (including costs of actions required under applicable Requirements of Law, including FDA Laws
and Federal Health Care Program Laws, or necessary to remedy any violation of any terms or conditions applicable to any Registrations),
including, but not limited to, withdrawal of approval, recall, revocation, suspension, import detention and seizure of any Product,
and (ii) any loss of recurring annual revenues as a result of any loss, suspension or limitation of any Registrations, which,
in the case of the foregoing clauses (i) and (ii), exceed $1,000,000, individually or in the aggregate, or (b) any Material Adverse
Effect.

 

    - 19 -

    

    

 

“Moody’s”
means Moody’s Investor Services, Inc.

 

“Mortgage”
means a mortgage, deed of trust or deed to secure debt, in form and substance satisfactory to Administrative Agent, made by a
Loan Party in favor of Administrative Agent for the benefit of the Secured Parties, securing the Obligations and delivered to
Administrative Agent.

 

“Multiemployer
Plan” means any Employee Benefit Plan which is a “multiemployer plan” as defined in Section 3(37) of ERISA.

 

“Net
Proceeds” means (a) with respect to any Asset Sale, an amount equal to: (i) all Cash payments received by Borrower
or any of its Subsidiaries from such Asset Sale, minus (ii) any bona fide costs or expenses incurred in connection with
such Asset Sale that are properly attributable to such Asset Sale to the extent paid or payable to non-Affiliates, including (A)
income or gains Taxes payable by the seller as a result of any gain recognized in connection with such Asset Sale during the Tax
period the sale occurs, (B) payment of the outstanding principal amount of, premium or penalty, if any, and interest on any Indebtedness
(other than the Loans) that is secured by a Lien on the stock or assets in question and that is required to be repaid under the
terms thereof as a result of such Asset Sale, (C) a reasonable reserve for any indemnification payments (fixed or contingent)
attributable to seller’s indemnities and representations and warranties to purchaser in respect of such Asset Sale undertaken
by Borrower or any of its Subsidiaries in connection with such Asset Sale , and (D) any reasonable and documented out-of-pocket
fees or expenses incurred in connection therewith; provided that upon release of any such reserve, the amount released
shall be considered Net Proceeds; and (b) with respect to any insurance, condemnation, taking or other casualty proceeds, an amount
equal to: (i) any Cash payments or proceeds received by Borrower or any of its Subsidiaries (A) under any casualty or business
interruption insurance policies in respect of any covered loss thereunder, or (B) as a result of the condemnation or taking of
any assets of Borrower or any of its Subsidiaries by any Person pursuant to the power of eminent domain, condemnation or otherwise,
or pursuant to a sale of any such assets to a purchaser with such power under threat of such a taking, minus (ii) (A) any
actual costs or expenses incurred by Borrower or any of its Subsidiaries in connection with the adjustment or settlement of any
claims of Borrower or such Subsidiary in respect thereof, and (B) any bona fide costs or expenses incurred in connection with
any sale of such assets as referred to in clause (b)(i)(B) of this definition to the extent paid or payable to non-Affiliates,
including income Taxes payable as a result of any gain recognized in connection therewith and properly attributable thereto.

 

“Non-US
Lender” has the meaning specified in Section 2.15(e)(i).

 

“Note”
means a promissory note evidencing the Initial Term Loan or a Delayed Draw Term Loan, as applicable.

 

“Notice”
means a Funding Notice or a Conversion/Continuation Notice.

 

“Obligations”
means all obligations of every nature of each Loan Party and its Subsidiaries from time to time owed to the Administrative Agent
(including former Administrative Agents), the Lenders or any of them, under any Loan Document, whether for principal, interest
(including interest which, but for the filing of a petition in bankruptcy with respect to such Loan Party, would have accrued
on any Obligation, whether or not a claim is allowed against such Loan Party for such interest in the related bankruptcy proceeding),
the Prepayment Premium (if any), fees, expenses, indemnification or otherwise and whether primary, secondary, direct, indirect,
contingent, fixed or otherwise (including obligations of performance).

 

    - 20 -

    

    

 

“OFAC”
has the meaning specified in the definition of “Anti-Terrorism Laws”.

 

“OFAC
Sanctions Programs” means (a) the Requirements of Law and Executive Orders administered by OFAC, including but
not limited to, Executive Order No. 13224, and (b) the list of Specially Designated Nationals and Blocked Persons administered
by OFAC, in each case, as renewed, extended, amended, or replaced.

 

“Organizational
Documents” means (a) with respect to any corporation, its certificate or articles of incorporation or organization,
as amended, and its by-laws, as amended, (b) with respect to any limited partnership, its certificate of limited partnership,
as amended, and its partnership agreement, as amended, (c) with respect to any general partnership, its partnership agreement,
as amended, and (d) with respect to any limited liability company, its articles of organization, as amended, and its operating
agreement, as amended. In the event any term or condition of this Agreement or any other Loan Document requires any Organizational
Document to be certified by a secretary of state or similar governmental official, the reference to any such “Organizational
Document” shall only be to a document of a type customarily certified by such governmental official.

 

“Other
Connection Taxes” has the meaning specified therefor in Section 2.15(b).

 

“Other
Taxes” has the meaning specified in Section 2.15(c).

 

“Participant
Register” has the meaning specified in Section 10.6(h)(ii).

 

“PATRIOT
Act” has the meaning specified in Section 4.29.

 

“Payment
Office” means Administrative Agent’s office located at 888 7th Avenue, 35th Floor New York, New York 10106, or
such other office or offices of Administrative Agent as may be designated in writing from time to time by Administrative Agent
to Collateral Agent and Company.

 

“PBGC”
means the Pension Benefit Guaranty Corporation or any successor thereto.

 

“Pension
Plan” means any Employee Benefit Plan, other than a Multiemployer Plan, which is subject to Section 412 of the
Internal Revenue Code or Section 302 of ERISA.

 

“Perfection
Certificate” means a certificate in form reasonably satisfactory to Administrative Agent that provides information
with respect to the assets of each Loan Party.

 

“Permitted
Acquisition” means any acquisition by Company or any of its wholly owned Guarantor Subsidiaries, whether by purchase,
merger or otherwise, of all or substantially all of the assets of, all of the Capital Stock of, or a business line or unit or
a division of, any Person; provided,

 

(a)           immediately
prior to, and after giving effect thereto, no Default or Event of Default shall have occurred and be continuing or would result
therefrom;

 

(b)           all
transactions in connection therewith shall be consummated, in all material respects, in accordance with all applicable laws and
in conformity with all applicable Governmental Authorizations;

 

    - 21 -

    

    

 

(c)           in
the case of the acquisition of Capital Stock, all of the Capital Stock (except for any such securities in the nature of directors’
qualifying shares required pursuant to applicable law) acquired or otherwise issued by such Person or any newly formed Guarantor
Subsidiary of Company in connection with such acquisition shall be owned 100% by Company or a Guarantor Subsidiary thereof, and
Company shall have taken, or caused to be taken, as of the date such Person becomes a Subsidiary of Company, each of the actions
set forth in Section 5.10 and/or Section 5.11, as applicable;

 

(d)           Borrower
and its Subsidiaries shall be in compliance with the covenants set forth in Section 6.8 on a pro forma basis after giving
effect to such acquisition as of the last day of the Fiscal Quarter most recently ended;

 

(e)           Company
shall have delivered to Administrative Agent at least 10 days (or such shorter period as agreed to by Administrative Agent in
writing) prior to such proposed acquisition, such information and documents that Administrative Agent may reasonably request,
including, without limitation, financial information with respect to such acquired assets and drafts of the respective acquisition
agreements related thereto;

 

(f)           the acquisition shall have been approved by the Board of Directors or other governing body or
controlling Person of the Person acquired or the Person from whom such assets or division is acquired; and

 

(g)           the
total consideration (excluding any portion thereof paid with proceeds of an Equity Issuance) paid in connection with all such
acquisitions consummated since the Closing Date shall not exceed $50,000,000.

 

“Permitted
Indebtedness” means:

 

(a)           the
Obligations;

 

(b)           Permitted
Intercompany Investments;

 

(c)           Indebtedness
incurred by Borrower or any of its Subsidiaries arising from agreements providing for indemnification or from guaranties or letters
of credit, surety bonds or performance bonds securing the performance of Company or any such Subsidiary pursuant to such agreements,
in connection with Permitted Acquisitions or Asset Sales permitted hereunder;

 

(d)           Indebtedness
which may be deemed to exist pursuant to any guaranties, performance, surety, statutory, appeal or similar obligations incurred
in the ordinary course of business and Indebtedness constituting guaranties in the ordinary course of business of the obligations
of suppliers, customers, franchisees and licensees of Borrower and its Subsidiaries;

 

(e)           Indebtedness
in respect of netting services, overdraft protections and otherwise in connection with deposit accounts;

 

(f)           Indebtedness
described in Schedule 6.1, and any Permitted Refinancing Indebtedness in respect of such Indebtedness;

 

(g)           Indebtedness
in an aggregate amount not to exceed at any time $1,000,000 with respect to (i) Capital Leases and (ii) purchase money Indebtedness
(including any Indebtedness acquired in connection with a Permitted Acquisition); provided that any such Indebtedness shall
be secured only by the asset subject to such Capital Lease or by the asset acquired in connection with the incurrence of such
Indebtedness;

 

    - 22 -

    

    

 

(h)           Indebtedness
owed to any Person providing property, casualty, liability, or other insurance to the Loan Parties, so long as the amount of such
Indebtedness is not in excess of the amount of the unpaid cost of, and shall be incurred only to defer the cost of, such insurance
for the period in which such Indebtedness is incurred and such Indebtedness is outstanding only during such period;

 

(i)           contingent
liabilities in respect of any indemnification obligation, adjustment of purchase price, non-compete, or similar obligation of
any Loan Party incurred in connection with the consummation of one or more Permitted Acquisitions;

 

(j)           Indebtedness
of a Person whose assets or Capital Stock are acquired by the Borrower or any of its Subsidiaries in a Permitted Acquisition in
an aggregate amount not to exceed $1,000,000 at any one time outstanding; provided, that such Indebtedness (i) is either
purchase money Indebtedness or a Capital Lease with respect to equipment or mortgage financing with respect to a facility, (ii)
was in existence prior to the date of such Permitted Acquisition, and (iii) was not incurred in connection with, or in contemplation
of, such Permitted Acquisition;

 

(k)           unsecured
Indebtedness owing to the seller party to a Permitted Acquisition that is incurred by the applicable Loan Party in connection
with the consummation of one or more Permitted Acquisitions so long as (i) the aggregate principal amount for all such Indebtedness
does not exceed $10,000,000 at any one time outstanding, and (ii) such Indebtedness is subordinated to the Obligations on terms
and conditions reasonably acceptable to the Administrative Agent, and (iii) such Indebtedness is otherwise on terms and conditions
(including all economic terms and the absence of covenants) reasonably acceptable to the Administrative Agent;

 

(l)           other
Indebtedness of Borrower and its Subsidiaries, which is unsecured and subordinated to the Obligations in a manner satisfactory
to Administrative Agent in an aggregate amount not to exceed at any time $5,000,000; and

 

(m)           Indebtedness
incurred in the ordinary course of business in connection with workers’ compensation, unemployment insurance and other types
of social security, or to secure the performance of tenders, statutory obligations, surety and appeal bonds, bids, leases, government
contracts, trade contracts, performance and return of money bonds and other similar obligations.

 

“Permitted
Intercompany Investments” means Investments by (a) a Loan Party to or in another Loan Party, (b) a Subsidiary that is
not a Loan Party to or in another Subsidiary that is not a Loan Party, and (c) a Subsidiary that is not a Loan Party to or in
a Loan Party, so long as, in the case of a loan or an advance, the parties thereto are party to an Intercompany Subordination
Agreement.

 

“Permitted
Investments” means:

 

(a)           Investments
in Cash and Cash Equivalents;

 

(b)           equity
Investments owned as of the Closing Date in any Subsidiary;

 

(c)           Permitted
Intercompany Investments;

 

    - 23 -

    

    

 

(d)           loans
and advances to employees of Borrower and its Subsidiaries (i) made in the ordinary course of business, and (ii) any refinancings
of such loans after the Closing Date, in each case, in an aggregate amount not to exceed $1,000,000;

 

(e)           Permitted
Acquisitions;

 

(f)           Investments
described in Schedule 6.7 as of the Closing Date;

 

(g)           any
Investments consisting of extensions of credit in the nature of accounts receivable or notes receivable arising from the grant
of trade credit in the ordinary course of business or received in compromise or resolution of (A) obligations of trade creditors
or customers that were incurred in the ordinary course of business of the Company or any of its Subsidiaries, including pursuant
to any plan of reorganization or similar arrangement upon the bankruptcy or insolvency of any trade creditor or customer; or (B)
litigation, arbitration or other disputes;

 

(h)           loans
and advances by Borrower or any of its Subsidiaries in lieu of, and not in excess of the amount of (after giving effect to any
other such loans or advances or Restricted Junior Payments in respect thereof), Restricted Junior Payments to the extent permitted
to be made to Borrower or any of its Subsidiaries in accordance with Section 6.5(a), (b) or (c); and

 

(i)           so
long as no Event of Default has occurred and is continuing or would result therefrom, other Investments (other than any Investment
constituting a disposition or contribution of the Products or the Product Patents) in an aggregate amount not to exceed $10,000,000
at any time outstanding.

 

“Permitted
Liens” means:

 

(a)           Liens
in favor of Administrative Agent for the benefit of Secured Parties granted pursuant to any Loan Document;

 

(b)           Liens
for Taxes if obligations with respect to such Taxes are being contested in good faith by appropriate proceedings promptly instituted
and diligently conducted and reserves required by GAAP have been made, so long as the aggregate amount of such Taxes does not
exceed $1,000,000;

 

(c)           statutory
Liens of landlords, banks (and rights of set off), of carriers, warehousemen, mechanics, repairmen, workmen and materialmen, and
other Liens imposed by law (other than any such Lien imposed pursuant to Section 401 (a)(29) or 412(n) of the Internal Revenue
Code or by ERISA), in each case incurred in the ordinary course of business for amounts not yet overdue;

 

(d)           Liens
incurred in the ordinary course of business in connection with workers’ compensation, unemployment insurance and other types
of social security, or to secure the performance of tenders, statutory obligations, surety and appeal bonds, bids, leases, government
contracts, trade contracts, performance and return of money bonds and other similar obligations, so long as no foreclosure, sale
or similar proceedings have been commenced with respect to any portion of the Collateral on account thereof;

 

(e)           easements,
rights of way, restrictions, encroachments, and other minor defects or irregularities in title, in each case which do not and
will not interfere in any material respect with the ordinary conduct of the business of Borrower or any of its Subsidiaries;

 

(f)           any
interest or title of a lessor or sublessor under any lease of real estate permitted hereunder;

 

    - 24 -

    

    

 

(g)           Liens
solely on any cash earnest money deposits made by Borrower or any of its Subsidiaries in connection with any letter of intent
or purchase agreement permitted hereunder;

 

(h)           purported
Liens evidenced by the filing of precautionary UCC financing statements relating solely to operating leases entered into in the
ordinary course of business;

 

(i)           Liens
in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with
the importation of goods;

 

(j)           any
zoning or similar law or right reserved to or vested in any governmental office or agency to control or regulate the use of any
real property;

 

(k)           Liens
described in Schedule 6.2; provided that any such Lien shall only secure the Indebtedness that it secures on the
Closing Date and any Permitted Refinancing Indebtedness in respect thereof;

 

(l)           Liens
securing Capital Leases or purchase money Indebtedness permitted pursuant to clause (g) of the definition of Permitted
Indebtedness; provided, any such Lien shall encumber only the asset subject to such Capital Lease or the asset acquired
with the proceeds of such Indebtedness;

 

(m)           Liens
granted in the ordinary course of business on the unearned portion of insurance premiums securing the financing of insurance premiums
to the extent the financing is permitted under the definition of Permitted Indebtedness;

 

(n)           Liens
assumed by Borrower and its Subsidiaries in connection with a Permitted Acquisition that secure Indebtedness permitted by clause
(j) of the definition of Permitted Indebtedness;

 

(o)           other
Liens incurred in the ordinary course of business of the Company or any Subsidiary of the Company with respect to obligations
that do not exceed $1,000,000 at any one time outstanding;

 

(p)           Liens
securing any judgments, writs or warrants of attachment or similar process not constituting an Event of Default under Section
8.1(h); and

 

(q)           Liens
that are contractual rights of setoff relating to purchase orders entered into with customers, vendors or suppliers of such Person
in the ordinary course of business.

 

“Permitted
Product Transaction” means a transaction that includes the granting of a license or sublicense of any rights under any
Product Patents or Registrations pursuant to a Product Agreement.

 

“Permitted
Refinancing Indebtedness” means any Indebtedness of the Company or any of its Subsidiaries issued in exchange for, or
the net proceeds of which are used to renew, refund, refinance, replace, defease or discharge other Indebtedness of the Company
or any of its Subsidiaries; provided that:

 

(a)           the
principal amount (or accreted value, if applicable) of such Permitted Refinancing Indebtedness does not exceed the principal amount
(or accreted value, if applicable) of the Indebtedness renewed, refunded, refinanced, replaced, defeased or discharged (plus all
accrued interest on the Indebtedness and the amount of all fees and expenses, including premiums, incurred in connection therewith);

 

(b)           such
Permitted Refinancing Indebtedness has a final maturity date later than the final maturity date of, and has a Weighted Average
Life to Maturity equal to or greater than the Weighted Average Life to Maturity of, the Indebtedness being renewed, refunded,
refinanced, replaced, defeased or discharged;

 

    - 25 -

    

    

 

(c)           if
the Indebtedness being renewed, refunded, refinanced, replaced, defeased or discharged is subordinated in right of payment to
the Obligations, such Permitted Refinancing Indebtedness is subordinated in right of payment to, the Obligations on terms at least
as favorable to the Administrative Agent and the Lenders as those contained in the documentation governing the Indebtedness being
renewed, refunded, refinanced, replaced, defeased or discharged; and

 

(d)           such
Indebtedness is incurred either by the Company or by the Subsidiary who is the obligor on the Indebtedness being renewed, refunded,
refinanced, replaced, defeased or discharged.

 

“Person”
means and includes natural persons, corporations, limited partnerships, general partnerships, limited liability companies, limited
liability partnerships, joint stock companies, Joint Ventures, associations, companies, trusts, banks, trust companies, land trusts,
business trusts or other organizations, whether or not legal entities, and Governmental Authorities.

 

“Pledge
and Security Agreement” means the Pledge and Security Agreement executed by Grantors in favor of Administrative
Agent for the benefit of the Secured Parties, as it may be amended, supplemented or otherwise modified from time to time in accordance
with and subject to the terms and conditions hereof and thereof.

 

“Prepayment
Premium” has the meaning specified in the Fee letter.

 

“Prime
Rate” means the rate of interest quoted in The Wall Street Journal, Money Rates Section as the Prime Rate (currently
defined as the base rate on corporate loans posted by at least 75% of the nation’s thirty (30) largest banks), as in effect
from time to time. The Prime Rate is a reference rate and does not necessarily represent the lowest or best rate actually charged
to any customer. Any Agent or any other Lender may make commercial loans or other loans at rates of interest at, above or below
the Prime Rate.

 

“Principal
Office” means, for Administrative Agent, such Person’s “Principal Office” as set forth on Appendix
B, or such other office as such Person may from time to time designate in writing in accordance with Section 10.1 to
Company and each Lender.

 

“Products”
means Annovera, Bijuva and Imvexxy.

 

“Product
Agreement” means any agreement entered into between Company or any of its Subsidiaries with another Person that includes
the granting of a license or sublicense of any rights under any Product Patents or Registrations that allows such Person to develop
or commercialize a Product outside the United States.

 

“Product
Patents” means the Annovera Patents, Bijuva Patents and Imvexxy Patents.

 

“Product
Revenue” means, for any period, (a) the consolidated gross revenues of Borrower and its Subsidiaries generated solely
through the commercial sale of Products by Borrower and its Subsidiaries during such period, less, without duplication, (b)(i)
trade, quantity and cash discounts allowed by Borrower, (ii) discounts, refunds, rebates, charge backs, retroactive price adjustments
and any other allowances which effectively reduce net selling price, (iii) product returns and allowances, (iv) allowances for
shipping or other distribution expenses, (iv) set-offs and counterclaims, and (v) any other similar and customary deductions used
by Borrower in determining net revenues, all, in respect of (a) and (b), as determined in accordance with GAAP and calculated
on a basis consistent with the Historical Financial Statements delivered to Administrative Agent prior to the Closing Date.

 

    - 26 -

    

    

 

“Pro
Rata Share” means, with respect to:

 

(a)
(i) a Lender’s obligation to make the Initial Term Loan and such Lender’s right to receive payment of the Facility
Fee in respect thereof, the percentage obtained by dividing (A) such Lender’s Initial Term Loan Commitment by (B) the Total
Initial Term Loan Commitment; (ii) a Lender’s obligation to make a Delayed Draw A-1 Term Loan and such Lender’s right
to receive payment of the Facility Fee in respect thereof, the percentage obtained by dividing (A) such Lender’s Delayed
Draw A-1 Term Loan Commitment by (B) the aggregate amount of the Lenders’ Delayed Draw A-1 Term Loan Commitments; and (iii)
a Lender’s obligation to make a Delayed Draw A-2 Term Loan and such Lender’s right to receive payment of the Facility
Fee in respect thereof, the percentage obtained by dividing (A) such Lender’s Delayed Draw A-1 Term Loan Commitment by (B)
the aggregate amount of the Lenders’ Delayed Draw A-2 Term Loan Commitments;

 

(b)
a Lender’s right to receive payments of interest, fees (other than the Facility Fee) and principal with respect to a Term
Loan, the percentage obtained by dividing (i) the aggregate unpaid principal amount of such Lender’s portion of the Term
Loan, by (ii) the aggregate unpaid principal amount of the Term Loan; and

 

(c)
all other matters the percentage obtained by dividing (i) the sum of such Lender’s Delayed Draw Term Loan Commitment and
the unpaid principal amount of such Lender’s portion of the Term Loan, by (ii) the sum of the Total Delayed Draw Term Loan
Commitment and the aggregate unpaid principal amount of the Term Loan.

 

“Protective
Advances” has the meaning specified in Section 9.11.

 

“Public
Health Laws” means all Requirements of Law relating to the procurement, development, clinical and non-clinical
evaluation, product approval or licensure, manufacture, production, analysis, distribution, dispensing, importation, exportation,
use, handling, quality, sale, labeling, promotion, or post market requirements of any drug, biologic or other product (including,
without limitation, any ingredient or component of the foregoing products) subject to regulation under the Federal Food, Drug,
and Cosmetic Act (21 U.S.C. et seq.) and the Public Health Service Act (42 U.S.C. et seq.), including without limitation the regulations
promulgated by the FDA at Title 21 of the Code of Federal Regulations and guidance, compliance policies and other guidelines issued
by the FDA.

 

“Qualified
Cash” means, as of any date of determination, the amount of unrestricted Cash and Cash Equivalents (other than
restrictions created by the Collateral Documents) of the Loan Parties that is in Deposit Accounts or in Securities Accounts, or
any combination thereof, which such Deposit Account or Securities Account is subject to a Control Agreement and is maintained
by a branch office of the bank or securities intermediary located within the United States.

 

“Recipient”
means Administrative Agent or any Lender.

 

“Register”
has the meaning specified in Section 2.3(b).

 

“Registrations”
shall mean authorizations, approvals, licenses, permits, certificates, or exemptions of or issued by any Governmental Authority
(including pre-market approval applications, pre-market notifications, investigational new drug applications, product recertifications,
manufacturing approvals and authorizations, pricing and reimbursement approvals, labeling approvals or their foreign equivalent),
and all applications for any of the foregoing, that are required for the research, development, manufacture, commercialization,
distribution, marketing, storage, transportation, pricing, Government Authority reimbursement, use and sale of Products.

 

    - 27 -

    

    

 

“Regulation
D” means Regulation D of the Board of Governors of the Federal Reserve System, as in effect from time to time.

 

“Regulatory
Action” means an administrative or regulatory enforcement action, proceeding or investigation, warning letter,
untitled letter, Form 483 inspectional observations or other notice of violation letter, recall, seizure, Section 305 notice or
other similar written communication, or consent decree, issued by the FDA.

 

“Reinvestment
Amounts” has the meaning specified term in Section 2.10(a)(ii).

 

“Related
Fund” means, with respect to any Lender that is an investment fund, any other investment fund that invests in
commercial loans and that is managed or advised by the same investment advisor as such Lender or by an Affiliate of such investment
advisor.

 

“Release”
means any release, spill, emission, leaking, pumping, pouring, injection, escaping, deposit, disposal, discharge, dispersal, dumping,
leaching or migration of any Hazardous Material into the indoor or outdoor environment (including the abandonment or disposal
of any barrels, containers or other closed receptacles containing any Hazardous Material), including the movement of any Hazardous
Material through the air, soil, surface water or groundwater.

 

“Remedial
Action” means all actions taken to (a) correct or address any actual or threatened non-compliance with Environmental
Law, (b) clean up, remove, remediate, contain, treat, monitor, assess, evaluate or in any other way address Hazardous Materials
in the indoor or outdoor environment; (c) prevent or minimize a Release or threatened Release of Hazardous Materials so they do
not migrate or endanger or threaten to endanger public health or welfare or the indoor or outdoor environment; (d) perform pre-remedial
studies and investigations and post-remedial operation and maintenance activities; or (e) perform any other actions authorized
or required by Environmental Law or Governmental Authority.

 

“Replacement
Lender” has the meaning specified in Section 2.18.

 

“Required
Lenders” means Lenders whose Pro Rata Share (calculated in accordance with clause (c) of the definition thereof)
aggregate at least 50.1%.

 

“Required
Prepayment Date” has the meaning specified in Section 2.11(a).

 

“Requirements
of Law” means, with respect to any Person, collectively, the common law and all federal, state, provincial, local,
foreign, multinational or international laws, statutes, codes, treaties, standards, rules and regulations, guidelines, ordinances,
orders, judgments, writs, injunctions, decrees (including administrative or judicial precedents or authorities) and the interpretation
or administration thereof by, and other determinations, directives, requirements or requests of, any Governmental Authority, in
each case having appropriate jurisdiction over and that are applicable to or binding upon such Person or any of its property or
to which such Person or any of its property is subject.

 

“Restricted
Junior Payment” means (a) any dividend or other distribution, direct or indirect, on account of any shares of
any class of Capital Stock of Borrower now or hereafter outstanding, except a dividend payable solely in shares of Capital Stock
to the holders of that class, together with any payment or distribution pursuant to a “plan of division” under the
Delaware Limited Liability Act or any comparable transaction under any similar law; (b) any redemption, retirement, sinking fund
or similar payment, purchase or other acquisition for value, direct or indirect, of any shares of any class of Capital Stock of
Borrower or any of its Subsidiaries that is not a Loan Party now or hereafter outstanding; (c) any payment made to retire, or
to obtain the surrender of, any outstanding warrants, options or other rights to acquire shares of any class of Capital Stock
of Borrower or any of its Subsidiaries that is not a Loan Party now or hereafter outstanding and (d) any payment or prepayment
of principal of, premium, if any, or interest on, or redemption, purchase, retirement, defeasance (including in substance or legal
defeasance), sinking fund or similar payment with respect to, any subordinated Indebtedness.

 

    - 28 -

    

    

 

“S&P”
means Standard & Poor’s Ratings Group, a division of The McGraw Hill Corporation.

 

“Secured
Parties” has the meaning assigned to that term in the Pledge and Security Agreement.

 

“Securities
Account” means a securities account (as defined in the UCC).

 

“Securities
Act” means the Securities Act of 1933, as amended from time to time, and any successor statute.

 

“Solvent”
means, with respect to any Loan Party, that as of the date of determination, both (a)(i) the sum of such Loan Party’s debt
(including contingent liabilities) does not exceed the present fair saleable value of such Loan Party’s present assets;
(ii) such Loan Party’s capital is not unreasonably small in relation to its business as contemplated on the Closing Date
or with respect to any transaction contemplated or undertaken after the Closing Date; and (iii) such Person has not incurred and
does not intend to incur, debts beyond its ability to pay such debts as they become due (whether at maturity or otherwise); and
(b) such Person is “solvent” within the meaning given that term and
similar terms under applicable laws relating to fraudulent transfers and conveyances. For purposes of this definition, the amount
of any contingent liability at any time shall be computed as the amount that, in light of all of the facts and circumstances existing
at such time, represents the amount that can reasonably be expected to become an actual or matured liability (irrespective of
whether such contingent liabilities meet the criteria for accrual under Statement of Financial Accounting Standard No. 5).

 

“Specified
Deposit Accounts” means each Deposit Account (other than any Excluded Account) of the Loan Parties held at Bank of America,
N.A.

 

“Specified
Product Component” means that portion of each of Annovera, Bijuva and Imvexxy described in clause (a) of each definition
thereof.

 

“Subsidiary”
means, with respect to any Person, any corporation, partnership, limited liability company, association, joint venture or other
business entity of which more than 50% of the total voting power of shares of stock or other ownership interests entitled (without
regard to the occurrence of any contingency) to vote in the election of the Person or Persons (whether directors, managers, trustees
or other Persons performing similar functions) having the power to direct or cause the direction of the management and policies
thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of
that Person or a combination thereof; provided, in determining the percentage of ownership interests of any Person controlled
by another Person, no ownership interest in the nature of a “qualifying share” of the former Person shall be deemed
to be outstanding.

 

“Tax”
means any present or future tax, levy, impost, duty, assessment, charge, fee, deduction or withholding (including backup withholding),
imposed by any Governmental Authority, including all interest, penalties, additions to tax or other liabilities with respect thereto.

 

    - 29 -

    

    

 

“Term
Loan” means, collectively, the Initial Term Loan and each Delayed Draw Term Loan.

 

“Term
Loan Commitment” means, collectively, the Initial Term Loan Commitment and the Delayed Draw Term Loan Commitments.

 

“Term
Loan Maturity Date” means the earlier of (a) March 31, 2024 and (b) the date that the Term Loan shall become
due and payable in full hereunder, whether by acceleration or otherwise.

 

“Terminated
Lender” has the meaning specified in Section 2.18.

 

“Total
Delayed Draw Term Loan Commitment” means the sum of the amounts of the Lenders’ Delayed Draw Term Loan Commitments.

 

“Total
Initial Term Loan Commitment” means the sum of the amounts of the Lenders’ Initial Term Loan Commitments.

 

“Transaction
Costs” means the reasonable and documented fees, costs and expenses payable by Borrower or any of its Subsidiaries
on or before the Closing Date in connection with the transactions contemplated by the Loan Documents.

 

“Type
of Loan” means with respect to any Term Loan, a Base Rate Loan or a LIBOR Rate Loan.

 

“UCC”
means the Uniform Commercial Code (or any similar or equivalent legislation) as in effect in any applicable jurisdiction.

 

“U.S.”
or “United States” means the United States of America.

 

“Waivable
Mandatory Prepayment” has the meaning specified in Section 2.11(b).

 

“Weighted
Average Life to Maturity” means, when applied to any Indebtedness at any date, the number of years obtained by dividing:

 

(a)           the
sum of the products obtained by multiplying (a) the amount of each then remaining installment, sinking fund, serial maturity or
other required payments of principal, including payment at final maturity, in respect of the Indebtedness, by (b) the number of
years (calculated to the nearest one-twelfth) that will elapse between such date and the making of such payment; by

 

(b)           the
then outstanding principal amount of such Indebtedness.

 

Section
1.2             Accounting and Other Terms.

 

(a)           Except
as otherwise expressly provided herein, all accounting terms not otherwise defined herein shall have the meanings assigned to
them in conformity with GAAP. Financial statements and other information required to be delivered by Borrower to Lenders pursuant
to Sections 5.1(b) and 5.1(c) shall be prepared in accordance with GAAP as in effect at the time of such preparation
(and delivered together with any reconciliation statements provided for in Section 5.1(f), if applicable). Subject to the
foregoing, calculations in connection with the definitions, covenants and other provisions hereof shall utilize accounting principles
and policies in conformity with those used to prepare the Historical Financial Statements. Notwithstanding the foregoing, or anything
else to the contrary in this Agreement or in any other Loan Document to the contrary for purposes of determining compliance with
any covenant (including the computation of any financial covenant) contained herein, Indebtedness of Borrower and its Subsidiaries
shall be deemed to be carried at 100% of the outstanding principal amount thereof.

 

    - 30 -

    

    

 

(b)           All
terms used in this Agreement which are defined in Article 8 or Article 9 of the UCC as in effect from time to time in the State
of New York and which are not otherwise defined herein shall have the same meanings herein as set forth therein, provided
that terms used herein which are defined in the UCC as in effect in the State of New York on the date hereof shall continue to
have the same meaning notwithstanding any replacement or amendment of such statute.

 

(c)           For
purposes of determining compliance with any incurrence or expenditure tests set forth in this Agreement, any amounts so incurred
or expended (to the extent incurred or expended in a currency other than Dollars ($)) shall be converted into Dollars on the basis
of the exchange rates (as shown on the Bloomberg currency page for such currency or, if the same does not provide such exchange
rate, by reference to such other recognized and publicly available service for displaying exchange rates as may be reasonably
selected by Administrative Agent or, in the event no such service is available, on such other basis as is reasonably satisfactory
to Administrative Agent) as in effect on the date of such incurrence or expenditure under any provision of any such Section that
has an aggregate Dollar limitation provided for therein (and to the extent the respective incurrence or expenditure test regulates
the aggregate amount outstanding at any time and it is expressed in terms of Dollars, all outstanding amounts originally incurred
or spent in currencies other than Dollars shall be converted into Dollars on the basis of the exchange rates (as shown on the
Bloomberg currency page for such currency or, if the same does not provide such exchange rate, by reference to such other recognized
and publicly available service for displaying exchange rates as may be reasonably selected by Administrative Agent or, in the
event no such service is available, on such other basis as is reasonably satisfactory to Administrative Agent) as in effect on
the date of any new incurrence or expenditures made under any provision of any such Section that regulates the Dollar amount outstanding
at any time).

 

Section
1.3           Interpretation, etc. Any of the
terms defined herein may, unless the context otherwise requires, be used in the singular or the plural, depending on the reference.
References herein to any Section, Appendix, Schedule or Exhibit shall be to a Section, an Appendix, a Schedule or an Exhibit,
as the case may be, hereof unless otherwise specifically provided. The use herein of the word “include” or “including,”
when following any general statement, term or matter, shall not be construed to limit such statement, term or matter to the specific
items or matters set forth immediately following such word or to similar items or matters, whether or not no limiting language
(such as “without limitation” or “but not limited to” or words of similar import) is used with reference
thereto, but rather shall be deemed to refer to all other items or matters that fall within the broadest possible scope of such
general statement, term or matter. The words “asset” and “property” shall be construed to have the same
meaning and effect and to refer to any right or interest in or to assets and properties of any kind whatsoever, whether real,
personal or mixed and whether tangible or intangible. Any reference herein or in any other Loan Document to the satisfaction,
repayment, or payment in full of the Obligations or Guaranteed Obligations shall mean the payment or repayment in full in immediately
available funds of (i) the principal amount of, and interest accrued and unpaid with respect to, all outstanding Loans, together
with the payment of any premium applicable to the repayment of the Loans, including any Prepayment Premium, (ii) all costs, expenses,
or indemnities payable pursuant to Section 10.2 or Section 10.3 of this Agreement that have accrued and are unpaid
regardless of whether demand has been made therefor and (iii) all fees, charges, expense reimbursement and other Obligations that
have accrued hereunder or under any other Loan Document and are unpaid and are payable hereunder and (b) the receipt by Administrative
Agent of cash collateral from any Loan Party in order to secure any other contingent Obligations for which a claim or demand for
payment has been made on or prior to such time or in respect of matters or circumstances known to an Agent or a Lender at such
time that are reasonably expected to result in any loss, cost, damage, or expense (including attorneys’ fees and legal expenses),
such cash collateral to be in such amount as Agents reasonably determine is appropriate to secure such contingent Obligations.
Notwithstanding anything in the Agreement to the contrary, (A) the Dodd-Frank Wall Street Reform and Consumer Protection Act and
all requests, rules, guidelines or directives thereunder or issued in connection therewith and (B) all requests, rules, guidelines
or directives concerning capital adequacy promulgated by the Bank for International Settlements, the Basel Committee on Banking
Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities shall, in each case,
be deemed to be enacted, adopted, issued, phased in or effective after the date of this Agreement regardless of the date enacted,
adopted, issued, phased in or effective. Unless the context requires otherwise (a) any definition of or reference to any Loan
Document, agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other
document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements
or modifications set forth in any Loan Document) and (b) any reference to any law or regulation shall (i) include all statutory
and regulatory provisions consolidating, amending, replacing or interpreting or supplementing such law or regulation, and (ii)
unless otherwise specified, refer to such law or regulation as amended, modified or supplemented from time to time. This Section
1.3 shall apply, mutatis mutandis, to all Loan Documents.

 

    - 31 -

    

    

 

Section
1.4            Time
References. Unless otherwise indicated herein, all references to time of day refer to Central Standard Time or Central
daylight saving time, as in effect in Dallas, Texas on such day. For purposes of the computation of a period of time from a
specified date to a later specified date, the word “from” means “from and including” and the words
“to” and “until” each means “to but excluding”; provided, however, that
with respect to a computation of fees or interest payable to Administrative Agent or any Lender, such period shall in any
event consist of at least one full day.

 

Article
II

LOANS

 

Section
2.1            Term
Loans.

 

(a)           Loan
Commitment. Subject to the terms and conditions hereof:

 

(i)           each
Lender severally agrees to make, on the Closing Date, an Initial Term Loan to Company in an amount equal to such Lender’s
Initial Term Loan Commitment;

 

(ii)          each
Lender severally agrees to make, after the Closing Date and at any time prior to the Delayed Draw Term Loan Commitment Termination
Date, a Delayed Draw A-1 Term Loan to Company in an aggregate amount equal to such Lender’s Delayed Draw A-1 Term Loan Commitment;
and

 

(iii)         each
Lender severally agrees to make, after the Closing Date and at any time prior to the Delayed Draw Term Loan Commitment Termination
Date, a Delayed Draw A-2 Term Loan to Company in an aggregate amount equal to such Lender’s Delayed Draw A-2 Term Loan Commitment.

 

Company
may make only one borrowing under the Initial Term Loan Commitment which shall be on the Closing Date. Any amount borrowed under
this Section 2.1(a) and subsequently repaid or prepaid may not be reborrowed. Subject to Section 2.9, all amounts
owed hereunder with respect to the Term Loan shall be paid in full no later than the Term Loan Maturity Date. Each Lender’s
Initial Term Loan Commitment shall terminate immediately and without further action on the Closing Date after giving effect to
the funding of such Lender’s Initial Term Loan Commitment on such date in an amount equal to such Lender’s Pro Rata
Share (calculated in accordance with clause (a)(i) of the definition thereof) of such funded Initial Term Loan. Each Lender’s
Delayed Draw A-1 Term Loan Commitment shall be permanently reduced immediately and without further action upon the funding of
each Delayed Draw A-1 Term Loan after the Closing Date in an amount equal to such Lender’s Pro Rata Share (calculated in
accordance with clause (a)(ii) of the definition thereof) of such funded Delayed Draw A-1 Term Loan. Each Lender’s Delayed
Draw A-1 Term Loan Commitment shall terminate immediately and without further action on the earlier to occur of (i) the Term Loan
Maturity Date and (ii) the applicable Delayed Draw Term Loan Commitment Termination Date after giving effect to the funding of
such Lender’s Delayed Draw A-1 Term Loan Commitment, if any, on such date. Each Lender’s Delayed Draw A-2 Term Loan
Commitment shall be permanently reduced immediately and without further action upon the funding of each Delayed Draw A-2 Term
Loan after the Closing Date in an amount equal to such Lender’s Pro Rata Share (calculated in accordance with clause (a)(iii)
of the definition thereof) of such funded Delayed Draw A-2 Term Loan. Each Lender’s Delayed Draw A-2 Term Loan Commitment
shall terminate immediately and without further action on the earlier to occur of (i) the Term Loan Maturity Date and (ii) the
applicable Delayed Draw Term Loan Commitment Termination Date after giving effect to the funding of such Lender’s Delayed
Draw A-2 Term Loan Commitment, if any, on such date.

 

    - 32 -

    

    

 

(b)           Borrowing
Mechanics for Term Loans.

 

(i)           Company
shall deliver to Administrative Agent a fully executed Funding Notice no later than three Business Days prior to the Closing Date
(or such shorter period permitted by Administrative Agent), with respect to Term Loans made on the Closing Date. Following the
Closing Date (and subject to the conditions set forth in Section 3.2), whenever Company desires that Lenders make a Delayed
Draw Term Loan, Company shall deliver to Administrative Agent a fully executed and delivered Funding Notice at least 15 Business
Days in advance of the proposed Credit Date (or such shorter period consented to by Administrative Agent). Except as otherwise
provided herein, a Funding Notice for a Term Loan that is a LIBOR Rate Loan shall be irrevocable on and after the related Interest
Rate Determination Date, and Company shall be bound to make a borrowing in accordance therewith. Promptly upon receipt by Administrative
Agent of any such Funding Notice, Administrative Agent shall notify each Lender of the proposed borrowing. Administrative Agent
and Lenders (A) may act without liability upon the basis of written or facsimile notice believed by Administrative Agent in good
faith to be from Company (or from any Authorized Officer thereof designated in writing purportedly from Company to Administrative
Agent), (B) shall be entitled to rely conclusively on any Authorized Officer’s authority to request a Term Loan on behalf
of Company until Administrative Agent receives written notice to the contrary, and (C) shall have no duty to verify the authenticity
of the signature appearing on any written Funding Notice.

 

(ii)           Each
Lender shall make its Initial Term Loan available to Administrative Agent not later than 12:00 p.m. on the applicable Credit Date,
by wire transfer of same day funds in Dollars, at Administrative Agent’s Principal Office. Upon satisfaction or waiver of
the conditions precedent specified herein, Administrative Agent shall make the proceeds of the Term Loans available to Company
on the applicable Credit Date by causing an amount of same day funds in Dollars equal to the proceeds of all such Loans received
by Administrative Agent from Lenders to be credited to the account of Company at Administrative Agent’s Principal Office
or to such other account as may be designated in writing to Administrative Agent by Company.

 

(c)           During
the Delayed Draw Term Loan Commitment Period, drawings under the (i) Delayed Draw A-1 Term Loan Commitment shall be (A) made on
not more than 1 date and (B) made in an aggregate amount not exceeding $50,000,000 and (ii) Delayed Draw A-2 Term Loan Commitment
shall be (A) made on not more than 1 date and (B) made in an aggregate amount not exceeding $50,000,000, and in each case for
clauses (i) and (ii) shall be subject to the satisfaction of the conditions set forth in Section 3.2.

 

    - 33 -

    

    

 

(d)           Pro
Rata Shares; Availability of Funds.

 

(i)           Pro
Rata Shares. All Loans shall be made by Lenders simultaneously and proportionately to their respective Pro Rata Shares, it
being understood that no Lender shall be responsible for any default by any other Lender in such other Lender’s obligation
to make a Loan requested hereunder nor shall any Term Loan Commitment of any Lender be increased or decreased as a result of a
default by any other Lender in such other Lender’s obligation to make a Loan requested hereunder or purchase a participation
required hereby.

 

(ii)           Availability
of Funds. Unless Administrative Agent shall have been notified by any Lender prior to the applicable Credit Date that such
Lender does not intend to make available to Administrative Agent the amount of such Lender’s Loan requested on such Credit
Date, Administrative Agent may assume that such Lender has made such amount available to Administrative Agent on such Credit Date
and Administrative Agent may, in its sole discretion, but shall not be obligated to, make available to Company a corresponding
amount on such Credit Date. If such corresponding amount is not in fact made available to Administrative Agent by such Lender,
Administrative Agent shall be entitled to recover such corresponding amount on demand from such Lender together with interest
thereon, for each day from such Credit Date until the date such amount is paid to Administrative Agent, at the customary rate
set by Administrative Agent for the correction of errors among banks for three Business Days and thereafter at the Base Rate.
If such Lender does not pay such corresponding amount forthwith upon Administrative Agent’s demand therefor, Administrative
Agent shall promptly notify Company and Company shall immediately pay such corresponding amount to Administrative Agent together
with interest thereon, for each day from such Credit Date until the date such amount is paid to Administrative Agent, at the rate
payable hereunder for Base Rate Loans for such Class of Loans. Nothing in this Section 2.1(d)(ii) shall be deemed to relieve
any Lender from its obligation to fulfill its Term Loan Commitments hereunder or to prejudice any rights that Company may have
against any Lender as a result of any default by such Lender hereunder.

 

Section
2.2            Use
of Proceeds. The proceeds of the Term Loans made on and after the Closing Date shall be applied by Company for working capital,
capital expenditures and general corporate purposes of Borrower and its Subsidiaries. No portion of the proceeds of the Term Loan
shall be used in any manner that causes or might cause such Credit Extension or the application of such proceeds to violate Regulation
T, Regulation U or Regulation X of the Board of Governors of the Federal Reserve System or any other regulation thereof or to
violate the Exchange Act.

 

Section
2.3            Evidence of Debt; Register; Lenders’
Books and Records; Notes.

 

(a)           Lenders’
Evidence of Debt. Each Lender shall maintain on its internal records an account or accounts evidencing the Obligations of
Company to such Lender, including the amounts of the Term Loans made by it and each repayment and prepayment in respect thereof.
Any such recordation shall be conclusive and binding on Company, absent manifest error; provided, that the failure to make
any such recordation, or any error in such recordation, shall not affect Company’s Obligations in respect of any Term Loans;
and provided further, in the event of any inconsistency between the Register and any Lender’s records, the recordations
in the Register shall govern.

 

(b)           Register.
Administrative Agent shall maintain at its Principal Office a register for the recordation of the names and addresses of
Lenders and the principal amount of the Term Loans (and stated interest therein) of each Lender from time to time (the
“Register”). The Register shall be available for inspection by
Company at any reasonable time and from time to time upon reasonable prior notice, and Administrative Agent shall notify
Company in writing following any updates to the Register made from time to time. Administrative Agent shall record in the
Register the Term Loans, and each repayment or prepayment in respect of the principal amount of the Term Loans, and any such
recordation shall be conclusive (absent manifest error) and binding on Company and each Lender, and Company, Administrative
Agent and Lenders shall treat each Person whose name is recorded in the Register pursuant to and in accordance with the terms
and conditions hereof as a Lender hereunder for any purposes of this Agreement; provided, failure to make any such recordation,
or any error in such recordation, or any failure to provide notice of any updates to the Register, shall not affect Company’s
Obligations in respect of any Term Loan. Company hereby designates the entity serving as Administrative Agent to serve as Company’s
non-fiduciary agent solely for purposes of maintaining the Register as provided in this Section 2.3, and Company hereby
agrees that, to the extent such entity serves in such capacity, the entity serving as Administrative Agent and its officers, directors,
employees, agents and affiliates shall constitute “Indemnitees.”

 

    - 34 -

    

    

 

(c)           Notes.
If so requested by any Lender by written notice to Company (with a copy to Administrative Agent) at least two Business Days prior
to the Closing Date, or at any time thereafter, Company shall execute and deliver to such Lender (and/or, if applicable and if
so specified in such notice, to any Person who is an assignee of such Lender pursuant to Section 10.6) on the Closing Date
(or, if such notice is delivered after the Closing Date, promptly after Company’s receipt of such notice) a Note or Notes.

 

Section
2.4            Interest.

 

(a)           Except
as otherwise set forth herein, each Loan shall bear interest on the unpaid principal amount thereof from the date made
through repayment (whether by acceleration or otherwise) thereof as follows:

 

(i)           if
a Base Rate Loan, at the Base Rate plus the Applicable Margin; or

 

(ii)           if
a LIBOR Rate Loan, at the Adjusted LIBOR Rate plus the Applicable Margin.

 

(b)           The
basis for determining the rate of interest with respect to any Loan, and the Interest Period with respect to any LIBOR Rate Loan,
shall be selected by Company and notified to Administrative Agent and Lenders pursuant to the applicable Funding Notice or Conversion/Continuation
Notice, as the case may be. If on any day a Loan is outstanding with respect to which a Funding Notice or Conversion/Continuation
Notice has not been delivered to Administrative Agent in accordance with the terms hereof specifying the applicable basis for
determining the rate of interest, then for that day such Loan shall be a Base Rate Loan.

 

(c)           In
connection with LIBOR Rate Loans there shall be no more than five Interest Periods outstanding at any time. In the event Company
fails to specify between a Base Rate Loan or a LIBOR Rate Loan in the applicable Funding Notice or Conversion/Continuation Notice,
such Loan (if outstanding as a LIBOR Rate Loan) will be automatically converted into a Base Rate Loan on the last day of the then
current Interest Period for such Loan (or if outstanding as a Base Rate Loan will remain as, or (if not then outstanding) will
be made as, a Base Rate Loan). In the event Company fails to specify an Interest Period for any LIBOR Rate Loan in the applicable
Funding Notice or Conversion/Continuation Notice, Company shall be deemed to have selected an Interest Period of three months.
At any time that a Default or an Event of Default has occurred and is continuing, Company no longer shall have the option to request
that any portion of the Loans be a LIBOR Rate Loan and such LIBOR Rate Loans shall automatically convert to Base Rate Loans on
the last day of the then current Interest Period. As soon as practicable after 10:00 a.m. (New York City time) on each Interest
Rate Determination Date, Administrative Agent shall determine (which determination shall, absent manifest error, be final, conclusive
and binding upon all parties) the interest rate that shall apply to the LIBOR Rate Loans for which an interest rate is then being
determined for the applicable Interest Period and shall promptly give notice thereof (in writing) to Company and each Lender.

 

    - 35 -

    

    

 

(d)           Interest
payable hereunder shall be computed on the basis of a 360 day year, in each case for the actual number of days elapsed in the
period during which it accrues. In computing interest on any Loan, the date of the making of such Loan or the first day of an
Interest Period applicable to such Loan or, with respect to a Base Rate Loan being converted from a LIBOR Rate Loan, the date
of conversion of such LIBOR Rate Loan to such Base Rate Loan, as the case may be, shall be included, and the date of payment of
such Loan or the expiration date of an Interest Period applicable to such Loan or, with respect to a Base Rate Loan being converted
to a LIBOR Rate Loan, the date of conversion of such Base Rate Loan to such LIBOR Rate Loan, as the case may be, shall be excluded;
provided, if a Loan is repaid on the same day on which it is made, one day's interest shall be paid on that Loan.

 

(e)           Except
as otherwise set forth herein, interest on each Term Loan shall be payable in cash and in arrears (i) on each Interest Payment
Date; (ii) upon any prepayment of that Term Loan, whether voluntary or mandatory, to the extent accrued on the amount being prepaid;
and (iii) at maturity, including final maturity.

 

Section
2.5            Conversion/Continuation.

 

(a)           Subject
to Section 2.17 and so long as no Default or Event of Default shall have occurred and then be continuing, Company shall
have the option:

 

(i)       to
convert at any time all or any part of any Term Loan equal to $5,000,000 and integral multiples of $1,000,000 in excess of that
amount from one Type of Loan to another Type of Loan; provided, a LIBOR Rate Loan may only be converted on the expiration
of the Interest Period applicable to such LIBOR Rate Loan unless Company shall pay all amounts due under Section 2.17 in
connection with any such conversion; or

 

(ii)      upon
the expiration of any Interest Period applicable to any LIBOR Rate Loan, to continue all or any portion of such Loan equal to
$5,000,000 and integral multiples of $1,000,000 in excess of that amount as a LIBOR Rate Loan.

 

(b)           Company
shall deliver a Conversion/Continuation Notice to Administrative Agent no later than 10:00 a.m. (New York City time) at least
one Business Day in advance of the proposed conversion date (in the case of a conversion to a Base Rate Loan) and at least three
Business Days in advance of the proposed conversion/continuation date (in the case of a conversion to, or a continuation of, a
LIBOR Rate Loan). Except as otherwise provided herein, a Conversion/Continuation Notice for conversion to, or continuation of,
any LIBOR Rate Loans shall be irrevocable on and after the related Interest Rate Determination Date, and Company shall be bound
to effect a conversion or continuation in accordance therewith.

 

Section
2.6            Default
Interest. Upon Company's receipt of written notice thereof from Administrative Agent following the occurrence and during the
continuance of an Event of Default, the principal amount of all Term Loans outstanding and, to the extent permitted by applicable
law, any accrued and unpaid interest payments on the Term Loans or any fees or other amounts owed hereunder (including any Prepayment
Premium, if applicable), shall from and after the first date of the occurrence of such Event of Default bear interest (including
post petition interest in any proceeding under the Bankruptcy Code or other applicable bankruptcy laws) payable on demand at a
rate that is 2.0% per annum in excess of the interest rate otherwise payable hereunder with respect to the Term Loans. All interest
payable at the Default Rate shall be payable in cash on demand. Payment or acceptance of the Default Rate of interest provided
for in this Section 2.6 is not a permitted alternative to timely payment and shall not constitute a waiver of any Default
or Event of Default or otherwise prejudice or limit any rights or remedies of Administrative Agent or any Lender.

 

    - 36 - 

     

    

 

Section
2.7           Fees.

 

(a)          Company
agrees to pay to Administrative Agent all fees payable by it in the Fee Letter in the amounts and at the times specified therein.

 

(b)          All
fees referred to in Section 2.7(a) shall be calculated on the basis of a 360 day year and the actual number of days elapsed.

 

Section
2.8           Repayment of Term Loans. Commencing on June 30, 2023
and on the last day of each Fiscal Quarter ending thereafter, the Borrower shall repay the principal amount of the Term Loan in
an amount equal to 25.0% of the aggregate principal balance of the Term Loan on June 30, 2023, which payments shall be applied
as follows: (a) first, the principal of the Initial Term Loan until paid in full, (b) second, the principal of the
Delayed Draw A-1 Term Loan until paid in full and (c) third, the principal of the Delayed Draw A-2 Term Loan until paid
in full. Notwithstanding the foregoing, the Term Loan, together with all other amounts owed hereunder with respect thereto, shall
be paid in full no later than the Term Loan Maturity Date.

 

Section
2.9            Voluntary Prepayments and Commitment Reductions.

 

(a)           Voluntary
Prepayments.

 

(i)       Subject
to the terms of the Fee Letter, Company may prepay at any time the Term Loan on any Business Day in whole or in part (together
with any amounts due pursuant to Section 2.19(c)), in an aggregate minimum amount of $5,000,000 and integral multiples
of $1,000,000 in excess of that amount.

 

(ii)       All
such prepayments shall be made (A) upon not less than one Business Day's prior written notice in the case of Base Rate Loans and
(B) upon not less than three Business Days' prior written notice in the case of LIBOR Rate Loans, in each case given to Administrative
Agent by 3:00 p.m. on the date required (and Administrative Agent will promptly transmit such notice to each Lender). Upon the
giving of any such notice, the principal amount of the Term Loans specified in such notice shall become due and payable on the
prepayment date specified therein. Any such voluntary prepayment shall be applied to the Term Loans as directed by the Borrower.

 

(b)           Voluntary
Commitment Reductions.

 

(i)       Company
may, upon not less than three Business Days' prior written to Administrative Agent (which original written notice Administrative
Agent will promptly transmit to each applicable Lender), at any time and from time to time terminate in whole or permanently reduce
in part any unused portion of the Delayed Draw Term Loan Commitments; provided, any such partial reduction of the Delayed
Draw Term Loan Commitments shall be in an aggregate minimum amount of $5,000,000 and integral multiples of $1,000,000 in excess
of that amount.

 

(ii)       Company's
notice to Administrative Agent shall designate (A) the date (which shall be a Business Day) of such termination or reduction and
the amount of any partial reduction and (B) whether such termination or reduction is for the Delayed Draw A-1 Term Loan Commitment
and/or the Delayed Draw A-2 Term Loan Commitment, and such termination or reduction of the Delayed Draw Term Loan Commitments
shall be effective on the date specified in Company's notice and shall reduce the Delayed Draw Term Loan of each Lender proportionately
to its Pro Rata Share thereof.

 

    - 37 - 

     

    

 

Section
2.10           Mandatory Prepayments.

 

(a)           Asset
Sales.

 

(i)       No
later than the fifth Business Day following the date of receipt by any Loan Party of any Net Proceeds from one or more Asset Sales
constituting a Permitted Product Transaction in excess of $40,000,000 in the aggregate for all such Permitted Product Transactions,
Company shall prepay the Term Loan as set forth in Section 2.11(a) in an aggregate amount equal to such Net Proceeds in
excess of $40,000,000.

 

(ii)       No
later than the fifth Business Day following the date of receipt by any Loan Party of any Net Proceeds from Asset Sales in excess
of $5,000,000 in the aggregate in any Fiscal Year that do not constitute a Permitted Product Transaction, Company shall prepay
the Term Loans set forth in Section 2.11(a) in an aggregate amount equal to such Net Proceeds in excess of $5,000,000 in
such Fiscal Year; provided, so long as (i) no Default or Event of Default shall have occurred and be continuing, (ii) Company
has delivered Administrative Agent prior written notice of Company's intention to apply such monies (the “Reinvestment
Amounts”) to reinvest in or to the costs of purchase of other assets used or useful in the business of the Loan Parties
including capital expenditures, (iii) the monies are held in a Deposit Account subject to a Control Agreement, and (iv) the Loan
Parties complete such reinvestment or purchase within 365 days after the initial receipt of such monies, the Loan Parties shall
have the option to apply such monies to the reinvestment in or the costs of purchase of other assets used or useful in the business
of the Loan Parties (including capital expenditures) unless and to the extent that such applicable period shall have expired without
such reinvestment or purchase being made or completed, in which case, any such amounts not so used to reinvest or purchase shall
be paid to Administrative Agent and applied in accordance with Section 2.11(a).

 

(iii)       Nothing
contained in this Section 2.10(a) shall permit Borrower or any of its Subsidiaries to sell or otherwise dispose of
any assets other than in accordance with Section 6.9.

 

(b)           Insurance/Condemnation
Proceeds. No later than the fifth Business Day following the date of receipt by any Loan Party, or Administrative Agent as
loss payee, of any Net Proceeds from insurance or any condemnation, taking or other casualty in excess of $5,000,000 in the aggregate
in any Fiscal Year, Company shall prepay the Term Loan in an aggregate amount equal to such Net Proceeds in excess of $5,000,000
in the aggregate in any Fiscal Year; provided, (i) so long as no Default or Event of Default shall have occurred and be
continuing, (ii) Company has delivered Administrative Agent prior written notice of Company's intention to apply the Reinvestment
Amounts to reinvest in or the costs of purchase of other assets used or useful in the business of the Loan Parties (including
capital expenditures), (iii) the monies are held in a Deposit Account subject to a Control Agreement, and (iv) the Loan Parties
complete such reinvestment or purchase within 365 days after the initial receipt of such monies, the Loan Parties shall have the
option to apply such monies to the reinvestment in or costs of purchase of other assets used or useful in the business of the
Loan Parties (including capital expenditures) unless and to the extent that such applicable period shall have expired without
such reinvestment or purchase being made or completed, in which case, any such amounts not so used to reinvest or purchase shall
be paid to Administrative Agent and applied in accordance with Section 2.11(a).

 

(c)           Issuance
of Debt. On the date of receipt by Borrower or any of its Subsidiaries of any Cash proceeds from the incurrence of any Indebtedness
of Borrower or any of its Subsidiaries (in each case, other than with respect to any Indebtedness permitted to be incurred pursuant
to Section 6.1), Company shall prepay the Term Loans as set forth in Section 2.11(a) in an aggregate amount equal
to 100% of such proceeds, net of underwriting discounts and commissions and other reasonable costs and expenses associated therewith,
in each case, paid to non-Affiliates, including reasonable legal fees and expenses.

 

    - 38 - 

     

    

 

(d)           Extraordinary
Receipts. On the date of receipt by Borrower or any of its Subsidiaries of any Extraordinary Receipts in excess of $5,000,000
in the aggregate in any Fiscal Year, Company shall prepay the Terms Loan as set forth in Section 2.11(a) in the amount
of such Extraordinary Receipts in excess of $5,000,000.

 

(e)           Prepayment
Certificate. Concurrently with any prepayment of the Term Loan pursuant to Section 2.10(a) through Section 2.10(d),
Company shall deliver to Administrative Agent a certificate of an Authorized Officer demonstrating the calculation of the amount
of the applicable net proceeds and compensation owing to Lenders pursuant to the Fee Letter, if any, as the case may be. In the
event that Company shall subsequently determine that the actual amount received exceeded the amount set forth in such certificate,
Company shall promptly make an additional prepayment of the Loans, and Company shall concurrently therewith deliver to Administrative
Agent a certificate of an Authorized Officer demonstrating the derivation of such excess.

 

Section
2.11           Application
of Prepayments.

 

(a)           Application
of Prepayments of Term Loans. Except in connection with any Waivable Mandatory Prepayment provided for in Section 2.11(b),
so long as no Application Event has occurred and is continuing, any mandatory prepayment of any Loan pursuant to Section 2.10,
in each case, shall be applied as follows:

 

first,
to prepay accrued and unpaid interest on the Term Loan;

 

second,
to pay any Prepayment Premium payable thereon; and

 

third,
to prepay (A) first, the principal of the Initial Term Loan to the installments thereof
on a pro rata basis until paid in full, (B) second, the principal of the Delayed Draw A-1 Term Loan to the installments
thereof on a pro rata basis until paid in full and (C) third, the principal of the Delayed Draw A-2 Term Loan to the installments
thereof on a pro rata basis until paid in full.

 

(b)           Waivable
Mandatory Prepayment. Anything contained herein to the contrary notwithstanding, in the event Company is required to make
any mandatory prepayment (a “Waivable Mandatory Prepayment”) of the
Term Loans pursuant to Section 2.8 and Section 2.10, not less than three Business Days prior to the date (the “Required
Prepayment Date”) on which Company is required to make such Waivable Mandatory Prepayment, Company shall notify
Administrative Agent of the amount of such prepayment, and Administrative Agent will promptly thereafter notify each Lender holding
an outstanding Term Loan of the amount of such Lender's Pro Rata Share of such Waivable Mandatory Prepayment and such Lender's
option to refuse such amount. Each such Lender may exercise such option by giving written notice to Company and Administrative
Agent of its election to do so on or before the first Business Day prior to the Required Prepayment Date (it being understood
that any Lender which does not notify Company and Administrative Agent of its election to exercise such option on or before the
first Business Day prior to the Required Prepayment Date shall be deemed to have elected, as of such date, not to exercise such
option). On the Required Prepayment Date, Company shall pay to Administrative Agent the amount of the Waivable Mandatory Prepayment,
which amount shall be applied (i) in an amount equal to that pro rata portion of the Waivable Mandatory Prepayment payable to
those Lenders that have elected not to exercise such option, to prepay the Term Loans of such Lenders (which prepayment shall
be applied in accordance with Section 2.11(a)), and (ii) to the extent of any excess, to Company for working capital and
general corporate purposes.

 

(c)           At
any time an Application Event has occurred and is continuing, all payments shall be applied pursuant to Section 2.12(f).
Nothing contained herein shall modify the provisions of Section 2.12(b) regarding the requirement that all prepayments
be accompanied by accrued interest on the principal amount being prepaid to the date of such prepayment and any applicable Prepayment
Premium, or any requirement otherwise contained herein to pay all other amounts as the same become due and payable in accordance
with and subject to the terms and conditions herein.

 

    - 39 - 

     

    

 

Section
2.12           General
Provisions Regarding Payments.

 

(a)           All
payments by Company of principal, interest, fees and other Obligations shall be made in Dollars in immediately available funds,
without defense, recoupment, setoff or counterclaim, free of any restriction or condition, and delivered to Administrative Agent,
for the account of Lenders, not later than 3:00 p.m. to Administrative Agent's Account; funds received by Administrative Agent
after that time on such due date shall be deemed to have been paid by Company on the next Business Day unless otherwise consented
to by Administrative Agent.

 

(b)           All
payments in respect of the principal amount of any Term Loan shall be accompanied by payment of accrued and unpaid interest on
the principal amount being repaid or prepaid, any applicable Prepayment Premium and all other amounts due and payable hereunder
with respect to the principal amount being repaid or prepaid.

 

(c)           Administrative
Agent shall promptly distribute to each Lender at such address as such Lender shall indicate in writing, such Lender's applicable
Pro Rata Share of all payments and prepayments of principal and interest due hereunder, together with all other amounts due with
respect thereto, including, without limitation, all fees payable with respect thereto, to the extent received by Administrative
Agent.

 

(d)           Subject
to the provisos set forth in the definition of “Interest Period”, whenever any payment to be made hereunder shall
be stated to be due on a day that is not a Business Day, such payment shall be made on the next succeeding Business Day and such
extension of time shall be included in the computation of the payment of interest hereunder or of the commitment fees hereunder.

 

(e)           Administrative
Agent shall deem any payment by or on behalf of Company hereunder that is not made in same day funds prior to 3:00 p.m. to be
a non-conforming payment. Any such payment shall not be deemed to have been received by Administrative Agent until the later of
(i) the time such funds become available funds, and (ii) the applicable next Business Day. Administrative Agent shall give
prompt telephonic notice to Company and each applicable Lender (confirmed in writing) if any payment is non-conforming. Any non-conforming
payment may constitute or become a Default or Event of Default in accordance with and subject to the terms and conditions of Section
8.1(a). Interest shall continue to accrue on any principal as to which a non-conforming payment is made until such funds become
available funds (but in no event less than the period from the date of such payment to the next succeeding applicable Business
Day) at the Default Rate determined pursuant to Section 2.6 from the date such amount was due and payable until the date
such amount is paid in full.

 

(f)           At
any time an Application Event has occurred and is continuing, or the maturity of the Obligations shall have been accelerated pursuant
to Section 8.1, all payments or proceeds received by Administrative Agent hereunder or under any Collateral Document in
respect of any of the Obligations, including, but not limited to all proceeds received by Administrative Agent in respect of any
sale, any collection from, or other realization upon all or any part of the Collateral, shall be applied in full or in part as
follows:

 

    - 40 - 

     

    

 

first,
ratably to pay the Obligations in respect of any fees (other than any Prepayment Premium), expense reimbursements, indemnities
and other amounts then due and payable to the Administrative Agent until paid in full;

 

second,
ratably to pay interest then due and payable in respect of Protective Advances until paid in full;

 

third,
ratably to pay principal of Protective Advances then due and payable until paid in full;

 

fourth,
ratably to pay the Obligations in respect of any fees (other than any Prepayment Premium) and indemnities then due and payable
to the Lenders with a Term Loan Commitment until paid in full;

 

fifth,
ratably to pay interest then due and payable in respect of the Term Loan until paid in full;

 

sixth,
ratably to pay (A) first, the principal of the Initial Term Loan until paid in full, (B) second, the principal of
the Delayed Draw A-1 Term Loan until paid in full and (C) third, the principal of the Delayed Draw A-2 Term Loan until
paid in full;

 

seventh,
ratably to pay the Obligations in respect of any Prepayment Premium then due and payable to the Lenders with a Term Loan Commitment
until paid in full;

 

eighth,
to the ratable payment of all other Obligations then due and payable until paid in full; and

 

ninth,
to Company or as otherwise directed by applicable law.

 

(g)           For
purposes of Section 2.12(f) (other than clause eighth, of Section 2.12(f)), “paid in full” means
payment in cash of all amounts due and payable under the Loan Documents in accordance with and subject to the terms and conditions
thereof, including loan fees, service fees, professional fees, interest (and specifically including interest accrued after the
commencement of any Insolvency Proceeding), default interest, interest on interest, and expense reimbursements, whether or not
same would be or is allowed or disallowed in whole or in part in any Insolvency Proceeding.

 

(h)           In
the event of a direct conflict between the priority provisions of Section 2.12(f) and other provisions contained in any
other Loan Document, it is the intention of the parties hereto that both such priority provisions in such documents shall be read
together and construed, to the fullest extent possible, to be in concert with each other. In the event of any actual, irreconcilable
conflict that cannot be resolved as aforesaid, the terms and provisions of Section 2.12(f) shall control and govern.

 

(i)           Borrower
hereby authorizes Administrative Agent to charge Company's accounts with Administrative Agent or any of its Affiliates in order
to cause timely payment to be made to Administrative Agent of all principal, interest, fees and expenses due hereunder (subject
to sufficient funds being available in its accounts for that purpose). The Lenders and Company also hereby authorize Administrative
Agent to, and Administrative Agent may, from time to time upon prior notice to Company, charge the Loan Account with any amount
due and payable by Company under any Loan Document. Each of the Lenders and Company agrees that Administrative Agent shall have
the right to make such charges whether or not any Default or Event of Default shall have occurred and be continuing or whether
any of the conditions precedent in Section 3.2 have been satisfied. Any amount charged to the Loan Account shall be deemed
a Loan hereunder made by the Lenders to Company, funded by Administrative Agent on behalf of the Lenders and subject to Section
2.2. The Lenders and Company confirm that any charges which Administrative Agent may so make to the Loan Account as herein
provided will be made as an accommodation to Company and solely at Administrative Agent's discretion, provided that Administrative
Agent shall from time to time upon the request of Collateral Agent, charge the Loan Account of Company with any amount due and
payable under any Loan Document.

 

    - 41 - 

     

    

 

(j)           
Notwithstanding the foregoing provisions hereof, if any Conversion/Continuation Notice is withdrawn as to any Affected Lender
or if any Affected Lender makes Base Rate Loans in lieu of its Pro Rata Share of any LIBOR Rate Loans, Administrative Agent shall
give effect thereto in apportioning payments received thereafter.

 

Section
2.13          Ratable Sharing. Lenders hereby agree among themselves
that, except as otherwise provided in the Collateral Documents with respect to amounts realized from the exercise of rights with
respect to Liens on the Collateral, if any of them shall, whether by voluntary payment (other than a voluntary prepayment of Term
Loans made and applied in accordance with the terms hereof), through the exercise of any right of set off or banker's lien, by
counterclaim or cross action or by the enforcement of any right under the Loan Documents or otherwise, or as adequate protection
of a deposit treated as cash collateral under the Bankruptcy Code, receive payment or reduction of a proportion of the aggregate
amount of principal, interest, fees and other amounts then due and owing to such Lender hereunder or under the other Loan Documents
(collectively, the “Aggregate Amounts Due” to such Lender) which is
greater than the proportion received by any other Lender in respect of the Aggregate Amounts Due to such other Lender having Term
Loans, then the Lender receiving such proportionately greater payment shall (a) notify Administrative Agent and each other Lender
of the receipt of such payment and (b) apply a portion of such payment to purchase participations (which it shall be deemed to
have purchased from each seller of a participation simultaneously upon the receipt by such seller of its portion of such payment)
in the Aggregate Amounts Due to the other Lenders so that all such recoveries of Aggregate Amounts Due shall be shared by all
Lenders having Term Loans in proportion to the Aggregate Amounts Due to them; provided, if all or part of such proportionately
greater payment received by such purchasing Lender is thereafter recovered from such Lender upon the bankruptcy or reorganization
of Company or otherwise, those purchases shall be rescinded and the purchase prices paid for such participations shall be returned
to such purchasing Lender ratably to the extent of such recovery, but without interest. Company expressly consents to the foregoing
arrangement and agrees that any holder of a participation so purchased may exercise any and all rights of banker's lien, set off
or counterclaim with respect to any and all monies owing by Company to that holder with respect thereto as fully as if that holder
were owed the amount of the participation held by that holder.

 

Section
2.14           Increased
Costs; Capital Adequacy.

 

(a)           Compensation
For Increased Costs and Taxes. Subject to the provisions of Section 2.15 (which shall be controlling with respect to
the matters covered thereby), in the event that any Lender shall determine (which determination shall, absent manifest error,
be final and conclusive and binding upon all parties hereto) that any law, treaty or governmental rule, regulation or order, or
any change therein or in the interpretation, administration or application thereof (including the introduction of any new law,
treaty or governmental rule, regulation or order) by any Governmental Authority having appropriate jurisdiction, or any determination
of a court or Governmental Authority having appropriate jurisdiction, in each case that becomes effective after the date hereof,
or compliance by such Lender with any guideline, request or directive issued or made after the date hereof by any central bank
or other governmental or quasi-Governmental Authority (whether or not having the force of law): (i) subjects such Recipient (or
its applicable lending office) to any additional Tax (other than (A) Indemnified Taxes, (B) Taxes described in clauses (ii)-(iv)
of the definition of Excluded Taxes and (C) Connection Income Taxes) with respect to this Agreement or any of the other Loan Documents
or any of its obligations hereunder or thereunder or any payments to such Lender (or its applicable lending office) of principal,
interest, fees or any other amount payable hereunder; (ii) imposes, modifies or holds applicable any reserve (including any marginal,
emergency, supplemental, special or other reserve), special deposit, compulsory loan, FDIC insurance or similar requirement against
assets held by, or deposits or other liabilities in or for the account of, or advances or loans by, or other credit extended by,
or any other acquisition of funds by, any office of such Lender (other than any such reserve or other requirements with respect
to LIBOR Rate Loans that are reflected in the definition of Adjusted LIBOR Rate); or (iii) imposes any other condition (other
than with respect to a Tax matter) on or affecting such Lender (or its applicable lending office) or its obligations hereunder
or the London interbank market; and the result of any of the foregoing is to increase the cost to such Lender or such other Recipient
of agreeing to make, making or maintaining Loans hereunder or to reduce any amount received or receivable by such Lender or such
other Recipient (or its applicable lending office) with respect thereto; then, in any such case, Company shall promptly pay to
such Lender or such other Recipient, upon receipt of the statement referred to in the next sentence, such additional amount or
amounts (in the form of an increased rate of, or a different method of calculating, interest or otherwise as such Lender in its
sole discretion shall determine) as may be necessary to compensate such Lender or such other Recipient for any such increased
cost or reduction in amounts received or receivable hereunder. Such Lender or such other Recipient shall deliver to Company (with
a copy to Administrative Agent) a written statement, setting forth in reasonable detail the basis for calculating the additional
amounts owed to such Lender or such other Recipient under this Section 2.14(a), which statement shall be conclusive and
binding upon all parties hereto absent manifest error.

 

    - 42 - 

     

    

 

(b)           Capital
Adequacy Adjustment. In the event that any Lender shall have determined that the adoption, effectiveness, phase in or applicability
after the Closing Date of any law, rule or regulation (or any provision thereof) regarding capital adequacy, or any change therein
or in the interpretation or administration thereof by any Governmental Authority, central bank or comparable agency charged with
the interpretation or administration thereof, in each case, having appropriate jurisdiction or compliance by any Lender (or its
applicable lending office) with any guideline, request or directive regarding capital adequacy (whether or not having the force
of law) of any such Governmental Authority, central bank or comparable agency, has or would have the effect of reducing the rate
of return on the capital of such Lender or any corporation controlling such Lender as a consequence of, or with reference to,
such Lender's Term Loans or other obligations hereunder with respect to the Term Loan to a level below that which such Lender
or such controlling corporation could have achieved but for such adoption, effectiveness, phase in, applicability, change or compliance
(taking into consideration the policies of such Lender or such controlling corporation with regard to capital adequacy), then
from time to time, within five Business Days after receipt by Company from such Lender of the statement referred to in the next
sentence, Company shall pay to such Lender such additional amount or amounts as will compensate such Lender or such controlling
corporation on an after Tax basis for such reduction. Such Lender shall deliver to Company (with a copy to Administrative Agent)
in accordance with Section 10.1 a written statement, setting forth in reasonable detail the basis for calculating the additional
amounts owed to Lender under this Section 2.14(b), which statement shall be conclusive and binding upon all parties hereto
absent manifest error.

 

Section
2.15           Taxes;
Withholding, etc. 

 

(a)           For
purpose of this Section, the term “applicable law” includes FATCA.

 

    - 43 - 

     

    

 

(b)           Withholding
of Taxes. All sums payable by or on account of any Obligation of any Loan Party hereunder and under the other Loan Documents
shall (except to the extent required by applicable law) be paid free and clear of, and without any deduction or withholding on
account of, any Tax, other than, to the extent required by applicable law, any of the following Taxes imposed on or with respect
to a Recipient or required to be withheld or deducted from a payment to a Recipient: (i) Taxes imposed on or measured by the Recipient's
net income (however denominated), franchise Taxes, and branch profits Taxes, imposed on the Recipient, in each case, (A) by the
jurisdiction (or any political subdivision thereof) under the laws of which such Recipient is organized or in which its principal
office is located or, in the case of any Lender, in which its applicable lending office is located or (B) as the result of any
other present or former connection between such Recipient and the jurisdiction imposing such Tax, other than connections arising
from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received
or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document (“Other
Connection Taxes”), (ii) in the case of a Lender, United States federal income withholding Taxes imposed on amounts
payable to or for the account of such Lender with respect to an applicable interest in a Loan or Commitment pursuant to a law
in effect on the date on which such Lender becomes a party hereto (other than pursuant to an assignment request by the Company
under Section 2.18) or such Lender changes its lending office, except that this clause (ii) shall not apply to the
extent that, pursuant to this Section 2.15 amounts with respect to such Taxes were payable either to such Lender's assignor
immediately before such Lender became a party hereto or to such Lender immediately before it changed its lending office, (iii)
Taxes attributable to such recipient Lender's failure to comply with Section 2.15(e) and (iv) withholding Taxes imposed
under FATCA (all such Taxes described in clauses (i)-(iv) above, collectively or individually, “Excluded Taxes”).
If any Loan Party or any other Person is required by law to make any deduction or withholding on account of any Indemnified Tax
from any sum paid or payable by or on account of any obligation of any Loan Party to Administrative Agent or any Lender under
any of the Loan Documents: (1) Company shall notify Administrative Agent of any such requirement or any change in any such requirement
as soon as Company becomes aware of it; (2) Company shall pay any such Tax in accordance with applicable law, such payment
to be made (if the liability to pay is imposed on any Loan Party) for its own account or (if that liability is imposed on Administrative
Agent or such Lender, as the case may be) on behalf of and in the name of Administrative Agent or such Lender; (3) the sum payable
by such Loan Party shall be increased to the extent necessary to ensure that, after the making of that deduction, withholding
or payment (including such deductions or withholdings applicable to additional sums payable under this Section), Administrative
Agent or such Lender, as the case may be, receives on the due date a net sum equal to what it would have received had no such
deduction, withholding or payment been required or made; and (4) within thirty days after paying any sum from which it is required
by law to make any deduction or withholding, Company shall deliver to Administrative Agent evidence satisfactory to the other
affected parties of such deduction, withholding or payment and of the remittance thereof to the relevant taxing or other authority.

 

(c)           Other
Taxes. The Loan Parties shall pay to the relevant Governmental Authorities any present or future stamp, court, intangible,
recording, filing or similar Taxes or documentary Taxes or any other excise or property Taxes that arise from any payment made
hereunder or from the execution, delivery or registration, performance or enforcement of, or from the receipt or perfection of
a security interest under or otherwise with respect to, this Agreement or any other Loan Document (“Other
Taxes”), provided that the definition of “Other Taxes” shall exclude Taxes that are Other Connection
Taxes imposed with respect to an assignment (other than an assignment made pursuant to Section 2.18). Within thirty days
after paying any such Other Taxes, each Loan Party shall deliver to Administrative Agent and any Lender evidence satisfactory
to Administrative Agent and Lenders that such Other Taxes have been paid to the relevant Governmental Authority.

 

(d)           Tax
Indemnification. The Loan Parties hereby jointly and severally indemnify and agree to hold Administrative Agent and Lender
harmless from and against all Indemnified Taxes (including, without limitation, Indemnified Taxes imposed or asserted on or attributable
to any amounts payable under this Section 2.15) paid by Administrative Agent or Lender or required to be withheld or deducted
from a payment to Administrative Agent or such Lender and any reasonable expenses arising therefrom or with respect thereto, whether
or not such Indemnified Taxes were correctly or legally asserted. Such indemnification shall be paid within ten days from the
date on which Administrative Agent or Lender makes written demand therefor specifying in reasonable detail the nature and amount
of such Indemnified Taxes and such written demand shall be conclusive absent manifest error.

 

    - 44 - 

     

    

 

(e)           Evidence
of Exemption From or Reduction of U.S. Withholding Tax.

 

(i)       Any
Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments under any Loan Document
shall deliver to Company and Administrative Agent, at the time or times reasonably requested by Company or Administrative Agent,
properly completed and executed documentation reasonably requested by Company or Administrative Agent as will permit such payments
to be made without, or at a reduced rate, of withholding. In addition, any Lender, if reasonably requested by Company or Administrative
Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by Company or Administrative
Agent to enable them to determine whether such Lender is subject to backup withholding or information reporting requirements.

 

(ii)       Each
Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document
that is not a United States person (as such term is defined in Section 7701(a)(30) of the Internal Revenue Code) for United States
federal income tax purposes (a “Non-US Lender”) shall deliver to Administrative
Agent and Company, on or about the Closing Date (in the case of each Lender listed on the signature pages hereof on the Closing
Date) or on or about the date such Person becomes a Lender hereunder, and at such other times as may be necessary in the determination
of Administrative Agent or Company (in its reasonable exercise of its discretion), (i) two original copies of Internal Revenue
Service Form W-8IMY (with appropriate attachments), W-8BEN, W-8BEN-E or W-8ECI (or any successor forms), as applicable, properly
completed and duly executed by such Lender to establish that such Lender is not subject to, or eligible for a reduction of, deduction
or withholding of United States federal income Tax with respect to any payments to such Lender of principal, interest, fees or
other amounts payable under any of the Loan Documents, and (ii) if such Lender is claiming exemption from United States federal
income Tax under Section 871(h) or 881(c) of the Internal Revenue Code, a Certificate Regarding Non-Bank Status (to the effect
that such Non-US Lender is not a “bank” within the meaning of Section 881(c)(3)(A) of the Internal Revenue Code, a
“10 percent shareholder” of the Borrower within the meaning of Section 871(h)(3)(B) of the Internal Revenue Code,
or a “controlled foreign corporation” described in Section 881(c)(3)(C) of the Internal Revenue Code), properly completed
and duly executed by such Lender. Each Lender required to deliver any forms or certificates with respect to United States federal
income Tax withholding matters pursuant to this Section 2.15(e) hereby agrees, from time to time after the initial delivery
by such Lender of such forms or certificates, whenever a lapse in time or change in circumstances renders such forms or certificates
obsolete or inaccurate in any material respect, that such Lender shall deliver to Administrative Agent and Company, two new original
copies of Internal Revenue Service Form W-8IMY (with appropriate attachments thereto), W-8BEN, W-8BEN-E or W-8ECI, as applicable,
and, if applicable, a Certificate Regarding Non-Bank Status (or any successor forms), and other supplementary documentation reasonably
requested by Borrower or Administrative Agent, as the case may be, properly completed and duly executed by such Lender, or notify
Administrative Agent and Company of its legal inability to deliver any such forms or certificates. Notwithstanding the above,
a Non-US Lender shall not be required to deliver any form pursuant to Section 2.15(e)(ii) that such Non-US Lender is not
legally able to deliver.

 

(iii)       If
a payment made to a Lender under any Loan Document would be subject to United States federal withholding Tax imposed by FATCA
if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section
1471(b) or 1472(b) of the Internal Revenue Code, as applicable), such Lender shall deliver to Company and Administrative Agent
at the time or times prescribed by law and at such time or times reasonably requested by Company or Administrative Agent such
documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Internal Revenue Code)
and such additional documentation reasonably requested by Company or Administrative Agent as may be necessary for Company and
Administrative Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender's
obligations under FATCA or to determine the amount, if any, to deduct and withhold from such payment. Solely for purposes of this
Section 2.15(e)(iii), FATCA shall include any amendments made to FATCA after the date of this Agreement. Notwithstanding
the above, a Lender shall not be required to deliver any form or other form of documentation pursuant to this Section 2.15(e)(iii)
that such Non-US Lender is not legally able to deliver.

 

    - 45 - 

     

    

 

(iv)       Each
Lender that is a United States person (as such term is defined in Section 7701(a)(30) of the Internal Revenue Code) for United
States federal income Tax purposes shall deliver to Administrative Agent and Company, on or about the Closing Date (in the case
of each such Lender listed on the signature pages hereof on the Closing Date) or on or about the date such Person becomes a Lender
hereunder, and at such other times as may be necessary in the determination of Administrative Agent or Company (in its reasonable
exercise of its discretion), two original copies of Internal Revenue Service Form W-9 (or any successor forms) properly completed
and duly executed by such Lender to establish that such Lender is not subject to United States backup withholding Taxes with respect
to any payments to such Lender of principal, interest, fees or other amounts payable under any of the Loan Documents.

 

(f)           Treatment
of Certain Refunds. If a recipient determines in its discretion exercised in good faith that it has received a refund of any
Taxes (including any Tax credit in lieu of a refund) that were indemnified by any Loan Party or with respect to which a Loan Party
paid additional amounts pursuant to this Section, it shall pay the amount equal to such refund to the applicable Loan Party (but
only to the extent of indemnity payments or additional amounts actually paid by such Loan Party with respect to the Taxes giving
rise to the refund), net of all out-of-pocket expenses (including Taxes) incurred by such recipient and without interest (other
than interest paid by the relevant Governmental Authority with respect to such refund). Loan Parties shall, upon request by the
recipient, repay to the recipient such amount paid over to such Loan Party (plus any penalties, interest or other charges imposed
by the relevant Governmental Authority) if the recipient is required to repay such refund to the Governmental Authority. Notwithstanding
anything herein to the contrary, no recipient shall be required to pay any amount to a Loan Party if such payment would place
it in a less favorable net after-Tax position than it would have been in if the Tax subject to indemnification and giving rise
to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with
respect to such Tax had never been paid. In no event shall Administrative Agent or any Lender be required to make its Tax returns
(or any other information relating to its Taxes that it deems confidential) available to any Loan Party.

 

(g)           Survival.
Each party's obligations under this Section 2.15 shall survive the resignation or replacement of Administrative Agent or
any assignment of rights by or replacement of a Lender, the termination of the Loan or Commitment, and the repayment, satisfaction,
discharge or full payment of any obligations under any Loan Document.

 

Section
2.16          Obligation
to Mitigate. Each Lender agrees that after the officer of such Lender responsible for administering its Term Loans becomes
aware of the occurrence of an event or the existence of a condition that would cause such Lender to become an Affected Lender
or that would entitle such Lender to receive payments under Section 2.13, 2.14, 2.15 or 2.19, it will,
to the extent not inconsistent with the internal policies of such Lender and any applicable legal or regulatory restrictions,
and to the extent it would not subject such Lender to any unreimbursed cost or expense and would not otherwise be disadvantageous
to such Lender, use reasonable efforts to (a) make, issue, fund or maintain its Credit Extensions, including any Affected
Loans, through another office of such Lender, or (b) take such other measures as such Lender may deem reasonable, if as a result
thereof the circumstances which would cause such Lender to be an Affected Lender would cease to exist or the additional amounts
which would otherwise be required to be paid to such Lender pursuant to Section 2.13, 2.14, 2.15 or 2.19
would be materially reduced and if, as determined by such Lender in its sole discretion exercised in good faith, the making,
issuing, funding or maintaining of such Term Loans through such other office or in accordance with such other measures, as the
case may be, would not otherwise adversely affect such Term Loans or the interests of such Lender; provided, such Lender
will not be obligated to utilize such other office pursuant to this Section 2.16 unless Company agrees to pay all reasonable
incremental expenses incurred by such Lender as a result of utilizing such other office as described above. A certificate as to
the amount of any such expenses payable by Company pursuant to this Section 2.16 (setting forth in reasonable detail the
basis for requesting such amount) submitted by such Lender to Company (with a copy to Administrative Agent) shall be conclusive
absent manifest error.

 

    - 46 - 

     

    

 

Section
2.17          Defaulting
Lenders. Anything contained herein to the contrary notwithstanding, in the event that any Lender violates any provision of
Section 9.5(c), or, other than at the direction or request of any regulatory agency or authority having appropriate jurisdiction,
defaults (in each case, a “Defaulting Lender”) in its obligation to
fund (a “Funding Default”) a Term Loan (in each case, a “Defaulted Loan”), then (a) during
any Default Period with respect to such Defaulting Lender, such Defaulting Lender shall be deemed not to be a “Lender”
for purposes of voting on any matters (including the granting of any consents or waivers) with respect to any of the Loan Documents;
and (b) to the extent permitted by applicable law, until such time as the Default Excess, if any, with respect to such Defaulting
Lender shall have been reduced to zero, (i) any voluntary prepayment of the Term Loans shall, if Administrative Agent so directs
at the time of making such voluntary prepayment, be applied to Term Loans of other Lenders as if such Defaulting Lender had no
Term Loans outstanding and the outstanding Term Loans of such Defaulting Lender were zero, and (ii) any mandatory prepayment of
the Term Loans shall, if Administrative Agent so directs at the time of making such mandatory prepayment, be applied to the Term
Loans of other Lenders (but not to the Term Loans of such Defaulting Lender) as if such Defaulting Lender had funded all Defaulted
Loans of such Defaulting Lender, it being understood and agreed that Company shall be entitled to retain any portion of any mandatory
prepayment of the Term Loans that is not paid to such Defaulting Lender solely as a result of the operation of the provisions
of this clause (b). No Term Loan Commitment of any Lender shall be increased or otherwise affected, and, except as otherwise
expressly provided in this Section 2.17, performance by Company of its obligations hereunder and the other Loan Documents
shall not be excused or otherwise modified as a result of any Funding Default or the operation of this Section 2.17. The
rights and remedies against a Defaulting Lender under this Section 2.17 are in addition to other rights and remedies which
Company may have against such Defaulting Lender with respect to any Funding Default and which Administrative Agent or any Lender
may have against such Defaulting Lender with respect to any Funding Default or violation of Section 9.5(c).

 

Section
2.18           Removal
or Replacement of a Lender. Anything contained herein to the contrary notwithstanding, in the event that: (a) (i) any Lender
(an “Increased Cost Lender”) shall give notice to Company that such
Lender is an Affected Lender or that such Lender is entitled to receive payments under Section 2.14, 2.15 or 2.16,
(ii) the circumstances which have caused such Lender to be an Affected Lender or which entitle such Lender to receive such payments
shall remain in effect, and (iii) such Lender shall fail to withdraw such notice within five Business Days after Company's request
for such withdrawal; or (b) (i) any Lender shall become a Defaulting Lender, (ii) the Default Period for such Defaulting Lender
shall remain in effect, and (iii) such Defaulting Lender shall fail to cure the default as a result of which it has become a Defaulting
Lender within five Business Days after Company's request that it cure such default; or (c) in connection with any proposed amendment,
modification, termination, waiver or consent with respect to any of the provisions hereof as contemplated by Section 10.5(b),
the consent of Administrative Agent and Required Lenders shall have been obtained but the consent of one or more of such other
Lenders (each a “Non-Consenting Lender”) whose consent is required
shall not have been obtained; then, with respect to each such Increased Cost Lender, Defaulting Lender or Non-Consenting Lender
(the “Terminated Lender”), Administrative Agent may (which, in the
case of an Increased-Cost Lender, only after receiving written request from Company to remove such Increased-Cost Lender), by
giving written notice to Company and any Terminated Lender of its election to do so, elect to cause such Terminated Lender (and
such Terminated Lender hereby irrevocably agrees) to assign its outstanding Term Loans in full to one or more Eligible Assignees
(each a “Replacement Lender”) in accordance with the provisions of
Section 10.6 and Terminated Lender shall pay any fees payable thereunder in connection with such assignment; provided,
(1) on the date of such assignment, the Replacement Lender shall pay to Terminated Lender an amount equal to the sum of (A) an
amount equal to the principal of, and all accrued interest on, all outstanding Loans of the Terminated Lender and (B) an amount
equal to all accrued, but theretofore unpaid fees owing to such Terminated Lender pursuant to Section 2.7 (except for any
Prepayment Premium (as defined in the Fee Letter)); (2) on the date of such assignment, Company shall pay any amounts payable
to such Terminated Lender pursuant to Section 2.14 or 2.15 (except for any Prepayment Premium (as defined in the
Fee Letter)); and (3) in the event such Terminated Lender is a Non-Consenting Lender, each Replacement Lender shall consent, at
the time of such assignment, to each matter in respect of which such Terminated Lender was a Non-Consenting Lender. Upon the prepayment
of all amounts owing to any Terminated Lender, such Terminated Lender shall no longer constitute a “Lender” for purposes
hereof; provided, any rights of such Terminated Lender to indemnification hereunder shall survive as to such Terminated
Lender.

 

    - 47 - 

     

    

 

Section
2.19           Making
or Maintaining LIBOR Rate Loans.

 

(a)           Inability
to Determine Applicable Interest Rate. In the event that Administrative Agent shall have made good faith efforts to implement
an Alternate Benchmark Rate and Administrative Agent shall have reasonably determined (which determination shall be final and
conclusive and binding upon all parties hereto), on any Interest Rate Determination Date with respect to any LIBOR Rate Loans,
that by reason of circumstances affecting the London interbank market adequate and fair means do not exist for ascertaining the
interest rate applicable to such LIBOR Rate Loans on the basis provided for in the definition of Adjusted LIBOR Rate, Administrative
Agent shall on such date give notice (by facsimile or by telephone confirmed in writing) in accordance with Section 10.1
of this Agreement to Company and each Lender of such determination, whereupon (i) no Loans may be made as, or converted to, LIBOR
Rate Loans until such time as Administrative Agent notifies Company and Lenders that the circumstances giving rise to such notice
no longer exist, and (ii) any Funding Notice or Conversion/Continuation Notice given by Company with respect to the Loans in respect
of which such determination was made shall be deemed to be rescinded by Company.

 

(b)           Illegality
or Impracticability of LIBOR Rate Loans. In the event that on any date any Lender shall have reasonably determined (which
determination shall be final and conclusive and binding upon all parties hereto but shall be made only after consultation with
Company and Administrative Agent) that the making, maintaining or continuation of its LIBOR Rate Loans (i) has become unlawful
as a result of compliance by such Lender in good faith with any law, treaty, governmental rule, regulation, guideline or order
(or would conflict with any such treaty, governmental rule, regulation, guideline or order not having the force of law even though
the failure to comply therewith would not be unlawful), or (ii) has become impracticable, as a result of contingencies occurring
after the date hereof which materially and adversely affect the London interbank market or the position of such Lender in that
market, then, and in any such event, such Lender shall be an “Affected Lender” and it shall on that day give
notice (by facsimile or by telephone confirmed in writing) in accordance with Section 10.1 of this Agreement to Company
and Administrative Agent of such determination (which notice Administrative Agent shall promptly transmit to each other Lender).
Thereafter (A) the obligation of the Affected Lender to make Loans as, or to convert Loans to, LIBOR Rate Loans shall be suspended
until such notice shall be withdrawn by the Affected Lender, (B) to the extent such determination by the Affected Lender relates
to a LIBOR Rate Loan then being requested by Company pursuant to a Funding Notice or a Conversion/Continuation Notice, the Affected
Lender shall make such Loan as (or continue such Loan as or convert such Loan to, as the case may be) a Base Rate Loan, (C) the
Affected Lender's obligation to maintain its outstanding LIBOR Rate Loans (the “Affected Loans”) shall be terminated
at the earlier to occur of the expiration of the Interest Period then in effect with respect to the Affected Loans or when required
by law, and (D) the Affected Loans shall automatically convert into Base Rate Loans on the date of such termination. Notwithstanding
the foregoing, to the extent a determination by an Affected Lender as described above relates to a LIBOR Rate Loan then being
requested by Company pursuant to a Funding Notice or a Conversion/Continuation Notice, Company shall have the option, subject
to the provisions of Section 2.19(c), to rescind such Funding Notice or Conversion/Continuation Notice as to all Lenders
by giving written notice to Administrative Agent of such rescission on the date on which the Affected Lender gives notice of its
determination as described above (which notice of rescission Administrative Agent shall promptly transmit to each other Lender).
Except as provided in the immediately preceding sentence, nothing in this Section 2.19(b) shall affect the obligation of
any Lender other than an Affected Lender to make or maintain Loans as, or to convert Loans to, LIBOR Rate Loans in accordance
with the terms hereof.

 

    - 48 - 

     

    

 

(c)           Compensation
for Breakage or Non-Commencement of Interest Periods. Company shall compensate each Lender, upon written request by such Lender
(which request shall set forth the basis for requesting such amounts), for all reasonable losses, expenses and liabilities (including
any interest paid or calculated to be due and payable by such Lender to lenders of funds borrowed by it to make or carry its LIBOR
Rate Loans and any loss, expense or liability sustained by such Lender in connection with the liquidation or re-employment of
such funds but excluding loss of anticipated profits) which such Lender may sustain: (i) if for any reason (other than a default
by such Lender) a borrowing of any LIBOR Rate Loan does not occur on a date specified therefor in a Funding Notice, or a conversion
to or continuation of any LIBOR Rate Loan does not occur on a date specified therefor in a Conversion/Continuation Notice; (ii)
if any prepayment or other principal payment of, or any conversion of, any of its LIBOR Rate Loans occurs on any day other than
the last day of an Interest Period applicable to that Loan (whether voluntary, mandatory, automatic, by reason of acceleration,
or otherwise); or (iii) if any prepayment of any of its LIBOR Rate Loans is not made on any date specified in a notice of prepayment
given by Company.

 

(d)           Booking
of LIBOR Rate Loans. Any Lender may make, carry or transfer LIBOR Rate Loans at, to, or for the account of any of its branch
offices or the office of an Affiliate of such Lender.

 

(e)           Assumptions
Concerning Funding of LIBOR Rate Loans. Calculation of all amounts payable to a Lender under this Section 2.19 and
under Section 2.14 shall be made as though such Lender had actually funded each of its relevant LIBOR Rate Loans through
the purchase of a LIBOR deposit bearing interest at the rate obtained pursuant to clause (a)(i) of the definition of Adjusted
LIBOR Rate in an amount equal to the amount of such LIBOR Rate Loan and having a maturity comparable to the relevant Interest
Period and through the transfer of such LIBOR deposit from an offshore office of such Lender to a domestic office of such Lender
in the United States of America; provided, however, each Lender may fund each of its LIBOR Rate Loans in any manner
it sees fit and the foregoing assumptions shall be utilized only for the purposes of calculating amounts payable under this Section
2.19 and under Section 2.14.

 

(f)           
Provisions with Respect to LIBOR. If prior to the commencement of any Interest Period for any LIBOR Rate Loan,

 

(i)       the
Administrative Agent shall have reasonably determined that adequate and reasonable means do not exist for ascertaining LIBOR for
such Interest Period, including, without limitation, because the Administrative Agent reasonably determines that either inadequate
or insufficient quotations of the London interbank offered rate exist or the use of “LIBOR” has been discontinued
(any determination of Administrative Agent to be conclusive and binding absent manifest error), or

 

    - 49 - 

     

    

 

(ii)       the
Administrative Agent shall have received notice from the Required Lenders that LIBOR does not adequately and fairly reflect the
cost to such Lenders of making, funding or maintaining their LIBOR Rate Loans for such Interest Period,

 

then
the Administrative Agent shall give written notice to Borrower and to the Lenders as soon as practicable thereafter. Until the
Administrative Agent shall notify Borrower and the Lenders that the circumstances giving rise to such notice no longer exist,
(A) the obligations of the Lenders to make LIBOR Rate Loans, or to continue or convert outstanding Loans as or into LIBOR Rate
Loans, shall be suspended and (B) all such affected Loans shall be converted into Base Rate Loans on the last day of the then
current Interest Period applicable thereto.

  

Article
III

CONDITIONS PRECEDENT

 

Section
3.1            Closing
Date. The obligation of each Lender to make a Credit Extension on the Closing Date is subject to the satisfaction, or waiver
in accordance with Section 10.5, of the following conditions on or before the Closing Date:

 

(a)           Loan
Documents. Administrative Agent shall have received copies of each Loan Document originally executed and delivered by each
applicable Loan Party for each Lender party to this Agreement on the Closing Date.

 

(b)           Organizational
Documents; Incumbency. Administrative Agent shall have received a Secretary's Certificate for each Loan Party attaching (i)
copies of each Organizational Document of such Loan Party and, to the extent applicable, certified as of a recent date by the
appropriate governmental official, each dated the Closing Date or a recent date prior thereto; (ii) signature and incumbency certificates
of the officers of such Person executing the Loan Documents to which it is a party; (iii) resolutions of the Board of Directors
or similar governing body of such Loan Party approving and authorizing the execution, delivery and performance of this Agreement
and the other Loan Documents to which it is a party or by which it or its assets may be bound as of the Closing Date, certified
as of the Closing Date by its secretary or an assistant secretary (or other duly authorized officer) as being in full force and
effect without modification or amendment; (iv) a good standing certificate from the applicable Governmental Authority (A) of such
Loan Party's jurisdiction of incorporation, organization or formation and (B) in each jurisdiction in which it is qualified as
a foreign corporation or other entity to do business (solely in the case of this subclause (B), except in jurisdictions where
the failure to be so qualified or in good standing has not had, and would not be reasonably expected to have, a Material Adverse
Effect), each dated a recent date prior to the Closing Date; and (v) such other documents as Administrative Agent may reasonably
request.

 

(c)           Organizational
and Capital Structure. The organizational structure and capital structure of Borrower and its Subsidiaries shall be as set
forth on Schedule 4.2.

 

(d)           Sources
and Uses. On or prior to the Closing Date, Company shall have delivered to Administrative Agent Company's reasonable best
estimate of all sources and uses of Cash and other proceeds of Term Loans on the Closing Date.

 

(e)           Governmental
Authorizations and Consents. Each Loan Party shall have obtained all Governmental Authorizations and all consents of other
Persons, in each case that are necessary in connection with the transactions contemplated by the Loan Documents and each of the
foregoing shall be in full force and effect and in form and substance reasonably satisfactory to Administrative Agent.

 

    - 50 - 

     

    

 

(f)           
Personal Property Collateral. In order to create in favor of Administrative Agent, for the benefit of Secured Parties,
a valid, perfected first priority security interest (subject to any exceptions permitted in the Collateral Documents) in the personal
property Collateral, Administrative Agent shall have received:

 

(i)       evidence
reasonably satisfactory to Administrative Agent of the compliance by each Loan Party of their obligations under the Pledge and
Security Agreement and the other Collateral Documents (including, without limitation, their obligations to authorize or execute,
as the case may be as required under the applicable Collateral Documents, and deliver UCC financing statements, originals of securities
(including stock certificates, if any, representing pledged Capital Stock along with appropriate endorsements), instruments and
chattel paper, and any agreements governing deposit and/or securities accounts as provided therein and a duly executed authorization
to pre-file UCC-1 financing statements which is effective as of the Closing Date), together with appropriate financing statements
on Form UCC-1 in form for filing in such office or offices as may be necessary or, in the reasonable discretion of Administrative
Agent, desirable to perfect the security interests purported to be created by each Pledge and Security Agreement and (B) evidence
reasonably satisfactory to Administrative Agent of filing of such UCC-1 financing statements; provided, that such evidence
of filing will not require the receipt on the Closing Date of certified copies of the filed UCC-1 financing statements;

 

(ii)       a
completed Perfection Certificate dated the Closing Date and executed by an Authorized Officer of each Loan Party, together with
all attachments contemplated thereby, including the results of a recent search, by a Person satisfactory to Administrative Agent,
of all effective UCC financing statements (or equivalent filings) made with respect to any assets or property of any Loan Party
in the jurisdictions specified in the Perfection Certificate, together with copies of all such filings disclosed by such search;
and

 

(iii)       evidence
that each Loan Party shall have taken or caused to be taken any other action, executed and delivered or caused to be executed
and delivered any other agreement, document and instrument (including, without limitation, evidence that Bank of America, N.A.
has agreed to the forms of, and is prepared to sign on or promptly after the Closing Date, one or more Control Agreements in respect
of the Specified Deposit Accounts) and made or caused to be made any other filing and recording reasonably required by Administrative
Agent, in each case, to the extent required by, and subject to the terms and conditions of, the Pledge and Security Agreement
or any other Collateral Document in effect on the Closing Date.

 

(g)           Financial
Statements. Lenders shall have received from Borrower (i) the Historical Financial Statements (it being agreed that the financial
statement for the month ended March 31, 2019 shall, if not available prior to the Closing Date, be delivered to Administrative
Agent promptly upon it becoming available after the Closing Date) and (ii) pro forma consolidated balance sheets of Borrower and
its Subsidiaries as at the Closing Date, and reflecting the transactions contemplated by the Loan Documents to occur on or prior
to the Closing Date, which pro forma financial statements shall be in form and substance reasonably satisfactory to Administrative
Agent.

 

(h)           Evidence
of Insurance. Administrative Agent shall have received a certificate from Company's insurance broker or other evidence reasonably
satisfactory to it that all insurance required to be maintained pursuant to Section 5.5 is in full force and effect.

 

    - 51 - 

     

    

 

(i)           
Opinions of Counsel to Loan Parties. The
Administrative Agent and its counsel shall have received copies of originally executed written opinions of DLA Piper LLP (US),
counsel for Loan Parties, and such other applicable counsel for Loan Parties, dated as of the Closing Date and otherwise in form
and substance reasonably satisfactory to Administrative Agent (and each Loan Party hereby instructs each such counsel to deliver
such opinions to Administrative Agent and Lenders).

 

(j)           
Fees. Substantially contemporaneously with the initial funding of the Term Loan on the Closing Date, Company shall have
paid to Administrative Agent, the fees and expenses then due and payable pursuant to Section 2.7 and Section 10.2.

 

(k)           Solvency
Certificate. On the Closing Date, Administrative Agent shall have received a Solvency Certificate of the chief financial officer
(or other substantially similar title) of Borrower substantially in the form of Exhibit F, dated as of the Closing Date
and addressed to Administrative Agent and Lenders.

 

(l)           
Closing Date Certificate. Company shall
have delivered to Administrative Agent an originally executed copy of the Closing Date Certificate, together with copies of all
attachments thereto.

 

(m)           No
Litigation. There shall not exist any action, suit, investigation, litigation or proceeding or other legal or regulatory developments
(including any Regulatory Action), pending or threatened in any court or before any arbitrator or Governmental Authority that
singly or in the aggregate, would have a Material Adverse Effect or would result in any Material Regulatory Liability.

 

(n)           Minimum
Qualified Cash. Administrative Agent shall have received evidence reasonably satisfactory to it that the Company shall have
unrestricted Cash and Cash Equivalents (other than restrictions created by the Collateral Documents) of at least $50,000,000 immediately
after giving effect to any Credit Extensions to be made on the Closing Date, including the payment of all Transaction Costs required
to be paid in Cash on the Closing Date.

 

(o)           No
Material Adverse Effect. Since December 31, 2018, no event, circumstance or change shall have occurred that has caused or
has resulted in, either in any case or in the aggregate, a Material Adverse Effect.

 

(p)           Completion
of Proceedings. All partnership, corporate and other proceedings taken or to be taken in connection with the transactions
contemplated hereby and all documents incidental thereto not previously found reasonably acceptable by Administrative Agent and
its counsel and communicated in writing to the Loan Parties and their counsel as such shall be reasonably satisfactory in form
and substance to Administrative Agent and such counsel.

 

(q)           Bank
Regulations. Administrative Agent shall have received all documentation and other information reasonably requested that is
required by bank regulatory authorities under applicable “know-your-customer” and anti-money laundering rules and
regulations, including the Patriot Act, and all such documentation and other information shall be in form and substance reasonably
satisfactory to the Administrative Agent.

 

(r)           Funding
Notice. Administrative Agent shall have received a fully executed and delivered Funding Notice.

 

(s)           Representations
and Warranties. The representations and warranties contained herein and in each other Loan Document or certificate delivered
to Administrative Agent or any Lender pursuant hereto or thereto on or prior to the date hereof shall be true and correct in all
material respects (except that such materiality qualifier shall not be applicable to any representations or warranties that already
are qualified or modified as to “materiality” or “Material Adverse Effect” in the text thereof, which
representations and warranties shall be true and correct in all respects subject to such qualification) on and as the date hereof
to the same extent as though made on and as of that date, except to the extent such representations and warranties specifically
relate to an earlier date, in which case such representations and warranties shall have been true and correct in all material
respects (except that such materiality qualifier shall not be applicable to any representations or warranties that already are
qualified or modified as to “materiality” or “Material Adverse Effect” in the text thereof, which representations
and warranties shall be true and correct in all respects subject to such qualification) on and as of such earlier date.

 

    - 52 - 

     

    

 

(t)           No
Default or Event of Default. No event shall have occurred and be continuing or would result from the consummation of the transactions
contemplated herein that would constitute an Event of Default or a Default.

 

(u)           No
Contravention. The making of the Term Loan shall not contravene any law, rule or regulation of any Governmental Authority
having appropriate jurisdiction over the Administrative Agent or any Lender that is applicable to Administrative Agent or any
Lender.

 

(v)           Existing
Indebtedness. Substantially contemporaneously with the initial funding of the Term Loan on the Closing Date, Borrower and
its Subsidiaries shall have (i) repaid in full all Existing Indebtedness, (ii) terminated any commitments to lend or make other
extensions of credit thereunder, and (iii) delivered to Administrative Agent all documents or instruments necessary to release
all Liens securing Existing Indebtedness or other obligations of Borrower and its Subsidiaries thereunder being repaid on the
Closing Date.

 

(w)           Registrations.
All Registrations from the FDA in respect of the Products shall be valid and subsisting and in full force and effect.

 

Each
Lender, by delivering its signature page to this Agreement and funding the Term Loan on the Closing Date, shall be deemed to have
acknowledged receipt of, and consented to and approved, each Loan Document and each other document, instrument or agreement required
to be approved by Administrative Agent, Required Lenders and/or Lenders, as applicable, on the Closing Date.

 

Section
3.2           Conditions
to Each Credit Extension.

 

(a)           Conditions
Precedent. The obligation of each Lender to make any Loan on any date following the Closing Date is subject to the satisfaction,
or waiver in accordance with Section 10.5, of the following conditions precedent:

 

(i)       Administrative
Agent shall have received a fully executed and delivered Funding Notice;

 

(ii)       as
of such Credit Date, the representations and warranties contained herein and in each other Loan Document or certificate delivered
to any Agent or any Lender pursuant hereto or thereto on or prior to the Credit Date shall be true and correct in all material
respects (except that such materiality qualifier shall not be applicable to any representations or warranties that already are
qualified or modified as to “materiality” or “Material Adverse Effect” in the text thereof, which representations
and warranties shall be true and correct in all respects subject to such qualification) on and as of that Credit Date to the same
extent as though made on and as of that date, except to the extent such representations and warranties specifically relate to
an earlier date, in which case such representations and warranties shall have been true and correct in all material respects (except
that such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified
as to “materiality” or “Material Adverse Effect” in the text thereof, which representations and warranties
shall be true and correct in all respects subject to such qualification) on and as of such earlier date;

 

    - 53 - 

     

    

 

(iii)       as
of such Credit Date, no event shall have occurred and be continuing or would result from the consummation of the applicable Credit
Extension that would constitute an Event of Default or a Default;

 

(iv)       Administrative
Agent shall have received evidence reasonably satisfactory to it that the Company shall have unrestricted Cash and Cash Equivalents
(other than restrictions created by the Collateral Documents) of at least $60,000,000 immediately after giving effect to any Credit
Extensions to be made on such Credit Date;

 

(v)       solely
in respect of any Delayed Draw A-1 Term Loan, Company shall have delivered, on or prior to December 31, 2019, evidence demonstrating
[***]; and

 

(vi)       solely
in respect of any Delayed Draw A-2 Term Loan, the Chief Financial Officer of Company shall have delivered a certificate (together
with such other evidence as is reasonably requested by Administrative Agent) representing and warranting, and otherwise demonstrating
to the reasonable satisfaction of Administrative Agent, that the Product Revenue for the Fiscal Quarter ending December 31, 2019
is greater than $11,000,000.

 

(b)           Notices.
Any Notice shall be executed by an Authorized Officer of Company in a writing delivered to Administrative Agent.

 

Article
IV

REPRESENTATIONS AND WARRANTIES

 

In
order to induce Agents and Lenders to enter into this Agreement and to make each Credit Extension to be made thereby, each Loan
Party represents and warrants to each Agent and Lender, on the Closing Date and on each Credit Date, that the following statements
are true and correct:

 

Section
4.1            Organization;
Requisite Power and Authority; Qualification. Each of Borrower and its Subsidiaries (a) is duly organized, validly existing
and in good standing under the laws of its jurisdiction of organization as identified in Schedule 4.1, (b) has all requisite
corporate power and authority to own and operate its properties, to carry on its business as now conducted and as proposed to
be conducted, to enter into the Loan Documents to which it is a party and to carry out the transactions contemplated thereby and,
in the case of Company, to make the borrowings hereunder, and (c) is qualified to do business and in good standing in every jurisdiction
wherever necessary to carry out its business and operations, except in jurisdictions where the failure to be so qualified or in
good standing has not had, and would not be reasonably expected to have, a Material Adverse Effect.

 

Section
4.2            Capital Stock and Ownership. The Capital Stock of
each of Borrower and its Subsidiaries has been duly authorized and validly issued and, if applicable, is fully paid and non-assessable.
Except as set forth on Schedule 4.2, as of the date hereof, there is no existing option, warrant, call, right, commitment
or other agreement to which Borrower or any of its Subsidiaries is a party requiring, and there is no membership interest or other
Capital Stock of Borrower or any of its Subsidiaries outstanding which upon conversion or exchange would require, the issuance
by Borrower or any of its Subsidiaries of any additional membership interests or other Capital Stock of Borrower or any of its
Subsidiaries or other securities convertible into, exchangeable for or evidencing the right to subscribe for or purchase, a membership
interest or other Capital Stock of Borrower or any of its Subsidiaries. Schedule 4.2 correctly sets forth the ownership
interest of Borrower and each of its Subsidiaries in their respective Subsidiaries.

 

    - 54 - 

     

    

 

Section
4.3           Due
Authorization. The execution, delivery and performance of the Loan Documents have been duly authorized by all necessary corporate
or limited liability, as applicable, action on the part of each Loan Party that is a party thereto.

 

Section
4.4            No
Conflict. The execution, delivery and performance by Loan Parties of the Loan Documents to which they are parties and the
consummation of the transactions contemplated by the Loan Documents do not and will not (a) violate any provision of any law or
any governmental rule or regulation of any Governmental Authority that is applicable to Borrower or any of its Subsidiaries, any
of the Organizational Documents of Borrower or any of its Subsidiaries, or any order, judgment or decree of any court or other
agency of government of any Governmental Authority that is binding on Borrower or any of its Subsidiaries; (b) conflict with,
result in a breach of or constitute (with due notice or lapse of time or both) a default under any material Contractual Obligation
of Borrower or any of its Subsidiaries; (c) result in or require the creation or imposition of any Lien upon any of the properties
or assets of Borrower or any of its Subsidiaries (other than any Liens created under any of the Loan Documents in favor of Administrative
Agent, on behalf of Secured Parties); (d) result in any default, non-compliance, suspension revocation, impairment, forfeiture
or non-renewal of any material permit, license, authorization or approval of any Governmental Authority having appropriate jurisdiction
that is applicable to its operations or any of its properties; or (e) require any approval or consents of stockholders, members
or partners of Borrower or any of its Subsidiaries, except for such approvals or consents which will be obtained on or before
the Closing Date and disclosed in writing to Lenders.

 

Section
4.5            Governmental Consents. The execution, delivery and
performance by Loan Parties of the Loan Documents to which they are parties and the consummation of the transactions contemplated
by the Loan Documents do not and will not require any registration with, consent or approval of, or notice to, or other action
to, with or by, any Governmental Authority except for filings and recordings with respect to the Collateral to be made, or otherwise
delivered to Administrative Agent for filing and/or recordation, as of the Closing Date.

 

Section
4.6            Binding Obligation. Each Loan Document has been duly
executed and delivered by each Loan Party that is a party thereto and is the legally valid and binding obligation of such Loan
Party, enforceable against such Loan Party in accordance with its respective terms, except as may be limited by bankruptcy, insolvency,
reorganization, moratorium or similar laws relating to or limiting creditors' rights generally or by equitable principles relating
to enforceability.

 

Section
4.7           Historical
Financial Statements. The Historical Financial Statements were prepared in conformity with GAAP and fairly present, in all
material respects, the financial position, on a consolidated basis, of the Persons described in such financial statements as at
the respective dates thereof and the results of operations and cash flows, on a consolidated basis, of the entities described
therein for each of the periods then ended, subject, in the case of any such unaudited financial statements, to changes resulting
from audit and normal year end adjustments. As of the Closing Date, neither Borrower nor any of its Subsidiaries has any contingent
liability or liability for taxes, long term lease or unusual forward or long term commitment that is not reflected in the Historical
Financial Statements or the notes thereto and which in any such case is material in relation to the business, operations, properties,
assets, condition (financial or otherwise) or prospects of Borrower and any of its Subsidiaries taken as a whole.

 

Section
4.8           [Reserved].

 

    - 55 - 

     

    

 

Section
4.9          No
Material Adverse Effect. Since December 31, 2018, no event, circumstance or change has occurred or has resulted in, either
in any case or in the aggregate, a Material Adverse Effect.

 

Section
4.10        Adverse
Proceedings, etc. As of the Closing Date, there are no Adverse Proceedings that (a) relate to any Loan Document or the transactions
contemplated hereby or thereby or (b) individually or in the aggregate, could materially impair the Administrative Agent's security
interest in the Collateral, the Borrower's and its Subsidiaries' respective rights, powers or remedies with respect to applicable
Products or would otherwise reasonably be expected to have a Material Adverse Effect. Neither Borrower nor any of its Subsidiaries
is in violation of or in default with respect to any final judgments, writs, injunctions, decrees, rules, laws or regulations
of any Governmental Authority having appropriate jurisdiction except to the extent such violation or default could not reasonably
be expected to result in a Material Adverse Effect.

 

Section
4.11        Payment
of Taxes. Except as otherwise permitted under Section 5.3, all U.S. federal and material state and local income tax
returns and other material reports of Borrower and its Subsidiaries required to be filed by any of them have been timely filed,
all such tax returns are true, complete and correct in all material respects, and all U.S. federal and material state and local
Taxes shown as due and payable on such tax returns and all assessments, fees and other governmental charges upon Borrower and
its Subsidiaries and upon their respective properties, assets, income, businesses and franchises which are due and payable have
been paid when due and payable. Borrower knows of no proposed Tax assessment against Borrower or any of its Subsidiaries which
is not being actively contested by Borrower or such Subsidiary in good faith and by appropriate proceedings; provided,
such reserves or other appropriate provisions, if any, as shall be required in conformity with GAAP shall have been made or provided
therefor.

 

Section
4.12        Properties,
Title. Each of Borrower and its Subsidiaries has (a) good, sufficient, marketable and legal title to (in the case of fee interests
in real property), (b) valid leasehold interests in (in the case of leasehold interests in real or personal property), and (c)
good and valid title to (in the case of all other personal property), all of their respective properties and assets reflected
in their respective Historical Financial Statements referred to in Section 4.7 and in the most recent financial statements
delivered pursuant to Section 5.1, in each case except for (i) assets disposed of since the date of such financial statements
in the ordinary course of business or as otherwise permitted under Section 6.9 or (ii) defects in title or interests
which would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. All such properties
and assets are in working order and condition, ordinary wear and tear excepted, and except as permitted by this Agreement or any
of the Collateral Documents, all such non-leasehold properties and assets are free and clear of Liens. As of the Closing Date,
Schedule 4.12 contains a true, accurate and complete list of all real property owned or leased by Borrower and its Subsidiaries
or where Collateral or books and records are located.

 

Section
4.13        Environmental
Matters. In each case of the following sub-clauses (a)-(d), except as any such failure or exception to the applicable representation
and warranty would not reasonably be expected to result in a Material Adverse Effect:

 

(a)         No
Environmental Claim has been asserted against any Loan Party or any predecessor in interest nor has any Loan Party received notice
of any threatened or pending Environmental Claim against Loan Party or any predecessor in interest.

 

(b)        There
has been no Release of Hazardous Materials and there are no Hazardous Materials present in violation of Environmental Law at any
of the properties currently owned or operated by any Loan Party.

 

     - 56 -

     

    

 

(c)         The
operation of the business of, and each of the properties owned or operated by, each Loan Party are in compliance with all Environmental
Laws.

 

(d)        Each
Loan Party holds and is in compliance Governmental Authorizations required under any Environmental Laws in connection with the
operations carried on by it and the properties owned or operated by it.

 

Section
4.14        No
Defaults. Neither Borrower nor any of its Subsidiaries (a) is in default in the performance, observance or fulfillment of
any of the obligations, covenants or conditions contained in any of its Contractual Obligations, and (b) no condition exists which,
with the giving of notice or the lapse of time or both, could constitute such a default, except , in each case of the foregoing
subclauses (a)-(b), where the consequences, direct or indirect, of such default or defaults, if any, could not reasonably be expected
to have a Material Adverse Effect.

 

Section
4.15        Material
Contracts. 

 

(a)       Schedule 4.15 contains
a true, correct and complete list of all the Material Contracts in effect on the Closing Date, which Material Contracts,
together with any updates provided pursuant to Section 5.1(l), are in full force and effect and no defaults givng any
party thereto the right to terminate such Material Contract currently exist thereunder (other than as described in Schedule
4.15 or in such updates).

 

(b)       Except
as described in Schedule 4.15, each Material Contract is a legal, valid and binding obligation of Borrower, its Subsidiaries
and, to the knowledge of Borrower, each other party thereto, is enforceable in accordance with its terms and is in full force
and effect, subject bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability
relating to or affecting creditors' rights and to general equity principles. Neither the Borrower nor its Subsidiaries, nor to
the knowledge of the Authorized Officers of Borrower or its Subsidiaries, any other party to any Material Contract, is or was
in material breach or default, under the terms of any Material Contract, and no condition existed or exists which, with the giving
of notice or the lapse of time or both, could constitute a material breach or default by Borrower or any of its Subsidiaries thereunder.

 

Section
4.16        Governmental
Regulation. Neither Borrower nor any of its Subsidiaries is subject to regulation under the Public Utility Holding Company
Act of 2005, the Federal Power Act or the Investment Company Act of 1940 or under any other federal or state statute or regulation
which may limit its ability to incur Indebtedness or which may otherwise render all or any portion of the Obligations unenforceable.
Neither Borrower nor any of its Subsidiaries is required to register as a “registered investment company” or a company
“controlled” by a “registered investment company” or a “principal underwriter” of a “registered
investment company” as such terms are defined in the Investment Company Act of 1940.

 

Section
4.17        Margin
Stock. Neither Borrower nor any of its Subsidiaries is engaged principally, or as one of its important activities, in the
business of extending credit for the purpose of purchasing or carrying any Margin Stock. No part of the proceeds of the Term Loans
made to such Loan Party will be used to purchase or carry any such Margin Stock or to extend credit to others for the purpose
of purchasing or carrying any such Margin Stock or for any purpose that violates, or is inconsistent with, the provisions of Regulation
T, U or X of the Board of Governors of the Federal Reserve System.

 

Section
4.18        Employee
Benefit Plans. No ERISA Event has occurred or is reasonably expected to occur that would reasonably be expected to result
in a Material Adverse Effect.

 

     - 57 -

     

    

 

Section
4.19        Certain
Fees. No broker's or finder's fee or commission will be payable with respect hereto or any of the transactions contemplated
hereby.

 

Section
4.20        Solvency.
The Loan Parties, on a consolidated basis, are and, upon the incurrence of the Credit Extension by the applicable Loan Party on
the Closing Date and on each date on which this representation and warranty is made, will be, Solvent.

 

Section
4.21        [Reserved].

 

Section
4.22        Compliance
with Statutes, etc. Each of Borrower and its Subsidiaries is in compliance with (i) its Organizational Documents and (ii)
all applicable laws, statutes, regulations and orders of, and all applicable restrictions imposed by, all Governmental Authorities
having appropriate jurisdiction, in respect of the conduct of its business and the ownership of its property, except such non-compliance
that, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect.

 

Section
4.23        Intellectual
Property.

 

(a)       Each
of Borrower and its Subsidiaries own, or hold licenses in, all trademarks, trade secrets, trade names, copyrights, patents, and
licenses that are necessary to the conduct of its business as currently conducted.

 

(b)       Schedule
4.23(b) sets forth a true, correct and complete listing in all material respects of all U.S. and foreign Product Patents as
of the Closing Date, and identifies the owner of each such Product Patent and the Product to which such Product Patent relates.
As of the Closing Date and except as identified in Schedule 4.23(b), (i) the owner listed on Schedule 4.23(b) for
each Product Patent is the exclusive owner of such patent/application and no Third Party has any right, title, interest or ownership
claim in such Product Patent, (ii) to the best of Borrower's and its Subsidiaries' knowledge, the Product Patents are valid, subsisting,
and enforceable; (iii) except for those patent applications that that are abandoned or lapse, in the case of provisional
patent applications, in the due course of patent prosecution and in accordance with the reasonable business judgment of the Company
and its subsidiaries in executing a comprehensive patent strategy designed to maximize and maintain exclusivity of the Products,
none of the Product Patents have lapsed or been abandoned, cancelled or expired; (iv) Company has taken commercially reasonable
steps to maintain such Product Patents, including by timely filing fees and responses; (v) each individual associated with the
filing and prosecution of the Product Patents, including the named inventors, has complied in all material respects with all applicable
duties of candor and good faith in dealing with any patent office, including the USPTO, in those jurisdictions where such duties
exist.

 

(c)       As
of the Closing Date, Schedule 4.23(c) sets forth a true, correct and complete listing, under separate headings, of all
material written Contractual Obligations (i) under which Company or its Subsidiaries uses or licenses any Product Patents that
any other Person owns, or owes any royalties or other payments to any Person for the use of any Product Patents, (ii) under which
Company or its Subsidiaries have granted any Person any right or interest in any Product Patents, and (iii) that otherwise limit
the Company or its Subsidiaries' use of or rights in the Product Patents (including co-existence agreements and covenants not
to sue). Company may update this list to add additional licenses, so long as such amendment occurs by written notice to Administrative
Agent, and subject to Company's obligations and restrictions under this Agreement.

 

(d)       There
is no opposition, interference, reexamination, derivation or other post-grant proceeding, injunction, claim, suit, action, subpoena,
hearing, inquiry, investigation (by the International Trade Commission or otherwise), complaint, arbitration, mediation, demand,
decree or other dispute, disagreement, proceeding or claim (collectively, “Disputes”) that is pending or currently
threatened in writing, that challenges the scope, validity, enforceability, ownership, or inventorship of the Product Patents.
Company and its Subsidiaries have not received any written notice that there is any, and to the knowledge of the Authorized Officers
of the Borrower and its Subsidiaries there is no, Person who is or claims to be an inventor under any of the Product Patents who
is not a named inventor thereof.

 

     - 58 -

     

    

 

(e)       To
the best of Borrower's knowledge, there is no past, pending or threatened, and no event has occurred or circumstance exists that
(with or without notice or lapse of time, or both) could reasonably be expected to give rise to or serve as a basis for any, action,
suit, or proceeding, or any investigation or written claim by any Person that claims or alleges that the manufacture, use, marketing,
sale, offer for sale, importation or distribution of any Product, once marketed, does or could infringe on any patent or other
intellectual property rights of any other Person or constitute misappropriation of any other Person's trade secrets or other intellectual
property rights anywhere in the world.

 

Section
4.24        Insurance.
Each of Borrower and its Subsidiaries (a) maintains insurance to such extent and against such risks, as is customary with
companies in the same or similar businesses, (b) is covered by workmen's compensation insurance in the amount required by
applicable law, (c) maintains commercial general liability insurance, which shall include product liability insurance, in the
amount customary with companies in the same or similar business against claims for personal injury or death on properties owned,
occupied or controlled by it, and (d) maintains such other insurance as may be required by any Governmental Authority. Schedule
4.24 sets forth a list of all insurance maintained by each Loan Party on the Closing Date.

 

Section
4.25        Common
Enterprise. Each Loan Party expects to derive benefit (and its Board of Directors or other governing body has determined that
it may reasonably be expected to derive benefit), directly and indirectly, from the credit extended by the Lenders to the Borrower
hereunder, both in their separate capacities and as members of a group of companies. Each Loan Party has determined that execution,
delivery, and performance of this Agreement and any other Loan Documents to be executed by such Loan Party is within its purpose,
will be of direct and indirect benefit to such Loan Party, and is in its best interest.

 

Section
4.26        Permits,
Etc. Each Loan Party has, and is in compliance with, all permits, licenses, authorizations, approvals, entitlements and accreditations
required by any Governmental Authority having appropriate jurisdiction for such Person to own, lease, manage or operate, or to
acquire, each business currently owned, leased, managed or operated, or to be acquired, by such Person, except for any such permits,
licenses, authroizations, approvals, entitlements and accreditations which, if not obtained, could not reasonably be expected
to have a Material Adverse Effect. No condition exists or event has occurred which, in itself or with the giving of notice or
lapse of time or both, would result in the suspension, revocation, impairment, forfeiture or non-renewal of any such permit, license,
authorization, approval, entitlement or accreditation, and there is no claim that any thereof is not in full force and effect,
except, in each case, to the extent any such condition, event or claim could not be reasonably be expected to have a Material
Adverse Effect.

 

Section
4.27        Bank
Accounts and Securities Accounts. Schedule 4.27 sets forth a complete and accurate list in all material aspects as
of the Closing Date of all deposit, checking and other bank accounts, all securities and other accounts maintained with any broker
dealer and all other similar accounts maintained by each Loan Party, together with a description thereof in reasonable detail
(i.e., the bank or broker dealer at which such deposit or other account is maintained and the account number and the purpose
thereof).

 

Section
4.28        Security
Interests. The Collateral Documents create in favor of Administrative Agent, for the benefit of Secured Parties, a legal,
valid and enforceable security interest in the Collateral secured thereby. Upon the filing of the UCC-1 financing statements described
in Section 3.1(f), the posssession by the Administrative Agent of any certificated Capital Stock or instrument owned by
such Loan Party, the recording of the Collateral Assignments for Security referred to in each Pledge and Security Agreement in
the United States Patent and Trademark Office and the United States Copyright Office and the taking of all other actions required
by the Pledge and Security Agreement, as applicable, such security interests in and Liens on the Collateral granted thereby shall
be perfected, first priority (subject to any Permitted Liens) security interests, and no further recordings or filings are or
will be required in connection with the creation, perfection or enforcement of such security interests and Liens, other than (a) the
filing of continuation statements in accordance with applicable law, (b) the recording of the Collateral Assignments for
Security pursuant to each Pledge and Security Agreement in the United States Patent and Trademark Office and the United States
Copyright Office, as applicable, with respect to after-acquired U.S. patent and trademark applications and registrations
and U.S. copyrights, and (c) the recordation of appropriate evidence of the security interest in the appropriate foreign registry
with respect to all foreign intellectual property and all other recordings and filings required in any jurisdiction other than
the U.S. in order to create, register or perfect any such security interests, in each case, so long as Administrative Agent has
not required any Loan Party to create, register or perfect such security interests in accordance with Section 5.11.

 

     - 59 -

     

    

 

Section
4.29        PATRIOT
ACT and FCPA. To the extent applicable, each Loan Party is in compliance with (a) the laws, regulations and Executive Orders
administered by OFAC, and (b) the Bank Secrecy Act, as amended by the Uniting and Strengthening America by Providing Appropriate
Tools Required to Intercept and Obstruct Terrorism (USA PATRIOT Act ) of 2001 (the “PATRIOT
Act”). Neither the Loan Parties nor any of their officers, directors, employees, agents or shareholders acting
on the Loan Parties' behalf shall use the proceeds of the Loans to make any payments, directly or indirectly (including through
any third party intermediary), to any Foreign Official in violation of the United States Foreign Corrupt Practices Act of 1977,
as amended (the “FCPA”). None of the Loan Parties nor any Affiliates
of any Loan Parties that are controlled by the Loan Parties, is in violation of any Anti-Terrorism Law or engages in or conspires
to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of
the Anti-Terrorism Laws. None of the Loan Parties, nor any Affiliates of any Loan Parties that are controlled by the Loan Parties,
or their respective agents acting or benefiting in any capacity in connection with the Loans or other transactions hereunder,
is a Blocked Person. None of the Loan Parties, nor any of their agents acting in any capacity in connection with the Loans or
other transactions hereunder (A) conducts any business or engages in making or receiving any contribution of funds, goods or services
to or for the benefit of any Blocked Person, or (B) deals in, or otherwise engages in any transaction relating to, any property
or interests in property blocked pursuant to any OFAC Sanctions Programs.

 

Section
4.30        Managerial
Assistance and Related Persons. Each Loan Party represents and warrants that (a) TSL has offered to make available to each
of them “significant managerial assistance” (as defined in Section 2(a)(47) of the Investment Company Act of 1940)
and, to the extent any Loan Party accepts such offer from TSL, the scope, terms and conditions of such significant managerial
assistance are set forth in a separate agreement between such Loan Party and TSL and (b) it is not a “person”
related to TSL as described in Section 57(b) or 57(e) of the Investment Company Act of 1940.

 

Section
4.31        Disclosure.
No representation or warranty of any Loan Party contained in any Loan Document or in any other documents, certificates or written
statements made or furnished to Lenders by or on behalf of Borrower or any of its Subsidiaries for use in connection with the
transactions contemplated hereby when taken as a whole contains any untrue statement of a material fact or omits to state a material
fact necessary in order to make the statements contained herein or therein not misleading in light of the circumstances in which
the same were made. Notwithstanding anything to the contrary in the foregoing, it is hereby understood and agreed by each party
to this Agreement that any projections, budgets, estimates, pro forma financial information, any other forward-looking statements
or information of a general economic or industry nature contained in such materials are based upon good faith estimates and assumptions
believed by Company to be reasonable at the time made, it being recognized by Lenders that such projections, budgets, estimates,
pro forma financial information and forward looking statements are not to be viewed as facts and that actual results during the
period or periods covered by any such projections, budgets, estimates, pro forma financial information and forward looking statements
may differ from the projected results and such differences may be material. There are no facts known (or which should upon the
reasonable exercise of diligence be known) to any Authorized Officer of the Company (other than matters of a general economic
nature) that, individually or in the aggregate, are material and pertinent in the transactions contemplated hereby or the Products
that have not been disclosed herein or in such other documents, certificates and statements furnished to Lenders for use in connection
with the transactions contemplated hereby.

 

     - 60 -

     

    

 

Section
4.32        Use
of Proceeds. The proceeds of the Term Loan shall be applied by Company for working capital, capital expenditures, and general
corporate purposes of Borrower and its Subsidiaries. No portion of the proceeds of any Credit Extension shall be used in any manner
that causes or might cause such Credit Extension or the application of such proceeds to violate Regulation T, Regulation U or
Regulation X of the Board of Governors of the Federal Reserve System or any other regulation thereof or to violate the Exchange
Act.

 

Section
4.33        Regulatory
Compliance.

 

(a)       Each
of Borrower and its Subsidiaries have all Registrations from the FDA, comparable foreign counterparts or any other Governmental
Authority required to conduct their respective businesses as currently conducted, except where the failure to have all such Registrations
would not reasonably be expected to, individually or in the aggregate, result in Material Regulatory Liabilities. Each of such
Registrations is valid and subsisting in full force and effect. To the knowledge of Borrower and its Subsidiaries, neither the
FDA nor any comparable Governmental Authority is considering limiting, suspending, or revoking such Registrations or changing
the marketing classification or labeling of any Products under such Registrations. To the knowledge of the Borrower and its Subsidiaries,
there is no false or materially misleading information or significant omission in any Product application or other notification,
submission or report to the FDA or any comparable Governmental Authority that was not corrected by subsequent submission, and
all such applications, notifications, submissions and reports provided by Borrower and its Subsidiaries were true, complete, and
correct in all material respects as of the date of submission to FDA or any comparable Governmental Authority. Borrower and its
Subsidiaries have not failed to fulfill and perform their material obligations which are due under each such Registration, and,
no event has occurred or condition or state of facts exists which would constitute a breach or default under any such Registration,
in each case that would reasonably be expected to cause the revocation, termination or suspension or material limitation of any
such Registration. To the knowledge of the Borrower and its Subsidiaries, any third party that develops, researches, manufactures,
commercializes, distributes, sells or markets Products pursuant to an agreement with Borrower or its Subsidiaries (a “Loan
Party Partner”) is in compliance with all Registrations from the FDA and any comparable Governmental Authority
insofar as they pertain to Products, and each such Loan Party Partner is in compliance with applicable Public Health Laws, except
where the failure to so be in compliance would not reasonably be expected to, individually or in the aggregate, result in Material
Regulatory Liabilities

 

(b)       Each
of Borrower and its Subsidiaries is in compliance, and has been in compliance, with all Public Health Laws, except to the extent
that any such non-compliance, individually or in the aggregate, could not reasonably be expected to result in Material Regulatory
Liabilities.

 

     - 61 -

     

    

 

(c)       To
the extent applicable, all products designed, developed, investigated, manufactured, prepared, assembled, packaged, tested, labeled,
distributed, sold, marketed or delivered by or on behalf of Borrower or any of its Subsidiaries, that are subject to the jurisdiction
of the FDA have been and are being designed, developed, investigated, manufactured, prepared, assembled, packaged, tested, labeled,
distributed, sold, marketed or delivered in compliance in all material respects with the Public Health Laws. To the knowledge
of Borrower and its Subsidiaries, there are no defects in the design or technology embodied in any Products that are reasonably
expected to prevent the safe and effective performance of any such Product for its intended use (other than such limitations specified
in the applicable package insert), except for such defects that would not reasonably be expected to, individually or in the aggregate,
result in Material Regulatory Liabilities or other Liabilities. None of the Products has been the subject of any products liability
or warranty action against Borrower or its Subsidiaries.

 

(d)       Neither
Borrower nor any of its Subsidiaries is currently subject to any material obligation arising pursuant to a Regulatory Action and,
to the knowledge of Borrower and its Subsidiaries, no such material obligation or Regulatory Action has been threatened by a Governmental
Authority in writing. In addition, and without limitation on the foregoing, except as set forth on Schedule 4.33(d)
neither Borrower nor any of its Subsidiaries has received any written notice or communication from the FDA, comparable foreign
counterparts or any other Governmental Authority alleging material non-compliance with any Public Health Law or comparable foreign
laws.

 

(e)       Except
as set forth on Schedule 4.33(e), (i) neither Borrower nor any of its Subsidiaries has received any written notice or communication
from the FDA or any other Governmental Authority alleging material noncompliance with any Public Health Law, including without
limitation any Form FDA 483, notice of inspectional observation, notice of adverse finding, notice of violation, warning letters,
untitled letters or other notices from the FDA and (ii) to the knowledge of Borrower and its Subsidiaries, no Loan Party Partner
has received any written notice or communication from the FDA or any other Governmental Authority alleging material noncompliance
with any Public Health Law, including without limitation any Form FDA 483, notice of inspectional observation, notice of adverse
finding, notice of violation, warning letters, untitled letters or other notices from the FDA relating to such Loan Party Partner's
work for Borrower or such Subsidiary. No Product has been seized, withdrawn, recalled, detained, or subject to a suspension (other
than in the ordinary course of business) of research, manufacturing, distribution or commercialization activity. Neither Borrower
nor any of its Subsidiaries is aware of any facts or circumstances that are reasonably likely to result in any recall of any Product.

 

Section
4.34        Government
Contracts. Except as set forth on Schedule 4.34 as of the Closing Date hereof, neither Borrower nor any of its Subsidiaries
is a party to any contract or agreement with any Governmental Authority and none of Borrower's or such Subsidiary's accounts receivables
or other rights to receive payment are subject to the Federal Assignment of Claims Act (31 U.S.C. Section 3727) or any similar
state, county or municipal law.

 

Section
4.35        Health
Care Regulatory Laws.

 

(a)       None
of Borrower and its Subsidiaries, nor, to their knowledge, any officer, director, managing employee or agent (as those terms are
defined in 42 C.F.R. § 1001.1001) thereof, is a party to, or bound by, any written order, individual integrity agreement,
corporate integrity agreement or other formal written agreement with any Governmental Authority concerning their compliance with
Federal Health Care Program Laws.

 

     - 62 -

     

    

 

(b)       None
of Borrower and its Subsidiaries, nor any officer, director, managing employee or agent (as those terms are defined in 42 C.F.R.
§ 1001.1001) thereof, nor to the knowledge of Borrower and its Subsidiaries, any Loan Party Partner: (i) has been charged
with or convicted of any criminal offense relating to the delivery of an item or service under any Federal Health Care Program;
(ii) has had a civil monetary penalty assessed against it, him or her under Section 1128A of the SSA; (iii) has been listed
on the U.S. General Services Administration published list of parties excluded from federal procurement programs and non-procurement
programs; or (iv) to the knowledge of Borrower and its Subsidiaries, is the target or subject of any current or potential investigation
relating to any of the foregoing or any Federal Health Care Program-related offense. None of Borrower and its Subsidiaries, nor
any officer, director, managing employee or agent (as those terms are defined in 42 C.F.R. § 1001.1001) thereof, nor
any Loan Party Partner, has been debarred, excluded, disqualified or suspended from participation in any Federal Health Care Program
or under any FDA Laws (including 21 U.S.C. § 335a).

 

(c)       None
of Borrower and its Subsidiaries, nor any officer, director, managing employee or agent (as those terms are defined in 42 C.F.R.
§ 1001.1001) thereof, nor to the knowledge of Borrower and its Subsidiaries, any Loan Party Partner, has engaged in any activity
that is in material violation of any Federal Health Care Program Laws, including the following:

 

(i)       knowingly
and willfully making or causing to be made a false statement or representation of a material fact in any application for any benefit
or payment;

 

(ii)       knowingly
and willfully making or causing to be made a false statement or representation of a material fact for use in determining rights
to any benefit or payment;

 

(iii)       knowingly
and willfully soliciting or receiving any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly
or covertly, in cash or kind (1) in return for referring an individual to a person for the furnishing or arranging for the furnishing
of any item or service for which payment may be made in whole or in part under any Federal Health Care Program; or (2) in return
for purchasing, leasing, or ordering, or arranging, or arranging for or recommending purchasing, leasing, or ordering any good,
facility, service or item for which payment may be made in whole or in part under any Federal Health Care Program in violation
of 42 U.S.C. Section 1320a-7b(b); or

 

(iv)       knowingly
and willfully offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or
covertly, in cash or in kind, to any person to induce such person (1) to refer an individual to a person for the furnishing or
arranging for the furnishing of any item or service for which payment may be made in whole or in part under a Federal Health Care
Program; or (2) to purchase, lease, order or arrange for or recommend purchasing, leasing or ordering any good, facility, service
or item for which payment may be made in whole or in part under a Federal Health Care Program in violation of 42 U.S.C. Section
1320a-7b(b).

 

(d)       To
the knowledge of Borrower and its Subsidiaries, no person has filed or has threatened to file against Borrower or any of its Subsidiaries,
an action relating to any FDA Law, Public Health Law or Federal Health Care Program Law under any whistleblower statute, including
without limitation, under the False Claims Act of 1863 (31 U.S.C. § 3729 et seq.).

 

(e)       Each
of Borrower and its Subsidiaries is in compliance in all material respects with HIPAA, and the provisions of all business associate
agreements (as such term is defined by HIPAA) to which it is a party, and has implemented reasonably adequate policies, procedures
and training designed to assure continued compliance and to detect non-compliance, except where the failure to implement such
policies, procedures, and training would not reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect.

 

     - 63 -

     

    

 

Article
V

AFFIRMATIVE COVENANTS

 

Each
Loan Party covenants and agrees that, so long as any Commitment is in effect and until payment in full of all Obligations (other
than any such contingent obligations or liabilities hereunder that by the express terms thereof survive such payment in full of
all Obligations), each Loan Party shall perform, and shall cause each of its Subsidiaries to perform, all covenants in this Article
V.

 

Section
5.1        Financial
Statements and Other Reports. Unless otherwise provided below, Borrower will deliver to Administrative Agent (for delivery
to the Lenders):

 

(a)       Cash
Reports. Promptly, but in any event within 5 Business Days, after the end of each fiscal month of the Company, a report (which
report may consist of bank statements) of the current Cash and Cash Equivalent balances (including the balances in each Deposit
Account of each Loan Party) of the Company and its Subsidiaries, which report shall identify (i) unrestricted (other than restrictions
created by the Collateral Documents) and restricted Cash and Cash Equivalents and (ii) those accounts that constitute Qualified
Cash; provided, that at any time the current Cash and Cash Equivalent balances of the Company and its Subsidiaries is less
than $75,000,000, Administrative Agent may request at any time, and the Company shall promptly provide, a report of at least 95%
of the current Cash and Cash Equivalent balances of the Company and its Subsidiaries, which report shall identify unrestricted
(other than restrictions created by the Collateral Documents) and restricted Cash and Cash Equivalents (or, if greater, all Cash
and Cash Equivalent balances required to satisfy the covenant set forth in Section 6.8).

 

(b)       Quarterly
Financial Statements. As soon as available, and in any event (i) within 45 days after the end of the first three Fiscal Quarters
of each Fiscal Year and (ii) within 60 days after the end of the fourth Fiscal Quarter of each Fiscal Year, the consolidated balance
sheets of Borrower and its Subsidiaries as at the end of such Fiscal Quarter and the related consolidated statements of income,
statements of income and cash flows of Borrower and its Subsidiaries for such Fiscal Quarter, setting forth in each case in comparative
form the corresponding figures for the corresponding periods of the previous Fiscal Year, all in reasonable detail, together with
a Financial Officer Certification with respect thereto;

 

(c)       Annual
Financial Statements. As soon as available, and in any event within 120 days after the end of each Fiscal Year, (i) the consolidated
balance sheets of Borrower and its Subsidiaries as at the end of such Fiscal Year and the related consolidated statements of income,
stockholders' equity and cash flows of Borrower and its Subsidiaries for such Fiscal Year, setting forth in each case in comparative
form the corresponding figures for the previous Fiscal Year, in reasonable detail, together with a Financial Officer Certification
with respect thereto; and (ii) with respect to such consolidated financial statements a report thereon of Grant Thornton LLP or
other independent certified public accountants of recognized national standing selected by Borrower, and reasonably satisfactory
to Administrative Agent (which report shall be unqualified as to going concern and scope of audit (other than with respect to
or resulting from an upcoming maturity of Indebtedness), and shall state that such consolidated financial statements fairly present,
in all material respects, the consolidated financial position of Borrower and its Subsidiaries as at the dates indicated and the
results of their operations and their cash flows for the periods indicated in conformity with GAAP);

 

(d)       Compliance
Certificate. Together with each delivery of financial statements of Borrower and its Subsidiaries pursuant to Section 5.1(b)
or Section 5.1(c), a duly executed and completed Compliance Certificate;

 

     - 64 -

     

    

 

Notwithstanding
the foregoing, the obligations in paragraphs (b), (c) and (d) of this Section 5.1 may be satisfied with respect to financial
information of Borrower and its Subsidiaries by furnishing Borrower's Form 10-K or 10-Q, as applicable, filed with the SEC; provided
that, to the extent such information is in lieu of information required to be provided under Section 5.1(c), such materials
are accompanied by an opinion of Grant Thornton LLP or other independent certified public accountants of recognized national standing
selected by Borrower, and reasonably satisfactory to Administrative Agent, which opinion shall meet the standards set forth in
Section 5.1(c).

 

(e)       Product
Information. As soon as available, and in any event within 45 days after the end of each Fiscal Quarter of each Fiscal Year
(including the fourth Fiscal Quarter of any Fiscal Year), a description of (i) the aggregate number of Product units sold by the
Loan Parties and the gross and net revenues with respect thereto presented on a monthly basis and (ii) the number of Product units
sold by VitaCare Prescription Services, Inc. and the gross and net revenues with respect thereto presented on a monthly basis.

 

(f)       Statements
of Reconciliation after Change in Accounting Principles. If, as a result of any change in accounting principles and policies
from those used in the preparation of the Historical Financial Statements, the information contained in the consolidated financial
statements of Borrower and its Subsidiaries delivered pursuant to Section 5.1(b) or Section 5.1(c) (to the extent
such information is applicable to the calculation of Product Revenue for purposes of determining the Borrower's compliance with
Section 6.8(b)) will differ in any material respect from the consolidated financial statements that would have been delivered
pursuant to such subdivisions had no such change in accounting principles and policies been made, then, together with the first
delivery of such financial statements after such change, one or more statements of reconciliation for all such prior financial
statements in form and substance satisfactory to Administrative Agent;

 

(g)       Notice
of Default. Promptly (but in any event within five (5) Business Days) upon any Authorized Officer of Borrower obtaining knowledge
(i) of any condition or event that constitutes a Default or an Event of Default or that written notice has been given to Borrower
with respect thereto; (ii) that any Person has given any written notice to Borrower or any of its Subsidiaries or taken any other
action which is reasonably likely to cause an Event of Default to occur pursuant to Section 8.1(b) of this Agreement; or
(iii) of the occurrence of any event or change that has caused or resulted in any case or in the aggregate, a Material Adverse
Effect or Material Regulatory Liabilities, a certificate of its Authorized Officers specifying the nature and period of existence
of such condition, event or change, or specifying the notice given and action taken by any such Person and the nature of such
claimed Event of Default, Default, default, event or condition, and what action Company has taken, is taking and proposes to take
with respect thereto;

 

(h)       Notice
of Litigation. Promptly (but in any event within five (5) Business Days) upon any Authorized Officer of Company obtaining
knowledge of (i) the institution of, or non-frivolous written threat of, any Adverse Proceeding or (ii) any material development
in any Adverse Proceeding that, in the case of either clause (i) or (ii) which relates to the Products, the Collateral
or the Material Contracts or which could reasonably be expected to result in Material Regulatory Liabilities, or which seeks to
enjoin or otherwise prevent the consummation of, or to recover any damages or obtain relief as a result of, the transactions contemplated
hereby, written notice thereof together with such other information as may be reasonably available to Company to enable Lenders
and their counsel to evaluate such matters;

 

(i)       ERISA.
Promptly (but in any event within five (5) Business Days) upon becoming aware of the occurrence of or forthcoming occurrence of
any ERISA Event that would reasonably be expected to result in a material Liability to a Loan Party, a written notice specifying
the nature thereof, what action a Loan Party or any ERISA Affiliate has taken, is taking or proposes to take with respect thereto
and, when known, any action taken or threatened by the Internal Revenue Service, the Department of Labor or the PBGC with respect
thereto;

 

     - 65 -

     

    

 

(j)       Insurance
Report. As soon as practicable and in any event within 30 days after the end of each Fiscal Year, a report in form and substance
reasonably satisfactory to Administrative Agent outlining all material changes in insurance coverage maintained as of the date
of such report by Borrower and its Subsidiaries compared to the last day of the prior Fiscal Year, and any material changes to
the insurance coverage planned to be maintained by Borrower and its Subsidiaries in the immediately succeeding Fiscal Year;

 

(k)        Regulatory
and Product Notices. Each Loan Party shall promptly (but in any event within five (5) Business Days) after the receipt or
occurrence thereof notify Administrative Agent of:

 

(i)       any
written notice received by Borrower or its Subsidiaries alleging potential or actual material violations of any Public Health
Law by Borrower or its Subsidiaries,

 

(ii)       any
written notice that the FDA (or international equivalent) is limiting, suspending or revoking any Registration,

 

(iii)       any
written notice that Borrower or its Subsidiaries has become subject to any Regulatory Action (other than any inspection or investigation
in the ordinary course of business),

 

(iv)       the
exclusion or debarment from any governmental health care program or debarment or disqualification by FDA of Borrower or its Subsidiaries
or its or their Authorized Officers,

 

(v)       any
written notice addressed to Borrower or any Subsidiary that a Borrower or any Subsidiary, or any of their licensees or sublicensees
(including licensees or sublicensees under the Product Agreements), is being investigated or is the subject of any allegation
of potential or actual violations of any Federal Health Care Program Laws, in each case, which could reasonably be expected to
result in a Material Adverse Effect,

 

(vi)       any
written notice that any Product of Borrower or its Subsidiaries has been seized, withdrawn, recalled, detained, or subject to
a suspension of manufacturing, or the commencement of any proceedings in the United States by a Governmental Authority having
appropriate jurisdiction seeking the withdrawal, recall, suspension, import detention, or seizure of any Product or Products are
pending or threatened in writing against Borrower or its Subsidiaries, or

 

(vii)       changing
the market classification or labeling of the Products of Borrower and its Subsidiaries under any such Registration in a manner
materially adverse to Borrower and its Subsidiaries,

 

except,
in each case of (i) through (vii) above, where such action would not reasonably be expected to have, either individually or in
the aggregate, Material Regulatory Liabilities;

 

(l)       Notice
Regarding Material Contracts. Promptly (but in any event within five (5) Business Days) (i) after a Loan Party or a Subsidiary
of a Loan Party receives a written notice of default or event of default under any Material Contract giving any party thereto
the right to terminate such Material Contract, (ii) after Loan Party or a Subsidiary of a Loan Party receives or otherwise becomes
aware of any (A) any dispute, purchase price adjustment, indemnity claim, exercise of rights of set-off or deduction (in each
case, not in the ordinary course of business) or (B) litigation (including litigation threatened in writing), in each case for
clauses (A) and (B) under or with respect any Material Contract, and (iii) after a new Material Contract is entered into, in each
case of clauses (i) through (iii), furnish a written statement describing such event, with copies of such notices or new contracts
together with all reasonably pertinent detail and information relating thereto, delivered to Administrative Agent, and an explanation
of any actions being taken with respect thereto;

 

     - 66 -

     

    

 

(m)       Information
Regarding Collateral. Company will furnish to Administrative Agent prior written notice of any change (a) in any Loan Party's
legal name or (b) in any Loan Party's corporate identity or corporate structure. Company agrees not to effect or permit any
change referred to in the preceding sentence unless all filings have been made under the UCC that are required in order for Administrative
Agent to continue at all times following such change to have a valid, legal and perfected security interest in all the Collateral
in which a security interest may be perfected by the filing of a UCC-1 in the state of organization or formation of the Company
or such applicable Guarantor and for such Collateral at all times following such change to have a valid, legal and perfected security
interest as contemplated in the Collateral Documents. Company also agrees promptly to notify Administrative Agent if any material
portion of the Collateral is damaged or destroyed;

 

(n)       Annual
Collateral Verification. Each year, at the time of delivery of annual financial statements with respect to the preceding Fiscal
Year pursuant to Section 5.1(c), Company shall deliver to Administrative Agent an Officer's Certificate either confirming
that there has been no change in such information since the date of the Perfection Certificate delivered on the Closing Date or
the date of the most recent certificate delivered pursuant to this Section 5.1(n) and/or identifying such changes;

 

(o)       Products.

 

(i)            Promptly,
but in any event within five (5) Business Days after the receipt by the Company or any of its Subsidiaries or any Authorized Officer
thereof obtaining knowledge of the occurrence thereof, notice of:

 

(A)       granting
any sublicenses under any Product Agreement;

 

(B)       entering
into any new Product Agreement (to the extent permitted under this Agreement); and

 

(C)       any
material communications with the FDA that could reasonably be expected to result in a Material Adverse Effect; and

 

(ii)       Quarterly,
in connection with the delivery of the Compliance Certificate required by Section 5.1(d), copies of royalty reports received
for such quarter pursuant to any Product Agreement;

 

(p)       Regulatory
Documentation. Company shall be responsible for, and shall maintain, with respect to each Product, all submissions to Governmental
Authorities relating to the Products, including clinical studies, tests and biostudies, including all Product non-disclosure agreements,
and the drug master files, as well as all correspondence with Governmental Authorities with respect thereto (including Registrations
and licenses and regulatory drug lists, and any amendments or supplements thereto). Concurrent with the delivery of a Compliance
Certificate following the end of each Fiscal Quarter in accordance with Section 5.1(d) and promptly following Administrative Agent's
reasonable request from time to time, Company shall promptly provide to Administrative Agent copies of any and all regulatory
filings submitted to any such Governmental Authorities and material correspondence sent to or received from Governmental Authorities,
in each case, with respect to the Products;

 

     - 67 -

     

    

 

(q)       Maintenance
of Product Patents. Company shall take all commercially reasonable steps to maintain the Product Patents, including by timely
filing fees and responses with the United States Patent and Trademark Office or any applicable foreign counterpart. Company shall
provide prompt written notice to Administrative Agent of any material occurrences with respect to any Product Patents, and, upon
Administrative Agent's request from time to time, shall promptly provide Administrative Agent with complete and correct copies
of any material correspondence sent by Company to or received from the United States Patent and Trademark Office or any applicable
foreign counterpart with respect to any Product Patent;

 

(r)       Other
Information. (A) Promptly upon their becoming available and in any event within five (5) Business Days of Borrower's receipt
thereof, copies of (i) all reports and all registration statements and prospectuses, if any, filed by Borrower or any of its Subsidiaries
with the Securities and Exchange Commission or any similar governmental or private regulatory authority and which is not otherwise
publicly available, and (ii) all amendments, waivers, consents, notices of default and reservations of rights with respect to
and received by Borrower or its Subsidiaries from any holder of its Indebtedness having a principal amount greater than $5,000,000,
(B) subject to any applicable confidentiality restrictions or restrictions under applicable law, promptly after submission to
any Governmental Authority, all documents and information furnished to such Governmental Authority in connection with any investigation
of any Loan Party (other than a routine inquiry), and (C) such other information and data with respect to Borrower or any of its
Subsidiaries as from time to time may be reasonably requested by Administrative Agent in writing in accordance with Section
10.1 of this Agreement.

 

Section
5.2        Existence.
Except as otherwise permitted under Section 6.9, each Loan Party will, and will cause each of Borrower's Subsidiaries to,
at all times preserve and keep in full force and effect its existence and all rights and Governmental Authorizations, qualifications,
franchises, licenses and permits material to its business and to conduct its business in each jurisdiction in which its business
is conducted, except, in each case, which such failure to do so would not, either individually or in the aggregate, be reasonably
expected to result in a Material Adverse Effect; provided, no Loan Party or any of Borrower's Subsidiaries shall be required
to preserve any such existence, right or Governmental Authorizations, qualifications, franchise, licenses and permits if such
Person's Board of Directors (or similar governing body) shall determine that the preservation thereof is no longer desirable in
the conduct of the business of such Person, and that the loss thereof is not disadvantageous in any material respect to such Person
or to Lenders.

 

Section
5.3        Payment
of Taxes and Claims. Each Loan Party will, and will cause each of Borrower's Subsidiaries to, (a) file all Tax returns required
to be filed by Borrower or any of its Subsidiaries and (b) pay (i) all Taxes exceeding $500,000 imposed upon it or any of its
properties or assets or in respect of any of its income, businesses or franchises before any penalty or fine accrues thereon and
(ii) all claims (including claims for labor, services, materials and supplies) for sums that have become due and payable and that
by law have or may become a Lien upon any of its properties or assets prior to the time when any penalty or fine shall be incurred
with respect thereto; provided, no such Tax or claim need be paid if it is being contested in good faith by appropriate
proceedings promptly instituted and diligently conducted, so long as (a) adequate reserve or other appropriate provision,
as shall be required in conformity with GAAP shall have been made therefor, and (b) in the case of a Tax or claim which has or
may become a Lien against any of the Collateral, such contest proceedings conclusively operate to stay imposition of any penalty,
fine or Lien resulting from the non-payment thereof. No Loan Party will, nor will it permit any of Borrower's Subsidiaries to,
file or consent to the filing of any consolidated income tax return with any Person (other than Borrower or its Subsidiaries).

 

     - 68 -

     

    

 

Section
5.4        Maintenance
of Properties. Each Loan Party will, and will cause each of Borrower's Subsidiaries to (a) maintain or cause to be maintained
in good repair, working order and condition, ordinary wear and tear excepted, all properties used or useful in the business of
Borrower and its Subsidiaries and from time to time will make or cause to be made all appropriate repairs, renewals and replacements
thereof, except, in each case, to the extent any such failure to maintain would not reasonably be expected to have a Material
Adverse Effect, and (b) comply at all times with the provisions of all material leases to which it is a party as lessee or under
which it occupies property, so as to prevent any loss or forfeiture thereof or thereunder, except, in each case, to the extent
any such failure to comply could not reasonably be expected to have a Material Adverse Effect.

 

Section
5.5        Insurance.

 

(a)       The
Loan Parties will maintain or cause to be maintained, with financially sound and reputable insurers, (i) business interruption
insurance reasonably satisfactory to Administrative Agent, and (ii) casualty insurance, such commercial general liability insurance,
third party property damage insurance or such other insurance with respect to liabilities, losses or damage in respect of the
assets, properties and businesses of the Loan Parties as may customarily be carried or maintained under similar circumstances
by Persons of established reputation engaged in similar businesses, in each case in such amounts (giving effect to self-insurance),
with such deductibles, covering such risks and otherwise on such terms and conditions as shall be customary for such Persons.
Each such commercial general policy of insurance shall (1) name Administrative Agent, on behalf of Lenders as an additional insured
thereunder as its interests may appear, and (2) in the case of each property insurance policy, contain a loss payable clause or
endorsement, satisfactory in form and substance to Administrative Agent, that names Administrative Agent, on behalf of Secured
Parties as the loss payee thereunder. If any Loan Party or any of its Subsidiaries fails to maintain such insurance, Administrative
Agent may, upon prior written notice to Company, arrange for such insurance, but at Company's expense and without any responsibility
on Administrative Agent's part for obtaining the insurance, the solvency of the insurance companies, the adequacy of the coverage,
or the collection of claims. Upon the occurrence and during the continuance of an Event of Default, Administrative Agent shall
have the sole right, in the name of the Lenders, any Loan Party and its Subsidiaries, to file claims under any insurance policies,
to receive, receipt and give acquittance for any payments that may be payable thereunder, and to execute any and all endorsements,
receipts, releases, assignments, reassignments or other documents that may be necessary to effect the collection, compromise or
settlement of any claims under any such insurance policies.

 

(b)       Each
of the insurance policies required to be maintained under this Section 5.5 shall provide for at least thirty (30) days'
prior written notice to Administrative Agent of the cancellation or substantial modification thereof. Receipt of such notice shall
entitle Administrative Agent (but Administrative Agent shall not be obligated), upon prior written notice to the Loan Parties,
to renew any such policies, cause the coverages and amounts thereof to be maintained at levels required pursuant to this Section
5.5 or otherwise to obtain similar insurance in place of such policies, in each case at the expense of the Loan Parties and
to the extent the Loan Parties have not so renewed such policies or obtained similar insurance in place therefor.

 

     - 69 -

     

    

 

Section
5.6        Books
and Records; Inspections. Each Loan Party will, and will cause each of Borrower's Subsidiaries to, (a) maintain at all times
at the chief executive office of Borrower copies of all material books and records of Borrower and its Subsidiaries, (b) keep
adequate books of record and account in which full, true and correct entries in all material respects are made of all dealings
and transactions in relation to its business and activities and (c) permit any representatives designated by Administrative
Agent or any Lender (including employees of Administrative Agent, any Lender or any consultants, auditors, accountants, lawyers
and appraisers retained by Administrative Agent) to visit any of the properties of any Loan Party and any of Borrower's Subsidiaries
to inspect, copy and take extracts from its and their financial and accounting records, all upon reasonable notice and at such
reasonable times during normal business hours (so long as no Default or Event of Default has occurred and is continuing) and as
often as may reasonably be requested; provided that, excluding any such visits and inspections during the occurrence and continuation
of an Event of Default, only the Administrative Agent on behalf of the Lenders may exercise rights of the Administrative Agent
and the Lenders under this Section 5.6 and the Administrative Agent shall not, absent the occurrence and continuance of
an Event of Default, exercise such rights more often than one time during any calendar year. The Loan Parties agree to pay the
reasonable and documented out-of-pocket costs and expenses incurred by the examiner in connection therewith. Notwithstanding anything
to the contrary in this Section 5.6, none of the Loan Parties or any of their Subsidiaries will be required to disclose
or permit the inspection or discussion of, any document, information or other matter (i) in respect of which disclosure to the
Agents or any Lender (or their respective representatives) is prohibited by applicable law or Contractual Obligations that (A)
are owed to any Person that is not an Affiliate of Borrower or its Subsidiaries that is controlled by Borrower or its Subsidiaries
pursuant to a binding agreement to which Borrower or its Subsidiaries are a party and (B) that have not been waived by such Person
following the use by Borrower or its Subsidiaries of commercailly reasonable efforts to obtain such waiver or (ii) that is subject
to attorney client or similar privilege or constitutes attorney work product.

 

Section
5.7        Lenders
Meetings and Conference Calls.

 

(a)       Borrower
will, upon the request of Administrative Agent or Required Lenders, participate in a meeting of Administrative Agent and Lenders
once during each Fiscal Year to be held at Company's corporate offices (or at such other location as may be agreed to by Company
and Administrative Agent) at such time as may be agreed to by Borrower and Administrative Agent.

 

(b)       Within
10 Business Days after delivery of financial statements and other information required to be delivered pursuant to Section
5.1(b), Borrower shall, upon request by the Administrative Agent, cause its chief financial officer or other Authorized Officers
to participate in a conference call with Administrative Agent and all Lenders who choose to participate in such conference call,
during which conference call the chief financial officer or such Authorized Officer shall review the financial condition of Borrower
and its Subsidiaries and such other matters as Administrative Agent or any Lender may reasonably request in a reasonable time
period in advance of such conference call.

 

Section
5.8        Compliance
with Laws.

 

(a)       Each
Loan Party will comply, and shall cause each of Borrower's Subsidiaries, to comply, with the requirements of all applicable laws,
rules, regulations and orders of any Governmental Authority (including all Environmental Laws), in each case, non-compliance with
which could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

 

(b)       Without
limiting the generality of the foregoing, each Loan Party shall, and shall cause each of Borrower's Subsidiaries to, comply with
all FDA Laws and Public Health Laws, and with all applicable Federal Health Care Program Laws, in each case, except where the
failure to comply would not reasonably be expected to result, either individually or in the aggregate, in Material Regulatory
Liabilities. All Products developed, manufactured, tested, investigated, distributed or marketed by or on behalf of the Loan Parties
and Borrower's Subsidiaries that are subject to the jurisdiction of the FDA or any comparable Governmental Authority have been
and shall be developed, tested, manufactured, investigated, distributed and marketed in compliance with the FDA Laws and any other
Requirement of Law, including, without limitation, pre-market notification, good manufacturing practices, labeling, advertising,
record-keeping, and adverse event reporting, in each case, except where the failure to comply would not reasonably be expected
to result, either individually or in the aggregate, in Material Regulatory Liabilities.

 

     - 70 -

     

    

 

Section
5.9        Environmental.

 

(a)       Each
Loan Party shall (i) keep its owned real property free of any Environmental Liens; (ii) maintain and comply in all material respects
with all Governmental Authorizations required under applicable Environmental Laws, except as any such failure which could not
reasonably be expected to result in a Material Adverse Effect; and (iii) take all steps to prevent any Release of Hazardous Materials
from any property owned or operated by any Loan Party, except as any such failure would not reasonably be expected to result in
a Material Adverse Effect.

 

(b)       The
Loan Parties shall promptly (but in any event within ten (10) Business Days) (i) notify Administrative Agent in writing (A) of
any material Environmental Claims asserted against or material Environmental Liabilities and Costs of any Loan Party, and (B)
any notice of Environmental Lien filed against any owned real property, and (ii) provide such other documents and information
as reasonably requested by Administrative Agent in relation to any matter pursuant to this Section 5.9(b).

 

Section
5.10        Subsidiaries.
In the event that any Person becomes a Subsidiary of Company, Company (including pursuant to a Permitted Acquisition) shall (a)
within 10 Business Days of such Person becoming a Subsidiary (or such later time as is consented to by Administrative Agent) cause
such Subsidiary to become a Guarantor hereunder and a Grantor under the Pledge and Security Agreement by executing and delivering
to Administrative Agent a Counterpart Agreement, and (b) take all such actions and execute and deliver, or cause to be executed
and delivered, all such documents, instruments, agreements, and certificates as are similar to those described in Sections
3.1(b), 3.1(f) and 3.1(i). With respect to each such Subsidiary, Company shall send to Administrative Agent
written notice within 10 Business Days of such Person becoming a Subsidiary (or such later time as is consented to by Administrative
Agent) setting forth with respect to such Person (i) the date on which such Person became a Subsidiary of Company, and (ii) all
of the data required to be set forth in Schedules 4.1 and 4.2 with respect to all Subsidiaries of Company; provided,
such written notice shall be deemed to supplement Schedules 4.1 and 4.2 for all purposes hereof.

 

Section
5.11        Further
Assurances. At any time or from time to time upon the written request of Administrative Agent, each Loan Party will, at its
expense, promptly execute, acknowledge and deliver such further documents and do such other acts and things within its control
as Administrative Agent may reasonably request in order to effect fully the purposes of the Loan Documents, including providing
Lenders with any information reasonably requested pursuant to Section 10.21. In furtherance and not in limitation of the
foregoing, each Loan Party shall take such actions as Administrative Agent may reasonably request from time to time to ensure
that the Obligations are guaranteed by the Guarantors and are secured by substantially all of the assets of Borrower's Subsidiaries
and all of the outstanding Capital Stock of Borrower's Subsidiaries, to the extent permitted under any Loan Document. Notwithstanding
anything to the contrary in the foregoing or anywhere else in this Agreement or in any other Loan Document, unless requested by
the Administrative Agent in its reasonable discretion, none of the Loan Parties or any of their Subsidiaries shall be required,
nor shall the Administrative Agent or any Lender be authorized, to take any action with respect to any assets or property of any
Loan Party located outside of the United States.

 

Section
5.12        Control
Agreements. Each of Borrower and each Guarantor Subsidiary shall hold all of its cash and Cash Equivalents in a Deposit Account
or Securities Account (other than any Excluded Accounts) subject to a Control Agreement. All such Control Agreements shall provide
for “springing” cash dominion with respect to each such account that is not an Excluded Account, including each disbursement
account. With respect to each Control Agreement providing for “springing” cash dominion, Administrative Agent will
not deliver to the relevant depository institution a notice or other instruction which provides for exclusive control over such
account by Administrative Agent until an Event of Default has occurred and is continuing.

 

     - 71 -

     

    

 

Section
5.13        Post-Closing
Matters. Company shall, and shall cause each of the Loan Parties to, satisfy the requirements set forth on Schedule 5.13
on or before the date specified for such requirement or such later date as is consented to by Administrative Agent.

 

Article
VI

NEGATIVE COVENANTS

 

Each
Loan Party covenants and agrees that, so long as any Commitment is in effect and until payment in full of all Obligations (other
than any such contingent obligations or liabilities hereunder that by the express terms thereof survive such payment in full of
all Obligations), such Loan Party shall perform, and shall cause each of its Subsidiaries to perform, all covenants in this Article
VI.

 

Section
6.1        Indebtedness.
No Loan Party shall, nor shall it permit any of Borrower's Subsidiaries to, directly or indirectly, create, incur, assume or guaranty,
or otherwise become or remain directly or indirectly liable with respect to any Indebtedness, in each case, except Permitted Indebtedness.

 

Section
6.2        Liens.
No Loan Party shall, nor shall it permit any of its Subsidiaries to, directly or indirectly, create, incur, assume or permit to
exist any Lien on or with respect to any property or asset of any kind (including any document or instrument in respect of goods
or accounts receivable) of Borrower or any of its Subsidiaries, whether now owned or hereafter acquired, or any income or profits
therefrom, or file or permit the filing of, or permit to remain in effect, any financing statement or other similar notice of
any Lien with respect to any such property, asset, income or profits under the UCC of any State or under any similar recording
or notice statute, in each case, except Permitted Liens.

 

Section
6.3        Material
Contracts. None of Borrower or any of its Subsidiaries shall agree to any set-off, counterclaim or other deduction under or
with respect to any Material Contract, other than any such set-off, counterclaim or other deduction that is in the ordinary course
of business and is explicitly required or permitted by the terms of such Material Contract as in effect on the date hereof or
as amended from time to time in accordance with the terms hereof. Borrower and its Subsidiaries shall not materially breach any
Material Contract or otherwise default under any Material Contract in such a manner as could reasonably be expected to give rise
to a termination right of any other party to such Material Contract.

 

Section
6.4        No
Further Negative Pledges. Except with respect to (a) specific property encumbered to secure payment of particular Indebtedness
or to be sold pursuant to an executed agreement with respect to an Asset Sale permitted under Section 6.9 and (b) restrictions
by reason of customary provisions restricting assignments, subletting or other transfers contained in leases, licenses and similar
agreements entered into in the ordinary course of business (provided that such restrictions are limited to the property or assets
secured by such Liens or the property or assets subject to such leases, licenses or similar agreements, as the case may be) no
Loan Party nor any of Borrower's Subsidiaries shall enter into any agreement prohibiting the creation or assumption of any Lien
upon any of its properties or assets, whether now owned or hereafter acquired, in each case, except Permitted Liens.

 

Section
6.5        Restricted
Junior Payments. No Loan Party shall, nor shall it permit any of its Subsidiaries through any manner or means or through any
other Person to, directly or indirectly, declare, order, pay, make or set apart, or agree to declare, order, pay, make or set
apart, any sum for any Restricted Junior Payment, in each case, except for:

 

(a)       cashless
repurchases of Capital Stock in the ordinary course of business in Borrower or any Subsidiary thereof deemed to occur upon exercise
of stock options or warrants if such Capital Stock represents a portion of the exercise price of such options or warrants;

 

     - 72 -

     

    

 

(b)       any
Loan Party may make Restricted Junior Payments in the form of its payment in cash to the relevant Governmental Authority of any
Taxes payable as a result of the vesting of Capital Stock in connection with equity-based compensation plans; provided,
the aggregate amount of all such Restricted Junior Payments shall not exceed $10,000,000 during the term of this Agreement; or

 

(c)       Borrower
may make payments of cash in lieu of fractional shares in connection with stock dividends, splits or combinations or conversions
or exercises of convertible securities.

 

Section
6.6        Restrictions
on Subsidiary Distributions. Except as provided herein, no Loan Party shall, nor shall it permit any of Borrower's Subsidiaries
to, create or otherwise cause or suffer to exist or become effective any consensual encumbrance or restriction of any kind, in
each case, except for Permitted Liens, on the ability of any Subsidiary of Company to (a) pay dividends or make any other distributions
on any of such Subsidiary's Capital Stock owned by Company or any other Subsidiary of Company, (b) repay or prepay any Indebtedness
owed by such Subsidiary to Company or any other Subsidiary of Company, (c) make loans or advances to Company or any other Subsidiary
of Company, or (d) transfer any of its property or assets to Company or any other Subsidiary of Company other than restrictions
(i) in agreements evidencing purchase money Indebtedness permitted by clause (g) of the definition of Permitted Indebtedness
that impose restrictions on the property so acquired, (ii) by reason of customary provisions restricting assignments, subletting
or other transfers contained in leases, licenses, joint venture agreements and similar agreements entered into in the ordinary
course of business, and (iii) that are or were created by virtue of any transfer of, agreement to transfer or option or right
with respect to any property, assets or Capital Stock not otherwise prohibited under this Agreement. No Loan Party shall, nor
shall it permit its Subsidiaries to, enter into any Contractual Obligations which would prohibit a Subsidiary of Borrower from
being a Loan Party.

 

Section
6.7        Investments.
Borrower shall not, nor shall it permit any of its Subsidiaries to, directly or indirectly, make or own any Investment in any
Person, including without limitation any Joint Venture, except Permitted Investments. Notwithstanding the foregoing, in no event
shall any Loan Party make any Investment which results in or facilitates in any manner any Restricted Junior Payment not otherwise
permitted under the terms of Section 6.5.

 

Section
6.8        Financial
Covenants.

 

(a)       Minimum
Qualified Cash. At all times, Borrower shall not permit Qualified Cash to be less than (a) $50,000,000 during the period commencing
on the Closing Date to (but not including) the Credit Date in respect of the first Delayed Draw Term Loan made hereunder and (b) $60,000,000
thereafter.

 

(b)       Minimum
Revenue. Borrower shall not permit Product Revenue for any Fiscal Quarter set forth below to be less than the amount set forth
opposite such Fiscal Quarter:

 

	Fiscal
    Quarter 

Ending	Product
    Revenue
	 	 
	December 31, 2020	$[***]
	 	 
	March 31, 2021	$[***]
	 	 
	June 30, 2021	$[***]
	 	 
	September 30, 2021	$[***]
	 	 
	December 31, 2021	$[***]

 

     - 73 -

     

    

 

	Fiscal
    Quarter 

Ending	Product
    Revenue
	 	 
	March 31, 2022	$[***]
	 	 
	June 30, 2022 and
    each Fiscal Quarter thereafter	$[***]

 

Section
6.9        Fundamental
Changes; Disposition of Assets; Acquisitions. No Loan Party shall, nor shall it permit any of Borrower's Subsidiaries to,
enter into any transaction of merger or consolidation, or liquidate, wind up or dissolve itself (or suffer any liquidation or
dissolution), including by means of a “plan of division” under the Delaware Limited Liability Company Act or any comparable
transaction under any similar law, or convey, sell, lease or sub lease (as lessor or sublessor), exchange, transfer or otherwise
dispose of, or otherwise enter into or consummate any Asset Sale, in one transaction or a series of transactions, all or any part
of its business, assets or property of any kind whatsoever (including, without limitation, any Product (including, without limitation,
any intellectual property rights related thereto) and any Product Agreement (including, without limitation, any of Company's rights
thereunder)), whether real, personal or mixed and whether tangible or intangible, whether now owned or hereafter acquired, or
acquire by purchase or otherwise (other than purchases or other acquisitions of inventory, materials and equipment and Capital
Expenditures in the ordinary course of business) the business, property or fixed assets of, or stock or other evidence of beneficial
ownership of, any Person or any division or line of business or other business unit of any Person, except:

 

(a)       any
Subsidiary of Borrower may be merged with or into Company or any Guarantor Subsidiary, or be liquidated, wound up or dissolved,
or all or any part of its business, property or assets may be conveyed, sold, leased, transferred or otherwise disposed of, in
one transaction or a series of transactions, to Company or any Guarantor Subsidiary; provided, in the case of such a merger,
Company or such Guarantor Subsidiary, as applicable shall be the continuing or surviving Person. Notwithstanding anything herein
to the contrary, neither Borrower nor any of its Subsidiaries shall divide or enter into any plan of division pursuant to Section
18-217 of the Delaware Limited Liability Company Act (or any similar statute or provision under applicable law);

 

(b)       Asset
Sales (other than (i) subject to Section 6.9(d), those constituting Permitted Product Transactions and (ii) any other Asset
Sale in respect of the Products or the Product Patents) in any Fiscal Year, the proceeds of which are less than $10,000,000 with
respect to any single Asset Sale or series of related Asset Sales made within the same Fiscal Year; provided (A) the consideration
received for such assets shall be in an amount at least equal to the fair market value thereof (determined in good faith by officers
of Company or the Board of Directors of Company (or similar governing body)), (B) no less than 85% thereof shall be paid in Cash,
and (C) if and to the extent required by Section 2.10(a)(ii), the Net Proceeds thereof shall be applied as required by
Section 2.10(a)(ii);

 

(c)       Permitted
Acquisitions and other Permitted Investments;

 

(d)       Asset
Sales constituting Permitted Product Transactions; provided that (i) no Event of Default shall have occurred and be continuing
or would result therefrom (it being understood that this clause (i) shall not prohibit the continued performance by any Loan Party
in the ordinary course of business under contracts entered into prior to the occurrence of any such Event of Default) and (ii)
the Net Proceeds thereof shall be applied as and to the extent required by Section 2.10(a)(i).

 

     - 74 -

     

    

 

(e)       Borrower
or any Subsidiary thereof may sell inventory and immaterial assets in the ordinary course of business;

 

(f)       Dispositions
of obsolete or worn out, retired or surplus property, whether now owned or hereafter acquired, in the ordinary course of business;

 

(g)       Borrower
or any Subsidiary thereof may surrender or waive contractual rights and settle or waive contractual or litigation claims in the
ordinary course of business; and

 

(h)       the
sale or discount with recourse of accounts receivable arising in the ordinary course of business in connection with the compromise
or collection thereof.

 

Section
6.10      Disposal
of Subsidiary Interests. Except for any sale of all of its interests in the Capital Stock of any of its Subsidiaries in compliance
with the provisions of Section 6.9, no Loan Party shall, nor shall it permit any of Borrower’s Subsidiaries to, (a)
directly or indirectly sell, assign, pledge or otherwise encumber or dispose of any Capital Stock of any of its Subsidiaries,
except to qualify directors if required by applicable law; or (b) permit any of its Subsidiaries directly or indirectly to sell,
assign, pledge or otherwise encumber or dispose of any Capital Stock of any of its Subsidiaries, except to another Loan Party
(subject to the restrictions on such disposition otherwise imposed hereunder), or to qualify directors if required by applicable
law.

 

Section
6.11      Sales and
Lease Backs. No Loan Party shall, nor shall it permit any of Borrower’s Subsidiaries to, directly or indirectly, become
or remain liable as lessee or as a guarantor or other surety with respect to any lease of any property (whether real, personal
or mixed), whether now owned or hereafter acquired, which such Loan Party (a) has sold or transferred or is to sell or to transfer
to any other Person (other than Borrower or any of its Subsidiaries) or (b) intends to use for substantially the same purpose
as any other property which has been or is to be sold or transferred by such Loan Party to any Person (other than Borrower or
any of its Subsidiaries) in connection with such lease.

 

Section
6.12      Transactions
with Shareholders and Affiliates. No Loan Party shall, nor shall it permit any of Borrower’s Subsidiaries to, directly
or indirectly, enter into or permit to exist any transaction (including the purchase, sale, lease or exchange of any property
or the rendering of any service) with any Affiliate of Borrower or of any such holder; provided, that the Loan Parties
and Borrower’s Subsidiaries may enter into or permit to exist any such transaction if both Administrative Agent has consented
thereto in writing prior to the consummation thereof and the terms of such transaction are not less favorable to Borrower or that
Subsidiary, as the case may be, than those that might be obtained at the time from a Person who is not such a holder or Affiliate;
further, provided, further, that the foregoing restrictions shall not apply to any of the following:

 

(a)       any
transaction among the Loan Parties expressly permitted hereunder;

 

(b)       reasonable
and customary fees paid to members of the Board of Directors (or similar governing body) of Borrower and its Subsidiaries;

 

(c)       compensation
arrangements for officers and other employees of Borrower and its Subsidiaries entered into in the ordinary course of business;

 

(d)       any
transaction between a Loan Party and any direct or indirect holder of not more than 20% of any class of Capital Stock of Borrower
so long as (i) such transaction is between a Loan Party and a federally regulated financial institution which occurs on an arm’s
length basis in the ordinary course such Loan Party’s business consistent with past practice, (ii) such transaction involves
the ordinary course financial services provided by such financial institution to such Loan Party, excluding any loan or other
form of Indebtedness which is not Permitted Indebtedness, and (iii) such transaction is not otherwise prohibited under the terms
of this Agreement; and

 

     - 75 -

     

    

 

(e)       transactions
described in Schedule 6.12.

 

Section
6.13      Conduct
of Business. From and after the Closing Date, no Loan Party shall, nor shall it permit any of its Subsidiaries to, engage
in any business other than the businesses engaged in by such Loan Party on the Closing Date (or any other business reasonably
related thereto).

 

Section
6.14     Changes to Certain
Agreements and Organizational Documents. No Loan Party shall (i) amend or permit any amendments to any Loan Party’s
Organizational Documents, including, without limitation, any amendment, modification or change to any of Loan Party’s Organizational
Documents to effect a division or plan of division pursuant to Section 18-217 of the Delaware Limited Liability Company Act (or
any similar statute or provision under applicable law); or (ii) amend or permit any amendments by any Loan Parties to, or terminate
or waive any provision of, any Material Contract if such amendment, termination, or waiver would be materially adverse to Administrative
Agent or the Lenders (it being understood that any amendment to a Material Contract to permit set-off or other deduction of amounts
payable thereunder (other than any set-off or other deduction in the ordinary course of business that does not increase the obligations
of a Loan Party) shall be deemed to be materially adverse to the Administrative Agent and the Lenders).

 

Section
6.15      Accounting
Methods. The Loan Parties will not and will not permit any of their Subsidiaries to modify or change its fiscal year or its
method of accounting (other than as may be required to conform to GAAP).

 

Section
6.16      Deposit
Accounts. No Loan Party shall establish or maintain a Deposit Account (other than an Excluded Account) or a Securities Account
that is not subject to a Control Agreement.

 

Section
6.17      Prepayments
of Certain Indebtedness. No Loan Party shall, directly or indirectly, voluntarily purchase, redeem, defease or prepay any
principal of, premium, if any, interest or other amount payable in respect of any Indebtedness prior to its scheduled maturity,
other than (a) the Obligations and (b) Indebtedness secured by a Permitted Lien if the asset securing such Indebtedness has been
sold or otherwise disposed of in accordance with Section 6.9.

 

Section
6.18      Anti-Terrorism
Laws. None of the Loan Parties (nor any of their Affiliates that are controlled by the Loan Parties) or agents shall:

 

(a)       conduct
any business or engage in any transaction or dealing with any Blocked Person, including the making or receiving any contribution
of funds, goods or services to or for the benefit of any Blocked Person,

 

(b)       deal
in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to the OFAC Sanctions
Programs or

 

(c)       engage
in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate,
any of the prohibitions set forth in the OFAC Sanctions Programs, the USA PATRIOT Act or any other Anti-Terrorism Law.

 

The
Company shall deliver to the Lenders any certification or other evidence requested from time to time by any Lender in its sole
discretion, confirming the Company’s compliance with this Section 6.18.

 

     - 76 -

     

    

 

Section
6.19      Anti-Corruption
Laws. No Loan Party shall use, or permit any of its Subsidiaries to use, directly or indirectly, any of the proceeds of any
Loan for the purpose of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else
of value, to any Person in violation of any Anti-Corruption Law.

 

Section
6.20       Real
Property. None of the Borrower or any of its Subsidiaries shall own any real property.

 

Article
VII

GUARANTY

 

Section
7.1        Guaranty
of the Obligations. Subject to the provisions of Section 7.2, Guarantors jointly and severally hereby irrevocably and
unconditionally guaranty for the ratable benefit of the Beneficiaries the due and punctual payment in full of all Obligations
when the same shall become due, whether at stated maturity, by required prepayment, declaration, acceleration, demand or otherwise
(including amounts that would become due but for the operation of the automatic stay under Section 362(a) of the Bankruptcy Code,
11 U.S.C. § 362(a)) (collectively, the “Guaranteed Obligations”).

 

Section
7.2        Contribution
by Guarantors. All Guarantors desire to allocate among themselves, in a fair and equitable manner, their obligations arising
under this Guaranty. Accordingly, in the event any payment or distribution is made on any date by a Guarantor under this Guaranty
such that its Aggregate Payments exceeds its Fair Share as of such date, such Guarantor shall be entitled to a contribution from
each of the other Guarantors in an amount sufficient to cause each Guarantor’s Aggregate Payments to equal its Fair Share
as of such date. “Fair Share” means, with respect to any Guarantor
as of any date of determination, an amount equal to (a) the ratio of (i) the Fair Share Contribution Amount with respect to such
Guarantor, to (ii) the aggregate of the Fair Share Contribution Amounts with respect to all Guarantors multiplied by, (b) the
aggregate amount paid or distributed on or before such date by all Guarantors under this Guaranty in respect of the obligations
Guaranteed. “Fair Share Contribution Amount” means, with respect to
any Guarantor as of any date of determination, the maximum aggregate amount of the obligations of such Guarantor under this Guaranty
that would not render its obligations hereunder subject to avoidance as a fraudulent transfer or conveyance under Section 548
of Title 11 of the United States Code or any comparable applicable provisions of state law; provided, solely for purposes
of calculating the “Fair Share Contribution Amount” with respect to
any Guarantor for purposes of this Section 7.2, any assets or liabilities of such Guarantor arising by virtue of any rights
to subrogation, reimbursement or indemnification or any rights to or obligations of contribution hereunder shall not be considered
as assets or liabilities of such Guarantor. “Aggregate Payments” means,
with respect to any Guarantor as of any date of determination, an amount equal to (A) the aggregate amount of all payments and
distributions made on or before such date by such Guarantor in respect of this Guaranty (including, without limitation, in respect
of this Section 7.2), minus (B) the aggregate amount of all payments received on or before such date by such Guarantor
from the other Guarantors as contributions under this Section 7.2. The amounts payable as contributions hereunder shall
be determined as of the date on which the related payment or distribution is made by the applicable Guarantor. The allocation
among Guarantors of their obligations as set forth in this Section 7.2 shall not be construed in any way to limit the liability
of any Guarantor hereunder. Each Guarantor is a third party beneficiary to the contribution agreement set forth in this Section
7.2.

 

Section
7.3        Payment
by Guarantors. Subject to Section 7.2, Guarantors hereby jointly and severally agree, in furtherance of the foregoing
and not in limitation of any other right which any Beneficiary may have at law or in equity against any Guarantor by virtue hereof,
that upon the failure of Company to pay any of the Guaranteed Obligations when and as the same shall become due, whether at stated
maturity, by required prepayment, declaration, acceleration, demand or otherwise (including amounts that would become due but
for the operation of the automatic stay under Section 362(a) of the Bankruptcy Code, 11 U.S.C. § 362(a)), Guarantors will
upon demand pay, or cause to be paid, in Cash, to Administrative Agent for the ratable benefit of Beneficiaries, an amount equal
to the sum of the unpaid principal amount of all Guaranteed Obligations then due as aforesaid, accrued and unpaid interest on
such Guaranteed Obligations (including interest which, but for Company’s becoming the subject of a case under the Bankruptcy
Code, would have accrued on such Guaranteed Obligations, whether or not a claim is allowed against Company for such interest in
the related bankruptcy case) and all other Guaranteed Obligations then owed to Beneficiaries as aforesaid.

 

     - 77 -

     

    

 

Section
7.4        Liability
of Guarantors Absolute. Each Guarantor agrees that its obligations hereunder are irrevocable, absolute, independent and unconditional
and shall not be affected by any circumstance which constitutes a legal or equitable discharge of a guarantor or surety other
than payment in full of the Guaranteed Obligations. In furtherance of the foregoing and without limiting the generality thereof,
each Guarantor agrees as follows:

 

(a)       this
Guaranty is a guaranty of payment when due and not of collectability. This Guaranty is a primary obligation of each Guarantor
and not merely a contract of surety;

 

(b)       Administrative
Agent may enforce this Guaranty upon the occurrence of an Event of Default notwithstanding the existence of any dispute between
Company and any Beneficiary with respect to the existence of such Event of Default;

 

(c)       the
obligations of each Guarantor hereunder are independent of the obligations of Company and the obligations of any other guarantor
(including any other Guarantor) of the obligations of Company, and a separate action or actions may be brought and prosecuted
against such Guarantor whether or not any action is brought against Company or any of such other guarantors and whether or not
Company is joined in any such action or actions;

 

(d)       payment
by any Guarantor of a portion, but not all, of the Guaranteed Obligations shall in no way limit, affect, modify or abridge any
Guarantor’s liability for any portion of the Guaranteed Obligations which has not been paid. Without limiting the generality
of the foregoing, if Administrative Agent is awarded a judgment in any suit brought to enforce any Guarantor’s covenant
to pay a portion of the Guaranteed Obligations, such judgment shall not be deemed to release such Guarantor from its covenant
to pay the portion of the Guaranteed Obligations that is not the subject of such suit, and such judgment shall not, except to
the extent satisfied by such Guarantor, limit, affect, modify or abridge any other Guarantor’s liability hereunder in respect
of the Guaranteed Obligations;

 

(e)       any
Beneficiary, upon such terms as it deems appropriate, without notice or demand and without affecting the validity or enforceability
hereof or giving rise to any reduction, limitation, impairment, discharge or termination of any Guarantor’s liability hereunder,
from time to time may (i) renew, extend, accelerate, increase the rate of interest on, or otherwise change the time, place, manner
or terms of payment of the Guaranteed Obligations; (ii) settle, compromise, release or discharge, or accept or refuse any offer
of performance with respect to, or substitutions for, the Guaranteed Obligations or any agreement relating thereto and/or subordinate
the payment of the same to the payment of any other obligations; (iii) request and accept other guaranties of the Guaranteed Obligations
and take and hold security for the payment hereof or the Guaranteed Obligations; (iv) release, surrender, exchange, substitute,
compromise, settle, rescind, waive, alter, subordinate or modify, with or without consideration, any security for payment of the
Guaranteed Obligations, any other guaranties of the Guaranteed Obligations, or any other obligation of any Person (including any
other Guarantor) with respect to the Guaranteed Obligations; (v) enforce and apply any security now or hereafter held by or for
the benefit of such Beneficiary in respect hereof or the Guaranteed Obligations and direct the order or manner of sale thereof,
or exercise any other right or remedy that such Beneficiary may have against any such security, in each case as such Beneficiary
in its discretion may determine consistent herewith and any applicable security agreement, including foreclosure on any such security
pursuant to one or more judicial or non-judicial sales, whether or not every aspect of any such sale is commercially reasonable,
and even though such action operates to impair or extinguish any right of reimbursement or subrogation or other right or remedy
of any Guarantor against Company or any security for the Guaranteed Obligations; and (vi) exercise any other rights available
to it under the Loan Documents; and

 

     - 78 -

     

    

 

(f)       this
Guaranty and the obligations of Guarantors hereunder shall be valid and enforceable and shall not be subject to any reduction,
limitation, impairment, discharge or termination for any reason (other than payment in full of the Guaranteed Obligations), including
the occurrence of any of the following, whether or not any Guarantor shall have had notice or knowledge of any of them: (i) any
failure or omission to assert or enforce or agreement or election not to assert or enforce, or the stay or enjoining, by order
of court, by operation of law or otherwise, of the exercise or enforcement of, any claim or demand or any right, power or remedy
(whether arising under the Loan Documents, at law, in equity or otherwise) with respect to the Guaranteed Obligations or any agreement
relating thereto, or with respect to any other guaranty of or security for the payment of the Guaranteed Obligations; (ii) any
rescission, waiver, amendment or modification of, or any consent to departure from, any of the terms or provisions (including
provisions relating to events of default) hereof, any of the other Loan Documents or any agreement or instrument executed pursuant
thereto, or of any other guaranty or security for the Guaranteed Obligations, in each case whether or not in accordance with the
terms hereof or such Loan Document or any agreement relating to such other guaranty or security; (iii) the Guaranteed Obligations,
or any agreement relating thereto, at any time being found to be illegal, invalid or unenforceable in any respect; (iv) the application
of payments received from any source (other than payments received pursuant to the other Loan Documents or from the proceeds of
any security for the Guaranteed Obligations, except to the extent such security also serves as collateral for indebtedness other
than the Guaranteed Obligations) to the payment of indebtedness other than the Guaranteed Obligations, even though any Beneficiary
might have elected to apply such payment to any part or all of the Guaranteed Obligations; (v) any Beneficiary’s consent
to the change, reorganization or termination of the corporate structure or existence of Borrower or any of its Subsidiaries and
to any corresponding restructuring of the Guaranteed Obligations; (vi) any failure to perfect or continue perfection of a security
interest in any collateral which secures any of the Guaranteed Obligations; (vii) any defenses, set offs or counterclaims which
Company may allege or assert against any Beneficiary in respect of the Guaranteed Obligations, including failure of consideration,
breach of warranty, payment, statute of frauds, statute of limitations, accord and satisfaction and usury; and (viii) any other
act or thing or omission, or delay to do any other act or thing, which may or might in any manner or to any extent vary the risk
of any Guarantor as an obligor in respect of the Guaranteed Obligations.

 

Section
7.5        Waivers
by Guarantors. Each Guarantor hereby waives, for the benefit of Beneficiaries: (a) any right to require any Beneficiary, as
a condition of payment or performance by such Guarantor, to (i) proceed against Company, any other guarantor (including any other
Guarantor) of the Guaranteed Obligations or any other Person, (ii) proceed against or exhaust any security held from Company,
any such other guarantor or any other Person, (iii) proceed against or have resort to any balance of any Deposit Account or credit
on the books of any Beneficiary in favor of Company or any other Person, or (iv) pursue any other remedy in the power of any Beneficiary
whatsoever; (b) any defense arising by reason of the incapacity, lack of authority or any disability or other defense of Company
or any other Guarantor including any defense based on or arising out of the lack of validity or the unenforceability of the Guaranteed
Obligations or any agreement or instrument relating thereto or by reason of the cessation of the liability of Company or any other
Guarantor from any cause other than payment in full of the Guaranteed Obligations; (c) any defense based upon any statute or rule
of law which provides that the obligation of a surety must be neither larger in amount nor in other respects more burdensome than
that of the principal; (d) any defense based upon any Beneficiary’s errors or omissions in the administration of the Guaranteed
Obligations, except behavior which amounts to bad faith; (e) (i) any principles or provisions of law, statutory or otherwise,
which are or might be in conflict with the terms hereof and any legal or equitable discharge of such Guarantor’s obligations
hereunder, (ii) the benefit of any statute of limitations affecting such Guarantor’s liability hereunder or the enforcement
hereof, (iii) any rights to set offs, recoupments and counterclaims, and (iv) promptness, diligence and any requirement that any
Beneficiary protect, secure, perfect or insure any security interest or lien or any property subject thereto; (f) notices, demands,
presentments, protests, notices of protest, notices of dishonor and notices of any action or inaction, including acceptance hereof,
notices of default hereunder or any agreement or instrument related thereto, notices of any renewal, extension or modification
of the Guaranteed Obligations or any agreement related thereto, notices of any extension of credit to Company and notices of any
of the matters referred to in Section 7.4 and any right to consent to any thereof; and (g) any defenses or benefits that
may be derived from or afforded by law which limit the liability of or exonerate guarantors or sureties, or which may conflict
with the terms hereof.

 

     - 79 -

     

    

 

Section
7.6        Guarantors’
Rights of Subrogation, Contribution, etc. Until the Guaranteed Obligations shall have been indefeasibly paid in full and the
Delayed Draw Term Loan Commitments have been terminated, each Guarantor hereby waives any claim, right or remedy, direct or indirect,
that such Guarantor now has or may hereafter have against Company or any other Guarantor or any of its assets in connection with
this Guaranty or the performance by such Guarantor of its obligations hereunder, in each case whether such claim, right or remedy
arises in equity, under contract, by statute, under common law or otherwise and including without limitation (a) any right of
subrogation, reimbursement or indemnification that such Guarantor now has or may hereafter have against Company with respect to
the Guaranteed Obligations, (b) any right to enforce, or to participate in, any claim, right or remedy that any Beneficiary now
has or may hereafter have against Company, and (c) any benefit of, and any right to participate in, any collateral or security
now or hereafter held by any Beneficiary. In addition, until the Guaranteed Obligations shall have been indefeasibly paid in full
and the Delayed Draw Term Loan Commitments have been terminated, each Guarantor shall withhold exercise of any right of contribution
such Guarantor may have against any other guarantor (including any other Guarantor) of the Guaranteed Obligations, including,
without limitation, any such right of contribution as contemplated by Section 7.2. Each Guarantor further agrees that,
to the extent the waiver or agreement to withhold the exercise of its rights of subrogation, reimbursement, indemnification and
contribution as set forth herein is found by a court of competent jurisdiction to be void or voidable for any reason, any rights
of subrogation, reimbursement or indemnification such Guarantor may have against Company or against any collateral or security,
and any rights of contribution such Guarantor may have against any such other guarantor, shall be junior and subordinate to any
rights any Beneficiary may have against Company, to all right, title and interest any Beneficiary may have in any such collateral
or security, and to any right any Beneficiary may have against such other guarantor. If any amount shall be paid to any Guarantor
on account of any such subrogation, reimbursement, indemnification or contribution rights at any time when all Guaranteed Obligations
shall not have been finally and indefeasibly paid in full, such amount shall be held in trust for Administrative Agent on behalf
of Beneficiaries and shall forthwith be paid over to Administrative Agent for the benefit of Beneficiaries to be credited and
applied against the Guaranteed Obligations, whether matured or unmatured, in accordance with the terms hereof.

 

Section
7.7        Subordination
of Other Obligations. Any Indebtedness of Company or any Guarantor now or hereafter held by any Guarantor is hereby subordinated
in right of payment to the Guaranteed Obligations, and any such indebtedness collected or received by such Guarantor after an
Event of Default has occurred and is continuing shall be held in trust for Administrative Agent on behalf of Beneficiaries and
shall forthwith be paid over to Administrative Agent for the benefit of Beneficiaries to be credited and applied against the Guaranteed
Obligations but without affecting, impairing or limiting in any manner the liability of such Guarantor under any other provision
hereof.

 

     - 80 -

     

    

 

Section
7.8       Continuing
Guaranty. This Guaranty is a continuing guaranty and shall remain in effect until all of the Guaranteed Obligations shall
have been indefeasibly paid in full and the Delayed Draw Term Loan Commitments have been terminated. Each Guarantor hereby irrevocably
waives any right to revoke this Guaranty as to future transactions giving rise to any Guaranteed Obligations.

 

Section
7.9       Authority
of Guarantors or Company. It is not necessary for any Beneficiary to inquire into the capacity or powers of any Guarantor
or Company or the officers, directors or agents acting or purporting to act on behalf of any of them.

 

Section
7.10      Financial
Condition of Company. Any Credit Extension may be made to Company or continued from time to time without notice to or authorization
from any Guarantor regardless of the financial or other condition of Company at the time of any such grant or continuation is
entered into, as the case may be. No Beneficiary shall have any obligation to disclose or discuss with any Guarantor its assessment,
or any Guarantor’s assessment, of the financial condition of Company. Each Guarantor has adequate means to obtain information
from Company on a continuing basis concerning the financial condition of Company and its ability to perform its obligations under
the Loan Documents, and each Guarantor assumes the responsibility for being and keeping informed of the financial condition of
Company and of all circumstances bearing upon the risk of non-payment of the Guaranteed Obligations. Each Guarantor hereby waives
and relinquishes any duty on the part of any Beneficiary to disclose any matter, fact or thing relating to the business, operations
or conditions of Company now known or hereafter known by any Beneficiary.

 

Section
7.11       Bankruptcy,
etc.

 

(a)       So
long as any Guaranteed Obligations remain outstanding, no Guarantor shall, without the prior written consent of Administrative
Agent acting pursuant to the instructions of Required Lenders, commence or join with any other Person in commencing any bankruptcy,
reorganization or insolvency case or proceeding of or against Company or any other Guarantor. The obligations of Guarantors hereunder
shall not be reduced, limited, impaired, discharged, deferred, suspended or terminated by any case or proceeding, voluntary or
involuntary, involving the bankruptcy, insolvency, receivership, reorganization, liquidation or arrangement of Company or any
other Guarantor or by any defense which Company or any other Guarantor may have by reason of the order, decree or decision of
any court or administrative body resulting from any such proceeding.

 

(b)       Each
Guarantor acknowledges and agrees that any interest on any portion of the Guaranteed Obligations which accrues after the commencement
of any case or proceeding referred to in clause (a) above (or, if interest on any portion of the Guaranteed Obligations
ceases to accrue by operation of law by reason of the commencement of such case or proceeding, such interest as would have accrued
on such portion of the Guaranteed Obligations if such case or proceeding had not been commenced) shall be included in the Guaranteed
Obligations because it is the intention of Guarantors and Beneficiaries that the Guaranteed Obligations which are guaranteed by
Guarantors pursuant hereto should be determined without regard to any rule of law or order which may relieve Company of any portion
of such Guaranteed Obligations. Guarantors will permit any trustee in bankruptcy, receiver, debtor in possession, assignee for
the benefit of creditors or similar person to pay Administrative Agent, or allow the claim of Administrative Agent in respect
of, any such interest accruing after the date on which such case or proceeding is commenced.

 

(c)       In
the event that all or any portion of the Guaranteed Obligations are paid by Company, the obligations of Guarantors hereunder shall
continue and remain in full force and effect or be reinstated, as the case may be, in the event that all or any part of such payment(s)
are rescinded or recovered directly or indirectly from any Beneficiary as a preference, fraudulent transfer or otherwise, and
any such payments which are so rescinded or recovered shall constitute Guaranteed Obligations for all purposes hereunder.

 

     - 81 -

     

    

 

Section
7.12     Discharge of
Guaranty Upon Sale of Guarantor. If all of the Capital Stock of any Guarantor or any of its successors in interest hereunder
shall be sold or otherwise disposed of (including by merger or consolidation) in accordance with the terms and conditions hereof,
the Guaranty of such Guarantor or such successor in interest, as the case may be, hereunder shall automatically be discharged
and released without any further action by any Beneficiary or any other Person effective as of the time of such sale or disposition.

 

Article
VIII

EVENTS OF DEFAULT

 

Section
8.1         Events
of Default. If any one or more of the following conditions or events shall occur:

 

(a)       Failure
to Make Payments When Due. Failure by Company to pay (i) the principal of and premium, if any, on any Term Loan whether at
stated maturity, by acceleration or otherwise; (ii) when due any installment of principal of any Term Loan, by notice of voluntary
prepayment, by mandatory prepayment or otherwise; or (iii) within three (3) Business Days when due any interest on any Term Loan
or any fee or any other amount due hereunder; or

 

(b)       Default
in Other Agreements. (i) Failure of any Loan Party or any of Borrower’s Subsidiaries to pay when due any principal of
or interest on or any other amount payable in respect of one or more items of Indebtedness (other than Indebtedness referred to
in Section 8.1(a)) in an individual principal amount of $5,000,000 or more or with an aggregate principal amount of $5,000,000
or more, in each case beyond the grace or cure period, if any, provided therefor; or (ii) breach or default by any Loan Party
with respect to any other material term of (A) one or more items of Indebtedness in the individual or aggregate principal amounts
referred to in clause (i) above, or (B) any loan agreement, mortgage, indenture or other agreement relating to such item(s)
of Indebtedness referred to in clause (i) above, in each case beyond the grace or cure period, if any, provided therefor, if the
effect of such breach or default is to cause, or to permit the holder or holders of that Indebtedness (or a trustee on behalf
of such holder or holders), to cause, that Indebtedness to become or be declared due and payable (or subject to a compulsory repurchase
or redeemable) or to require the prepayment, redemption, repurchase or defeasance of, or to cause Borrower or any of Borrower’s
Subsidiaries to make any offer to prepay, redeem, repurchase or defease such Indebtedness, prior to its stated maturity or the
stated maturity of any underlying obligation, as the case may be; or

 

(c)       Breach
of Covenants. Failure of any Loan Party to perform or comply with any term or condition contained in (i) Section 2.2,
Section 5.1(a)-(m), Section 5.1(o)-(r), Section 5.2, Section 5.3, Section 5.5, Section 5.8,
Section 5.9, Section 5.12, Section 5.13 or Article VI or (ii) Section 5.4, Section 5.6, Section
5.7, Section 5.10 or Section 5.11, and, solely in the case of this clause (ii), such failure shall continue
unremedied for 10 Business Days following notice of such failure; or

 

(d)       Breach
of Representations, etc. Any representation, warranty, certification or other statement made or deemed made by any Loan Party
in any Loan Document or in any statement or certificate at any time given by any Loan Party or any of Borrower’s Subsidiaries
in writing pursuant hereto or thereto or in connection herewith or therewith shall be false in any material respect (except that
such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified
as to “materiality” or “Material Adverse Effect” in the text thereof, which representations and warranties
shall be true and correct in all respects subject to such qualification) as of the date made or deemed made; or

 

     - 82 -

     

    

 

(e)       Other
Defaults Under Loan Documents. Any Loan Party shall default in the performance of or compliance with any term contained herein
or any of the other Loan Documents, other than any such term referred to in any other Section of this Section 8.1, and
such default shall not have been remedied or waived within thirty days after the earlier of (i) an Authorized Officer of such
Loan Party becoming aware of such default, or (ii) receipt by Company of written notice from Administrative Agent of such default;
or

 

(f)        Involuntary
Bankruptcy; Appointment of Receiver, etc. (i) A court of competent jurisdiction shall enter a decree or order for relief in
respect of Borrower or any of its Subsidiaries in an involuntary case under the Bankruptcy Code or under any other applicable
bankruptcy, insolvency or similar law now or hereafter in effect, which decree or order is not stayed; or any other similar relief
shall be granted under any applicable federal or state law; or (ii) an involuntary case shall be commenced against Borrower or
any of its Subsidiaries under the Bankruptcy Code or under any other applicable bankruptcy, insolvency or similar law now or hereafter
in effect; or a decree or order of a court having jurisdiction in the premises for the appointment of a receiver, liquidator,
sequestrator, trustee, custodian or other officer having similar powers over Borrower or any of its Subsidiaries, or over all
or a substantial part of its property, shall have been entered; or there shall have occurred the involuntary appointment of an
interim receiver, trustee or other custodian of Borrowers or any of its Subsidiaries for all or a substantial part of its property;
or a warrant of attachment, execution or similar process shall have been issued against any substantial part of the property of
Borrower or any of its Subsidiaries, and any such event described in the foregoing clause (i) or (ii) shall continue
for sixty days without having been dismissed, bonded or discharged; or

 

(g)       Voluntary
Bankruptcy; Appointment of Receiver, etc. (i) Borrower or any of its Subsidiaries shall have an order for relief entered with
respect to it or shall commence a voluntary case under the Bankruptcy Code or under any other applicable bankruptcy, insolvency
or similar law now or hereafter in effect, or shall consent to the entry of an order for relief in an involuntary case, or to
the conversion of an involuntary case to a voluntary case, under any such law, or shall consent to the appointment of or taking
possession by a receiver, trustee or other custodian for all or a substantial part of its property; or Borrower or any of its
Subsidiaries shall make any assignment for the benefit of creditors; or (ii) Borrower or any of its Subsidiaries shall be unable,
or shall fail generally, or shall admit in writing its inability, to pay its debts as such debts become due; or the Board of Directors
(or similar governing body) of Borrower or any of its Subsidiaries shall adopt any resolution or otherwise authorize any action
to approve any of the actions referred to herein; or

 

(h)       Judgments
and Attachments. Any money judgment, writ or warrant of attachment or similar process involving (i) in any individual case
an amount in excess of $5,000,000 or (ii) in the aggregate at any time an amount in excess of $5,000,000 (in either case to the
extent not adequately covered by insurance as to which a solvent and unaffiliated insurance company has not denied coverage) shall
be entered or filed against Borrower or any of its Subsidiaries or any of their respective assets and shall remain undischarged,
unvacated, unbonded or unstayed for a period of sixty days (or in any event later than five days prior to the date of any proposed
sale thereunder); or

 

(i)        Dissolution.
Any order, judgment or decree by a Governmental Authority having appropriate jurisdiction shall be entered against any Loan Party
or any of its Subsidiaries decreeing the dissolution or split up of such Loan Party or any of its Subsidiaries and such order
shall remain undischarged or unstayed for a period in excess of forty-five days; or

 

     - 83 -

     

    

 

(j)        Change
of Control. A Change of Control shall occur; or

 

(k)       Guaranties,
Collateral Documents and other Loan Documents. At any time after the execution and delivery thereof, (i) the Guaranty for
any reason, other than the satisfaction in full of all Obligations, shall cease to be in full force and effect (other than in
accordance with its terms) or shall be declared to be null and void or any Guarantor shall repudiate its obligations thereunder,
(ii) this Agreement or any Collateral Document ceases to be in full force and effect (other than by reason of a release of Collateral
in accordance with the terms hereof or thereof or the satisfaction in full of the Obligations in accordance with the terms hereof)
or shall be declared null and void, or Administrative Agent shall not have or shall cease to have a valid and perfected Lien in
any Collateral purported to be covered by the Collateral Documents with the priority required by the relevant Collateral Document,
in each case for any reason other than the failure of Administrative Agent or any Secured Party to take any action within its
control, or (iii) any Loan Party shall contest the validity or enforceability of any Loan Document in writing or deny in writing
that it has any further liability, including with respect to future advances by Lenders, under any Loan Document to which it is
a party; or

 

(l)        Proceedings.
The indictment of any Loan Party or any of its Subsidiaries under any criminal statute, or commencement of criminal or civil proceedings
against any Loan Party or any of its Subsidiaries pursuant to which statute or proceedings the penalties or remedies sought or
available include forfeiture to any Governmental Authority of any material portion of the property of such Person; or

 

(m)       ERISA.
The imposition of a Lien pursuant to the Internal Revenue Code or ERISA on any Loan Party with respect to any Pension Plan or
Multiemployer Plan; or

 

(n)       Material
Contracts. The termination of any Material Contract by Company or any other party thereto unless such Material Contract is
contemporaneously replaced by or substituted with a substantially similar contract (i) with another Person who is not a Loan Party
and (ii) containing terms and conditions that (A) taken as a whole are substantially similar to or better than the terms and conditions
of the terminated Material Contract or any other similar Material Contract then in existence or (B) are reasonably acceptable
to Administrative Agent; or

 

(o)       Cessation
of Development or Commercialization. At any time prior to February 15, 2021, Borrower ceases using commercially reasonable
efforts to develop or commercialize any Specified Product Component.

 

Section
8.2        Remedies.
Upon the occurrence and during the continuance of any Event of Default, Administrative Agent shall at the request of the Required
Lenders:

 

(a)       declare
all or any portion of the unpaid principal amount of all outstanding Term Loans, all interest accrued and unpaid thereon, and
all other amounts owing or payable hereunder or under any other Loan Document to be immediately due and payable; without presentment,
demand, protest or other notice of any kind, all of which are hereby expressly waived by each Loan Party; and/or

 

(b)       exercise
on behalf of themselves and the Lenders all rights and remedies available to them and the Lenders under the Loan Documents or
applicable law;

 

provided,
that upon the occurrence of any event specified in Section 8.1(f) or (g) above, the unpaid principal amount of all
outstanding Term Loans and all interest and other amounts as aforesaid shall automatically become due and payable without further
act of Administrative Agent or any Lender.

 

     - 84 -

     

    

 

Section
8.3 Rights Not Exclusive. The rights provided
for in this Agreement and the other Loan Documents are cumulative and are not exclusive of any other rights, powers, privileges
or remedies provided by law or in equity, or under any other instrument, document or agreement now existing or hereafter arising.

 

Article
IX

ADMINISTRATIVE AGENT

 

Section
9.1        Appointment
of Administrative Agent.

 

(a)       TSL
is hereby appointed Administrative Agent hereunder and under the other Loan Documents and each Lender hereby authorizes TSL, in
such capacity, to act as its agent in accordance with the terms hereof and the other Loan Documents to perform, exercise and enforce
any and all other rights and remedies of the Lenders with respect to the Loan Parties, the Obligations or otherwise related to
any of same to the extent reasonably incidental to the exercise by Administrative Agent of the rights and remedies specifically
authorized to be exercised by Administrative Agent by the terms of this Agreement or any other Loan Parties.

 

(b)       Administrative
Agent hereby agrees to act upon the express conditions contained herein and the other Loan Documents, as applicable. The provisions
of this Article IX are solely for the benefit of Administrative Agent and Lenders and no Loan Party shall have any rights
as a third party beneficiary of any of the provisions thereof. In performing its functions and duties hereunder, Administrative
Agent shall act solely as an agent of Lenders and does not assume and shall not be deemed to have assumed any obligation towards
or relationship of agency or trust with or for Borrower or any of its Subsidiaries.

 

Section
9.2        Powers
and Duties. Each Lender irrevocably authorizes Administrative Agent to take such action on such Lender’s behalf and
to exercise such powers, rights and remedies hereunder and under the other Loan Documents as are specifically delegated or granted
to Administrative Agent by the terms hereof and thereof, together with such powers, rights and remedies as are reasonably incidental
thereto. Administrative Agent shall have only those duties and responsibilities that are expressly specified herein and the other
Loan Documents. Administrative Agent may exercise such powers, rights and remedies and perform such duties by or through its agents
or employees Administrative Agent shall not have, by reason hereof or any of the other Loan Documents, a fiduciary relationship
in respect of any Lender; and nothing herein or any of the other Loan Documents, expressed or implied, is intended to or shall
be so construed as to impose upon Administrative Agent any obligations in respect hereof or any of the other Loan Documents except
as expressly set forth herein or therein.

 

Section
9.3        General Immunity.

 

(a)       No
Responsibility for Certain Matters. Administrative Agent shall not be responsible to any Lender for the execution, effectiveness,
genuineness, validity, enforceability, collectability or sufficiency hereof or any other Loan Document or for any representations,
warranties, recitals or statements made herein or therein or made in any written or oral statements or in any financial or other
statements, instruments, reports or certificates or any other documents furnished or made by Administrative Agent to Lenders or
by or on behalf of any Loan Party to Administrative Agent or any Lender in connection with the Loan Documents and the transactions
contemplated thereby or for the financial condition or business affairs of any Loan Party or any other Person liable for the payment
of any Obligations, nor shall Administrative Agent be required to ascertain or inquire as to the performance or observance of
any of the terms, conditions, provisions, covenants or agreements contained in any of the Loan Documents or as to the use of the
proceeds of the Loans or as to the existence or possible existence of any Event of Default or Default or to make any disclosures
with respect to the foregoing. Anything contained herein to the contrary notwithstanding, Administrative Agent shall not have
any liability arising from confirmations of the amount of outstanding Term Loans or the component amounts thereof. In addition,
Administrative Agent shall not be responsible or have any liability for, or have any duty to ascertain, inquire into, monitor
or enforce, compliance with the provisions hereof relating to Disqualified Institutions. Without limiting the generality of the
foregoing, Administrative Agent shall not ‎(x) be obligated to ascertain, monitor or inquire as to whether any Lender or participant
or prospective Lender or participant is a Disqualified Institution or (y) have any liability with respect to or arising out of
any assignment or participation of loans, or disclosure of confidential information, to, or the restrictions on any exercise of
rights or remedies of, any Disqualified Institution.

 

     - 85 -

     

    

 

(b)       Exculpatory
Provisions. Neither Administrative Agent nor any of its officers, partners, directors, employees or agents shall be liable
to Lenders for any action taken or omitted by Administrative Agent under or in connection with any of the Loan Documents except
to the extent caused by Administrative Agent’s gross negligence or willful misconduct, as determined by a court of competent
jurisdiction in a final, non-appealable order. Administrative Agent shall be entitled to refrain from any act or the taking of
any action (including the failure to take an action) in connection herewith or any of the other Loan Documents or from the exercise
of any power, discretion or authority vested in it hereunder or thereunder unless and until Administrative Agent shall have received
instructions in respect thereof from Required Lenders (or such other Lenders as may be required to give such instructions under
Section 10.5) and, upon receipt of such instructions from Required Lenders (or such other Lenders, as the case may be),
Administrative Agent shall be entitled to act or (where so instructed) refrain from acting, or to exercise such power, discretion
or authority, in accordance with such instructions. Without prejudice to the generality of the foregoing, (i) Administrative Agent
shall be entitled to rely, and shall be fully protected in relying, upon any communication, instrument or document believed by
it to be genuine and correct and to have been signed or sent by the proper Person or Persons, and shall be entitled to rely and
shall be protected in relying on opinions and judgments of attorneys (who may be attorneys for Borrower and its Subsidiaries),
accountants, experts and other professional advisors selected by it; and (ii) no Lender shall have any right of action whatsoever
against Administrative Agent as a result of Administrative Agent acting or (where so instructed) refraining from acting hereunder
or any of the other Loan Documents in accordance with the instructions of Required Lenders (or such other Lenders as may be required
to give such instructions under Section 10.5).

 

(c)       Notice
of Default. Administrative Agent shall not be deemed to have knowledge or notice of the occurrence of any Default or Event
of Default, except with respect to Events of Default in the payment of principal, interest and fees required to be paid to Administrative
Agent for the account of the Lenders, unless Administrative Agent shall have received written notice from a Lender or the Loan
Party referring to this Agreement, describing such Default or Event of Default and stating that such notice is a “notice
of default.” Administrative Agent will notify the Lenders of its receipt of any such notice. Administrative Agent shall
take such action with respect to any such Default or Event of Default as may be directed by the Required Lenders in accordance
with Article VIII; provided, however, that unless and until Administrative Agent has received any such direction,
Administrative Agent may (but shall not be obligated to) take such action, or refrain from taking such action, with respect to
such Default or Event of Default as it shall deem advisable or in the best interest of the Lenders.

 

Section
9.4        Administrative
Agent Entitled to Act as Lender. The agency hereby created shall in no way impair or affect any of the rights and powers of,
or impose any duties or obligations upon, Administrative Agent in its individual capacity as a Lender hereunder. With respect
to its participation in the Term Loans, Administrative Agent shall have the same rights and powers hereunder as any other Lender
and may exercise the same as if it were not performing the duties and functions delegated to it hereunder, and the term “Lender”
shall, unless the context clearly otherwise indicates, include Administrative Agent in its individual capacity. Administrative
Agent and its Affiliates may accept deposits from, lend money to, own securities of, and generally engage in any kind of banking,
trust, financial advisory or other business with Borrower or any of its Affiliates as if it were not performing the duties specified
herein, and may accept fees and other consideration from Company for services in connection herewith and otherwise without having
to account for the same to Lenders.

 

     - 86 -

     

    

 

Section
9.5         Lenders’
Representations, Warranties and Acknowledgment.

 

(a)       Each
Lender represents and warrants that it has made its own independent investigation of the financial condition and affairs of Borrower
and its Subsidiaries in connection with Credit Extensions hereunder and that it has made and shall continue to make its own appraisal
of the creditworthiness of Borrower and its Subsidiaries. Administrative Agent shall not have any duty or responsibility, either
initially or on a continuing basis, to make any such investigation or any such appraisal on behalf of Lenders or to provide any
Lender with any credit or other information with respect thereto, whether coming into its possession before the making of the
Term Loans or at any time or times thereafter, and Administrative Agent shall not have any responsibility with respect to the
accuracy of or the completeness of any information provided to Lenders.

 

(b)       Each
Lender, by delivering its signature page to this Agreement and funding its Term Loan on the Closing Date, shall be deemed to have
acknowledged receipt of, and consented to and approved, each Loan Document and each other document required to be approved by
Administrative Agent, Required Lenders or Lenders, as applicable on the Closing Date.

 

(c)       Each
Lender (i) represents and warrants that as of the Closing Date neither such Lender nor its Affiliates or Related Funds owns or
controls, or owns or controls any Person owning or controlling, any trade debt or Indebtedness of any Loan Party other than the
Obligations or any Capital Stock of any Loan Party and (ii) covenants and agrees that from and after the Closing Date neither
such Lender nor its Affiliates and Related Funds shall purchase any trade debt or Indebtedness of any Loan Party other than the
Obligations or Capital Stock described in clause (i) above without the prior written consent of Administrative Agent.

 

Section
9.6       Right
to Indemnity. EACH LENDER, IN PROPORTION TO ITS PRO RATA SHARE, SEVERALLY AGREES TO INDEMNIFY ADMINISTRATIVE AGENT, ITS AFFILIATES
AND ITS RESPECTIVE OFFICERS, PARTNERS, DIRECTORS, TRUSTEES, MEMBERS, INVESTORS, ADVISORS, PARTNERS, EMPLOYEES AND AGENTS OF ADMINISTRATIVE
AGENT (EACH, AN “INDEMNITEE AGENT PARTY”), TO THE EXTENT THAT SUCH
INDEMNITEE AGENT PARTY SHALL NOT HAVE BEEN REIMBURSED BY ANY LOAN PARTY, FOR AND AGAINST ANY AND ALL LIABILITIES, OBLIGATIONS,
LOSSES, DAMAGES, PENALTIES, ACTIONS, JUDGMENTS, SUITS, COSTS, EXPENSES (INCLUDING COUNSEL FEES AND DISBURSEMENTS) OR DISBURSEMENTS
OF ANY KIND OR NATURE WHATSOEVER WHICH MAY BE IMPOSED ON, INCURRED BY OR ASSERTED AGAINST SUCH INDEMNITEE AGENT PARTY IN EXERCISING
ITS POWERS, RIGHTS AND REMEDIES OR PERFORMING ITS DUTIES HEREUNDER OR UNDER THE OTHER LOAN DOCUMENTS OR OTHERWISE IN ITS CAPACITY
AS SUCH INDEMNITEE AGENT PARTY IN ANY WAY RELATING TO OR ARISING OUT OF THIS AGREEMENT OR THE OTHER LOAN DOCUMENTS, IN ALL
CASES, WHETHER OR NOT CAUSED BY OR ARISING, IN WHOLE OR IN PART, OUT OF THE COMPARATIVE, CONTRIBUTORY, OR SOLE NEGLIGENCE OF SUCH
INDEMNITEE AGENT PARTY; PROVIDED, NO LENDER SHALL BE LIABLE FOR ANY PORTION OF SUCH LIABILITIES, OBLIGATIONS, LOSSES,
DAMAGES, PENALTIES, ACTIONS, JUDGMENTS, SUITS, COSTS, EXPENSES OR DISBURSEMENTS RESULTING FROM SUCH INDEMNITEE AGENT PARTY’S
GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, AS DETERMINED BY A COURT OF COMPETENT JURISDICTION IN A FINAL, NON-APPEALABLE ORDER. IF
ANY INDEMNITY FURNISHED TO ANY INDEMNITEE AGENT PARTY FOR ANY PURPOSE SHALL, IN THE OPINION OF SUCH INDEMNITEE AGENT PARTY, BE
INSUFFICIENT OR BECOME IMPAIRED, SUCH INDEMNITEE AGENT PARTY MAY CALL FOR ADDITIONAL INDEMNITY AND CEASE, OR NOT COMMENCE, TO
DO THE ACTS INDEMNIFIED AGAINST UNTIL SUCH ADDITIONAL INDEMNITY IS FURNISHED; PROVIDED, IN NO EVENT SHALL THIS SENTENCE
REQUIRE ANY LENDER TO INDEMNIFY ANY INDEMNITEE AGENT PARTY AGAINST ANY LIABILITY, OBLIGATION, LOSS, DAMAGE, PENALTY, ACTION, JUDGMENT,
SUIT, COST, EXPENSE OR DISBURSEMENT IN EXCESS OF SUCH LENDER’S PRO RATA SHARE THEREOF; AND PROVIDED FURTHER, THIS
SENTENCE SHALL NOT BE DEEMED TO REQUIRE ANY LENDER TO INDEMNIFY ANY INDEMNITEE AGENT PARTY AGAINST ANY LIABILITY, OBLIGATION,
LOSS, DAMAGE, PENALTY, ACTION, JUDGMENT, SUIT, COST, EXPENSE OR DISBURSEMENT DESCRIBED IN THE PROVISO IN THE IMMEDIATELY PRECEDING
SENTENCE.

 

     - 87 -

     

    

 

Section
9.7        Successor Administrative Agent.

 

(a)       Administrative
Agent may resign at any time by giving thirty days’ (or such shorter period as shall be agreed by the Required Lenders)
prior written notice thereof to Lenders and Company. Upon any such notice of resignation, Required Lenders shall have the right,
upon five Business Days’ notice to Company, to appoint a successor Administrative Agent. If no successor shall have been
so appointed by the Required Lenders and shall have accepted such appointment within thirty (30) days after the retiring Administrative
Agent gives notice of its resignation, then the retiring Administrative Agent may, on behalf of the Lenders appoint a successor
Administrative Agent from among the Lenders. Upon the acceptance of any appointment as Administrative Agent hereunder by a successor
Administrative Agent that successor Administrative Agent shall thereupon succeed to and become vested with all the rights, powers,
privileges and duties of the retiring Administrative Agent, and the retiring Administrative Agent shall promptly (i) transfer
to such successor Administrative Agent all sums, securities or Capital Stock and other items of Collateral held under the Collateral
Documents, together with all records and other documents necessary or appropriate in connection with the performance of the duties
of the successor Administrative Agent under the Loan Documents, and (ii) execute and deliver to such successor Administrative
Agent such amendments to financing statements, and take such other actions, as may be necessary or appropriate in connection with
the assignment to such successor Administrative Agent of the security interests created under the Collateral Documents, whereupon
such retiring Administrative Agent shall be discharged from its duties and obligations hereunder. After any retiring Administrative
Agent’s resignation hereunder as Administrative Agent, the provisions of this Article IX shall inure to its benefit
as to any actions taken or omitted to be taken by it while it was Administrative Agent hereunder.

 

(b)       Notwithstanding
anything herein to the contrary, Administrative Agent may assign its rights and duties as Administrative Agent, as applicable,
hereunder to an Affiliate of TSL without the prior written consent of, or prior written notice to, Company or the Lenders; provided
that Company and the Lenders may deem and treat such assigning Administrative Agent as Administrative Agent for all purposes
hereof, unless and until such assigning Administrative Agent provides written notice to Company and the Lenders of such assignment.
Upon such assignment such Affiliate shall succeed to and become vested with all rights, powers, privileges and duties as Administrative
Agent hereunder and under the other Loan Documents.

 

     - 88 -

     

    

 

(c)       Administrative
Agent may perform any and all of its duties and exercise its rights and powers under this Agreement or under any other Loan Document
by or through any one or more sub-agents appointed by Administrative Agent. Administrative Agent and any such sub-agent may perform
any and all of its duties and exercise its rights and powers by or through their respective Affiliates. The exculpatory, indemnification
and other provisions of Section 9.3, Section 9.6 and of this Section 9.7 shall apply to any of the Affiliates
of Administrative Agent and shall apply to their respective activities in connection with the syndication of the credit facilities
provided for herein as well as activities as Administrative Agent. All of the rights, benefits and privileges (including the exculpatory
and indemnification provisions) of Section 9.3, Section 9.6 and of this Section 9.7 shall apply to any such
sub-agent and to the Affiliates of any such sub-agent, and shall apply to their respective activities as sub-agent as if such
sub-agent and Affiliates were named herein. Notwithstanding anything herein to the contrary, with respect to each sub-agent appointed
by Administrative Agent, (i) such sub-agent shall be a third party beneficiary under this Agreement with respect to all such rights,
benefits and privileges (including exculpatory and rights to indemnification) and shall have all of the rights, benefits and privileges
of a third party beneficiary, including an independent right of action to enforce such rights, benefits and privileges (including
exculpatory rights and rights to indemnification) directly, without the consent or joinder of any other Person, against any or
all of the Loan Parties and the Lenders, (ii) such rights, benefits and privileges (including exculpatory rights and rights to
indemnification) shall not be modified or amended without the consent of such sub-agent, and (iii) such sub-agent shall only have
obligations to Administrative Agent and not to any Loan Party, Lender or any other Person and no Loan Party, Lender or any other
Person shall have the rights, directly or indirectly, as a third party beneficiary or otherwise, against such sub-agent.

 

Section
9.8        Collateral
Documents and Guaranty.

 

(a)       Administrative
Agent under Collateral Documents and Guaranty. Each Lender hereby further authorizes Administrative Agent on behalf of and
for the benefit of Lenders, to be the agent for and representative of Lenders with respect to the Guaranty, the Collateral and
the Collateral Documents. Subject to Section 10.5, without further written consent or authorization from Lenders, Administrative
Agent may execute any documents or instruments necessary to (i) release any Lien encumbering any item of Collateral that is the
subject of a sale or other disposition of assets permitted hereby or to which Required Lenders (or such other Lenders as may be
required to give such consent under Section 10.5) have otherwise consented, or (ii) release any Guarantor from the Guaranty
pursuant to Section 7.12 or with respect to which Required Lenders (or such other Lenders as may be required to give such
consent under Section 10.5) have otherwise consented.

 

(b)       Right
to Realize on Collateral and Enforce Guaranty. Anything contained in any of the Loan Documents to the contrary notwithstanding,
Company, Administrative Agent and each Lender hereby agree that (i) no Lender shall have any right individually to realize upon
any of the Collateral or to enforce the Guaranty, it being understood and agreed that all powers, rights and remedies hereunder
may be exercised solely by Administrative Agent, on behalf of Lenders in accordance with the terms hereof and all powers, rights
and remedies under the Collateral Documents may be exercised solely by Administrative Agent, and (ii) in the event of a foreclosure
by Administrative Agent on any of the Collateral pursuant to a public or private sale or any sale of the Collateral in a case
under the Bankruptcy Code, Administrative Agent or any Lender may be the purchaser of any or all of such Collateral at any such
sale and Administrative Agent, as agent for and representative of Secured Parties (but not any Lender or Lenders in its or their
respective individual capacities unless Required Lenders shall otherwise agree in writing) shall be entitled, for the purpose
of bidding and making settlement or payment of the purchase price for all or any portion of the Collateral sold at any such public
sale, to use and apply any of the Obligations as a credit on account of the purchase price for any collateral payable by Administrative
Agent at such sale.

 

Section
9.9       Agency
for Perfection. Administrative Agent and each Lender hereby appoints each other Lender as agent and bailee for the purpose
of perfection the security interests in and liens upon the Collateral in assets which, in accordance with Article 9 of the UCC,
can be perfected only by possession or control (or where the security interest of a secured party with possession or control has
priority over the security interest of another secured party) and Administrative Agent and each Lender hereby acknowledges that
it holds possession of or otherwise controls any such Collateral for the benefit of the Lenders as secured party. Should any Lender
obtain possession or control of any such Collateral, such Lender shall notify Administrative Agent thereof, and, promptly upon
Administrative Agent’s request therefore shall deliver such Collateral to Administrative Agent or in accordance with Administrative
Agent’s instructions. In addition, Administrative Agent shall also have the power and authority hereunder to appoint such
other sub-agents as may be necessary or required under applicable state law or otherwise to perform its duties and enforce its
rights with respect to the Collateral and under the Loan Documents. Each Loan Party by its execution and delivery of this Agreement
hereby consents to the foregoing.

 

     - 89 -

     

    

 

Section
9.10       Reports
and Other Information; Confidentiality; Disclaimers. By becoming a party to this Agreement, each Lender:

 

(a)       is
deemed to have requested that Administrative Agent furnish such Lender or Administrative Agent, promptly after it becomes available,
a copy of each field audit or examination report with respect to Borrower or its Subsidiaries (each a “Report”
and collectively, “Reports”) prepared by or at the request of Administrative
Agent, and Administrative Agent shall so furnish each Lender with such Reports,

 

(b)       expressly
agrees and acknowledges that Administrative Agent does not (i) make any representation or warranty as to the accuracy of any Report,
and (ii) shall not be liable for any information contained in any Report,

 

(c)       expressly
agrees and acknowledges that the Reports are not comprehensive audits or examinations, that Administrative Agent or other party
performing any audit or examination will inspect only specific information regarding Borrower and its Subsidiaries and will rely
significantly upon Borrower’ and its Subsidiaries’ books and records, as well as on representations of such Person’s
personnel,

 

(d)       agrees
to keep all Reports and other material, non-public information regarding Borrower and its Subsidiaries and their operations, assets,
and existing and contemplated business plans in a confidential manner in accordance with Section 10.17, and

 

(e)       without
limiting the generality of any other indemnification provision contained in this Agreement, agrees: (i) to hold Administrative
Agent and any other Lender preparing a Report harmless from any action the indemnifying Lender may take or fail to take or any
conclusion the indemnifying Lender may reach or draw from any Report in connection with any loans or other credit accommodations
that the indemnifying Lender has made or may make to Company, or the indemnifying Lender’s participation in, or the indemnifying
Lender’s purchase of, a loan or loans of Company, and (ii) to pay and protect, and indemnify, defend and hold Administrative
Agent, and any such other Lender preparing a Report harmless from and against, the claims, actions, proceedings, damages, costs,
expenses, and other amounts (including, attorneys’ fees and costs) incurred by Administrative Agent and any such other Lender
or Agent preparing a Report as the direct or indirect result of any third parties who might obtain all or part of any Report through
the indemnifying Lender or Agent.

 

In
addition to the foregoing: (x) any Lender may from time to time request of Administrative Agent in writing that Administrative
Agent provide to such Lender a copy of any report or document provided by Borrower or its Subsidiaries to Administrative Agent
that has not been contemporaneously provided by Borrower or such Subsidiary to such Lender, and, upon receipt of such request,
Administrative Agent promptly shall provide a copy of same to such Lender, (y) to the extent that Administrative Agent is entitled,
under any provision of the Loan Documents, to request additional reports or information from Borrower or its Subsidiaries, any
Lender may, from time to time, reasonably request Administrative Agent to exercise such right as specified in such Lender’s
notice to Administrative Agent, whereupon Administrative Agent promptly shall request of Company the additional reports or information
reasonably specified by such Lender, and, upon receipt thereof from Company or such Subsidiary, Administrative Agent promptly
shall provide a copy of same to such Lender, and (z) any time that Administrative Agent renders to Company a statement regarding
the Loan Account, Administrative Agent shall send a copy of such statement to each Lender.

 

     - 90 -

     

    

 

Section
9.11      Protective
Advances. Subject to the limitations set forth below, Administrative Agent is authorized by Company and the Lenders, from
time to time in Administrative Agent’s sole discretion (but Administrative Agent shall have absolutely no obligation to),
to make disbursements or advances to Company, which Administrative Agent, in its sole discretion, deems necessary or desirable
(i) to preserve or protect the Collateral, or any portion thereof, (ii) to enhance the likelihood of, or maximize the amount of,
repayment of the Loans and other Obligations, or (iii) to pay any other amount chargeable to or required to be paid by Company
pursuant to the terms of this Agreement and the other Loan Documents, including, without limitation, payments of principal, interest,
fees and reimbursable expenses (any of such Loans are in this clause (c) referred to as “Protective Advances”);
provided, that Administrative Agent shall not make any Protective Advance (other than with respect to the payment of payroll,
insurance premiums and rent or leased properties) unless an Event of Default has occurred and is continuing or Borrower has consented
to the making of such Protective Advance. Protective Advances may be made even if the conditions precedent set forth in Article
III have not been satisfied. The interest rate on all Protective Advances shall be at the Base Rate plus the Applicable Margin
for Term Loans. Each Protective Advance shall be secured by the Liens in favor of Collateral Agent in and to the Collateral and
shall constitute Obligations hereunder. The Protective Advances shall constitute Obligations hereunder which may be charged to
the Loan Account in accordance with Section 2.12(i). Company shall pay the unpaid principal amount and all unpaid and accrued
interest of each Protective Advance on the earlier of the Term Loan Maturity Date and the date on which demand for payment is
made by the Administrative Agent. Administrative Agent shall notify each Lender and Company in writing in advance of each such
Protective Advance, which notice shall (y) include a description of the purpose of such Protective Advance and (z) indicate the
date on or after which such Protective Advance may be made. Without limitation to its obligations pursuant to Section 9.6,
each Lender agrees that it shall make available to Administrative Agent, upon such Agent’s demand, in Dollars in immediately
available funds, the amount equal to such Lender’s Pro Rata Share of each such Protective Advance. If such funds are not
made available to Administrative Agent by such Lender, Administrative Agent shall be entitled to recover such funds on demand
from such Lender, together with interest thereon for each day from the date such payment was due until the date such amount is
paid to Administrative Agent, at the Federal Funds Rate for three Business Days and thereafter at the Base Rate.

 

Article
X

MISCELLANEOUS

 

Section
10.1       Notices.

 

(a)       Notices
Generally. Unless otherwise specifically provided herein, any notice or other communication herein required or permitted to
be given to a Loan Party, Administrative Agent, shall be sent to such Person’s address as set forth on Appendix B
or in the other relevant Loan Document, and in the case of any Lender, the address as indicated on Appendix B or otherwise indicated
to Administrative Agent in writing. Each notice hereunder shall be in writing and may be personally served or sent by United States
certified mail, return receipt, or courier service and shall be deemed to have been given when delivered in person or by certified
mail or courier service and signed for against receipt thereof; provided, no notice to Administrative Agent shall be effective
until received by Administrative Agent.

 

     - 91 -

     

    

 

(b)       Electronic
Communications.

 

(i)       Administrative
Agent and Company may, in its discretion, agree to accept notices and other communications to it hereunder by electronic communications
pursuant to procedures approved by it and agreed to in writing within a reasonable time prior to such delivery of such notice
and other communications; provided that approval of such procedures may be limited to particular notices or communications.
Notices and other communications to the Lenders hereunder may be delivered or furnished by electronic communication (including
e-mail and Internet or intranet websites) pursuant to procedures approved by the Administrative Agent, provided that the
foregoing shall not apply to notices to any Lender pursuant to Article II if such Lender has notified the Administrative
Agent that it is incapable of receiving notices under such Article by electronic communication.

 

(ii)       Subject
to the foregoing clause (i), (A) notices and other communications sent to an e-mail address shall be deemed received upon the
sender’s receipt of an acknowledgement from the intended recipient (such as by the “return receipt requested”
function, as available, return e-mail or other written acknowledgement), and (B) notices or communications to Lenders posted to
an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient, at its e-mail address
as described in the foregoing clause (A), of notification that such notice or communication is available and identifying
the website address therefor; provided that, for both clauses (A) and (B) above, if such notice, email or
other communication is not sent during the normal business hours of the recipient, such notice or communication shall be deemed
to have been sent at the opening of business on the next Business Day for the recipient.

 

Section
10.2     Expenses.
Subject to Section 5.6, whether or not the transactions contemplated hereby shall be consummated, Company agrees to pay
promptly (a) all of Administrative Agent’s actual and reasonable out-of-pocket costs and expenses of preparation of the
Loan Documents and any consents, amendments, waivers or other modifications thereto; (b) all the reasonable and documented out-of-pocket
fees, expenses and disbursements of counsel to Administrative Agent in connection with the negotiation, preparation, execution
and administration of the Loan Documents and any consents, amendments, waivers or other modifications thereto and any other documents
or matters requested by Company; (c) all the actual documented costs and reasonable expenses of creating and perfecting Liens
in favor of Administrative Agent, for the benefit of Secured Parties, including filing and recording fees, expenses and taxes,
stamp or documentary taxes, search fees, title insurance premiums and reasonable fees, expenses and disbursements of counsel to
Administrative Agent and of counsel providing any opinions that Administrative Agent or Required Lenders may request in respect
of the Collateral or the Liens created pursuant to the Collateral Documents; (d) all of Administrative Agent ‘s actual documented
costs and reasonable and documented out-of-pocket fees, expenses for, and disbursements of any of Administrative Agent’s
auditors, accountants, or consultants, and all reasonable and documented out-of-pocket attorneys’ fees (including expenses
and disbursements of outside counsel) incurred by Administrative Agent; (e) all the actual documented costs and reasonable and
documented expenses (including the reasonable and documented out-of-pocket fees, expenses and disbursements of any appraisers,
consultants, advisors and agents employed or retained by Administrative Agent and its counsel) in connection with the custody
or preservation of any of the Collateral; (f) all the actual documented costs and reasonable and documented out-of-pocket expenses
of Administrative Agent and Lenders in connection with the attendance at any meetings in connection with this Agreement and the
other Loan Documents (including the meetings referred to in Section 5.7; (g) all other actual and reasonable and documented
out-of-pocket costs and expenses incurred by Administrative Agent in connection with the syndication of the Loans and Commitments
and the negotiation, preparation and execution of the Loan Documents and any consents, amendments, waivers or other modifications
thereto and the transactions contemplated thereby; and (h) after the occurrence and continuance of a Default or an Event of Default,
all costs and expenses, including reasonable attorneys’ fees (including allocated costs of internal counsel) and costs of
settlement, incurred by Administrative Agent and Lenders in enforcing any Obligations of or in collecting any payments due from
any Loan Party hereunder or under the other Loan Documents by reason of such Default or Event of Default (including in connection
with the sale of, collection from, or other realization upon any of the Collateral or the enforcement of the Guaranty) or in connection
with any refinancing or restructuring of the credit arrangements provided hereunder in the nature of a “work out”
or pursuant to any insolvency or bankruptcy cases or proceedings.

 

     - 92 -

     

    

 

Section
10.3      Indemnity.

 

(a)       IN
ADDITION TO THE PAYMENT OF EXPENSES PURSUANT TO SECTION 10.2, WHETHER OR NOT THE TRANSACTIONS CONTEMPLATED HEREBY SHALL
BE CONSUMMATED, EACH LOAN PARTY AGREES TO DEFEND (SUBJECT TO INDEMNITEES’ SELECTION OF COUNSEL), INDEMNIFY, PAY AND HOLD
HARMLESS, ADMINISTRATIVE AGENT AND LENDER, THEIR AFFILIATES AND THEIR RESPECTIVE OFFICERS, PARTNERS, DIRECTORS, TRUSTEES, MEMBERS,
INVESTORS, ADVISORS, PARTNERS, EMPLOYEES AND AGENTS OF ADMINISTRATIVE AGENT AND EACH LENDER (EACH, AN “INDEMNITEE”),
FROM AND AGAINST ANY AND ALL INDEMNIFIED LIABILITIES, IN ALL CASES, WHETHER OR NOT CAUSED BY OR ARISING, IN WHOLE OR IN PART,
OUT OF THE COMPARATIVE, CONTRIBUTORY, OR SOLE NEGLIGENCE OF SUCH INDEMNITEE; PROVIDED, NO LOAN PARTY SHALL HAVE ANY
OBLIGATION TO ANY INDEMNITEE HEREUNDER WITH RESPECT TO (I) ANY INDEMNIFIED LIABILITIES TO THE EXTENT SUCH INDEMNIFIED LIABILITIES
ARISE FROM THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, AS DETERMINED BY A COURT OF COMPETENT JURISDICTION IN A FINAL ORDER SUBJECT
TO NO FURTHER APPEAL, OF THAT INDEMNITEE OR ANY OF ITS AFFILIATES OR (II) ANY SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES RELATING
TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT OR ARISING OUT OF ITS ACTIVITIES IN CONNECTION HEREWITH OR THEREWITH (WHETHER BEFORE
OR AFTER THE CLOSING DATE). TO THE EXTENT THAT THE UNDERTAKINGS TO DEFEND, INDEMNIFY, PAY AND HOLD HARMLESS SET FORTH IN THIS
SECTION 10.3 MAY BE UNENFORCEABLE IN WHOLE OR IN PART BECAUSE THEY ARE VIOLATIVE OF ANY LAW OR PUBLIC POLICY, THE APPLICABLE
LOAN PARTY SHALL CONTRIBUTE THE MAXIMUM PORTION THAT IT IS PERMITTED TO PAY AND SATISFY UNDER APPLICABLE LAW TO THE PAYMENT AND
SATISFACTION OF ALL INDEMNIFIED LIABILITIES INCURRED BY INDEMNITEES OR ANY OF THEM.

 

(b)       To
the extent permitted by applicable law, no Loan Party shall assert, and each Loan Party hereby waives, any claim against Lenders,
Administrative Agent and their respective Affiliates, directors, employees, attorneys or agents, on any theory of liability, for
special, indirect, consequential or punitive damages (as opposed to direct or actual damages) (whether or not the claim therefor
is based on contract, tort or duty imposed by any applicable legal requirement) arising out of, in connection with, as a result
of, or in any way related to, this Agreement or any Loan Document or any agreement or instrument contemplated hereby or thereby
or referred to herein or therein, the transactions contemplated hereby or thereby, any Loan or the use of the proceeds thereof
or any act or omission or event occurring in connection therewith, and Company hereby waives, releases and agrees not to sue upon
any such claim or any such damages, whether or not accrued and whether or not known or suspected to exist in its favor.

 

Section
10.4      Set-Off.
In addition to any rights now or hereafter granted under applicable law and not by way of limitation of any such rights, upon
the occurrence of any Event of Default each Lender, and their respective Affiliates is hereby authorized by each Loan Party at
any time or from time to time subject to the consent of Administrative Agent (such consent not to be unreasonably withheld or
delayed), without notice to any Loan Party or to any other Person (other than Administrative Agent), any such notice being hereby
expressly waived, to set off and to appropriate and to apply any and all deposits (general or special, including Indebtedness
evidenced by certificates of deposit, whether matured or unmatured, but not including trust accounts (in whatever currency)) and
any other Indebtedness at any time held or owing by such Lender to or for the credit or the account of any Loan Party (in whatever
currency) against and on account of the obligations and liabilities of any Loan Party to such Lender hereunder, the participations
under the other Loan Documents, including all claims of any nature or description arising out of or connected hereto, or with
any other Loan Document, irrespective of whether or not (a) such Lender shall have made any demand hereunder, (b) the principal
of or the interest on the Term Loans or any other amounts due hereunder shall have become due and payable pursuant to Article
II and although such obligations and liabilities, or any of them, may be contingent or unmatured or (c) such obligation or
liability is owed to a branch or office of such Lender different from the branch or office holding such deposit or obligation
or such Indebtedness.

 

     - 93 -

     

    

 

Section
10.5      Amendments
and Waivers.

 

(a)       Required
Lenders’ Consent. Subject to Section 10.5(b) and 10.5(b)(i), no amendment, modification, termination or
waiver of any provision of the Loan Documents, or consent to any departure by any Loan Party therefrom, shall in any event be
effective without the written concurrence of the Borrower, Administrative Agent and the Required Lenders.

 

(b)       Affected
Lenders’ Consent. Without the written consent of each Lender (other than a Defaulting Lender) that would be affected
thereby, no amendment, modification, termination, or consent shall be effective if the effect thereof would:

 

(i)       extend
the scheduled final maturity of any Loan or Note;

 

(ii)       waive,
reduce or postpone any scheduled repayment (but not prepayment);

 

(iii)       reduce
the rate of interest on any Loan (other than any waiver of any increase in the interest rate applicable to any Loan pursuant to
Section 2.6) or any fee payable hereunder;

 

(iv)       extend
the time for payment of any such interest or fees;

 

(v)       reduce
the principal amount of any Loan;

 

(vi)       amend,
modify, terminate or waive any provision of this Section 10.5(b) or Section 10.5(b)(i);

 

(vii)       amend
the definition of “Required Lenders” or “Pro Rata Share”;

 

(viii)       release
all or substantially all of the Collateral or all or substantially all of the Guarantors from the Guaranty except as expressly
provided in the Loan Documents;

 

(ix)       subordinate
any of the Obligations or any Lien created by this Agreement or any other Loan Document; or

 

(x)       consent
to the assignment or transfer by any Loan Party of any of its rights and obligations under any Loan Document.

 

(c)       Other
Consents. No amendment, modification, termination or waiver of any provision of the Loan Documents, or consent to any departure
by any Loan Party therefrom, shall amend, modify, terminate or waive any provision of Article IX as the same applies to
Administrative agent, or any other provision hereof as the same applies to the rights or obligations of Administrative Agent,
in each case without the consent of Administrative Agent.

 

     - 94 -

     

    

 

(d)       Execution
of Amendments, etc. Administrative Agent may, but shall have no obligation to, with the concurrence of any Lender, execute
amendments, modifications, waivers or consents on behalf of such Lender. Any waiver or consent shall be effective only in the
specific instance and for the specific purpose for which it was given. No notice to or demand on any Loan Party in any case shall
entitle any Loan Party to any other or further notice or demand in similar or other circumstances. Any amendment, modification,
termination, waiver or consent effected in accordance with this Section 10.5 shall be binding upon each Lender at the time
outstanding, each future Lender and, if signed by a Loan Party, on such Loan Party.

 

Section
10.6      Successors
and Assigns; Participations.

 

(a)       Generally.
This Agreement shall be binding upon the parties hereto and their respective successors and permitted assigns and shall inure
to the benefit of the parties hereto and the successors and permitted assigns of Lenders. No Loan Party’s rights or obligations
hereunder nor any interest therein may be assigned or delegated by any Loan Party without the prior written consent of all Lenders.
Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto,
Indemnitee Agent Parties under Section 9.6, Indemnitees under Section 10.3, their respective successors and assigns
permitted hereby and, to the extent expressly contemplated hereby, Affiliates of each of the Administrative Agent and Lenders)
any legal or equitable right, remedy or claim under or by reason of this Agreement.

 

(b)       Register.
Company, Administrative Agent and Lenders shall deem and treat the Persons listed as Lenders in the Register as the holders and
owners of the corresponding Commitments and Loans listed therein for all purposes hereof, and no assignment or transfer of any
such Commitment or Loan shall be effective, in each case, unless and until an Assignment Agreement effecting the assignment or
transfer thereof shall have been delivered to and accepted by Administrative Agent and recorded in the Register as provided in
Section 10.6(e). Prior to such recordation, all amounts owed with respect to the applicable Commitment or Loan shall be
owed to the Lender listed in the Register as the owner thereof, and any request, authority or consent of any Person who, at the
time of making such request or giving such authority or consent, is listed in the Register as a Lender shall be conclusive and
binding on any subsequent holder, assignee or transferee of the corresponding Commitments or Loans.

 

(c)       Right
to Assign. Each Lender shall have the right at any time to sell, assign or transfer all or a portion of its rights and obligations
under this Agreement, including, without limitation, all or a portion of its Commitment or Loans owing to it or other Obligations
(provided, however, that each such assignment shall be of a uniform, and not varying, percentage of all rights and
obligations under and in respect of any Loan and any related Commitments):

 

(i)       to
any Person meeting the criteria of clause (a) of the definition of the term of “Eligible
Assignee” upon the giving of notice to Company and Administrative Agent in accordance with Section 10.1
of this Agreement; and

 

(ii)       to
any Person otherwise constituting an Eligible Assignee with the consent of Administrative Agent and subject to the terms of the
Assignment Letter; provided, each such assignment pursuant to this Section 10.6(c)(ii) shall be in an aggregate
amount of not less than $1,000,000 (or such lesser amount as may be agreed to by Company and Administrative Agent).

 

     - 95 -

     

    

 

(d)       Mechanics.
The assigning Lender and the permitted assignee thereof shall execute and deliver to Administrative Agent (i) an Assignment Agreement,
together with such forms or certificates with respect to United States federal income Tax withholding matters pursuant to Section
2.15(e) as if such assignee were a Lender, and (ii) a joinder to the Assignment Letter.

 

(e)       Notice
of Assignment. Upon its receipt and acceptance of a duly executed and completed Assignment Agreement, any forms or certificates
required by this Agreement in connection therewith, Administrative Agent shall record the information contained in such Assignment
Agreement in the Register, shall give written notice thereof to Company promptly (and in any event, within 30 days upon Administrative
Agent’s receipt and acceptance thereof; provided, such assignment shall be effective upon receipt and acceptance
by Administrative Agent notwithstanding whether Administrative Agent delivers notice thereof to Company) and shall maintain a
copy of such Assignment Agreement.

 

(f)       Representations
and Warranties of Assignee. Each Lender, upon execution and delivery hereof or upon executing and delivering an Assignment
Agreement, as the case may be, represents and warrants as of the Closing Date or as of the applicable Effective Date (as defined
in the applicable Assignment Agreement) that (i) it is an Eligible Assignee; (ii) it has experience and expertise in the making
of or investing in commitments or loans such as the applicable Commitments or Loans, as the case may be; (iii) it will make or
invest in, as the case may be, its Commitments or Loans for its own account in the ordinary course of its business and without
a view to distribution of such Commitments or Loans within the meaning of the Securities Act or the Exchange Act or other federal
securities laws; (iv) such Lender does not own or control, or own or control any Person owning or controlling, any trade debt
or Indebtedness of any Loan Party other than the Obligations or any Capital Stock of any Loan Party; and (v) the representations
and warranties set forth in Section 9.5 of this Agreement are true and correct with respect to such Lender as of the Closing
Date or such applicable Effective Date.

 

(g)       Effect
of Assignment. Subject to the terms and conditions of this Section 10.6, as of the later (i) of the “Effective
Date” specified in the applicable Assignment Agreement or (ii) the date such assignment is recorded in the Register: (A)
the permitted assignee thereunder shall have the rights and obligations of a “Lender” hereunder to the extent such
rights and obligations hereunder have been properly assigned to it pursuant to such Assignment Agreement and shall thereafter
be a party hereto and a “Lender” for all purposes hereof; (B) the assigning Lender thereunder shall, to the extent
that rights and obligations hereunder have been assigned thereby pursuant to such Assignment Agreement, relinquish its rights
(other than any rights which survive the termination hereof under Section 10.8) and be released from its obligations hereunder
(and, in the case of an Assignment Agreement covering all or the remaining portion of an assigning Lender’s rights and obligations
hereunder, such Lender shall cease to be a party hereto; provided, anything contained in any of the Loan Documents to the
contrary notwithstanding, such assigning Lender shall continue to be entitled to the benefit of all indemnities hereunder as specified
herein with respect to matters arising out of the prior involvement of such assigning Lender as a Lender hereunder); (C) the Commitments
shall be modified to reflect the Commitment of such assignee and any Commitment of such assigning Lender, if any; and (D) if any
such assignment occurs after the issuance of any Note hereunder, the assigning Lender shall, upon the effectiveness of such assignment
or as promptly thereafter as practicable, surrender its applicable Notes to Administrative Agent for cancellation, and thereupon
Company shall issue and deliver new Notes, if so requested in writing by the assignee and/or assigning Lender, to such assignee
and/or to such assigning Lender, with appropriate insertions, to reflect the new Commitments and/or outstanding Loans of the assignee
and/or the assigning Lender.

 

     - 96 -

     

    

 

(h)       Participations.

 

(i)       Each
Lender shall have the right at any time, without the consent of, or notice to the Borrower, to sell one or more participations
to any Person (other than Borrower, any of its Subsidiaries or any of its Affiliates) in all or any part of its Commitments, Loans
or in any other Obligation. The holder of any such participation, other than an Affiliate of the Lender granting such participation,
shall not be entitled to require such Lender to take or omit to take any action hereunder except with respect to any amendment,
modification or waiver that would (i) extend the final scheduled maturity of any Term Loan or Note in which such participant is
participating, or reduce the rate or extend the time of payment of interest or fees thereon (except in connection with a waiver
of applicability of any post default increase in interest rates) or reduce the principal amount thereof, or increase the amount
of the participant’s participation over the amount thereof then in effect (it being understood that a waiver of any Default
or Event of Default or of a mandatory reduction in the Commitment shall not constitute a change in the terms of such participation,
and that an increase in any Commitment or Loan shall be permitted without the consent of any participant if the participant’s
participation is not increased as a result thereof), (ii) consent to the assignment or transfer by any Loan Party of any of its
rights and obligations under this Agreement, or (iii) release all or substantially all of the Collateral under the Collateral
Documents or all or substantially all of the Guarantors from the Guaranty (in each case, except as expressly provided in the Loan
Documents) supporting the Loans hereunder in which such participant is participating. Company agrees that each participant shall
be entitled to the benefits of Sections 2.14, 2.15 and 2.19(c) to the same extent as if it were a Lender
and had acquired its interest by assignment pursuant to Section 10.6(c); provided, a participant that would be a
Non-US Lender if it were a Lender shall not be entitled to the benefits of Section 2.15 unless, at the time such participant
is claiming such benefits, Company is notified of the participation sold to such participant and such participant agrees, for
the benefit of Company, to comply with Section 2.15 as though it were a Lender. To the extent permitted by law, each participant
also shall be entitled to the benefits of Section 10.4 as though it were a Lender, provided such Participant agrees to
be subject to Section 2.13 as though it were a Lender.

 

(ii)       In
the event that any Lender sells participations in its Commitments, Loans or in any other Obligation hereunder in accordance with
and subject to the terms and conditions of the foregoing subclause (i), such Lender shall, acting solely for this purpose as a
non-fiduciary agent of Company, maintain a register on which it enters the name of all participants in the Commitments, Loans
or Obligations held by it and the principal amount (and stated interest thereon) of the portion of such Commitments, Loans or
Obligations which are the subject of the participation (the “Participant Register”).
A Commitment, Loan or Obligation hereunder may be participate in whole or in part only by registration of such participation on
the Participant Register (and each Note shall expressly so provide). The Participant Register shall be available for inspection
by Company at any reasonable time and from time to time upon reasonable prior notice.

 

(i)       Certain
Other Assignments. In addition to any other assignment permitted pursuant to this Section 10.6, any Lender or Agent
may assign, pledge and/or grant a security interest in, all or any portion of its Loans, the other Obligations owed by or to such
Lender, and its Notes, if any, to secure obligations of such Lender or Agent or any of its Affiliates to any Person providing
any loan, letter of credit or other extension of credit or financial arrangement to or for the account of such Lender or Agent
or any of its Affiliates and any agent, trustee or representative of such Person (without the consent of, or notice to, or any
other action by, any other party hereto), including, without limitation, any Federal Reserve Bank as collateral security pursuant
to Regulation A of the Board of Governors of the Federal Reserve System and any operating circular issued by such Federal Reserve
Bank; provided, no Lender or Agent, as between Company and such Lender or Agent, shall be relieved of any of its obligations
hereunder as a result of any such assignment and pledge; provided further, in no event shall such Person, agent, trustee
or representative of such Person or the applicable Federal Reserve Bank be considered to be a “Lender” or “Agent”
or be entitled to require the assigning Lender or Agent to take or omit to take any action hereunder.

 

     - 97 -

     

    

 

Section
10.7       Independence
of Covenants. All covenants hereunder shall be given independent effect so that if a particular action or condition is not
permitted by any of such covenants, the fact that it would be permitted by an exception to, or would otherwise be within the limitations
of, another covenant shall not avoid the occurrence of a Default or an Event of Default if such action is taken or condition exists.

 

Section
10.8      Survival
of Representations, Warranties and Agreements. All representations, warranties and agreements made herein shall survive the
execution and delivery hereof and the making of any Credit Extension. Notwithstanding anything herein or implied by law to the
contrary, the agreements of each Loan Party set forth in Sections,2.14, 2.15, 2.19(c), 10.2,
10.3, 10.4, and 10.10 and the agreements of Lenders set forth in Section 2.13, 9.3(b) and 9.6
shall survive the payment of the Term Loans and the termination hereof.

 

Section
10.9      No Waiver;
Remedies Cumulative. No failure or delay on the part of Administrative Agent or any Lender in the exercise of any power, right
or privilege hereunder or under any other Loan Document shall impair such power, right or privilege or be construed to be a waiver
of any default or acquiescence therein, nor shall any single or partial exercise of any such power, right or privilege preclude
other or further exercise thereof or of any other power, right or privilege. The rights, powers and remedies given to Administrative
Agent and each Lender hereby are cumulative and shall be in addition to and independent of all rights, powers and remedies existing
by virtue of any statute or rule of law or in any of the other Loan Documents. Any forbearance or failure to exercise, and any
delay in exercising, any right, power or remedy hereunder shall not impair any such right, power or remedy or be construed to
be a waiver thereof, nor shall it preclude the further exercise of any such right, power or remedy.

 

Section
10.10     Marshalling;
Payments Set Aside. Neither Administrative Agent nor any Lender shall be under any obligation to marshal any assets in favor
of any Loan Party or any other Person or against or in payment of any or all of the Obligations. To the extent that any Loan Party
makes a payment or payments to Administrative Agent or Lenders (or to Administrative Agent, on behalf of Lenders), or Administrative
Agent or Lenders enforce any security interests or exercise their rights of setoff, and such payment or payments or the proceeds
of such enforcement or setoff or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set
aside and/or required to be repaid to a trustee, receiver or any other party under any bankruptcy law, any other state or federal
law, common law or any equitable cause, then, to the extent of such recovery, the obligation or part thereof originally intended
to be satisfied, and all Liens, rights and remedies therefor or related thereto, shall be revived and continued in full force
and effect as if such payment or payments had not been made or such enforcement or setoff had not occurred.

 

Section
10.11    Severability.
In case any provision in or obligation hereunder or any Note or other Loan Document shall be invalid, illegal or unenforceable
in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision
or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.

 

Section
10.12   Obligations Several; Independent
Nature of Lenders’ Rights. The obligations of Lenders hereunder are several and no Lender shall be responsible for the
obligations or Commitment of any other Lender hereunder. Nothing contained herein or in any other Loan Document, and no action
taken by Lenders pursuant hereto or thereto, shall be deemed to constitute Lenders as a partnership, an association, a joint venture
or any other kind of entity. The amounts payable at any time hereunder to each Lender shall be a separate and independent debt,
and, subject to Section 9.8, each Lender shall be entitled to protect and enforce its rights arising under this Agreement
and the other Loan Documents and it shall not be necessary for any other Lender to be joined as an additional party in any proceeding
for such purpose.

 

Section
10.13    Headings. Section
headings herein are included herein for convenience of reference only and shall not constitute a part hereof for any other purpose
or be given any substantive effect.

 

     - 98 -

     

    

 

Section
10.14   APPLICABLE LAW. THIS
AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN
ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED IN THE STATE OF NEW YORK.

 

Section
10.15    CONSENT TO JURISDICTION.

 

(a)       ALL
JUDICIAL PROCEEDINGS BROUGHT AGAINST ANY LOAN PARTY ARISING OUT OF OR RELATING HERETO OR ANY OTHER LOAN DOCUMENT, OR ANY OF THE
OBLIGATIONS, MAY BE BROUGHT IN ANY STATE OR FEDERAL COURT OF COMPETENT JURISDICTION IN THE STATE, COUNTY AND CITY OF NEW YORK.
BY EXECUTING AND DELIVERING THIS AGREEMENT, EACH PARTY HERETO IRREVOCABLY (I) ACCEPTS GENERALLY AND UNCONDITIONALLY THE NON-EXCLUSIVE
JURISDICTION AND VENUE OF SUCH COURTS; (II) WAIVES ANY DEFENSE OF FORUM NON CONVENIENS; (III) AGREES THAT SERVICE OF ALL PROCESS
IN ANY SUCH PROCEEDING IN ANY SUCH COURT MAY BE MADE BY REGISTERED OR CERTIFIED MAIL, RETURN RECEIPT REQUESTED, TO THE APPLICABLE
PARTY AT ITS ADDRESS PROVIDED IN ACCORDANCE WITH SECTION 10.1 IS SUFFICIENT TO CONFER PERSONAL JURISDICTION OVER THE APPLICABLE
PARTY IN ANY SUCH PROCEEDING IN ANY SUCH COURT, AND OTHERWISE CONSTITUTES EFFECTIVE AND BINDING SERVICE IN EVERY RESPECT; AND
(IV) AGREES THAT ADMINSTRATIVE AGENT AND LENDERS RETAIN THE RIGHT TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY LAW OR TO
BRING PROCEEDINGS AGAINST ANY LOAN PARTY IN THE COURTS OF ANY OTHER JURISDICTION IF REQUIRED BY LAW.

 

(b)       EACH
PARTY HEREBY AGREES THAT PROCESS MAY BE SERVED ON IT BY CERTIFIED MAIL, RETURN RECEIPT REQUESTED, TO THE ADDRESSES PERTAINING
TO IT AS SPECIFIED IN SECTION 10.1. ANY AND ALL SERVICE OF PROCESS AND ANY OTHER NOTICE IN ANY SUCH ACTION, SUIT OR PROCEEDING
SHALL BE EFFECTIVE AGAINST ANY SUCH PARTY IF GIVEN BY REGISTERED OR CERTIFIED MAIL, RETURN RECEIPT REQUESTED, OR BY ANY OTHER
MEANS OR MAIL WHICH REQUIRES A SIGNED RECEIPT, POSTAGE PREPAID, MAILED AS PROVIDED ABOVE.

 

Section
10.16   WAIVER OF JURY TRIAL.
EACH OF THE PARTIES HERETO HEREBY AGREES TO WAIVE ITS RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED
UPON OR ARISING HEREUNDER OR UNDER ANY OF THE OTHER LOAN DOCUMENTS OR ANY DEALINGS BETWEEN THEM RELATING TO THE SUBJECT MATTER
OF THIS LOAN TRANSACTION OR THE LENDER/BORROWER RELATIONSHIP THAT IS BEING ESTABLISHED. THE SCOPE OF THIS WAIVER IS INTENDED TO
BE ALL ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION,
INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. EACH PARTY HERETO
ACKNOWLEDGES THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS ALREADY RELIED ON
THIS WAIVER IN ENTERING INTO THIS AGREEMENT, AND THAT EACH WILL CONTINUE TO RELY ON THIS WAIVER IN ITS RELATED FUTURE DEALINGS.
EACH PARTY HERETO FURTHER WARRANTS AND REPRESENTS THAT IT HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL AND THAT IT KNOWINGLY
AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. THIS WAIVER IS IRREVOCABLE, MEANING THAT
IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING (OTHER THAN BY A MUTUAL WRITTEN WAIVER SPECIFICALLY REFERRING TO THIS SECTION
10.16 AND EXECUTED BY EACH OF THE PARTIES HERETO), AND THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS
OR MODIFICATIONS HERETO OR ANY OF THE OTHER LOAN DOCUMENTS OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THE LOANS MADE
HEREUNDER. IN THE EVENT OF LITIGATION, THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.

 

     - 99 -

     

    

 

Section
10.17    Confidentiality.
Administrative Agent and Lender shall hold all non-public information (whether delivered prior to or after the Closing Date) regarding
Company and its Subsidiaries and their businesses identified as such by Company (or in the case of information which has not been
identified by Company as confidential, is similar to other information which has been idenfied as confidential and which is readily
identifiable as confidential) and obtained by such Lender from Company or its Subsidiaries pursuant to the requirements hereof
in accordance with such Lender’s customary procedures for handling confidential information of such nature, it being understood
and agreed by Company that, in any event, Administrative Agent or Lender may make (i) disclosures of such information to Affiliates
of Administrative Agent or Lender and to their agents, advisors, directors and shareholders (and to other persons authorized by
a Lender or Agent to organize, present or disseminate such information in connection with disclosures otherwise made in accordance
with this Section 10.17), (ii) disclosures of such information reasonably required by any bona fide or potential assignee,
transferee or participant in connection with the contemplated assignment, transfer or participation by any such Lender of any
Loans or any participations therein, (iii) disclosure to any rating agency when required by it, (iv) disclosure to any Lender’s
financing sources, provided that prior to any disclosure, such financing source is informed of the confidential nature
of the information, (v) disclosures of such information to any actual or potential investors and partners of Administrative Agent
any Lender or their Affiliates, provided that prior to any disclosure, such investor or partner is informed of the confidential
nature of the information, (vi) disclosures in connection with the exercise of any remedies hereunder or under any other Loan
Document or any action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder
or thereunder and (vii) disclosure required or requested in connection with any public filings, whether pursuant to any securities
laws or regulations or rules promulgated therefor (including the Investment Company Act of 1940 or otherwise) or representative
thereof or by the National Association of Insurance Commissioners (and any successor thereto) or pursuant to legal or judicial
process; provided, unless specifically prohibited by applicable law or court order, Administrative Agent and Lender shall
make reasonable efforts to notify Company of any request by any Governmental Authority or representative thereof (other than any
such request in connection with any examination of the financial condition or other routine examination of such Lender by such
Governmental Authority) for disclosure of any such non-public information prior to disclosure of such information and shall cooperate
with any efforts of Company to seek confidential treatment of such information. Notwithstanding anything to the contrary set forth
herein, each party (and each of their respective employees, representatives or other agents) may disclose to any and all persons,
without limitations of any kind, the tax treatment and tax structure of the transactions contemplated by this Agreement and all
materials of any kind (including opinions and other tax analyses) that are provided to any such party relating to such tax treatment
and tax structure. However, any information relating to the tax treatment or tax structure shall remain subject to the confidentiality
provisions hereof (and the foregoing sentence shall not apply) to the extent reasonably necessary to enable the parties hereto,
their respective Affiliates, and their and their respective Affiliates’ directors and employees to comply with applicable
securities laws. For this purpose, “tax treatment” and “tax structure” mean any facts relevant to the
federal income tax treatment of the transactions contemplated by this Agreement but does not include information relating to the
identity of any of the parties hereto or any of their respective Affiliates or the parties to a transaction. Notwithstanding the
foregoing, on or after the Closing Date, Administrative Agent and any Lender may, at its own expense, issue news releases and
publish “tombstone” advertisements and other announcements relating to this transaction in newspapers, trade journals
and other appropriate media (which may include use of logos of one or more of the Loan Parties) (collectively, “Trade
Announcements”). No Loan Party shall permit any of its Affiliates to, issue any Trade Announcement, press release or
other public disclosure using the name, logo or otherwise referring to Administrative Agent, any Lender or any of its Affiliates
without the consent of Administrative Agent or such Lender, except to the extent required to do so under applicable Requirements
of Law and then, if practicable, only after consulting with Administrative Agent or such Lender. The obligations of confidentiality
set forth in this Section 10.17 shall survive until the date that is [***] years following the termination of this Agreement;
provided, that notwithstanding the foregoing, such obligations of confidentiality shall survive until the date that is
[***] years following the Closing Date in respect of (a) [***] and (b) [***]. Any information that remains subject to the confidentiality
obligations of this Section 10.17 that is held by Administrative Agent or any Lender as of the date of the expiration of
the applicable periods set forth in the preceding sentence shall thereafter be promptly destroyed by Administrative Agent or such
Lender; provided, that any such information that is required to be held by Administrative Agent or such Lender following
the expiration of the applicable period set forth in the preceding sentence shall continue to be subject to the confidentiality
obligations set forth in this Section 10.17.

 

     - 100 -

     

    

 

Section
10.18    Usury Savings Clause.
Notwithstanding any other provision herein, the aggregate interest rate charged or agreed to be paid with respect to any of the
Obligations, including all charges or fees in connection therewith deemed in the nature of interest under applicable law shall
not exceed the Highest Lawful Rate. If the rate of interest (determined without regard to the preceding sentence) under this Agreement
at any time exceeds the Highest Lawful Rate, the outstanding amount of the Loans made hereunder shall bear interest at the Highest
Lawful Rate until the total amount of interest due hereunder equals the amount of interest which would have been due hereunder
if the stated rates of interest set forth in this Agreement had at all times been in effect. In addition, if when the Loans made
hereunder are repaid in full the total interest due hereunder (taking into account the increase provided for above) is less than
the total amount of interest which would have been due hereunder if the stated rates of interest set forth in this Agreement had
at all times been in effect, then to the extent permitted by law, Company shall pay to Administrative Agent an amount equal to
the difference between the amount of interest paid and the amount of interest which would have been paid if the Highest Lawful
Rate had at all times been in effect. Notwithstanding the foregoing, it is the intention of Lenders and Company to conform strictly
to any applicable usury laws. Accordingly, if any Lender contracts for, charges, or receives any consideration which constitutes
interest in excess of the Highest Lawful Rate, then any such excess shall be cancelled automatically and, if previously paid,
shall at such Lender’s option be applied to the outstanding amount of the Loans made hereunder or be refunded to Company.
In determining whether the interest contracted for, charged, or received by Administrative Agent or a Lender exceeds the Highest
Lawful Rate, such Person may, to the extent permitted by applicable law, (a) characterize any payment that is not principal as
an expense, fee, or premium rather than interest, (b) exclude voluntary prepayments and the effects thereof, and (c) amortize,
prorate, allocate, and spread in equal or unequal parts the total amount of interest, throughout the contemplated term of the
Obligations hereunder.

 

Section
10.19    Counterparts.
This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an
original, but all such counterparts together shall constitute but one and the same instrument. Delivery of an executed counterpart
of this Agreement by telecopier or electronic mail shall be equally as effective as delivery of an original executed counterpart
of this Agreement. Any party delivering an executed counterpart of this Agreement by telecopier or electronic mail also shall
deliver an original executed counterpart of this Agreement but the failure to deliver an original executed counterpart shall not
affect the validity, enforceability, and binding effect of this Agreement. The foregoing shall apply to each other Loan Document
mutatis mutandis.

 

Section
10.20    Effectiveness.
This Agreement shall become effective upon the execution of a counterpart hereof by each of the parties hereto and receipt by
Company and Administrative Agent of written notification of such execution and authorization of delivery thereof.

 

     - 101 -

     

    

 

Section
10.21    PATRIOT Act Notice.
Each Lender and Agent (for itself and not on behalf of any Lender) hereby notifies the Loan Parties that pursuant to the requirements
of the PATRIOT Act, it may be required to obtain, verify and record information that identifies each Loan Party, which information
includes the name and address of the Loan Parties and other information that will allow such Lender or Agent, as applicable, to
identify the Loan Parties in accordance with the PATRIOT Act.

 

[Remainder
of page intentionally left blank]

 

     - 102 -

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by their respective officers
thereunto duly authorized as of the date first written above.

 

	 	THERAPEUTICSMD,
    INC.
	 	 
	 	By:	/s/
    Daniel Cartwright
	 	Name:
    Daniel Cartwright
	 	Title:
                                         Chief Financial Officer and Treasurer

                                                

                                                

 

	 	VITAMEDMD, LLC
	 	 	 
	 	By:	/s/
    Daniel Cartwright	 
	 	Name: Daniel Cartwright
	 	Title: Chief Financial Officer and Treasurer

 

	 	BOCAGREENMD, INC.
	 	 	 
	 	By:	/s/
    Daniel Cartwright	 
	 	Name: Daniel Cartwright
	 	Title: Chief Financial Officer and Treasurer

 

	 	VITACARE PRESCRIPTION SERVICES, INC.
	 	 	 
	 	By:	/s/
    Daniel Cartwright	 
	 	Name: Daniel Cartwright
	 	Title: Chief Financial Officer and Assistant Treasurer

 

    S-1

    

    

 

	 	TPG
    SPECIALTY LENDING, INC.,
	 	as
                    Administrative Agent and Lender

         

	 	By:	/s/
    Joshua Easterly
	 		Name: Joshua Easterly
	 		Title: CEO

 

    S-2

    

    

 

	 	TOP
    IV TALENTS, LLC,
	 	as
                    Lender

         

	 	By:	/s/
    Joshua Peck
	 	 	Name:
    Joshua Peck
	 	 	Title:
    Vice President

 

	 	TAO
    TALENTS, LLC,
	 	as
                    Lender

         

	 	By:	/s/
    Joshua Peck
	 	 	Name:
    Joshua Peck
	 	 	Title:
    Vice President

 

    S-3

    

    

 

APPENDIX
A-1

TO FINANCING AGREEMENT

 

Initial
Term Loan Commitment

 

	Lender	Initial
    Term Loan Commitment	Pro
    Rata Share
	 	 	 
	TPG Specialty Lending,
    Inc.	$[***]	[***]%
	 	 	 
	TOP IV Talents,
    LLC	$[***]	[***]%
	 	 	 
	TAO Talents, LLC	$[***]	[***]%
	 	 	 
	Total	$200,000,000.00	100%

 

    S-1

    

    

 

APPENDIX
A-2

TO FINANCING AGREEMENT

 

Delayed
Draw A-1 Term Loan Commitments

 

	Lender	Delayed
    Draw A-1 Term Loan Commitment	Pro
    Rata Share
	 	 	 
	TPG Specialty Lending,
    Inc.	$[***]	[***]%
	 	 	 
	TOP IV Talents,
    LLC	$[***]	[***]%
	 	 	 
	TAO Talents, LLC	$[***]	[***]%
	 	 	 
	Total	$50,000,000.00	100%

 

    S-1

    

    

 

APPENDIX
A-3

TO FINANCING AGREEMENT

 

Delayed
Draw A-2 Term Loan Commitments

 

	Lender	Delayed
    Draw A-2 Term Loan Commitment	Pro
    Rata Share
	 	 	 
	TPG Specialty Lending,
    Inc.	$[***]	[***]%
	 	 	 
	TOP IV Talents,
    LLC	$[***]	[***]%
	 	 	 
	TAO Talents, LLC	$[***]	[***]%
	 	 	 
	Total	$50,000,000.00	100%

 

    S-1

    

    

 

APPENDIX
B

TO FINANCING AGREEMENT

 

Notice
Addresses

 

THERAPEUTICSMD,
INC.

6800
Broken Sound Parkway NW

Third Floor

Boca Raton, FL 33487

Attention: Daniel Cartwright, Chief Financial Officer

Email: [***]

 

VITAMEDMD,
LLC

BOCAGREENMD,
INC.

VITACARE
PRESCRIPTION SERVICES, INC.

 

6800
Broken Sound Parkway NW

Third Floor

Boca Raton, FL 33487

Attention: Daniel Cartwright, Chief Financial Officer

Email: [***]

 

in
each case, with a copy to:

 

DLA
Piper LLP

200 South Biscayne Boulevard

Suite 2500

Miami, FL 33131

Attention: Joshua M. Samek

Email: [***]

 

 

    APPENDIX B

    

    

 

TPG
SPECIALTY LENDING, INC., as

Administrative
Agent and a Lender

 

Administrative
Agent’s Principal Office:

888
7th Avenue, 35th Floor

New
York, NY 10106

Attention: Parker Hooper

Facsimile: [***]

Email: [***]

 

with
a copy to:

 

Schulte
Roth & Zabel LLP

919 Third Avenue

New
York, New York 10022

Attention: Frederic L. Ragucci

Email: [***]

 

TOP
IV TALENTS, LLC and

TAO
TALENTS, LLC

as Lenders

[***]

[***]

Attention: TSSPOps

Facsimile: [***]

 

with
a copy to:

 

Schulte
Roth & Zabel LLP

919 Third Avenue

New
York, New York 10022

Attention: Frederic L. Ragucci

Email: [***]

 

 

    APPENDIX B

    

    

 

Schedule
5.13

Post-Closing
Matters

 

1.       [***]

 

2.       [***]

 

3.       [***]

 

4.       [***]

 

5.       Not
later than the date that is 5 Business Days after the Closing Date, the Loan Parties shall have (a) delivered to Administrative
Agent evidence that VitaMedMD LLC has irrevocably opted into Article 8 of the UCC and caused the membership interests therein
to be deemed to be securities for purposes of Article 8 of the UCC, (b) caused such membership interests to be certificated and
(c) delivered such certificated securities (along with appropriate instruments of transfer) to Administrative Agent.

 

 

    APPENDIX B

    

    

 

Schedule
4.1

 

Organization

 

	

    Borrower or Guarantor	

    State of Organization
	TherapeuticsMD,
    Inc.	Nevada
	VitaMedMD
    LLC	Delaware
	BocaGreenMD,
    Inc.	Nevada
	VitaCare
    Prescription Services, Inc.	Florida

 

    2

    

    

 

Schedule
4.2

 

Capital
Stock and Ownership

 

		1.	Existing
                                         Options, Warrants, Calls, Rights, Commitments or Other Agreements Issued by Borrower:1

 

		a.	2009
                                         Long Term Incentive Compensation Plan, as amended

 

		i.	Shares
                                         Outstanding: 15,128,745

 

		ii.	Shares
                                         Available: 44,300

 

		b.	Amended
                                         and Restated 2012 Stock Incentive Plan

 

		i.	Shares
                                         Outstanding: 7,358,974

 

		ii.	Shares
                                         Available: 2,392,833

 

		c.	Warrants:
                                         1,832,571

 

		2.	Organizational
                                         and Capital Structure:

 

	

    Borrower or Guarantor	

    Capitalization
	TherapeuticsMD,
    Inc.	Publicly
    Held
	VitaMedMD
    LLC	100%
    – TherapeuticsMD, Inc.
	BocaGreenMD,
    Inc.	100%
    – TherapeuticsMD, Inc.
	VitaCare
    Prescription Services, Inc.	100%
    – TherapeuticsMD, Inc.

 

 

1
As of March 31, 2019.

 

    3

    

    

 

 

Schedule
4.12

 

Properties; title

 

	

    Borrower or Guarantor	

    Location	Leasehold
                                         or Fee

        

	TherapeuticsMD,
    Inc.	6800
                                         Broken Sound Parkway NW, 

                                         Suite 100

        Boca
        Raton, FL 33487
	Leasehold
	TherapeuticsMD,
    Inc.	6800
                                         Broken Sound Parkway NW, 

                                         Suite 125

        Boca
        Raton, FL 33487
	Leasehold
	TherapeuticsMD,
    Inc.	6800
                                         Broken Sound Parkway NW, 

                                         Suite 150

        Boca
        Raton, FL 33487
	Leasehold
	TherapeuticsMD,
                                         Inc. (Lessor);

        VitaMedMD
        LLC (books and 

        records); BocaGreenMD, Inc. 

        (books and records)
	6800
                                         Broken Sound Parkway NW, 

                                         Suite 300

        Boca
        Raton, FL 33487
	Leasehold

        

	TherapeuticsMD,
    Inc. (Lessor); 

    VitaCare Prescription Services, 

    Inc. (books and records)	951
                                         Yamato Road

        Boca
        Raton, FL 33487
	Leasehold

 

    4

    

    

 

Schedule
4.15

 

material contracts

 

		1.	[***]

 

		2.	[***]

 

		3.	[***]

 

		4.	[***]

  

    5

    

    

 

Schedule
4.23(b)-(c)

 

intellectual property23

 

(b)

 

PRODUCT
PATENTS

 

Issued
Patents:

 

	 	Patent

                                                                                Number
	Title	Filing Date

                                                                                (mm/dd/yy)
	Issue Date

                                                                                (mm/dd/yy)
	Country
	1.        	8,577,716	System
    and Method of Ongoing Evaluation Reporting and Analysis	09/17/09	11/05/13	US
	2.        	8,633,178	Natural
    Combination Hormone Replacement Formulations and Therapies	11/21/12	01/21/14	US
	3.        	8,846,648	Natural
    Combination Hormone Replacement Formulations and Therapies	12/06/13	09/30/14	US
	4.        	8,846,649	Natural
    Combination Hormone Replacement Formulations and Therapies	12/06/13	09/30/14	US
	5.        	8,933,059	Natural
    Combination Hormone Replacement Formulations and Therapies	12/06/13	01/13/15	US
	6.        	8,987,237	Natural
    Combination Hormone Replacement Formulations and Therapies	12/06/13	03/24/15	US
	7.        	8,987,238	Natural
    Combination Hormone Replacement Formulations and Therapies	12/06/13	03/24/15	US
	8.        	8,993,548	Natural
    Combination Hormone Replacement Formulations and Therapies	09/03/14	03/31/15	US
	9.        	8,993,549	Natural
    Combination Hormone Replacement Formulations and Therapies	09/03/14	03/31/15	US
	10.        	9,006,222	Natural
    Combination Hormone Replacement Formulations and Therapies	12/06/13	04/14/15	US
	11.        	9,012,434	Natural
    Combination Hormone Replacement Formulations and Therapies	12/06/13	04/21/15	US
	12.        	9,114,145	Natural
    Combination Hormone Replacement Formulations and Therapies	09/03/14	08/25/15	US
	13.        	9,114,146	Natural
    Combination Hormone Replacement Formulations and Therapies	09/03/14	08/25/15	US

 

 

2
Borrower is the holder of all intellectual property unless otherwise indicated.

 

3
Key: pink - Imvexxy, purple - Bijuva, blue – Annovera.

 

    6

     

    

 

	 	Patent

                                                                                Number
	Title	Filing Date

                                                                                (mm/dd/yy)
	Issue Date

                                                                                (mm/dd/yy)
	Country
	14.        	9,180,091	Soluble
    Estradiol Capsule for Vaginal Insertion	12/20/13	10/10/15	US
	15.        	9,248,136	Transdermal
    Hormone Replacement Therapies	12/12/13	02/02/16	US
	16.        	9,289,382	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	02/17/15	03/22/16	US
	17.        	9,296,780*	Process
    for Alkynylating 16-Substituted-17-Keto Steroids	12/19/12	03/29/16	US
	18.        	9,301,920	Natural
    Combination Hormone Replacement Formulations and Therapies	03/15/13	04/05/16	US
	19.        	D801,518	Pharmaceutical
    Capsule	06/22/15	10/31/17	US
	20.        	9,931,349	Steroid
    Hormone Pharmaceutical Composition	03/30/17	04/03/18	US
	21.        	10,052,386	Progesterone
    Formulations	12/11/13	08/21/18	US
	22.        	10,098,894	Transdermal
    Cream	07/29/15	10/16/18	US
	23.        	10,206,932	Natural
    Combination Hormone Replacement Formulations and Therapies	05/22/15	02/19/19	US
	24.        	10,258,630	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	02/09/18	04/17/19	US
	25.        	89459	Pharmaceutical
    Capsule	12/22/15	02/17/16	AR
	26.        	366507	Pharmaceutical
    Capsule	12/21/15	01/12/16	AU
	27.        	2012340589	Natural
    Combination Hormone Replacement Formulations and Therapies	11/21/12	08/25/16	AU
	28.        	2013211876	Transdermal
    Hormone Replacement Therapies	01/25/13	05/25/17	AU
	29.        	2013277236	Natural
    Combination Hormone Replacement Formulations and Therapies	06/18/13	08/03/17	AU
	30.        	2013277234	Soluble
    Estradiol Capsule for Vaginal Insertion	06/18/13	08/10/17	AU
	31.        	MX
    358440 B	Soluble
    Estradiol Capsule for Vaginal Insertion	06/18/13	08/03/18	MX
	32.        	166,044	Pharmaceutical
    Capsule	12/17/15	08/16/16	CA
	33.        	002916247-0001	Pharmaceutical
    Capsule	12/18/15	08/10/16	EP

 

 

* Licensed patent or patent application.

 

    7

     

    

 

	 	Patent

                                                                                Number
	Title	Filing Date

                                                                                (mm/dd/yy)
	Issue Date

                                                                                (mm/dd/yy)
	Country
	34.        	302015005859-5	Pharmaceutical
    Capsule	12/21/15	01/30/18	BR
	35.        	6285866	Natural
    Combination Hormone Replacement Formulations and Therapies	11/21/12	02/09/18	JP
	36.        	6298460	Progesterone
    Formulations	06/18/13	03/02/18	JP
	37.        	MX
    50237 B	Pharmaceutical
    Capsule	12/18/15	07/19/17	MX
	38.        	30-2015-0065043	Pharmaceutical
    Capsule	12/18/15	03/06/17	KR
	39.        	101179	Pharmaceutical
    Capsule	12/21/15	01/10/17	RU
	40.        	A2015/01935	Pharmaceutical
    Capsule	12/21/15	05/16/17	ZA
	41.        	2015/00211	Natural
    Combination Hormone Replacement Therapies	06/18/13	07/27/16	ZA
	42.        	2015/00212	Progesterone
    Formulations	06/18/13	04/26/17	ZA
	43.        	6334519	Natural
    Combination Hormone Replacement Therapies	06/18/13	05/11/18	JP
	44.        	6342334	Transdermal
    Hormone Replacement Therapies	01/25/13	05/25/18	JP
	45.        	6342389	Transdermal
    Hormone Replacement Therapies	06/18/13	05/25/18	JP
	46.        	6397402	Soluble
    Estradiol Capsule for Vaginal Insertion	06/18/13	09/07/18	JP
	47.        	2013277235	Transdermal
    Hormone Replacement Therapies	06/18/13	08/02/18	AU
	48.        	2013277233	Progesterone
    Formulations	06/18/13	09/13/18	AU
	49.        	1624393	Pharmaceutical
    Capsule	12/21/15	01/18/19	JP
	50.        	2861234B	Progesterone
    Formulations	06/18/13	03/27/19	EP
	51.        	2806742B	Transdermal
    Hormone Replacement Therapies	01/25/13	03/27/19	EP

 

Pending
Patent Applications:

 

	 	Application

                                                                                Number
	Title	Application

                                                                                Date

                                                                                (mm/dd/yy)
	Country
	1.        	16/104,101	Natural
    Combination Hormone Replacement Formulations and Therapies	08/16/18	US

 

    8

     

    

 

	 	Application

                                                                                Number
	Title	Application

                                                                                Date

                                                                                (mm/dd/yy)
	Country
	2.        	BR1120140124442	Natural
    Combination Hormone Replacement Formulations and Therapies	11/21/12	BR
	3.        	2,856,520	Natural
    Combination Hormone Replacement Formulations and Therapies	11/21/12	CA
	4.        	12850845.4	Natural
    Combination Hormone Replacement Formulations and Therapies	11/21/12	EP
	5.        	2017-173842	Natural
    Combination Hormone Replacement Formulations and Therapies	11/21/12	JP
	6.	MX/a/2014/006256	Natural
    Combination Hormone Replacement Formulations and Therapies	11/21/12	MX
	7.        	15/090,493	Natural
    Combination Hormone Replacement Formulations and Therapies	04/04/16	US
	8.        	20140101244	Natural
    Combination Hormone Replacement Formulations and Therapies	03/17/14	AR
	9.        	2017206262	Natural
    Combination Hormone Replacement Formulations and Therapies	07/20/17	AU
	10.        	BR1120140319103	Natural
    Combination Hormone Replacement Formulations and Therapies	06/18/13	BR
	11.        	2,876,977	Natural
    Combination Hormone Replacement Formulations and Therapies	06/18/13	CA
	12.        	13806855.6	Natural
    Combination Hormone Replacement Formulations and Therapies	06/18/13	EP
	13.        	236358	Natural
    Combination Hormone Replacement Formulations and Therapies	06/18/13	IL
	14.        	2017-176379	Natural
    Combination Hormone Replacement Formulations and Therapies	06/18/13	JP
	15.        	10-2015-7001189	Natural
    Combination Hormone Replacement Formulations and Therapies	06/18/13	KR
	16.        	MX/a/2014/015898	Natural
    Combination Hormone Replacement Formulations and Therapies	06/18/13	MX
	17.        	2015100533	Natural
    Combination Hormone Replacement Formulations and Therapies	06/18/13	RU
	18.        	15/999,040	Natural
    Combination Hormone Replacement Formulations and Therapies	08/16/18	US
	19.        	14/512,046	Natural
    Combination Hormone Replacement Formulations and Therapies	10/10/14	US

 

    9

     

    

 

	 	Application

                                                                                Number
	Title	Application

                                                                                Date

                                                                                (mm/dd/yy)
	Country
	20.        	20150101608	Natural
    Combination Hormone Replacement Formulations and Therapies	05/22/15	AR
	21.        	2015264003	Natural
    Combination Hormone Replacement Formulations and Therapies	05/22/15	AU
	22.        	BR112016
    027359 1	Natural
    Combination Hormone Replacement Formulations and Therapies	05/22/15	BR
	23.        	2,947,767	Natural
    Combination Hormone Replacement Formulations and Therapies	05/22/15	CA
	24.        	15727528.0	Natural
    Combination Hormone Replacement Formulations and Therapies	05/22/15	EP
	25.        	248985	Natural
    Combination Hormone Replacement Formulations and Therapies	05/22/15	IL
	26.        	2016-565647	Natural
    Combination Hormone Replacement Formulations and Therapies	05/22/15	JP
	27.        	10-2016-7032773	Natural
    Combination Hormone Replacement Formulations and Therapies	05/22/15	KR
	28.        	MX/a/2016/014281	Natural
    Combination Hormone Replacement Formulations and Therapies	05/22/15	MX
	29.        	2016143081	Natural
    Combination Hormone Replacement Formulations and Therapies	05/22/15	RU
	30.        	2016/07541	Natural
    Combination Hormone Replacement Formulations and Therapies	05/22/15	ZA
	31.        	15/832,757	Natural
    Combination Hormone Replacement Formulations and Therapies	12/05/17	US
	32.        	PCT/US2017/064788	Natural
    Combination Hormone Replacement Formulations and Therapies	12/05/17	PCT
	33.        	15/832,750	Natural
    Combination Hormone Replacement Formulations and Therapies	12/05/17	US
	34.        	16/244,020	Natural
    Combination Hormone Replacement Formulations and Therapies	01/09/19	US
	35.        	16/355,532	Natural
    Combination Hormone Replacement Formulations and Therapies	03/15/19	US
	36.        	62/822,609	Natural
    Combination Hormone Replacement Formulations and Therapies	03/22/19	US
	37.        	14/649,818	Soluble
    Estradiol Capsule for Vaginal Insertion	12/17/15	US
	38.        	2017208300	Soluble
    Estradiol Capsule for Vaginal Insertion	06/18/13	AU

 

    10

     

    

 

	 	Application

                                                                                Number
	Title	Application

                                                                                Date

                                                                                (mm/dd/yy)
	Country
	39.        	BR1120140319146	Soluble
    Estradiol Capsule for Vaginal Insertion	06/18/13	BR
	40.        	2,876,968	Soluble
    Estradiol Capsule for Vaginal Insertion	06/18/13	CA
	41.        	13807188.1	Soluble
    Estradiol Capsule for Vaginal Insertion	06/18/13	EP
	42.        	236359	Soluble
    Estradiol Capsule for Vaginal Insertion	06/18/13	IL
	43.        	10-2015-7001193	Soluble
    Estradiol Capsule for Vaginal Insertion	06/18/13	KR
	44.        	MX/A/2018/009466	Soluble
    Estradiol Capsule for Vaginal Insertion	08/02/18	MX
	45.        	2015100531	Soluble
    Estradiol Capsule for Vaginal Insertion	06/18/13	RU
	46.        	2014/09278	Soluble
    Estradiol Capsule for Vaginal Insertion	06/18/13	ZA
	47.        	2018-162966	Soluble
    Estradiol Capsule for Vaginal Insertion	06/18/13	JP
	48.        	14/521,230	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	US
	49.        	20140103975	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	AR
	50.        	2014349132	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	AU
	51.        	BR1120160090080	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	BR
	52.        	2,926,342	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	CA
	53.        	14862905.8	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	EP
	54.        	245139	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	IL
	55.        	2016-516086	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	JP
	56.        	10-2016-7010901	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	KR
	57.        	MX/A/2016/005092	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	MX
	58.        	2016118396	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	RU
	59.        	2016/01933	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	ZA

 

    11

     

    

 

	 	Application

                                                                                Number
	Title	Application

                                                                                Date

                                                                                (mm/dd/yy)
	Country
	60.        	14/521,002	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	US
	61.        	15/372,385	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	US
	62.        	PCT/US2016/065466	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	PCT
	63.        	20160103768	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	AR
	64.        	2016366200	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	AU
	65.        	BR1120180114839	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	BR
	66.        	3,007,636	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	CA
	67.        	16873806.0	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	EP
	68.        	19122548.1	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	04/17/19	HK
	69.        	259884	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	IL
	70.        	2018-529574	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	JP
	71.        	10-2018-7019331	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	KR
	72.        	MX/A/2018/006882	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	MX
	73.        	743229	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	NZ
	74.        	2018121094	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	RU
	75.        	2018/03804	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	ZA
	76.        	62/680,715	Vaginal
    Inserted Estradiol Pharmaceutical Formulations and Methods	06/06/18	US

 

    12

     

    

 

	 	Application

                                                                                Number
	Title	Application

                                                                                Date

                                                                                (mm/dd/yy)
	Country
	77.        	15/893,542**	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	02/09/18	US
	78.        	15/893,550**	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	02/09/18	US
	79.        	15/975,733	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	05/09/18	US
	80.        	15/975,723	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	05/09/18	US
	81.        	15/781,840	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	06/06/18	US
	82.        	16/004,338	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	06/08/18	US
	83.        	PCT/US2018/36790	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	06/08/18	PCT
	84.        	16/006,721	Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods	06/12/18	US
	85.        	16/037,452	Progesterone
    Formulations	07/17/18	US
	86.        	2018222947	Progesterone
    Formulations	06/18/13	AU
	87.        	BR1120140318379	Progesterone
    Formulations	06/18/13	BR
	88.        	2,876,964	Progesterone
    Formulations	06/18/13	CA
	89.        	MX/a/2014/015900	Progesterone
    Formulations	06/18/13	MX
	90.        	MX/a/2018/009467	Progesterone
    Formulations	08/02/18	MX
	91.        	15/454,898	Progesterone
    Formulations Having a Desirable PK Profile	03/09/17	US
	92.        	20150100920	Progesterone
    Compositions	03/27/15	AR
	93.        	2015237243	Progesterone
    Formulations	03/27/15	AU
	94.        	BR1120160225708	Progesterone
    Formulations	03/27/15	BR
	95.        	2,942,568	Progesterone
    Formulations	03/27/15	CA
	96.        	15768772.4	Progesterone
    Formulations	03/27/15	EP
	97.        	247828	Progesterone
    Formulations	03/27/15	IL

 

 

** Application contains allowable subject matter and a patent will issue in due course.

 

    13

     

    

 

	 	Application

                                                                                Number
	Title	Application

                                                                                Date

                                                                                (mm/dd/yy)
	Country
	98.        	2016-557059	Progesterone
    Formulations	03/24/15	JP
	99.        	10-2016-7029519	Progesterone
    Formulations	03/27/15	KR
	100.        	MX/A/2016/011706	Progesterone
    Formulations	03/27/15	MX
	101.        	2016136666	Progesterone
    Formulations	03/27/15	RU
	102.        	2016/06309	Progesterone
    Formulations	03/27/15	ZA
	103.        	16/273,955	Progesterone
    Formulations Having a Desirable PK Profile	02/12/19	US
	104.        	16/125,201	Transdermal
    Cream	09/07/18	US
	105.        	P20150102431	Transdermal
    Cream	07/29/15	AR
	106.        	2015296609	Transdermal
    Cream	07/29/15	AU
	107.        	BR112016
    029338 0	Transdermal
    Cream	07/29/15	BR
	108.        	2,951,284	Transdermal
    Cream	07/29/15	CA
	109.        	15827543.8	Transdermal
    Cream	07/29/15	EP
	110.        	248984	Transdermal
    Cream	07/29/15	IL
	111.        	2016-571728	Transdermal
    Cream	07/29/15	JP
	112.        	10-2017-7002451	Transdermal
    Cream	07/29/15	KR
	113.        	MX/a/2016/013693	Transdermal
    Cream	07/29/15	MX
	114.        	2016141135	Transdermal
    Cream	07/29/15	RU
	115.        	2016/07317	Transdermal
    Cream	07/29/15	ZA
	116.        	15/420,019	Transdermal
    Cream	01/30/17	US
	117.        	[***]	[***]	[***]	[***]
	118.        	[***]	[***]	[***]	[***]
	119.        	[***]	[***]	[***]	[***]
	120.        	15/217,301	Formulations
    for Solubilizing Hormones	07/22/16	US
	121.        	BR112014
    018439 9	Transdermal
    Hormone Replacement Therapies	01/25/13	BR
	122.        	2,861,346	Transdermal
    Hormone Replacement Therapies	01/25/13	CA
	123.        	MX/A/2014/009093	Transdermal
    Hormone Replacement Therapies	01/25/13	MX

 

    14

     

    

 

	 	Application

                                                                                Number
	Title	Application

                                                                                Date

                                                                                (mm/dd/yy)
	Country
	124.        	13/843,362	Transdermal
    Hormone Replacement Therapies	03/15/13	US
	125.        	1120140318247	Transdermal
    Hormone Replacement Therapies	06/18/13	BR
	126.        	2,876,947	Transdermal
    Hormone Replacement Therapies	06/18/13	CA
	127.        	13807463.8	Transdermal
    Hormone Replacement Therapies	06/18/13	EP
	128.        	MX/A/2014/015897	Transdermal
    Hormone Replacement Therapies	06/18/13	MX
	129.        	2015/00210	Transdermal
    Hormone Replacement Therapies	06/18/13	ZA
	130.        	15/475,052	Steroid
    Hormone Pharmaceutical Composition	03/30/17	US
	131.        	PCT/US2017/025211	Steroid
    Hormone Pharmaceutical Composition	03/30/17	PCT
	132.        	20170100832	Steroid
    Hormone Pharmaceutical Composition	04/03/17	AR
	133.        	2017239679	Steroid
    Hormone Pharmaceutical Composition	03/30/17	AU
	134.        	BR1120180698776	Steroid
    Hormone Pharmaceutical Composition	03/30/17	BR
	135.        	3,019,375	Steroid
    Hormone Pharmaceutical Composition	03/30/17	CA
	136.        	17776724.1	Steroid
    Hormone Pharmaceutical Composition	03/30/17	EP
	137.        	261924	Steroid
    Hormone Pharmaceutical Composition	03/30/17	IL
	138.        	2018-550593	Steroid
    Hormone Pharmaceutical Composition	03/30/17	JP
	139.        	10-2018-7031666	Steroid
    Hormone Pharmaceutical Composition	03/30/17	KR
	140.        	MX/A/2018/011706	Steroid
    Hormone Pharmaceutical Composition	03/30/17	MX
	141.        	746686	Steroid
    Hormone Pharmaceutical Composition	03/30/17	NZ
	142.        	2018133921	Steroid
    Hormone Pharmaceutical Composition	03/30/17	RU
	143.        	2018/06413	Steroid
    Hormone Pharmaceutical Composition	03/30/17	ZA
	144.        	15/475,068	Steroid
    Hormone Pharmaceutical Composition in Medium Chain Oils	03/30/17	US
	145.        	20170100831	Steroid
    Hormone Compositions in Medium Chain Oils	04/03/17	AR
	146.        	PCT/US2017/025220	Steroid
    Hormone Compositions in Medium Chain Oils	03/30/17	PCT
	147.        	15/473,742	Steroid
    Hormone Compositions in Medium Chain Oils	03/30/17	US

 

    15

     

    

 

	 	Application

                                                                                Number
	Title	Application

                                                                                Date

                                                                                (mm/dd/yy)
	Country
	148.        	16/359,839	Steroid
    Hormone Compositions in Medium Chain Oils	03/20/19	US
	149.        	PCT/US2017/024955	Steroid
    Hormone Compositions in Medium Chain Oils	03/30/17	PCT
	150.        	15/901,467	Steroid
    Hormone Compositions in Medium Chain Oils	02/21/18	US
	151.        	20170100830	Steroid
    Hormone Compositions in Medium Chain Oils	04/03/17	AR
	152.        	2017239645	Steroid
    Hormone Compositions in Medium Chain Oils	03/30/17	AU
	153.        	BR1120180701998	Steroid
    Hormone Compositions in Medium Chain Oils	03/30/17	BR
	154.        	3,020,153	Steroid
    Hormone Compositions in Medium Chain Oils	03/30/17	CA
	155.        	17776645.8	Steroid
    Hormone Compositions in Medium Chain Oils	03/30/17	EP
	156.        	261930	Steroid
    Hormone Compositions in Medium Chain Oils	03/30/17	IL
	157.        	2018-550564	Steroid
    Hormone Compositions in Medium Chain Oils	03/30/17	JP
	158.        	10-2018-7031878	Steroid
    Hormone Compositions in Medium Chain Oils	03/30/17	KR
	159.        	MX/A/2018/011705	Steroid
    Hormone Compositions in Medium Chain Oils	03/30/17	MX
	160.        	746682	Steroid
    Hormone Compositions in Medium Chain Oils	03/30/17	NZ
	161.        	2018133932	Steroid
    Hormone Compositions in Medium Chain Oils	03/30/17	RU
	162.        	2018/06414	Steroid
    Hormone Compositions in Medium Chain Oils	03/30/17	ZA
	163.        	PCT/US2017/024994	Steroid
    Hormone Compositions in Medium Chain Oils	03/30/17	PCT
	164.        	20170100829	Steroid
    Hormone Compositions in Medium Chain Oils	04/03/17	AR
	165.        	[***]	[***]	[***]	[***]
	166.        	[***]	[***]	[***]	[***]

 

    16

     

    

 

	 	Application

                                                                                Number
	Title	Application

                                                                                Date

                                                                                (mm/dd/yy)
	Country
	167.        	[***]	[***]	[***]	[***]
	168.        	[***]	[***]	[***]	[***]
	169.        	[***]*	[***]	[***]	[***]

 

(c)(i)

 

Borrower
has licensed certain Product Patents and is obligated to pay royalties and other payments pursuant to that certain License Agreement,
dated July 30, 2018, between Borrower and The Population Council, Inc.

 

(c)(ii)

 

Borrower
has licensed certain Product Patents pursuant to that certain License and Supply Agreement, dated July 30, 2018, as amended, between
Borrower and Knight Pharmaceuticals, Inc.

 

(c)(iii)

 

Other
than the contracts in (c)(i) and (c)(ii) listed above, none.

 

    17

     

    

 

Schedule
4.24

 

insurance

 

		1.	The
                                         Company is covered by general liability and certain other insurance in the amounts and
                                         coverage limits as set forth in the certificate attached hereto as Annex A.

 

		2.	The
                                         Company is covered by workmen’s compensation insurance in the amounts and coverage
                                         limits as set forth in the certificate attached hereto as Annex B.

 

    18

     

    

 

Schedule
4.24

 

Annex
A

 

[***]

 

    19

     

    

 

Schedule
4.24

 

Annex
B

 

[***]

 

 

 

    20

     

    

 

Schedule
4.27

 

bank accounts and securities accounts

 

	Company	Bank
    or Broker	Address	Account
    No.	Account
    Type
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]

 

    21

     

    

 

Schedule
4.33(d)-(e)

 

regulatory compliance

 

None.

 

    22

     

    

 

Schedule
4.34

 

GOVERNMENT CONTRACTS

 

None.

 

    23

     

    

 

Schedule
6.1

 

permitted indebtedness

 

None.

 

    24

     

    

 

Schedule
6.2

 

permitted liens

 

None.

 

    25

     

    

 

Schedule
6.7

 

permitted investments

 

None.

 

    26

     

    

 

Schedule
6.12

 

Transactions with Shareholders and Affiliates

 

None.

 

    1TherapeuticsMD, Inc. 10-Q 

 

Exhibit
10.2

 

CERTAIN
IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM
TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.

 

Execution
Version

 

PLEDGE
AND SECURITY AGREEMENT

 

dated
as of April 24, 2019

 

among

 

EACH
OF THE GRANTORS PARTY HERETO

 

and

 

TPG
SPECIALTY LENDING, INC.,

 

as
Administrative Agent

 

     

    

    

 

TABLE
OF CONTENTS

 

	SECTION
    1. DEFINITIONS; GRANT OF SECURITY	1
	1.1   General
    Definitions	1
	1.2   Definitions;
    Interpretation	6
	SECTION
    2. GRANT OF SECURITY	7
	2.1   Grant
    of Security	7
	2.2   Certain
    Limited Exclusions	8
	SECTION
    3. SECURITY FOR OBLIGATIONS; GRANTORS REMAIN LIABLE	9
	3.1   Security
    for Obligations	9
	3.2   Continuing
    Liability Under Collateral	9
	SECTION
    4. REPRESENTATIONS AND WARRANTIES AND COVENANTS	9
	4.1   Generally	9
	4.2   [Reserved]	12
	4.3   Receivables	12
	4.4   Investment
    Related Property	14
	4.5   Material
    Contracts	20
	4.6   Letter
    of Credit Rights	21
	4.7   Intellectual
    Property	21
	4.8   Commercial
    Tort Claims	25
	SECTION
    5. ACCESS; RIGHT OF INSPECTION AND FURTHER ASSURANCES; ADDITIONAL GRANTORS	25
	5.1   [Reserved]	25
	5.2   Further
    Assurances	25
	5.3   Additional
    Grantors	26
	SECTION
    6. ADMINISTRATIVE AGENT APPOINTED ATTORNEY-IN-FACT	26
	6.1   Power
    of Attorney	26
	6.2   No
    Duty on the Part of Administrative Agent or Secured Parties	27
	SECTION
    7. REMEDIES.	27
	7.1   Generally	27
	7.2   Application
    of Proceeds	29
	7.3   Sales
    on Credit	30
	7.4   Deposit
    Accounts	30
	7.5   Investment
    Related Property	30
	7.6   Intellectual
    Property	30
	7.7   Cash
    Proceeds	32
	 	 
	SECTION
    8. [RESERVED]	32
	SECTION
    9. CONTINUING SECURITY INTEREST; TRANSFER OF TERM LOANS	33
	SECTION
    10. STANDARD OF CARE; ADMINISTRATIVE AGENT MAY PERFORM	33
	SECTION
    11. MISCELLANEOUS	33

 

Schedules

 

     i

    

    

 

SCHEDULE
4.1 — GENERAL INFORMATION

SCHEDULE
4.4 — INVESTMENT RELATED PROPERTY

SCHEDULE
4.5 — MATERIAL CONTRACTS

SCHEDULE
4.6 — DESCRIPTION OF LETTERS OF CREDIT

SCHEDULE
4.7 — INTELLECTUAL PROPERTY - EXCEPTIONS

SCHEDULE
4.8 — COMMERCIAL TORT CLAIMS

 

Exhibits

 

EXHIBIT
A — PLEDGE SUPPLEMENT

EXHIBIT
B — TRADEMARK SECURITY AGREEMENT

EXHIBIT
C — COPYRIGHT SECURITY AGREEMENT

EXHIBIT
D — PATENT SECURITY AGREEMENT

 

     ii

    

    

 

This
PLEDGE AND SECURITY AGREEMENT, dated as of April 24, 2019 (as amended, restated, supplemented or otherwise modified from time
to time in accordance with and subject to the terms and conditions hereof, this “Agreement”), among EACH OF
THE UNDERSIGNED, whether as an original signatory hereto or as an Additional Grantor (as herein defined) (each, a “Grantor”),
and TPG Specialty Lending, Inc., as administrative agent for the Secured Parties (as herein defined) (in such capacity as administrative
agent, the “Administrative Agent”).

 

RECITALS:

 

WHEREAS,
reference is made to that certain Financing Agreement, dated as of the date hereof (as it may be amended, restated, supplemented
or otherwise modified from time to time, the “Financing Agreement”), by and among THERAPEUTICSMD,
INC., a Nevada corporation, as borrower (“Company” or “Borrower”), and certain Subsidiaries
of the Borrower, as Guarantors, the Lenders from time to time party thereto and the Administrative Agent;

 

WHEREAS,
in consideration of the extensions of credit and other accommodations of Lenders as set forth in the Financing Agreement, each
Grantor has agreed to secure such Grantor’s obligations under the Loan Documents as set forth herein;

 

WHEREAS,
each Grantor (other than Borrower) is a direct or indirect domestic Subsidiary of Borrower;

 

WHEREAS,
each Grantor will directly or indirectly obtain benefits from the Financing Agreement and, accordingly, desires to execute this
Agreement in order to induce the Lenders to extend credit pursuant to the Financing Agreement and other Loan Documents; and

 

NOW,
THEREFORE, in consideration of the premises and the agreements, provisions and covenants herein contained, each Grantor and
the Administrative Agent agree as follows:

 

Section
1. DEFINITIONS; GRANT OF SECURITY.

 

		1.1	General
                                         Definitions. In this Agreement, the following terms shall have the following meanings:

 

“Account
Debtor” shall mean each Person (or any successor or assign of such Person) who is obligated with respect to a Receivable
or any Supporting Obligation related thereto.

 

“Accounts”
shall mean all “accounts” as defined in Article 9 of the UCC.

 

“Additional
Grantors” shall have the meaning assigned in Section 5.3.

 

“Agreement”
shall have the meaning set forth in the preamble.

 

“Assigned
Agreements” shall mean all agreements and contracts to which such Grantor is a party as of the date hereof, or to which
such Grantor becomes a party after the date hereof, including, without limitation, each Material Contract, as each such agreement
may be amended, supplemented or otherwise modified from time to time.

 

“Borrower”
has the meaning set forth in the recitals.

 

    	 	1	 

    	 

    

 

“Cash
Proceeds” shall have the meaning assigned in Section 7.7.

 

“Chattel
Paper” shall mean all “chattel paper” as defined in Article 9 of the UCC, including, without limitation, “electronic
chattel paper” or “tangible chattel paper”, as each term is defined in Article 9 of the UCC.

 

“Collateral”
shall have the meaning assigned in Section 2.1.

 

“Collateral
Records” shall mean books, records, ledger cards, files, correspondence, customer lists, blueprints, technical specifications,
manuals, computer software, computer printouts, tapes, disks and related data processing software and similar items that at any
time evidence or contain information relating to any of the Collateral or are otherwise necessary or helpful in the collection
thereof or realization thereupon.

 

“Collateral
Support” shall mean all personal property assigned, hypothecated or otherwise securing any Collateral and shall include
any security agreement or other agreement granting a lien or security interest in such real or personal property.

 

“Commercial
Tort Claims” shall mean all “commercial tort claims” as defined in Article 9 of the UCC, including, without
limitation, all commercial tort claims listed on Schedule4.8 (as such schedule may be amended or supplemented from time
to time).

 

“Commodities
Accounts” (i) shall mean all “commodity accounts” as defined in Article 9 of the UCC and (ii) shall include,
without limitation, all of the accounts listed on Schedule 4.4 under the heading “Commodities Accounts”
(as such schedule may be amended or supplemented from time to time).

 

“Copyright
Licenses” shall mean any and all agreements providing for the granting of any right in or to Copyrights (whether such
Grantor is licensee or licensor thereunder) including, without limitation, each agreement referred to in Schedule 4.7(B)
(as such schedule may be amended or supplemented from time to time).

 

“Copyrights”
shall mean all United States, and foreign copyrights (including Community designs), including but not limited to copyrights in
software and databases, and all Mask Works (as defined under 17 U.S.C. 901 of the U.S. Copyright Act), whether registered or unregistered,
and, with respect to any and all of the foregoing: (i) all registrations and applications therefor including, without limitation,
the registrations and applications referred to in Schedule 4.7(A) (as such schedule may be amended or supplemented
from time to time), (ii) all extensions and renewals thereof, (iii) all rights corresponding thereto throughout the world, (iv)
all rights to sue for past, present and future infringements thereof, and (v) all Proceeds of the foregoing, including, without
limitation, licenses, royalties, income, payments, claims, damages and proceeds of suit.

 

“Documents”
shall mean all “documents” as defined in Article 9 of the UCC.

 

“Equipment”
shall mean: (i) all “equipment” as defined in Article 9 of the UCC, (ii) all machinery, manufacturing equipment, data
processing equipment, computers, office equipment, furnishings, furniture, appliances, fixtures and tools (in each case, regardless
of whether characterized as equipment under the UCC) and (iii) all accessions or additions thereto, all parts thereof, whether
or not at any time of determination incorporated or installed therein or attached thereto, and all replacements therefor, wherever
located, now or hereafter existing, including any fixtures.

 

    	 	2	 

    	 

    

 

“Financing
Agreement” shall have the meaning set forth in the recitals.

 

“General
Intangibles” (i) shall mean all “general intangibles” as defined in Article 9 of the UCC, including “payment
intangibles” also as defined in Article 9 of the UCC and (ii) shall include, without limitation, all interest rate or currency
protection or hedging arrangements, all tax refunds, licenses, permits, concessions and authorizations, all Assigned Agreements
and all Intellectual Property (in each case, regardless of whether characterized as general intangibles under the UCC).

 

“Goods”
(i) shall mean all “goods” as defined in Article 9 of the UCC and (ii) shall include, without limitation, all Inventory
and Equipment (in each case, regardless of whether characterized as goods under the UCC).

 

“Grantors”
shall have the meaning set forth in the preamble.

 

“Indemnitee”
shall mean the Administrative Agent, and its Affiliates’ officers, partners, directors, trustees, employees, agents.

 

“Instruments”
shall mean all “instruments” as defined in Article 9 of the UCC.

 

“Insurance”
shall mean all insurance policies covering any or all of the Collateral (regardless of whether the Administrative Agent is the
loss payee thereof).

 

“Intellectual
Property” shall mean, collectively, the Copyrights, the Copyright Licenses, the Patents, the Patent Licenses, the Trademarks,
the Trademark Licenses, the Trade Secrets, and the Trade Secret Licenses.

 

“Inventory”
shall mean (i) all “inventory” as defined in Article 9 of the UCC and (ii) all goods held for sale or lease or to be
furnished under contracts of service or so leased or furnished, all raw materials, work in process, finished goods, and materials
used or consumed in the manufacture, packing, shipping, advertising, selling, leasing, furnishing or production of such inventory
or otherwise used or consumed in any Grantor’s business; all goods in which any Grantor has an interest in mass or a joint or
other interest or right of any kind; and all goods which are returned to or repossessed by any Grantor, all computer programs
embedded in any goods and all accessions thereto and products thereof (in each case, regardless of whether characterized as inventory
under the UCC).

 

“Investment
Accounts” shall mean the Administrative Agent’s Account, Securities Accounts, Commodities Accounts and Deposit Accounts.

 

“Investment
Related Property” shall mean: (i) all “investment property” (as such term is defined in Article 9 of the UCC)
and (ii) all of the following (regardless of whether classified as investment property under the UCC): all Pledged Equity Interests,
Pledged Debt, the Investment Accounts and certificates of deposit.

 

“Letter
of Credit Right” shall mean “letter-of-credit right” as defined in Article 9 of the UCC.

 

“Money”
shall mean “money” as defined in the UCC.

 

    	 	3	 

    	 

    

 

“Non-Assignable
Contract” shall mean any agreement, contract or license to which any Grantor is a party that by its terms purports to
restrict or prevent the assignment or granting of a security interest therein (either by its terms or by any federal or state
statutory prohibition or otherwise irrespective of whether such prohibition or restriction is enforceable under Section 9-406
through 409 of the UCC).

 

“Patent
Licenses” shall mean all agreements providing for the granting of any right in or to Patents (whether such Grantor is
licensee or licensor thereunder).

 

“Patents”
shall mean all United States and foreign patents and certificates of invention and applications for any of the foregoing, including,
but not limited to: (i) each patent and patent application referred to in Schedule 4.7(C) hereto (as such schedule may
be amended or supplemented from time to time) and including but not limited to the Annovera Patents, Bijuva Patents and Imvexxy
Patents, (ii) all reissues, divisions, continuations, continuations-in-part, extensions, renewals, and reexaminations thereof,
(iii) all rights corresponding thereto throughout the world, (iv) all inventions and improvements described therein, (v) all rights
to sue for past, present and future infringements thereof, (vi) all licenses, claims, damages, and proceeds of suit arising therefrom,
and (vii) all Proceeds of the foregoing, including, without limitation, licenses, royalties, income, payments, claims, damages,
and proceeds of suit.

 

“Pledge
Supplement” shall mean any supplement to this agreement in substantially the form of Exhibit A.

 

“Pledged
Debt” shall mean all Indebtedness owed to such Grantor, including, without limitation, all Indebtedness described on
Schedule 4.4(A) under the heading “Pledged Debt” (as such schedule may be amended or supplemented from time to
time), issued by the obligors named therein, the instruments evidencing such Indebtedness, and all interest, cash, instruments
and other property or proceeds from time to time received, receivable or otherwise distributed in respect of or in exchange for
any or all of such Indebtedness.

 

“Pledged
Equity Interests” shall mean all Pledged Stock, Pledged LLC Interests, Pledged Partnership Interests and Pledged Trust
Interests.

 

“Pledged
LLC Interests” shall mean all interests in any limited liability company including, without limitation, all limited liability
company interests listed on Schedule 4.4(A) under the heading “Pledged LLC Interests” (as such schedule may be
amended or supplemented from time to time) and the certificates, if any, representing such limited liability company interests
and any interest of such Grantor on the books and records of such limited liability company or on the books and records of any
securities intermediary pertaining to such interest and all dividends, distributions, cash, warrants, rights, options, instruments,
securities and other property or proceeds from time to time received, receivable or otherwise distributed in respect of or in
exchange for any or all of such limited liability company interests.

 

“Pledged
Partnership Interests” shall mean all interests in any general partnership, limited partnership, limited liability partnership
or other partnership including, without limitation, all partnership interests listed on Schedule 4.4(A) under the heading
“Pledged Partnership Interests” (as such schedule may be amended or supplemented from time to time) and the certificates,
if any, representing such partnership interests and any interest of such Grantor on the books and records of such partnership
or on the books and records of any securities intermediary pertaining to such interest and all dividends, distributions, cash,
warrants, rights, options, instruments, securities and other property or proceeds from time to time received, receivable or otherwise
distributed in respect of or in exchange for any or all of such partnership interests.

 

    	 	4	 

    	 

    

 

“Pledged
Stock” shall mean all shares of capital stock owned by such Grantor, including, without limitation, all shares of capital
stock described on Schedule 4.4(A) under the heading “Pledged Stock” (as such schedule may be amended or supplemented
from time to time), and the certificates, if any, representing such shares and any interest of such Grantor in the entries on
the books of the issuer of such shares or on the books of any securities intermediary pertaining to such shares, and all dividends,
distributions, cash, warrants, rights, options, instruments, securities and other property or proceeds from time to time received,
receivable or otherwise distributed in respect of or in exchange for any or all of such shares.

 

“Pledged
Trust Interests” shall mean all interests in a Delaware business trust or other trust including, without limitation,
all trust interests listed on Schedule 4.4(A) under the heading “Pledged Trust Interests” (as such schedule may
be amended or supplemented from time to time) and the certificates, if any, representing such trust interests and any interest
of such Grantor on the books and records of such trust or on the books and records of any securities intermediary pertaining to
such interest and all dividends, distributions, cash, warrants, rights, options, instruments, securities and other property or
proceeds from time to time received, receivable or otherwise distributed in respect of or in exchange for any or all of such trust
interests.

 

“Proceeds”
shall mean: (i) all “proceeds” as defined in Article 9 of the UCC, (ii) payments or distributions made with respect
to any Investment Related Property and (iii) whatever is receivable or received when Collateral or proceeds are sold, exchanged,
collected or otherwise disposed of, whether such disposition is voluntary or involuntary.

 

“Receivables”
shall mean all rights to payment, whether or not earned by performance, with respect to (i) goods or other property sold, leased,
licensed, assigned or otherwise disposed of and (ii) services rendered or to be rendered, in each case, including, without limitation,
all such rights constituting or evidenced by any Account, Chattel Paper, Instrument, General Intangible or Investment Related
Property, together with all of Grantor’s rights, if any, in any goods or other property giving rise to such right to payment and
all Collateral Support and Supporting Obligations related thereto and all Receivables Records.

 

“Receivables
Records” shall mean (i) all copies of all documents, instruments or other writings or electronic records or other Records
evidencing the Receivables, (ii) all books, correspondence, credit or other files, Records, ledger sheets or cards, invoices,
and other papers relating to Receivables, including, without limitation, all tapes, cards, computer tapes, computer discs, computer
runs, record keeping systems and other papers and documents relating to the Receivables, whether in the possession or under the
control of Grantor or any computer bureau or agent from time to time acting for Grantor or otherwise, (iii) all evidences of the
filing of financing statements and the registration of other instruments in connection therewith, and amendments, supplements
or other modifications thereto, notices to other creditors or secured parties, and certificates, acknowledgments, or other writings,
including, without limitation, lien search reports, from filing or other registration officers, (iv) all credit information, reports
and memoranda relating thereto and (v) all other written or otherwise documented forms of information related in any way to the
foregoing or any Receivable.

 

“Record”
shall have the meaning specified in Article 9 of the UCC.

 

“Secured
Obligations” shall have the meaning assigned in Section 3.1.

 

    	 	5	 

    	 

    

 

“Secured
Parties” shall mean the Administrative Agent and the Lenders and shall include, without limitation, any former Administrative
Agent or Lender to the extent that any Obligations owing to such Person were incurred while such Person was an Administrative
Agent or Lender and such Obligations have not been paid or satisfied in full.

 

“Securities
Accounts” (i) shall mean all “securities accounts” as defined in Article 8 of the UCC and (ii) shall include,
without limitation, all of the accounts listed on Schedule 4.4(A) under the heading “Securities Accounts” (as such schedule
may be amended or supplemented from time to time).

 

“Supporting
Obligation” shall mean all “supporting obligations” as defined in Article 9 of the UCC.

 

“Trademark
Licenses” shall mean any and all agreements providing for the granting of any right in or to Trademarks (whether such
Grantor is licensee or licensor thereunder) including, without limitation, each agreement referred to in Schedule 4.7(F)
(as such schedule may be amended or supplemented from time to time).

 

“Trademarks”
shall mean all United States, and foreign trademarks, trade names, corporate names, company names, business names, fictitious
business names, Internet domain names, service marks, certification marks, collective marks, logos, other source or business identifiers,
designs and general intangibles of a like nature, all registrations and applications for any of the foregoing including, but not
limited to: (i) the registrations and applications referred to in Schedule 4.7(E) (as such schedule may be amended or supplemented
from time to time), (ii) all extensions or renewals of any of the foregoing, (iii) all of the goodwill of the business connected
with the use of and symbolized by the foregoing, (iv) the right to sue for past, present and future infringement or dilution of
any of the foregoing or for any injury to goodwill, and (v) all Proceeds of the foregoing, including, without limitation, licenses,
royalties, income, payments, claims, damages, and proceeds of suit.

 

“Trade
Secret Licenses” shall mean any and all agreements providing for the granting of any right in or to Trade Secrets (whether
such Grantor is licensee or licensor thereunder) including, without limitation, each agreement referred to in Schedule 4.7(G)
(as such schedule may be amended or supplemented from time to time).

 

“Trade
Secrets” shall mean all trade secrets and all other confidential or proprietary information and know-how protectable
by applicable law, whether or not such Trade Secret has been reduced to a writing or other tangible form, including all documents
and things embodying, incorporating, or referring in any way to such Trade Secret, including but not limited to: (i) the right
to sue for past, present and future misappropriation or other violation of any Trade Secret, and (ii) all Proceeds of the foregoing,
including, without limitation, licenses, royalties, income, payments, claims, damages, and proceeds of suit.

 

“UCC”
shall mean the Uniform Commercial Code as in effect from time to time in the State of New York or, when the context implies, the
Uniform Commercial Code as in effect from time to time in any other applicable jurisdiction.

 

“United
States” shall mean the United States of America.

 

    	 	6	 

    	 

    

 

1.2          
Definitions; Interpretation. All
capitalized terms used herein (including the preamble and recitals hereto) and not otherwise defined herein shall have the meanings
ascribed thereto in the Financing Agreement or, if not defined therein, in the UCC. References to “Sections,” “Exhibits”
and “Schedules” shall be to Sections, Exhibits and Schedules, as the case may be, of this Agreement unless otherwise
specifically provided. Section headings in this Agreement are included herein for convenience of reference only and shall not
constitute a part of this Agreement for any other purpose or be given any substantive effect. Any of the terms defined herein
may, unless the context otherwise requires, be used in the singular or the plural, depending on the reference. The use herein
of the word “include” or “including”, when following any general statement, term or matter, shall not be construed
to limit such statement, term or matter to the specific items or matters set forth immediately following such word or to similar
items or matters, whether or not nonlimiting language (such as “without limitation” or “but not limited to”
or words of similar import) is used with reference thereto, but rather shall be deemed to refer to all other items or matters
that fall within the broadest possible scope of such general statement, term or matter. If any conflict or inconsistency exists
between this Agreement and the Financing Agreement, the Financing Agreement shall govern. All references herein to provisions
of the UCC shall include all successor provisions under any subsequent version or amendment to any Article of the UCC.

 

Section
2. GRANT OF SECURITY.

 

2.1          
Grant of Security. Subject
to Section 2.2, each Grantor hereby grants to the Administrative Agent a security interest in and continuing Lien on all of such
Grantor’s right, title and interest in, to and under all personal property of such Grantor including, but not limited to the following,
in each case whether now owned or existing or hereafter acquired or arising and wherever located (all of which being hereinafter
collectively referred to as the “Collateral” and excluding, for the avoidance of doubt, any Excluded Assets (as
defined below)): 

 

(a)       Accounts;

 

(b)       Chattel
Paper;

 

(c)       Documents;

 

(d)       General
Intangibles;

 

(e)       Goods;

 

(f)        Instruments;

 

(g)       Insurance;

 

(h)       Intellectual
Property;

 

(i)        Investment
Related Property;

 

(j)        Letter
of Credit Rights;

 

(k)        Money
(including, for the avoidance of doubt, Money in the Administrative Agent’s Account);

 

(l)        Receivables
and Receivable Records;

 

    	 	7	 

    	 

    

 

(m)      Commercial
Tort Claims described on Schedule 4.8 and as supplemented by any written notification given by a Grantor to Administrative
Agent pursuant to Section 4.8;

 

(n)       to
the extent not otherwise included above, all Collateral Records, Collateral Support and Supporting Obligations relating to any
of the foregoing;

 

(o)       to
the extent not covered by the preceding clauses of this Section 2.1, all other tangible and intangible personal property
of such Grantor (whether or not subject to the UCC), including, without limitation, all bank and other accounts and all cash and
all investments therein, all proceeds, products, offspring, accessions, rents, profits, income, benefits, substitutions and replacements
of and to any of the property of such Grantor described in the preceding clauses of this Section 2.1 hereof (including,
without limitation, any proceeds of insurance thereon and all causes of action, claims and warranties now or hereafter held by
such Grantor in respect of any of the items listed above), and all books, correspondence, files and other Records, including,
without limitation, all tapes, disks, cards, software, data and computer programs in the possession or under the control of such
Grantor or any other Person from time to time acting for such Grantor that at any time evidence or contain information relating
to any of the property described in the preceding clauses of this Section 2 hereof or are otherwise necessary or helpful
in the collection or realization thereof; and

 

(p)       to
the extent not otherwise included above, all Proceeds, products, accessions, rents and profits of or in respect of any of the
foregoing.

 

2.2          
Certain Limited Exclusions. Notwithstanding
anything herein or in any other Loan Document to the contrary, in no event shall the Collateral include or the security interest
granted under Section 2.1 hereof attach to or shall any perfection requirements be required with respect to (a) any of
such Grantor’s right, title or interest in any license, contract, lease or agreement to which such Grantor is a party or any of
its right, title or interest thereunder to the extent, but only to the extent, that such a grant would, under the express terms
of such license, contract, lease or agreement result in a breach of the terms of, constitute a default under or create a right
of termination in favor of any party thereto (other than any Grantor) such license, contract, lease or agreement (other than to
the extent that any such term (A) has been waived or (B) would be rendered ineffective pursuant to Sections 9-406, 9-408, 9-409
of the UCC or other applicable provisions of the UCC of any relevant jurisdiction or any other applicable law (including the Bankruptcy
Code) or principles of equity); provided, that (x) immediately upon the ineffectiveness, lapse, termination or waiver of
any such provision, the Collateral shall include, and such Grantor shall be deemed to have granted a security interest in, all
such right, title and interest as if such provision had never been in effect and (y) the foregoing exclusion shall in no way be
construed so as to limit, impair or otherwise affect the Administrative Agent’s unconditional continuing security interest in
and liens upon any rights or interests of a Grantor in or to (1) monies due or to become due under or in connection with
any such license, contract, lease or agreement, or (2) any proceeds from the sale, license, lease, or other dispositions
of any such license, contract, lease or agreement); (b) any intent-to-use United States trademark applications for which an amendment
to allege use or statement of use has not been filed under 15 U.S.C. § 1051(c) or 15 U.S.C. §1051(d), respectively,
or if filed, has not been deemed in conformance with 15 U.S.C. §1051(a) or examined and accepted, respectively, by the United
States Patent and Trademark Office, provided that upon such filing and acceptance, such intent-to-use applications shall
be included in the definition of Collateral; (c) any Excluded Account; (d) those assets as to which the Administrative Agent reasonably
determines that the costs of obtaining such security interests in such assets or perfection thereof are excessive in relation
to the benefit to the Administrative Agent and the Lenders of the security to be afforded thereby; (e) motor vehicles, airplanes
and other assets subject to certificates of title to the extent (i) a lien therein cannot be perfected by the filing of UCC financing
statements and (ii) the aggregate fair market value of all such assets is less than $250,000; (f) letter of credit rights less
than $250,000 in the aggregate, to the extent a lien therein cannot be perfected by the filing of UCC financing statements, and
Commercial Tort Claims less than $250,000 in the aggregate; (g) any governmental licenses or state or local franchises, charters
and authorizations to the extent a security interest is prohibited or restricted thereby after giving effect to the applicable
anti-assignment provisions of applicable law (including the UCC), other than proceeds and receivables thereof, the assignment
of which is expressly deemed effective under applicable law notwithstanding such prohibition, and (h) assets which a pledge thereof
or a security interest therein is prohibited by applicable law (including the UCC), other than proceeds and receivables thereof,
the assignment of which is expressly deemed effective under applicable law notwithstanding such prohibition (the property referred
to in this Section 2.2 being collectively referred to as “Excluded Assets”).

 

    	 	8	 

    	 

    

 

Section
3. SECURITY FOR OBLIGATIONS; GRANTORS REMAIN
LIABLE.

 

3.1          
Security for Obligations. This
Agreement secures, and the Collateral is collateral security for, the prompt and complete payment or performance in full when
due, whether at stated maturity, by required prepayment, declaration, acceleration, demand or otherwise (including the payment
of amounts that would become due but for the operation of the automatic stay under Section 362(a) of the Bankruptcy Code, 11 U.S.C.
§362(a) (and any successor provision thereof)), of all Obligations with respect to every Grantor, in each case, in accordance
with and subject to the terms and conditions of the Financing Agreement (the “Secured Obligations”).

 

3.2          
Continuing Liability Under Collateral.
Notwithstanding anything herein to the contrary, (i) each Grantor
shall remain liable for all obligations under the Collateral and nothing contained herein is intended or shall be a delegation
of duties to the Administrative Agent or any Secured Party, (ii) each Grantor shall remain liable under each of the agreements
included in the Collateral, including, without limitation, any agreements relating to Pledged Partnership Interests or Pledged
LLC Interests, to perform all of the obligations undertaken by it thereunder all in accordance with and pursuant to the terms
and provisions thereof and neither the Administrative Agent nor any Secured Party shall have any obligation or liability under
any of such agreements by reason of or arising out of this Agreement or any other document related thereto nor shall the Administrative
Agent nor any Secured Party have any obligation to make any inquiry as to the nature or sufficiency of any payment received by
it or have any obligation to take any action to collect or enforce any rights under any agreement included in the Collateral,
including, without limitation, any agreements relating to Pledged Partnership Interests or Pledged LLC Interests, and (iii) the
exercise by the Administrative Agent of any of its rights hereunder shall not release any Grantor from any of its duties or obligations
under the contracts and agreements included in the Collateral.

 

Section
4. REPRESENTATIONS AND WARRANTIES AND COVENANTS.

 

4.1          
Generally.

 

(a)           
Representations and Warranties. Each Grantor
hereby represents and warrants that:

 

(i)           
it owns the Collateral purported to be owned
by it or otherwise has the rights it purports to have in each item of Collateral and, as to all Collateral whether now existing
or hereafter acquired, will continue to own or have such rights in each item of the Collateral, in each case free and clear of
any and all Liens, rights or claims of all other Persons, in each case other than Permitted Liens;

 

    	 	9	 

    	 

    

 

(ii)          
it has indicated on Schedule 4.1(A) (as
such schedule may be amended or supplemented from time to time): (w) the type of organization of such Grantor, (x) the jurisdiction
of organization of such Grantor, (y) its organizational identification number and (z) the jurisdiction where the chief executive
office or its sole place of business is located;

 

(iii)         
as of the date hereof, the full legal name of
such Grantor is as set forth on Schedule 4.1(A) and it has not done in the last five (5) years, and does not do, business
under any other name (including any trade-name or fictitious business name) except for those names set forth on Schedule 4.1(B);

 

(iv)         
as of the date hereof, except as provided on
Schedule 4.1(C), it has not changed its name, jurisdiction of organization, chief executive office or sole place of business
or its corporate structure in any way (e.g., by merger, consolidation, change in corporate form or otherwise) within the
past five (5) years;

 

(v)          
it has not within the last five (5) years become
bound (whether as a result of merger or otherwise) as debtor under a security agreement entered into by another Person, which
has not heretofore been terminated or which does not relate to Permitted Indebtedness;

 

(vi)         
[reserved];

 

(vii)       
(u) upon the filing of all UCC financing statements
naming each Grantor as “debtor” and the Administrative Agent as “secured party” and describing the Collateral
in the filing offices set forth opposite such Grantor’s name on Schedule 4.1(E) hereof (as such schedule may be amended
or supplemented from time to time) and other filings delivered by each Grantor, (v) upon delivery of all Instruments, Chattel
Paper and certificated Pledged Equity Interests and Pledged Debt, (w) upon sufficient identification of Commercial Tort Claims,
(x) upon execution of a control agreement establishing the Administrative Agent’s “control” (within the meaning of Section
8-106, 9-106 or 9-104 of the UCC, as applicable) with respect to any Investment Account, (y) upon consent of the issuer with respect
to Letter of Credit Rights, and (z) to the extent not subject to Article 9 of the UCC, upon recordation of the security interests
granted hereunder in Patents, Trademarks and Copyrights in the applicable intellectual property registries, including but not
limited to the United States Patent and Trademark Office and the United States Copyright Office, the security interests in the
Collateral granted to the Administrative Agent hereunder constitute valid and perfected first priority (subject in priority only
to the Permitted Liens that, pursuant to the definition of the term “Permitted Liens”, are (i) prior to the Liens in
favor of the Administrative Agent by operation of law or (ii) not prohibited from being prior to the Liens in favor of the Administrative
Agent) Liens (subject to Permitted Liens) on all of the Collateral;

 

(viii)       
substantially contemporaneously with the initial
funding of the Term Loan on the Closing Date, all actions and consents, including all filings, notices, registrations and recordings
necessary or, in the reasonable discretion of the Administrative Agent, desirable for the exercise by the Administrative Agent
of the voting or other rights provided for in this Agreement or the exercise of remedies in respect of the Collateral have been
made or obtained;

 

    	 	10	 

    	 

    

 

(ix)          
other than the financing statements filed in
favor of the Administrative Agent, no effective UCC financing statement, fixture filing or other instrument similar in effect
in the United States under any applicable law covering all or any part of the Collateral is on file in any filing or recording
office in the United States except for financing statements filed in connection with Permitted Liens;

 

(x)           
no authorization, approval or other action by,
and no notice to or filing with, any Governmental Authority or regulatory body is required for either (i) the pledge or grant
by any Grantor of the Liens purported to be created in favor of the Administrative Agent hereunder or (ii) the exercise by Administrative
Agent of any rights or remedies in respect of any Collateral (whether specifically granted or created hereunder or created or
provided for by applicable law), except (A) for the filings contemplated by clause (vii) above and (B) as may be required, in
connection with the disposition of any Investment Related Property, by laws generally affecting the offering and sale of Capital
Stock;

 

(xi)          
all information supplied by any Grantor with
respect to any of the Collateral (in each case taken as a whole with respect to any particular Collateral) is accurate and complete
in all material respects (it being understood and agreed by each party to this Agreement that any projections, budgets, estimates,
pro forma financial information, any other forward-looking statements or information of a general economic or industry nature
contained in such materials are based upon good faith estimates and assumptions believed by such Grantor to be reasonable at the
time made, it being recognized by Administrative Agent and Lenders that such projections, budgets, estimates, pro forma financial
information and forward looking statements are not to be viewed as facts and that actual results during the period or periods
covered by any such projections, budgets, estimates, pro forma financial information and forward looking statements may differ
from the projected results, and such differences may be material);

 

(xii)         
none of the Collateral constitutes, or is the
Proceeds of, “farm products” (as defined in the UCC);

 

(xiii)        
it does not own any “as extracted collateral”
(as defined in the UCC) or any timber to be cut;

 

(xiv)        
such Grantor has not become bound as a debtor,
either by contract or by operation of law, by a security agreement previously entered into by another Person (other than a security
agreement related to any Permitted Indebtedness); and

 

(xv)         
as of the date hereof, such Grantor has been
duly organized as an entity of the type as set forth opposite such Grantor’s name on Schedule 4.1(A) solely under the laws
of the jurisdiction as set forth opposite such Grantor’s name on Schedule 4.1(A) and remains duly existing as such.

 

(b)          
Covenants and Agreements. Each Grantor
hereby covenants and agrees that:

 

(i)           
except for the security interest created by this
Agreement, it shall not create or suffer to exist any Lien upon or with respect to any of the Collateral, except Permitted Liens,
and such Grantor shall defend the Collateral against all Persons at any time claiming any interest therein;

 

    	 	11	 

    	 

    

 

(ii)          
it shall not produce, use or permit any Collateral
to be used unlawfully or in violation of any provision of this Agreement or in violation in any material respect of any applicable
statute, regulation or ordinance or any policy of insurance covering the Collateral;

 

(iii)         
it shall not change such Grantor’s legal name,
legal identity, corporate structure (e.g., by merger, consolidation, change in corporate form or otherwise) sole place of business,
chief executive office, type of organization or jurisdiction of organization unless it shall have (a) notified the Administrative
Agent thereof in writing at least five (5) Business Days prior to (or such shorter period acceptable to Administrative Agent in
its sole discretion) any such change or establishment, identifying such new proposed name, identity, corporate structure, sole
place of business, chief executive office or jurisdiction of organization and providing such other information in connection therewith
as the Administrative Agent may reasonably request and (b) taken all actions necessary to maintain the continuous validity, perfection
and the same or better priority of the Administrative Agent’s security interest in the Collateral intended to be granted and agreed
to hereby;

 

(iv)         
[reserved];

 

(v)         
Subject to Section 5.3 of the Financing Agreement,
it shall pay promptly when due all property and other taxes, assessments and governmental charges or levies imposed upon, and
all claims (including claims for labor, materials and supplies) against, the Collateral;

 

(vi)         
it shall not take or (to the extent in its control)
permit any action which could materially impair the Administrative Agent’s rights in the Collateral; and

 

(vii)        
it shall not sell, transfer or assign (by operation
of law or otherwise) any Collateral except as otherwise in accordance with the Financing Agreement.

 

4.2          
[Reserved].

 

4.3          
Receivables.

 

(a)           
Representations and Warranties. Each Grantor
represents and warrants that:

 

(i)           
each Receivable (a) is and will be the legal,
valid and binding obligation of the Account Debtor in respect thereof, representing an unsatisfied obligation of such Account
Debtor and (b) is and will be enforceable in accordance with its terms and will be in compliance in all material respects with
all applicable laws, whether federal, state, local or foreign (except as may be limited by bankruptcy, insolvency, reorganization,
moratorium or similar laws relating to or limiting creditors’ rights generally or by equitable principles relating to enforceability);

 

(ii)          
none of the Account Debtors in respect of any
Receivable that constitutes Collateral is the government of the United States, any agency or instrumentality thereof, any state
or municipality or any foreign sovereign; and no Receivable requires the consent of the Account Debtor in respect thereof in connection
with the pledge hereunder, except any consent which has been obtained; and

 

    	 	12	 

    	 

    

 

(iii)         
no Receivable is evidenced by, or constitutes,
an Instrument or Chattel Paper which has not been delivered to, or otherwise subjected to the control of, the Administrative Agent
to the extent required by, and in accordance with Section 4.3(c).

 

(b)          
Covenants and Agreements: Each Grantor
hereby covenants and agrees that:

 

(i)           
it shall keep and maintain at its own cost and
expense reasonably satisfactory and complete records of the Receivables in all material respects, including, but not limited to,
copies of all documentation with respect to all Receivables and records of all material dealings therewith;

 

(ii)          
it shall mark conspicuously, in form and manner
reasonably satisfactory to the Administrative Agent, all Chattel Paper and Instruments with an appropriate reference to the fact
that the Administrative Agent has a security interest therein;

 

(iii)         
it shall perform in all material respects all
of its obligations with respect to the Receivables;

 

(iv)         
except as otherwise provided in this subsection,
each Grantor shall use commercially reasonable efforts to continue to collect all amounts due or to become due to such Grantor
under the Receivables and any Supporting Obligation and diligently exercise each material right it may have under any Receivable
any Supporting Obligation or Collateral Support, in each case, at its own expense, and in connection with such collections and
exercise, if an Event of Default has occurred and is continuing, such Grantor shall use commercially reasonable efforts to take
such action as such Grantor or the Administrative Agent may deem necessary. Notwithstanding the foregoing, the Administrative
Agent shall have the right at any time following the occurrence and during the continuation of an Event of Default to notify,
or require any Grantor to notify, any Account Debtor of the Administrative Agent’s security interest in the Receivables and any
Supporting Obligation and, in addition, at any time following the occurrence and during the continuation of an Event of Default,
the Administrative Agent may: (1) direct the Account Debtors under any Receivables to make payment of all amounts due or to become
due to such Grantor thereunder directly to the Administrative Agent; (2) notify, or require any Grantor to notify, each Person
maintaining a lockbox or similar arrangement to which Account Debtors under any Receivables have been directed to make payment
to remit all amounts representing collections on checks and other payment items from time to time sent to or deposited in such
lockbox or other arrangement directly to the Administrative Agent; and (3) enforce, at the expense of such Grantor, collection
of any such Receivables and to adjust, settle or compromise the amount or payment thereof, in the same manner and to the same
extent as such Grantor might have done. If the Administrative Agent notifies any Grantor that it has elected to collect the Receivables
in accordance with and subject to the preceding sentence, any payments of Receivables received by such Grantor shall be forthwith
(and in any event within two (2) Business Days) deposited by such Grantor in the exact form received, duly indorsed by such Grantor
to the Administrative Agent if required, in the Administrative Agent’s Account, and until so turned over, all amounts and proceeds
(including checks and other instruments) received by such Grantor in respect of the Receivables, any Supporting Obligation or
Collateral Support shall be received in trust for the benefit of the Administrative Agent hereunder and shall be segregated from
other funds of such Grantor and such Grantor shall not adjust, settle or compromise the amount or payment of any Receivable, or
release wholly or partly any Account Debtor or obligor thereof, or allow any credit or discount thereon; and

 

    	 	13	 

    	 

    

 

(v)          
it shall use its commercially reasonable efforts
to keep in full force and effect any Supporting Obligation or Collateral Support relating to any Receivable.

 

(c)           
Delivery and Control of Receivables.
With respect to any Receivable that evidences an amount greater than $250,000 and that is evidenced by, or constitutes, Chattel
Paper or Instruments, each Grantor shall cause each originally executed copy thereof to be delivered to the Administrative Agent
(or its agent or designee) appropriately indorsed to the Administrative Agent or indorsed in blank: (i) with respect to any such
Receivables in existence on the date hereof, on or prior to the date hereof and (ii) with respect to any such Receivables hereafter
arising, within thirty (30) days of such Grantor acquiring rights therein. With respect to any Receivable that evidences an amount
greater than $250,000 and that would constitute “electronic chattel paper” under Article 9 of the UCC, each Grantor
shall take all steps necessary to give the Administrative Agent control over such Receivables (within the meaning of Section 9-105
of the UCC): (i) with respect to any such Receivables in existence on the date hereof, on or prior to the date hereof and (ii)
with respect to any such Receivables hereafter arising, within thirty (30) days of such Grantor acquiring rights therein.
Any Receivable not otherwise required to be delivered or subjected to the control of the Administrative Agent in accordance with
this subsection (c) shall be delivered or subjected to such control upon written request of the Administrative Agent at
any time following the occurrence and during the continuance of an Event of Default.

 

4.4          
Investment Related Property.

 

		4.4.1	Investment
                                         Related Property Generally

 

(a)           
Covenants and Agreements. Each Grantor
hereby covenants and agrees that:

 

(i)           
in the event it acquires rights in any Investment
Related Property after the date hereof, it shall deliver to the Administrative Agent a completed Pledge Supplement, substantially
in the form of Exhibit A attached hereto, together with all Supplements to Schedules thereto, reflecting such new Investment
Related Property and all other Investment Related Property; notwithstanding the foregoing, it is understood and agreed that the
security interest of the Administrative Agent shall attach to all Investment Related Property immediately upon any Grantor’s acquisition
of rights therein and shall not be affected by the failure of any Grantor to deliver a supplement to Schedule 4.4 as required
hereby;

 

(ii)          
in the event such Grantor receives any dividends,
economic interest or distributions on any Investment Related Property, or any securities or other property upon the merger, consolidation,
liquidation or dissolution of any issuer of any Investment Related Property, then (a) such dividends, interest or distributions
and securities or other property shall be included in the definition of Collateral without further action and (b) such Grantor
shall promptly take all steps, if any, necessary to ensure the validity, perfection, priority and, if applicable, control of the
Administrative Agent over such Investment Related Property to the extent required by this Agreement (including, without limitation,
delivery thereof to the Administrative Agent) and pending any such action such Grantor shall be deemed to hold such dividends,
interest, distributions, securities or other property in trust for the benefit of the Administrative Agent and shall segregate
such dividends, distributions, Capital Stock or other property from all other property of such Grantor; and

 

    	 	14	 

    	 

    

 

(iii)         
each Grantor consents to the grant by each other
Grantor of a Security Interest in all Investment Related Property to the Administrative Agent.

 

(b)           
Delivery and Control.

 

(i)           
Each Grantor agrees that with respect to any
Investment Related Property in which it currently has rights it shall comply with the provisions of this Section 4.4.1(b)
on or before the Closing Date and with respect to any Investment Related Property hereafter acquired by such Grantor it shall
comply with the provisions of this Section 4.4.1(b) immediately upon acquiring rights therein, in each case in form and
substance reasonably satisfactory to the Administrative Agent. With respect to any Investment Related Property evidencing an amount
greater than $250,000 that is represented by a certificate or that is an “instrument” (other than any Investment Related
Property credited to a Securities Account) it shall cause such certificate or instrument to be delivered to the Administrative
Agent, indorsed in blank by an “effective indorsement” (as defined in Section 8-107 of the UCC), regardless of whether
such certificate constitutes a “certificated security” for purposes of the UCC. With respect to any Investment Related
Property that is an “uncertificated security” for purposes of the UCC (other than any “uncertificated securities”
credited to a Securities Account or any “uncertificated securities” which are General Intangibles), it shall cause
the issuer of such uncertificated security to either (i) register the Administrative Agent as the registered owner thereof on
the books and records of the issuer or (ii) execute an agreement in form and substance reasonably satisfactory to the Administrative
Agent, pursuant to which such issuer agrees to comply with the Administrative Agent’s instructions with respect to such uncertificated
security without further consent by such Grantor.

 

In
addition to the foregoing, if any issuer of any Investment Related Property is located in a jurisdiction outside of the United
States, upon the request of the Administrative Agent, each Grantor shall take such additional actions, including, without limitation,
causing the issuer to register the pledge on its books and records or making such filings or recordings, in each case as may be
necessary or advisable, under the laws of such issuer’s jurisdiction to insure the validity, perfection and priority of the security
interest of the Administrative Agent, subject to Permitted Liens. Upon the occurrence and during the continuance of an Event of
Default, the Administrative Agent shall have the right, without notice to any Grantor, to transfer all or any portion of the Investment
Related Property to its name or the name of its nominee or agent. In addition, the Administrative Agent shall have the right at
any time following the occurrence and during the continuance of an Event of Default, without notice to any Grantor, to exchange
any certificates or instruments representing any Investment Related Property for certificates or instruments of smaller or larger
denominations.

 

    	 	15	 

    	 

    

 

(c)           
Voting and Distributions.

 

(i)           
So long as no Event of Default shall have occurred
and be continuing:

 

		(1)	except
                                         as otherwise provided under the covenants and agreements relating to investment related
                                         property in this Agreement or elsewhere herein or in the Financing Agreement, each Grantor
                                         shall be entitled to exercise or refrain from exercising any and all voting and other
                                         consensual rights pertaining to the Investment Related Property or any part thereof for
                                         any purpose not inconsistent with the terms of this Agreement or the Financing Agreement;
                                         provided, no Grantor shall exercise or refrain from exercising any such right
                                         if the Administrative Agent shall have notified such Grantor that, in the Administrative
                                         Agent’s reasonable discretion, such action would have a Material Adverse Effect on the
                                         value of the Investment Related Property or any part thereof; it being understood, however,
                                         that neither the voting by such Grantor of any Pledged Stock for, or such Grantor’s consent
                                         to, the election of directors (or similar governing body) at a regularly scheduled annual
                                         or other meeting of stockholders or with respect to incidental matters at any such meeting,
                                         nor such Grantor’s consent to or approval of any action otherwise permitted under this
                                         Agreement and the Financing Agreement, shall be deemed inconsistent with the terms of
                                         this Agreement or the Financing Agreement within the meaning of this Section 4.4.1(c)(i)(1).

 

(ii)          
Upon the occurrence and during the continuation
of an Event of Default:

 

		(1)	all
                                         rights of each Grantor to exercise or refrain from exercising the voting and other consensual
                                         rights which it would otherwise be entitled to exercise pursuant hereto shall cease and
                                         all such rights shall thereupon become vested in the Administrative Agent who shall thereupon
                                         have the sole right to exercise such voting and other consensual rights; and

 

		(2)	in
                                         order to permit the Administrative Agent to exercise the voting and other consensual
                                         rights which it may be entitled to exercise pursuant hereto and to receive all dividends
                                         and other distributions which it may be entitled to receive hereunder: (A) each Grantor
                                         shall promptly execute and deliver (or cause to be executed and delivered) to the Administrative
                                         Agent all proxies, dividend payment orders and other instruments as the Administrative
                                         Agent may from time to time reasonably request and (B) each Grantor acknowledges that
                                         the Administrative Agent may utilize the power of attorney set forth in Section 6.1.

 

		4.4.2	Pledged
                                         Equity Interests

 

(a)           
Representations and Warranties. Each Grantor
hereby represents and warrants, that:

 

(i)           
as of the date hereof, Schedule 4.4(A)
sets forth under the headings “Pledged Stock, “Pledged LLC Interests,” “Pledged Partnership Interests”
and “Pledged Trust Interests,” respectively, all of the Pledged Stock, Pledged LLC Interests, Pledged Partnership Interests
and Pledged Trust Interests owned by any Grantor and such Pledged Equity Interests constitute the percentage of issued and outstanding
shares of stock, percentage of membership interests, percentage of partnership interests or percentage of beneficial interest
of the respective issuers thereof indicated on such Schedule;

 

    	 	16	 

    	 

    

 

(ii)          
as of the date hereof, except as set forth on
Schedule 4.4(B), it has not acquired any equity interests of another entity or substantially all the assets of another
entity within the past five (5) years;

 

(iii)         
it is the record and beneficial owner of the
Pledged Equity Interests free of all Liens, rights or claims of other Persons other than Permitted Liens and, as of the date hereof,
except as set forth on Schedule 4.2 to the Financing Agreement, there are no outstanding warrants, options or other rights to
purchase, or shareholder, voting trust or similar agreements outstanding with respect to, or property that is convertible into,
or that requires the issuance or sale of, any Pledged Equity Interests;

 

(iv)         
without limiting the generality of Section
4.1(a)(v), no consent of any Person including any other general or limited partner, any other member of a limited liability
company, any other shareholder or any other trust beneficiary is necessary in connection with the creation, perfection or first
priority status of the security interest of the Administrative Agent in any Pledged Equity Interests (subject to any Permitted
Liens) or the exercise by the Administrative Agent of the voting or other rights provided for in this Agreement or the exercise
of remedies in respect thereof;

 

(v)          
none of the Pledged LLC Interests nor Pledged
Partnership Interests are or represent interests in issuers that: (a) are registered as investment companies or (b) are dealt
in or traded on securities exchanges or markets; and

 

(vi)         
none of the Pledged LLC Interests and Pledged
Partnership Interests are or represent interests in issuers that have opted to be treated as securities under the uniform commercial
code of any jurisdiction.

 

(b)          
Covenants and Agreements. Each Grantor
hereby covenants and agrees that:

 

(i)           
without the prior written consent of the Administrative
Agent, it shall not vote to enable or take any other action to: (a) amend or terminate any partnership agreement, limited liability
company agreement, certificate of incorporation, by-laws or other organizational documents in any way that materially adversely
affects the validity, perfection or priority of the Administrative Agent’s security interest in such applicable Pledged Stock,
Pledged LLC Interests, Pledged Partnership Interests and Pledged Trust Interests, (b) permit any issuer of any Pledged Equity
Interest to issue any additional stock, partnership interests, limited liability company interests or other equity interests of
any nature or to issue securities convertible into or granting the right of purchase or exchange for any stock or other equity
interest of any nature of such issuer, (c) other than as permitted under the Financing Agreement, permit any issuer of any Pledged
Equity Interest to dispose of all or a material portion of their assets, (d) waive any default under or breach of any material
terms of organizational document relating to the issuer of any Pledged Equity Interest or the material terms of any Pledged Debt,
or (e) cause any issuer of any Pledged Partnership Interests or Pledged LLC Interests which are not securities (for purposes of
the UCC) on the date hereof to elect or otherwise take any action to cause such Pledged Partnership Interests or Pledged LLC Interests
to be treated as securities for purposes of the UCC; provided, however, notwithstanding the foregoing, if any issuer
of any Pledged Partnership Interests or Pledged LLC Interests takes any such action in violation of the foregoing in this clause
(b)(i)(e), such Grantor shall promptly notify the Administrative Agent in writing of any such election or action and, in such
event, shall take all steps necessary to establish the Administrative Agent’s “control” thereof;

 

    	 	17	 

    	 

    

 

(ii)          
it shall comply in all material respects with
all of its obligations under any partnership agreement or limited liability company agreement relating to Pledged Partnership
Interests or Pledged LLC Interests and shall use commercially reasonable efforts to enforce all of its rights with respect to
any Investment Related Property;

 

(iii)         
except as permitted by the Financing Agreement,
without the prior written consent of the Administrative Agent, it shall not permit any issuer of any Pledged Equity Interest to
merge or consolidate unless (i) such issuer creates a security interest that is perfected by a filed financing statement (that
is not effective solely under section 9-508 of the UCC) in collateral in which such new debtor has or acquires rights, and (ii)
all the outstanding capital stock or other equity interests of the surviving or resulting corporation, limited liability company,
partnership or other entity is, upon such merger or consolidation, pledged hereunder in accordance with the terms hereof and no
cash, securities or other property is distributed in respect of the outstanding equity interests of any other constituent Grantor;
and

 

(iv)        
each Grantor consents to the grant by each other
Grantor of a security interest in all Investment Related Property to the Administrative Agent and, without limiting the foregoing,
consents to the transfer at any time following the occurrence and continuance of an Event of Default of any Pledged Partnership
Interest and any Pledged LLC Interest to the Administrative Agent or its nominee and to the substitution of the Administrative
Agent or its nominee as a partner in any partnership or as a member in any limited liability company with all the rights and powers
related thereto.

 

		4.4.3	Pledged
                                         Debt

 

(a)           
Representations and Warranties. Each Grantor
hereby represents and warrants that:

 

(i)           
as of the date hereof, Schedule 4.4 sets
forth under the heading “Pledged Debt” all of the Pledged Debt owned by any Grantor and all of such Pledged Debt has
been duly authorized or issued, and delivered and is the legal, valid and binding obligation of the issuers thereof (except as
may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or limiting creditors’ rights
generally or by equitable principles relating to enforceability) and is not in default in any material respect.

 

(b)          
Covenants and Agreements. Each Grantor
hereby covenants and agrees that:

 

(i)           
it shall notify the Administrative Agent of any
default under any Pledged Debt that has caused, either in any individual case or in the aggregate, a Material Adverse Effect.

 

    	 	18	 

    	 

    

 

		4.4.4	Investment
                                         Accounts

 

(a)           
Representations and Warranties. Each Grantor
hereby represents and warrants that:

 

(i)           
as of the date hereof, Schedule 4.4 hereto
sets forth under the headings “Securities Accounts” and “Commodities Accounts,” respectively, all of the Securities
Accounts and Commodities Accounts in which each Grantor has an interest. Each Grantor is the sole entitlement holder of each such
Securities Account and Commodity Account, and such Grantor has not consented to, and is not otherwise aware of, any Person (other
than the Administrative Agent pursuant hereto) having “control” (within the meanings of Sections 8-106 and 9-106 of
the UCC) over, or any other interest in, any such Securities Account or Commodity Account or securities or other property credited
thereto, in each case, except for any applicable depositary bank or institution holding such Securities Account or Commodity Account
on behalf of such Grantor;

 

(ii)          
as of the date hereof, Schedule 4.4 hereto
sets forth under the headings “Deposit Accounts” all of the Deposit Accounts owned by each Grantor. Each Grantor is
the sole account holder of each such Deposit Account and such Grantor has not consented to, and is not otherwise aware of, any
Person (other than the Administrative Agent pursuant hereto) having either sole dominion and control (within the meaning of common
law) or “control” (within the meanings of Section 9-104 of the UCC) over, or any other interest in, any such Deposit
Account or any money or other property deposited therein, in each case, except for any applicable depositary bank or institution
holding such Deposit Account on behalf of such Grantor; and

 

(iii)         
Each Grantor has taken all actions necessary,
including those specified in Section 4.4.4(b), to: (a) establish Administrative Agent’s “control” (within the
meanings of Sections 8-106 and 9-106 of the UCC) over any portion of the Investment Related Property constituting Certificated
Securities, Securities Accounts, Securities Entitlements or Commodities Accounts (each as defined in the UCC); (b) establish the
Administrative Agent’s “control” (within the meaning of Section 9-104 of the UCC) over all Deposit Accounts (other than
Excluded Accounts); and (c) deliver all Instruments evidencing obligations in an amount greater than $250,000 to the Administrative
Agent.

 

(b)          
Covenant and Agreement. Each Grantor hereby
covenants and agrees with the Administrative Agent and each other Secured Party that it shall not close or terminate any Investment
Account without the prior consent of the Administrative Agent and unless a successor or replacement account has been established
with the consent of the Administrative Agent with respect to which successor or replacement account a control agreement has been
entered into by the appropriate Grantor, Administrative Agent and securities intermediary or depository institution at which such
successor or replacement account is to be maintained in accordance with the provisions of Section 4.4.4(c).

 

(c)           
Delivery and Control

 

(i)           
With respect to any Investment Related Property
consisting of Securities Accounts or Securities Entitlements, it shall cause the securities intermediary maintaining such Securities
Account or Securities Entitlement to enter into an agreement, in form and substance reasonably satisfactory to the Administrative
Agent, pursuant to which, subject to the terms and conditions thereof, it shall agree to comply with the Administrative Agent’s
“entitlement orders” without further consent by such Grantor. With respect to any Investment Related Property that is
a “Deposit Account” (other than any Excluded Account) it shall cause the depositary institution maintaining such account
to enter into an agreement, in form and substance reasonably satisfactory to the Administrative Agent, pursuant to which, and
subject to the terms and conditions thereof, the Administrative Agent shall have control over such Deposit Account (within the
meaning of the common law) and “control” (within the meaning of Section 9-104 of the UCC) over such Deposit Account.
At all times prior to the occurrence and continuance of an Event of Default, the Grantors shall have full access to the cash on
deposit in such Deposit Accounts, and the Administrative Agent agrees not to deliver a control notice or take any other action
to control such Deposit Accounts unless and until an Event of Default has occurred and is continuing. Upon the occurrence of an
Event of Default, with respect to any Deposit Account (other than an Excluded Account) subject to a Control Agreement, the Administrative
Agent may give instructions and directions to such bank or depositary institution to wire all amounts on deposit in such Deposit
Account each Business Day to the Administrative Agent’s Account. Each Grantor shall have entered into such control agreement or
agreements with respect to: (i) any Securities Accounts, Securities Entitlements or Deposit Accounts (other than any Excluded
Accounts) that exist on the Closing Date, as of or prior to the Closing Date (except as otherwise agreed to by the Administrative
Agent in writing) and (ii) any Securities Accounts or Securities Entitlements evidencing an amount greater than $250,000 or Deposit
Accounts (other than any Excluded Accounts) that are created or acquired after the Closing Date, as of or prior to the deposit
or transfer of any such Securities Entitlements or funds, whether constituting moneys or investments, into such Securities Accounts
or such Deposit Accounts.

 

    	 	19	 

    	 

    

 

4.5          
Material Contracts.

 

(a)           
Representations and Warranties. Each Grantor
hereby represents and warrants that:

 

(i)           
Schedule 4.5 (as such schedule may be
amended or supplemented from time to time) sets forth all of the Material Contracts to which such Grantor has rights; and

 

(ii)          
the Material Contracts, true and complete copies
(including any amendments or supplements thereof) of which have been furnished to the Administrative Agent, to such Grantor’s
knowledge, have been duly authorized, executed and delivered by all parties thereto, are in full force and effect and are binding
upon and enforceable against all parties thereto in accordance with their respective terms (except as may be limited by bankruptcy,
insolvency, reorganization, moratorium or similar laws relating to or limiting creditors’ rights generally or by equitable principles
relating to enforceability). There exists no default under any Material Contract by any party thereto giving any party thereto
the right to terminate such Material Contract and neither such Grantor, nor to its knowledge, any other Person party thereto is
likely to become in default thereunder and no Person party thereto has any defenses, counterclaims or right of set-off with respect
to any Material Contract (except as provided under such Material Contract.

 

(b)          
Covenants and Agreements. Each Grantor
hereby covenants and agrees that:

 

(i)           
in addition to any rights under the Section of
this Agreement relating to Receivables, after the occurrence and during the continuance of an Event of Default, the Administrative
Agent may at any time notify, or require any Grantor to so notify, the counterparty on any Material Contract of the security interest
of the Administrative Agent therein. In addition, after the occurrence and during the continuance of an Event of Default, the
Administrative Agent may upon written notice to the applicable Grantor, notify, or require any Grantor to notify, the counterparty
to make all payments under the Material Contracts required to be paid to such Grantor directly to the Administrative Agent;

 

    	 	20	 

    	 

    

 

(ii)          
it shall perform in all material respects all
of its obligations with respect to the Material Contracts;

 

(iii)         
it shall promptly and diligently use commercially
reasonable efforts to exercise each material right (except the right of termination) it may have under any Material Contract,
any Supporting Obligation or Collateral Support, in each case, at its own expense, and in connection with such collections and
exercise after the occurrence and during the continuance of an Event of Default, such Grantor shall take such action as such Grantor
or the Administrative Agent may deem necessary or, in the Administrative Agent’s reasonable discretion, advisable;

 

(iv)         
it shall use commercially reasonable efforts
to keep in full force and effect any Supporting Obligation or Collateral Support relating to any Material Contract.

 

4.6          
Letter of Credit Rights.

 

(a)           
Representations and Warranties. Each Grantor
hereby represents and warrants that all material letters of credit to which such Grantor has rights is listed on Schedule 4.6
(as such schedule may be amended or supplemented from time to time) hereto.

 

(b)           
Covenants and Agreements. Each Grantor
hereby covenants and agrees that with respect to any material letter of credit hereafter arising it shall obtain the consent of
the issuer thereof to the assignment of the proceeds of the letter of credit to the Administrative Agent and shall deliver to
the Administrative Agent a completed Pledge Supplement, substantially in the form of Exhibit A attached hereto, together
with all Supplements to Schedules thereto.

 

4.7          
Intellectual Property.

 

(a)           
Representations and Warranties. As of
the date hereof, except as disclosed in Schedule 4.7(H), each Grantor hereby represents and warrants that:

 

(i)           
Schedule 4.7 sets forth a true and complete
list of (1) all United States, state and foreign registrations of and applications for Patents, Trademarks, and Copyrights owned
by each Grantor, including but not limited to the Annovera Patents, the Bijuva Patents and the Imvexxy Patents and (2) all Patent
Licenses, Trademark Licenses, Trade Secret Licenses and Copyright Licenses to which a Grantor is a party and which are material
to the business of such Grantor;

 

(ii)          
it is the sole and exclusive owner of the entire
right, title, and interest in and to all Intellectual Property listed on Schedule 4.7, and owns or has the valid right
to use all other Intellectual Property material to or necessary to conduct its business, free and clear of all Liens, claims,
encumbrances and licenses, in each case except for Permitted Liens and the licenses set forth on Schedule 4.7(B), (D),
(F) and (G);

 

(iii)         
all Intellectual Property is subsisting and has
not been adjudged invalid or unenforceable, in whole or in part, and each Grantor has performed all acts and has paid all renewal,
maintenance, and other fees and taxes required to maintain each and every material registration and application of Copyrights,
Patents and Trademarks in full force and effect;

 

    	 	21	 

    	 

    

 

(iv)        
to the best of such Grantor’s knowledge,
all Intellectual Property is valid and enforceable; no holding, decision, or judgment has been rendered in any action or proceeding
before any court or administrative authority challenging the validity of, such Grantor’s right to register, or such Grantor’s
rights to own or use, any Intellectual Property and no such action or proceeding is pending or, to the best of such Grantor’s
knowledge, threatened;

 

(v)         
all registrations and applications for Copyrights,
Patents and Trademarks are standing in the name of each Grantor, and none of the Trademarks, Patents, Copyrights or Trade Secrets
has been licensed by any Grantor to any Affiliate or third party, except as disclosed in Schedule 4.7(B), (D), (F)
or (G);

 

(vi)          each
Grantor has been using commercially reasonable statutory notice of registration in connection with its use of registered Trademarks,
commercially reasonable marking practices in connection with the use of Patents, and commercially reasonable notice of copyright
in connection with the publication of Copyrights material to the business of such Grantor;

 

(vii)        
each Grantor uses commercially reasonable standards
of quality in the manufacture, distribution, and sale of all products sold and in the provision of all services rendered under
or in connection with all Trademark Collateral and has taken all action necessary to insure that all licensees of the Trademark
Collateral owned by such Grantor use such commercially reasonable standards of quality;

 

(viii)      
to the best of such Grantor’s knowledge,
the conduct of such Grantor’s business does not infringe upon or otherwise violate any trademark, patent, copyright, trade secret
or other intellectual property right owned or controlled by a third party; no claim has been made that the use of any Intellectual
Property owned or used by Grantor (or any of its respective licensees) violates the asserted rights of any third party;

 

(ix)         
to the best of each Grantor’s knowledge, no third
party is infringing upon or otherwise violating any rights in any Intellectual Property owned or used by such Grantor, or any
of its respective licensees;

 

(x)           
each Grantor has taken reasonable steps to maintain
the confidentiality of and otherwise protect and enforce its rights in all trade secrets owned by such Grantor that are necessary
in the business of such Grantor;

 

(xi)          
no settlement or consents, covenants not to sue,
nonassertion assurances, or releases have been entered into by Grantor or to which Grantor is bound that adversely affect Grantor’s
rights to own or use any Intellectual Property set forth in Schedule 4.7;

 

(xii)        
each Grantor has not made a previous assignment,
sale, transfer or agreement constituting a present or future assignment, sale, transfer or agreement of any Intellectual Property
set forth in Schedule 4.7 that has not been terminated or released. There is no effective financing statement on file or recorded
in any public office in the United States, granting a security interest in or otherwise encumbering any part of the Intellectual
Property, other than in favor of the Administrative Agent.

 

    	 	22	 

    	 

    

 

(b)           
Covenants and Agreements. Each Grantor
hereby covenants and agrees as follows:

 

(i)           
it shall not do any act or omit to do any act
whereby any of the Intellectual Property which is material to the business of Grantor may lapse, or become abandoned, dedicated
to the public, or unenforceable, or which would adversely affect the validity, grant, or enforceability of the security interest
granted therein;

 

(ii)          
it shall not, with respect to any Trademarks
which are material to the business of any Grantor, cease the use of any of such Trademarks or fail to maintain the level of the
quality of products sold and services rendered under any of such Trademark at a level at least substantially consistent with the
quality of such products and services as of the date hereof, and each Grantor shall take all steps necessary to insure that licensees
of such Trademarks use such consistent standards of quality;

 

(iii)         
it shall, within thirty (30) days of the creation
or acquisition of any Copyrightable work which is material to the business of Grantor, apply to register the Copyright in the
United States Copyright Office;

 

(iv)         
it shall promptly notify the Administrative Agent
if it knows or has reason to know that all or part of any Annovera Patent, Bijuva Patent, Imvexxy Patent, or any item of the Intellectual
Property that is material to the business of any Grantor may become (a) abandoned or dedicated to the public or placed in the
public domain, except at the end of the natural term of any of the aforementioned patents, (b) invalid or unenforceable, or (c)
subject to any adverse determination or development (including the institution of proceedings) in any action or proceeding in
the United States Patent and Trademark Office, the United States Copyright Office, any state registry, any foreign counterpart
of the foregoing, or any court;

 

(v)          
it shall take all reasonable steps in the United
States Patent and Trademark Office, the United States Copyright Office, any state registry or any foreign counterpart of the foregoing,
to pursue any application and maintain any registration of each Trademark, Patent, and Copyright that is owned by any Grantor
and material to its business which is now or shall become included in the Intellectual Property including, but not limited to,
those items on Schedule 4.7(A), (C) and (E);

 

(vi)         
in the event that any material Intellectual Property
owned by or exclusively licensed to any Grantor is infringed, misappropriated, or diluted by a third party, such Grantor shall
promptly take all reasonable actions to stop such infringement, misappropriation, or dilution and protect its rights in such Intellectual
Property including, but not limited to, the initiation of a suit for injunctive relief and to recover damages;

 

(vii)        
it shall promptly (but in no event more than
forty-five (45) days after any Grantor obtains knowledge thereof) report to the Administrative Agent (i) the filing of any application
to register any material Intellectual Property with the United States Patent and Trademark Office or the United States Copyright
Office (whether such application is filed by such Grantor or through any agent, employee, licensee, or designee thereof) and (ii)
the registration of any such material Intellectual Property by any such office, in each case by executing and delivering to the
Administrative Agent a completed Pledge Supplement, substantially in the form of Exhibit A attached hereto, together with
all Supplements to Schedules thereto;

 

    	 	23	 

    	 

    

 

(viii)       
it shall, promptly upon the reasonable request
of the Administrative Agent, execute and deliver to the Administrative Agent any document required to acknowledge, confirm, register,
record, or perfect, in each case, to the extent required by this Agreement, the Administrative Agent’s interest in any part of
the Intellectual Property, whether now owned or hereafter acquired;

 

(ix)          
except with the prior consent of the Administrative
Agent or as permitted under the Financing Agreement, each Grantor shall not execute, and there will not be on file in any public
office in the United States, any financing statement or other document or instruments, except financing statements or other documents
or instruments filed or to be filed in favor of the Administrative Agent and each Grantor shall not sell, assign, transfer, license,
grant any option, or create or suffer to exist any Lien upon or with respect to the Intellectual Property, except for Permitted
Liens and the Lien created by and under this Agreement and the other Loan Documents;

 

(x)           
it shall hereafter use commercially reasonable
efforts so as not to permit the inclusion in any contract to which it hereafter becomes a party of any provision that could or
might in any way materially impair or prevent the creation of a security interest in, or the assignment of, such Grantor’s rights
and interests in any property included within the definitions of any Intellectual Property acquired under such contracts;

 

(xi)         
it shall take reasonable steps to maintain the
confidentiality of, and otherwise protect and enforce its rights in, the Intellectual Property that is necessary in the conduct
of such Grantor’s business, including, as applicable (A) protecting the secrecy and confidentiality of its confidential information
and Trade Secrets by having and enforcing a policy requiring all current employees, consultants, licensees, vendors and contractors
with access to such information to execute appropriate confidentiality agreements and (B) taking actions reasonably necessary
to ensure that no Trade Secret falls into the public domain;

 

(xii)         
it shall use proper statutory notice in connection
with its use of any of the Intellectual Property; and

 

(xiii)        
it shall continue to collect, at its own expense,
all amounts due or to become due to such Grantor in respect of the Intellectual Property or any portion thereof. In connection
with such collections, each Grantor may take (and, at the Administrative Agent’s reasonable direction, shall take) such action
as such Grantor or the Administrative Agent may deem reasonably necessary to enforce collection of such amounts. Notwithstanding
the foregoing, the Administrative Agent shall have the right at any time following the occurrence and during the continuance of
an Event of Default, to notify, or require any Grantor to notify, any obligors with respect to any such amounts of the existence
of the security interest created hereby.

 

    	 	24	 

    	 

    

 

4.8          
Commercial Tort Claims

 

(a)           
Representations and Warranties. As of
the date hereof, each Grantor hereby represents and warrants that Schedule 4.8 sets forth all Commercial Tort Claims of
each Grantor in a stated amount greater than $250,000; and

 

(b)          
Covenants and Agreements. Each Grantor
hereby covenants and agrees that with respect to any Commercial Tort Claim in a stated amount greater than $250,000 hereafter
arising it shall deliver to the Administrative Agent a completed Pledge Supplement, substantially in the form of Exhibit A
attached hereto, together with all Supplements to Schedules thereto, identifying such new Commercial Tort Claims.

 

Section
5. ACCESS; RIGHT OF INSPECTION AND FURTHER ASSURANCES;
ADDITIONAL GRANTORS.

 

5.1          
[Reserved].

 

5.2          
Further Assurances.

 

(a)           
Each Grantor agrees that from time to time, at
the expense of such Grantor, that it shall promptly execute and deliver all further instruments and documents, and take all further
action, that may be necessary, or that the Administrative Agent may reasonably request, in order to create and/or maintain the
validity, perfection or priority of and protect any security interest granted hereby or to enable the Administrative Agent to
exercise and enforce its rights and remedies hereunder with respect to any Collateral. Without limiting the generality of the
foregoing, each Grantor shall:

 

(i)           
file such financing or continuation statements,
or amendments thereto, and execute and deliver such other agreements, instruments, endorsements, powers of attorney or notices,
as may be necessary or desirable, or as the Administrative Agent may reasonably request, in order to perfect and preserve the
security interests granted or purported to be granted hereby;

 

(ii)         
subject to Section 5.2(c), take all actions
necessary to ensure the recordation of appropriate evidence of the Liens and security interest granted hereunder in the Intellectual
Property with any intellectual property registry in which said Intellectual Property is registered or in which an application
for registration is pending including, without limitation, the United States Patent and Trademark Office, the United States Copyright
Office, the various Secretaries of State, and the foreign counterparts on any of the foregoing; and

 

(iii)         
at the Administrative Agent’s reasonable written
request, appear in and defend any action or proceeding that may affect such Grantor’s title to or the Administrative Agent’s security
interest in all or any part of the Collateral.

 

(b)           
Subject to Section 5.2(c), Each Grantor
hereby authorizes the Administrative Agent to file a Record or Records, including, without limitation, financing or continuation
statements, and amendments thereto, in any jurisdictions and with any filing offices as are necessary or, in the Administrative
Agent’s reasonable discretion, advisable to perfect the security interest granted to the Administrative Agent herein. Such
financing statements may describe the Collateral in the same manner as described herein or may contain an indication or description
of collateral that describes such property in any other manner as the Administrative Agent may determine, in its sole discretion,
is necessary, advisable or prudent to ensure the perfection of the security interest in the Collateral granted to the Administrative
Agent herein, including, without limitation, describing such property as “all assets” or “all personal property,
whether now owned or hereafter acquired.” Each Grantor shall furnish to the Administrative Agent from time to time statements
and schedules further identifying and describing the Collateral and such other reports in connection with the Collateral as the
Administrative Agent may reasonably request in writing, all in reasonable detail.

 

    	 	25	 

    	 

    

 

(c)           
Notwithstanding anything to the contrary in this
Agreement or in any other Loan Document, unless requested by the Administrative Agent in its reasonable discretion, none of the
Grantors or any of their Subsidiaries shall be required, nor shall the Administrative Agent or any Lender be authorized, to take
any action with respect to any assets or property of any Grantor located outside of the United States.

 

5.3          
Additional Grantors.
From time to time subsequent to the date hereof, additional Persons may become parties hereto as additional Grantors (each, an
“Additional Grantor”), by executing a Counterpart Agreement. Upon delivery of any such counterpart agreement
to the Administrative Agent, notice of which is hereby waived by Grantors, each Additional Grantor shall be a Grantor and shall
be as fully a party hereto as if Additional Grantor were an original signatory hereto. Each Grantor expressly agrees that its
obligations arising hereunder shall not be affected or diminished by the addition or release of any other Grantor hereunder, nor
by any election of Administrative Agent not to cause any Subsidiary of Borrower to become an Additional Grantor hereunder. This
Agreement shall be fully effective as to any Grantor that is or becomes a party hereto regardless of whether any other Person
becomes or fails to become or ceases to be a Grantor hereunder. For the avoidance of doubt, unless requested by the Administrative
Agent in its sole discretion, no Foreign Subsidiary of Borrower shall be a Grantor or otherwise be required to pledge its assets.

 

Section
6. ADMINISTRATIVE AGENT APPOINTED ATTORNEY-IN-FACT.

 

6.1          
Power of Attorney. Each
Grantor hereby irrevocably appoints the Administrative Agent (such appointment being coupled with an interest) as such Grantor’s
attorney-in-fact, with full authority in the place and stead of such Grantor and in the name of such Grantor, the Administrative
Agent or otherwise, from time to time in the Administrative Agent’s discretion to take any action and to execute any instrument
that the Administrative Agent may deem reasonably necessary to accomplish the purposes of this Agreement, including, without limitation,
the following:

 

(a)           
upon the occurrence and during the continuance
of any Event of Default, to obtain and adjust insurance required to be maintained by such Grantor or paid to the Administrative
Agent pursuant to the Financing Agreement;

 

(b)           
upon the occurrence and during the continuance
of any Event of Default, to ask for, demand, collect, sue for, recover, compound, receive and give acquittance and receipts for
moneys due and to become due under or in respect of any of the Collateral;

 

(c)            
upon the occurrence and during the continuance
of any Event of Default, to receive, endorse and collect any drafts or other instruments, documents and chattel paper in connection
with clause (b) above;

 

(d)           
upon the occurrence and during the continuance
of any Event of Default, to file any claims or take any action or institute any proceedings that the Administrative Agent may
deem necessary or desirable for the collection of any of the Collateral or otherwise to enforce the rights of the Administrative
Agent with respect to any of the Collateral;

 

    	 	26	 

    	 

    

 

(e)           
to prepare and file any UCC financing statements
against such Grantor as debtor;

 

(f)           
to prepare, sign, and file for recordation in
any intellectual property registry, appropriate evidence of the lien and security interest granted herein in the Intellectual
Property in the name of such Grantor as debtor;

 

(g)           
to take or cause to be taken all actions necessary
to perform or comply or cause performance or compliance with the terms of this Agreement, including, without limitation, access
to pay or discharge taxes or Liens (other than Permitted Liens) levied or placed upon or threatened against the Collateral, the
legality or validity thereof and the amounts necessary to discharge the same to be determined by the Administrative Agent in its
reasonable discretion, any such payments made by the Administrative Agent to become obligations of such Grantor to the Administrative
Agent, due and payable immediately without demand; and

 

(h)          
upon the occurrence and during the continuance
of any Event of Default, generally to sell, transfer, pledge, make any agreement with respect to or otherwise deal with any of
the Collateral as fully and completely as though the Administrative Agent were the absolute owner thereof for all purposes, and
to do, at the Administrative Agent’s option and such Grantor’s expense, at any time or from time to time, all acts and things
that the Administrative Agent deems reasonably necessary to protect, preserve or realize upon the Collateral and the Administrative
Agent’s security interest therein in order to effect the intent of this Agreement, all as fully and effectively as such Grantor
might do.

 

6.2          
No Duty on the Part of Administrative
Agent or Secured Parties. The powers conferred on the Administrative
Agent hereunder are solely to protect the interests of the Secured Parties in the Collateral and shall not impose any duty upon
the Administrative Agent or any Secured Party to exercise any such powers. The Administrative Agent and the Secured Parties shall
be accountable only for amounts that they actually receive as a result of the exercise of such powers, and neither they nor any
of their officers, directors, employees or agents shall be responsible to any Grantor for any act or failure to act hereunder,
except for their own (or any of their respective Affiliate’s) gross negligence or willful misconduct.

 

Section
7. REMEDIES.

 

7.1          
Generally.
If any Event of Default shall have occurred and be continuing the Administrative Agent shall have the following rights and remedies:

 

(a)           
The Administrative Agent may exercise in respect
of the Collateral, in addition to all other rights and remedies provided for herein or otherwise available to it at law or in
equity, all the rights and remedies of the Administrative Agent on default under the UCC (whether or not the UCC applies to the
affected Collateral) to collect, enforce or satisfy any Secured Obligations then owing, whether by acceleration or otherwise,
and also may pursue any of the following separately, successively or simultaneously:

 

(i)            
require any Grantor to, and each Grantor hereby
agrees that it shall at its expense and promptly upon request of the Administrative Agent forthwith, assemble all or part of the
Collateral as directed by the Administrative Agent and make it available to the Administrative Agent at a place to be designated
by the Administrative Agent that is reasonably convenient to both parties;

 

    	 	27	 

    	 

    

 

(ii)          
enter onto the property where any Collateral
is located and take possession thereof with or without judicial process;

 

(iii)         
prior to the disposition of the Collateral, store,
process, repair or recondition the Collateral or otherwise prepare the Collateral for disposition in any manner to the extent
the Administrative Agent deems appropriate; and

 

(iv)         
without notice except as specified below or under
the UCC, sell, assign, lease, license (on an exclusive or nonexclusive basis) or otherwise dispose of the Collateral or any part
thereof in one or more parcels at public or private sale, at any of the Administrative Agent’s offices or elsewhere, for cash,
on credit or for future delivery, at such time or times and at such price or prices and upon such other terms as the Administrative
Agent may deem commercially reasonable.

 

(b)          
The Administrative Agent or any Secured Party
may be the purchaser of any or all of the Collateral at any public or private (to the extent to the portion of the Collateral
being privately sold is of a kind that is customarily sold on a recognized market or the subject of widely distributed standard
price quotations) sale in accordance with the UCC and the Administrative Agent, as Administrative Agent for and representative
of the Secured Parties, shall be entitled, for the purpose of bidding and making settlement or payment of the purchase price for
all or any portion of the Collateral sold at any such sale made in accordance with the UCC, to use and apply any of the Secured
Obligations as a credit on account of the purchase price for any Collateral payable by the Administrative Agent at such sale.
Each purchaser at any such sale shall hold the property sold absolutely free from any claim or right on the part of any Grantor,
and each Grantor hereby waives (to the extent permitted by applicable law) all rights of redemption, stay and/or appraisal which
it now has or may at any time in the future have under any rule of law or statute now existing or hereafter enacted. Each Grantor
agrees that, to the extent notice of sale shall be required by law, at least ten (10) days’ notice to such Grantor of the time
and place of any public sale or the time after which any private sale is to be made shall constitute reasonable notification.
The Administrative Agent shall not be obligated to make any sale of Collateral regardless of notice of sale having been given.
The Administrative Agent may adjourn any public or private sale from time to time by announcement at the time and place fixed
therefor, and such sale may, without further notice, be made at the time and place to which it was so adjourned. Each Grantor
agrees that it would not be commercially unreasonable for the Administrative Agent to dispose of the Collateral or any portion
thereof by using Internet sites that provide for the auction of assets of the types included in the Collateral or that have the
reasonable capability of doing so, or that match buyers and sellers of assets. Each Grantor hereby waives any claims against the
Administrative Agent arising by reason of the fact that the price at which any Collateral may have been sold at such a private
sale was less than the price which might have been obtained at a public sale, even if the Administrative Agent accepts the first
offer received and does not offer such Collateral to more than one offeree. If the proceeds of any sale or other disposition of
the Collateral are insufficient to pay all the Secured Obligations, Grantors shall be liable for the deficiency and the fees of
any attorneys employed by the Administrative Agent to collect such deficiency. Each Grantor further agrees that a breach of any
of the covenants contained in this Section will cause irreparable injury to the Administrative Agent, that the Administrative
Agent has no adequate remedy at law in respect of such breach and, as a consequence, that each and every covenant contained in
this Section shall be specifically enforceable against such Grantor, and such Grantor hereby waives and agrees not to assert any
defenses against an action for specific performance of such covenants except for a defense that no default has occurred giving
rise to the Secured Obligations becoming due and payable prior to their stated maturities. Nothing in this Section shall in any
way alter the rights of the Administrative Agent hereunder.

 

    	 	28	 

    	 

    

 

(c)          
The Administrative Agent may sell the Collateral
without giving any warranties as to the Collateral. The Administrative Agent may specifically disclaim or modify any warranties
of title or the like. This procedure will not be considered to adversely affect the commercial reasonableness of any sale of the
Collateral.

 

(d)           
The Administrative Agent shall have no obligation
to marshal any of the Collateral.

 

(e)           
The Administrative Agent may: (1) direct
the Account Debtors under any Receivables to make payment of all amounts due or to become due to such Grantor thereunder directly
to the Administrative Agent; (2) notify, or require any Grantor to notify, each Person maintaining a lockbox or similar arrangement
to which Account Debtors under any Receivables have been directed to make payment to remit all amounts representing collections
on checks and other payment items from time to time sent to or deposited in such lockbox or other arrangement directly to the
Administrative Agent; and (3) enforce, at the expense of such Grantor, collection of any such Receivables and to adjust,
settle or compromise the amount or payment thereof, in the same manner and to the same extent as such Grantor might have done.
If the Administrative Agent notifies any Grantor that it has elected to collect the Receivables in accordance with the preceding
sentence, any payments of Receivables received by such Grantor shall be forthwith (and in any event within two (2) Business Days)
deposited by such Grantor in the exact form received, duly indorsed by such Grantor to the Administrative Agent if required, in
the Administrative Agent’s Account maintained under the sole dominion and control of the Administrative Agent, and until so turned
over, all amounts and proceeds (including checks and other instruments) received by such Grantor in respect of the Receivables,
any Supporting Obligation or Collateral Support shall be received in trust for the benefit of the Administrative Agent hereunder
and shall be segregated from other funds of such Grantor and such Grantor shall not adjust, settle or compromise the amount or
payment of any Receivable, or release wholly or partly any Account Debtor or obligor thereof, or allow any credit or discount
thereon

 

(f)           
The Administrative Agent may exercise control
over any Investment Accounts, whether or not such Investment Accounts are created before or after the Closing Date. The Administrative
Agent shall have the right, without notice to any Grantor, to transfer all or any portion of the Investment Related Property to
its name or the name of its nominee or agent. In addition, the Administrative Agent shall have the right at any time, without
notice to any Grantor, to exchange any certificates or instruments representing any Investment Related Property for certificates
or instruments of smaller or larger denominations.

 

(g)           
With respect to any Deposit Account (other than
an Excluded Account), the Administrative Agent may give instructions and directions to such bank or depositary institution to
wire all amounts on deposit in such Deposit Account each Business Day to the Administrative Agent’s Account. All amounts received
or deposited into the Administrative Agent’s Account after the occurrence of an Event of Default shall be applied to the payment
of the outstanding Obligations in accordance with the Financing Agreement.

 

7.2          
Application of Proceeds. Except
as expressly provided elsewhere in this Agreement, all proceeds received by the Administrative Agent in respect of any sale, any
collection from, or other realization upon all or any part of the Collateral shall be applied in full or in part by the Administrative
Agent against the Secured Obligations as set forth in Section 2.11(a) of the Financing Agreement.

 

    	 	29	 

    	 

    

 

7.3          
Sales on Credit. If
Administrative Agent sells any of the Collateral upon credit, Grantor will be credited only with payments actually made by purchaser
and received by Administrative Agent and applied to indebtedness of the purchaser. In the event the purchaser fails to pay for
the Collateral, Administrative Agent may resell the Collateral and Grantor shall be credited with proceeds of the sale.

 

7.4          
Deposit Accounts.

 

If
any Event of Default shall have occurred and be continuing, the Administrative Agent may apply the balance from any Deposit Account
or instruct the bank at which any Deposit Account is maintained to pay the balance of any Deposit Account to or for the benefit
of the Administrative Agent.

 

7.5          
Investment Related Property.

 

Each
Grantor recognizes that, by reason of certain prohibitions contained in the Securities Act and applicable state securities laws,
the Administrative Agent may be compelled, with respect to any sale of all or any part of the Investment Related Property conducted
without prior registration or qualification of such Investment Related Property under the Securities Act and/or such state securities
laws, to limit purchasers to those who will agree, among other things, to acquire the Investment Related Property for their own
account, for investment and not with a view to the distribution or resale thereof. Each Grantor acknowledges that any such private
sale may be at prices and on terms less favorable than those obtainable through a public sale without such restrictions (including
a public offering made pursuant to a registration statement under the Securities Act) and, notwithstanding such circumstances,
each Grantor agrees that any such private sale shall be deemed to have been made in a commercially reasonable manner and that
the Administrative Agent shall have no obligation to engage in public sales and no obligation to delay the sale of any Investment
Related Property for the period of time necessary to permit the issuer thereof to register it for a form of public sale requiring
registration under the Securities Act or under applicable state securities laws, even if such issuer would, or should, agree to
so register it. If the Administrative Agent determines to exercise its right to sell any or all of the Investment Related Property,
upon written request, each Grantor shall and shall cause each issuer of any Pledged Stock to be sold hereunder, each partnership
and each limited liability company from time to time to furnish to the Administrative Agent all such information as the Administrative
Agent may request in order to determine the number and nature of interest, shares or other instruments included in the Investment
Related Property which may be sold by the Administrative Agent in exempt transactions under the Securities Act and the rules and
regulations of the Capital Stock and Exchange Commission thereunder, as the same are from time to time in effect.

 

7.6          
Intellectual Property.

 

(a)           
Anything contained herein to the contrary notwithstanding,
upon the occurrence and during the continuation of an Event of Default:

 

(i)           
the Administrative Agent shall have the right
(but not the obligation) to bring suit or otherwise commence any action or proceeding in the name of any Grantor, the Administrative
Agent or otherwise, in the Administrative Agent’s sole discretion, to enforce any Intellectual Property, in which event such Grantor
shall, at the request of the Administrative Agent, do any and all lawful acts and execute any and all documents required by the
Administrative Agent in aid of such enforcement and such Grantor shall promptly, upon demand, reimburse and indemnify the Administrative
Agent as provided in Section 10 hereof in connection with the exercise of its rights under this Section, and, to the extent
that the Administrative Agent shall elect not to bring suit to enforce any Intellectual Property as provided in this Section,
each Grantor agrees to use all reasonable measures, whether by action, suit, proceeding or otherwise, to prevent the infringement
or other violation of any of such Grantor’s rights in the Intellectual Property by others and for that purpose agrees to diligently
maintain any action, suit or proceeding against any Person so infringing as shall be necessary to prevent such infringement or
violation;

 

    	 	30	 

    	 

    

 

(ii)          
upon written demand from the Administrative Agent,
each Grantor shall grant, assign, convey or otherwise transfer to the Administrative Agent or such Administrative Agent’s designee
all of such Grantor’s right, title and interest in and to the Intellectual Property and shall execute and deliver to the Administrative
Agent such documents as are necessary or appropriate to carry out the intent and purposes of this Agreement;

 

(iii)         
each Grantor agrees that such an assignment and/or
recording shall be applied to reduce the Secured Obligations outstanding only to the extent that the Administrative Agent (or
any Secured Party) receives cash proceeds in respect of the sale of, or other realization upon, the Intellectual Property;

 

(iv)         
within five (5) Business Days after written notice
from the Administrative Agent, each Grantor shall make reasonable efforts to make available to the Administrative Agent, to the
extent within such Grantor’s power and authority, such personnel in such Grantor’s employ on the date of such Event of Default
as the Administrative Agent may reasonably designate, by name, title or job responsibility, to permit such Grantor to continue,
directly or indirectly, to produce, advertise and sell the products and services sold or delivered by such Grantor under or in
connection with the Trademarks, Trademark Licenses, such persons to be available to perform their prior functions on the Administrative
Agent’s behalf and to be compensated by the Administrative Agent at such Grantor’s expense on a per diem, pro-rata basis consistent
with the salary and benefit structure applicable to each as of the date of such Event of Default; and

 

(v)          
the Administrative Agent shall have the right
to notify, or require each Grantor to notify, any obligors with respect to amounts due or to become due to such Grantor in respect
of the Intellectual Property, of the existence of the security interest created herein, to direct such obligors to make payment
of all such amounts directly to the Administrative Agent, and, upon such notification and at the expense of such Grantor, to enforce
collection of any such amounts and to adjust, settle or compromise the amount or payment thereof, in the same manner and to the
same extent as such Grantor might have done;

 

		(1)	all
                                         amounts and proceeds (including checks and other instruments) received by Grantor in
                                         respect of amounts due to such Grantor in respect of the Collateral or any portion thereof
                                         shall be received in trust for the benefit of the Administrative Agent hereunder, shall
                                         be segregated from other funds of such Grantor and shall be forthwith paid over or delivered
                                         to the Administrative Agent in the same form as so received (with any necessary endorsement)
                                         to be held as cash Collateral and applied as provided by Section 7.7 hereof; and

 

    	 	31	 

    	 

    

 

		(2)	Grantor
                                         shall not adjust, settle or compromise the amount or payment of any such amount or release
                                         wholly or partly any obligor with respect thereto or allow any credit or discount thereon.

 

(b)          
If (i) an Event of Default shall have occurred
and, by reason of cure, waiver, modification, amendment or otherwise, no longer be continuing, (ii) no other Event of Default
shall have occurred and be continuing, (iii) an assignment or other transfer to the Administrative Agent of any rights, title
and interests in and to the Intellectual Property shall have been previously made and shall have become absolute and effective,
and (iv) the Secured Obligations shall not have become immediately due and payable, upon the written request of any Grantor, the
Administrative Agent shall promptly execute and deliver to such Grantor, at such Grantor’s sole cost and expense, such assignments
or other transfer as may be necessary to reassign to such Grantor any such rights, title and interests as may have been assigned
to the Administrative Agent as aforesaid, subject to any disposition thereof that may have been made by the Administrative Agent;
provided that after giving effect to such reassignment, the Administrative Agent’s security interest granted pursuant hereto,
as well as all other rights and remedies of the Administrative Agent granted hereunder, shall continue to be in full force and
effect; and provided further, the rights, title and interests so reassigned shall be free and clear of any other Liens
granted by or on behalf of the Administrative Agent and the Secured Parties.

 

(c)           
Solely for the purpose of enabling the Administrative
Agent to exercise rights and remedies under this Section 7 and at such time as the Administrative Agent shall be lawfully
entitled to exercise such rights and remedies, each Grantor hereby grants to the Administrative Agent, to the extent it has the
right to do so, an irrevocable, nonexclusive license (exercisable without payment of royalty or other compensation to such Grantor),
subject, in the case of Trademarks, to sufficient rights to quality control and inspection in favor of such Grantor to avoid the
risk of invalidation of said Trademarks, to use, operate under, license, or sublicense any Intellectual Property now owned or
hereafter acquired by such Grantor, and wherever the same may be located.

 

7.7          
Cash Proceeds.
In addition to the rights of the Administrative Agent specified in Section 4.3 with respect to payments of Receivables,
upon the occurrence and during the continuance of any Event of Default, all proceeds of any Collateral received by any Grantor
consisting of cash, checks and other non-cash items (“Cash Proceeds”) shall be held by such Grantor in trust
for the Administrative Agent, segregated from other funds of such Grantor, and shall, forthwith upon receipt by such Grantor (and,
in any event, within two (2) Business Days of receipt thereof), be turned over to the Administrative Agent in the exact form
received by such Grantor (duly indorsed by such Grantor to the Administrative Agent, if required) and deposited into the Administrative
Agent’s Account; and any such Cash Proceeds received by the Administrative Agent (whether from a Grantor or otherwise) shall be
applied by the Administrative Agent against the Secured Obligations in accordance with Section 2.11(a) of the Financing Agreement.
Subject to Section 4.3, any Cash Proceeds received by the Administrative Agent (whether from a Grantor or otherwise): (i)
at any time that no Event of Default shall have occurred and be continuing, shall be returned to the Grantor and (ii) if
an Event of Default shall have occurred and be continuing, may, in the sole discretion of the Administrative Agent, (A) be held
by the Administrative Agent for the ratable benefit of the Secured Parties, as collateral security for the Secured Obligations
(whether matured or unmatured) and/or (B) then or at any time thereafter may be applied by the Administrative Agent against the
Secured Obligations then due and owing.

 

Section
8. [RESERVED].

 

    	 	32	 

    	 

    

 

Section
9. CONTINUING SECURITY INTEREST; TRANSFER OF
TERM LOANS.

 

This
Agreement shall create a continuing security interest in the Collateral and shall remain in full force and effect until the payment
in full of all Secured Obligations (other than any such contingent obligations or liabilities hereunder or under the Financing
Agreement that by the express terms thereof survive such payment in full of all Secured Obligations) and be binding upon each
Grantor, its successors and assigns, and inure, together with the rights and remedies of the Administrative Agent hereunder, to
the benefit of the Administrative Agent and its successors, permitted transferees and permitted assigns. Without limiting the
generality of the foregoing, but subject to the terms and conditions of the Financing Agreement, any Lender may assign or otherwise
transfer the Term Loan held by it to any other Person, and such other Person shall thereupon become vested with all the benefits
in respect thereof granted to Lenders herein or otherwise. Upon the payment in full of all Secured Obligations (other than any
such contingent obligations or liabilities hereunder or under the Financing Agreement that by the express terms thereof survive
such payment in full of all Secured Obligations), the security interest granted hereby shall automatically terminate hereunder
and of record and all rights to the Collateral shall revert to Grantors. Upon any such termination the Administrative Agent shall,
at Grantors’ expense, execute and deliver to Grantors or otherwise authorize the filing of such documents, agreements and instruments
as Grantors shall reasonably request, including financing statement amendments to evidence such termination. Upon any disposition
of property permitted by the Financing Agreement, the Liens granted herein shall be deemed to be automatically released and such
property shall automatically revert to the applicable Grantor (or such other applicable Person) with no further action on the
part of any Person. The Administrative Agent shall, at Grantor’s expense, execute and deliver or otherwise authorize the filing
of such documents, agreements and instruments as Grantors shall reasonably request, in form and substance reasonably satisfactory
to the Administrative Agent, including financing statement amendments to evidence such release.

 

Section
10. STANDARD OF CARE.

 

The
powers conferred on the Administrative Agent hereunder are solely to protect its interest in the Collateral and shall not impose
any duty upon it to exercise any such powers. Except for the exercise of reasonable care in the custody of any Collateral in its
possession and the accounting for moneys actually received by it hereunder, the Administrative Agent shall have no duty as to
any Collateral or as to the taking of any necessary steps to preserve rights against prior parties or any other rights pertaining
to any Collateral. The Administrative Agent shall be deemed to have exercised reasonable care in the custody and preservation
of Collateral in its possession if such Collateral is accorded treatment substantially equal to that which the Administrative
Agent accords its own property. Neither the Administrative Agent nor any of its directors, officers, employees or agents shall
be liable for failure to demand, collect or realize upon all or any part of the Collateral or for any delay in doing so or shall
be under any obligation to sell or otherwise dispose of any Collateral upon the request of any Grantor or otherwise.

 

    	 	33	 

    	 

    

 

Section
11. MISCELLANEOUS.

 

Any
notice required or permitted to be given under this Agreement shall be given in accordance with Section 10.1 of the Financing
Agreement. No failure or delay on the part of the Administrative Agent in the exercise of any power, right or privilege hereunder
or under any other Loan Document shall impair such power, right or privilege or be construed to be a waiver of any default or
acquiescence therein, nor shall any single or partial exercise of any such power, right or privilege preclude other or further
exercise thereof or of any other power, right or privilege. All rights and remedies existing under this Agreement and the other
Loan Documents are cumulative to, and not exclusive of, any rights or remedies otherwise available. In case any provision in or
obligation under this Agreement shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability
of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way
be affected or impaired thereby. All covenants hereunder shall be given independent effect so that if a particular action or condition
is not permitted by any of such covenants, the fact that it would be permitted by an exception to, or would otherwise be within
the limitations of, another covenant shall not avoid the occurrence of a Default or an Event of Default if such action is taken
or condition exists. This Agreement shall be binding upon and inure to the benefit of the Administrative Agent and Grantors and
their respective successors and permitted assigns. No Grantor shall, without the prior written consent of the Administrative Agent
given in accordance with the Financing Agreement, assign any right, duty or obligation hereunder. This Agreement and the other
Loan Documents embody the entire agreement and understanding between Grantors and the Administrative Agent and supersede all prior
agreements and understandings between such parties relating to the subject matter hereof and thereof. Accordingly, the Loan Documents
may not be contradicted by evidence of prior, contemporaneous or subsequent oral agreements of the parties. There are no unwritten
oral agreements between the parties. This Agreement may be executed in one or more counterparts and by different parties hereto
in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts
together shall constitute but one and the same instrument; signature pages may be detached from multiple separate counterparts
and attached to a single counterpart so that all signature pages are physically attached to the same document. Delivery of an
executed counterpart of this Agreement by facsimile or electronic mail shall be equally effective as delivery of an original executed
counterpart.

 

SECTIONS
10.5 (AMENDMENTS AND WAIVERS), 10.14 (APPLICABLE LAW), 10.15 (CONSENT TO JURISDICTION) and 10.16 (WAIVER OF JURY TRIAL) OF THE
FINANCING AGREEMENT ARE HEREBY INCORPORATED BY REFERENCE, MUTATIS MUTANDIS. 

 

    	 	34	 

    	 

    

 

IN
WITNESS WHEREOF, each Grantor and the Administrative Agent have caused this Agreement to be duly executed and delivered by their
respective officers thereunto duly authorized as of the date first written above.

 

	 	GRANTRORS:
	 	 	 
	 	THERAPEUTICSMD, INC.
	 	 	 
	 	By:	/s/ Daniel
    Cartwright
	 	Name: Daniel Cartwright
	 	Title: Chief Financial Officer and
    Treasurer
	 	 	 
	 	VITAMEDMD, LLC
	 	 	 
	 	By:	/s/ Daniel
    Cartwright
	 	Name: Daniel Cartwright
	 	Title: Chief Financial Officer and
    Treasurer
	 	 	 
	 	BOCAGREENMD, INC.
	 	 	 
	 	By:	/s/ Daniel
    Cartwright
	 	Name: Daniel Cartwright
	 	Title: Chief Financial Officer and
    Treasurer
	 	 	 
	 	VITACARE PRESCRIPTION SERVICES,
    INC.
	 	 	 
	 	By:	/s/ Daniel
    Cartwright
	 	Name: Daniel Cartwright
	 	Title: Chief Financial Officer and
    Assistant Treasurer

 

[Signature
Page to Pledge and Security Agreement]

 

     

     

    

 

	 	TPG SPECIALTY LENDING, INC.
	 	as the Administrative Agent
	 	 	 
	 	By:	/s/ Joshua
    Easterly
	 	 	Name: Joshua Easterly
	 	 	Title: CEO

 

[Signature
Page to Pledge and Security Agreement]

 

     

     

    

 

SCHEDULE 4.1

TO PLEDGE AND SECURITY AGREEMENT

  

GENERAL INFORMATION

 

		(A)	Full Legal Name, Type of Organization, Jurisdiction of Organization, Chief Executive Office/Sole
Place of Business and Organizational Identification Number of each Grantor:

 

	
        Full
Legal

Name
	
        Type
of

Organization
	
        Jurisdiction
of

Organization
	
        Chief
Executive

Office/Sole Place of Business
	
        Organization
I.D.#

	TherapeuticsMD, Inc.	Corporation	Nevada	6800 Broken Sound Parkway NW, Suite 300, Boca Raton, Palm Beach County, FL 33487	20101548400
	VitaMedMD LLC	Limited Liability Company	Delaware	See above.	4546519
	BocaGreenMD, Inc.	Corporation	Nevada	See above.	NV20121021440
	VitaCare Prescription Services, Inc.	Corporation	Florida	See above.	P15000042489

 

		(B)	Other Names (including any Trade-Name or Fictitious Business Name) under which each Grantor has conducted
business for the past five (5) years:

 

	Full Legal Name	Trade Name or Fictitious Business Name
	None.	 

 

		(C)	Changes in Name, Jurisdiction of Organization, Chief Executive Office or Sole Place of Business and
Corporate Structure within past five (5) years:

 

	Name of Grantor	Date of Change	Description of Change
	None.	 	 

 

		(D)	[Reserved]

 

		(E)	Financing Statements:

 

	Name of Grantor	Filing Jurisdiction(s)
	TherapeuticsMD, Inc.	Nevada, UCC #2018015124-8
	VitaMedMD LLC	Delaware, UCC #20183582687
	BocaGreenMD, Inc.	Nevada, UCC #2018015125-0
	VitaCare Prescription Services, Inc.	Florida, UCC #201805366147

 

    SCHEDULE 4.1 - 1

     

    

 

SCHEDULE 4.4

TO PLEDGE AND SECURITY AGREEMENT

 

INVESTMENT RELATED PROPERTY

 

		(A)	Pledged Stock:

 

	Grantor	Stock

Issuer	Class of Stock	
        Certificated

        (Y/N)
	Stock

Certificate

No.	Par

Value	No. of

Pledged

Stock	% of

Outstanding Stock of the Stock Issuer
	TherapeuticsMD, Inc.	BocaGreenMD, Inc.	Common 	Yes 	No. 1	$0.001	1,000	100%
	TherapeuticsMD, Inc.	VitaCare Prescription Services, Inc.	Common 	Yes 	No. 1	$0.01	1,000	100%

 

Pledged LLC Interests:

 

	Grantor	Limited

Liability

Company	Certificated

(Y/N)	Certificate

No. (if any)	No. of Pledged Units	% of

Outstanding LLC Interests of the Limited Liability Company
	TherapeuticsMD, Inc.	VitaMedMD LLC	No	N/A	N/A	100%

 

Pledged Partnership Interests:

 

	Grantor	Partnership	Type of Partnership Interests (e.g., general or limited)	Certificated

(Y/N)	Certificate No.

(if any)	% of

Outstanding Partnership Interests of the Partnership
	None.	 	 	 	 	 

 

Pledged Trust Interests:

 

	Grantor	Trust	Class of Trust

Interests	Certificated

(Y/N)	Certificate No.

(if any)	% of

Outstanding Trust Interests of the Trust
	None.	 	 	 	 	 

 

    SCHEDULE 4.4 - 1

     

    

 

Pledged Debt:

 

	Grantor	Issuer	Original Principal

Amount	Outstanding Principal Balance	Issue Date	Maturity Date
	None.	 	 	 	 	 

 

Securities Account:

 

	Grantor	Name of Securities Intermediary	Account Number	Account Name
	[***]	[***]	[***]	[***]

 

Commodities Accounts:

 

	Grantor	Name of

Commodities Intermediary	Account Number	Account Name
	None.	 	 	 

 

Deposit Accounts:

 

	Grantor	Name of

Depositary Bank	Account Number	Account Name
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]

 

		(B)	

 

	Name of Grantor	Date of Acquisition	Description of Acquisition
	None.	 	 

 

		(C)	

 

	Name of Grantor	Name of Issuer of Pledged LLC

Interest/Pledged Partnership Interest
	None.	 

 

    SCHEDULE 4.4 - 2

     

    

 

SCHEDULE 4.5

TO PLEDGE AND SECURITY AGREEMENT

 

MATERIAL CONTRACTS

 

	Name of Grantor	Description of Material Contract
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]

 

    SCHEDULE 4.5 - 1

     

    

 

SCHEDULE 4.6

TO PLEDGE AND SECURITY AGREEMENT

 

DESCRIPTION OF LETTERS OF CREDIT

 

	Name of Grantor	Description of Letters of Credit
	None.	 

 

    SCHEDULE 4.6 - 1

     

    

 

SCHEDULE 4.7

TO PLEDGE AND SECURITY AGREEMENT

 

INTELLECTUAL PROPERTY -
EXCEPTIONS12

 

		(A)	Copyrights

 

None.

 

		(B)	Copyright Licenses

 

None.

 

		(C)	Patents

 

Issued Patents:

 

	 	Patent Number	Title	Filing Date (mm/dd/yy)	Issue Date (mm/dd/yy)	Country
	1. 	8,577,716	System and Method of Ongoing Evaluation Reporting and Analysis	09/17/09	11/05/13	US
	2. 	8,633,178	Natural Combination Hormone Replacement Formulations and Therapies	11/21/12	01/21/14	US
	3. 	8,846,648	Natural Combination Hormone Replacement Formulations and Therapies	12/06/13	09/30/14	US
	4. 	8,846,649	Natural Combination Hormone Replacement Formulations and Therapies	12/06/13	09/30/14	US
	5. 	8,933,059	Natural Combination Hormone Replacement Formulations and Therapies	12/06/13	01/13/15	US
	6. 	8,987,237	Natural Combination Hormone Replacement Formulations and Therapies	12/06/13	03/24/15	US
	7. 	8,987,238	Natural Combination Hormone Replacement Formulations and Therapies	12/06/13	03/24/15	US
	8. 	8,993,548	Natural Combination Hormone Replacement Formulations and Therapies	09/03/14	03/31/15	US
	9. 	8,993,549	Natural Combination Hormone Replacement Formulations and Therapies	09/03/14	03/31/15	US
	10. 	9,006,222	Natural Combination Hormone Replacement Formulations and Therapies	12/06/13	04/14/15	US

 

 

1
Borrower is the holder of all intellectual property unless otherwise indicated.

 

2
Key: pink - Imvexxy, purple - Bijuva, blue – Annovera.

 

    SCHEDULE 4.7 - 1

     

    

 

	 	Patent Number	Title	Filing Date (mm/dd/yy)	Issue Date (mm/dd/yy)	Country
	11. 	9,012,434	Natural Combination Hormone Replacement Formulations and Therapies	12/06/13	04/21/15	US
	12. 	9,114,145	Natural Combination Hormone Replacement Formulations and Therapies	09/03/14	08/25/15	US
	13. 	9,114,146	Natural Combination Hormone Replacement Formulations and Therapies	09/03/14	08/25/15	US
	14. 	9,180,091	Soluble Estradiol Capsule for Vaginal Insertion	12/20/13	10/10/15	US
	15. 	9,248,136	Transdermal Hormone Replacement Therapies	12/12/13	02/02/16	US
	16. 	9,289,382	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	02/17/15	03/22/16	US
	17. 	9,296,780*	Process for Alkynylating 16-Substituted-17-Keto Steroids	12/19/12	03/29/16	US
	18. 	9,301,920	Natural Combination Hormone Replacement Formulations and Therapies	03/15/13	04/05/16	US
	19. 	D801,518	Pharmaceutical Capsule	06/22/15	10/31/17	US
	20. 	9,931,349	Steroid Hormone Pharmaceutical Composition	03/30/17	04/03/18	US
	21. 	10,052,386	Progesterone Formulations	12/11/13	08/21/18	US
	22. 	10,098,894	Transdermal Cream	07/29/15	10/16/18	US
	23. 	10,206,932	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	02/19/19	US
	24. 	10,258,630	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods 	02/09/18	04/17/19	US
	25. 	89459	Pharmaceutical Capsule	12/22/15	02/17/16	AR
	26. 	366507	Pharmaceutical Capsule	12/21/15	01/12/16	AU
	27. 	2012340589	Natural Combination Hormone Replacement Formulations and Therapies	11/21/12	08/25/16	AU
	28. 	2013211876	Transdermal Hormone Replacement Therapies	01/25/13	05/25/17	AU
	29. 	2013277236	Natural Combination Hormone Replacement Formulations and Therapies	06/18/13	08/03/17 	AU

 

 

* Licensed
patent or patent application.

 

    SCHEDULE 4.7 - 2

     

    

 

	 	Patent Number	Title	Filing Date (mm/dd/yy)	Issue Date (mm/dd/yy)	Country
	30. 	2013277234	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	08/10/17	AU
	31. 	MX 358440 B	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	08/03/18	MX
	32. 	166,044	Pharmaceutical Capsule	12/17/15	08/16/16	CA
	33. 	002916247-0001	Pharmaceutical Capsule	12/18/15	08/10/16	EP
	34. 	302015005859-5	Pharmaceutical Capsule	12/21/15	01/30/18	BR
	35. 	6285866	Natural Combination Hormone Replacement Formulations and Therapies	11/21/12	02/09/18	JP
	36. 	6298460	Progesterone Formulations	06/18/13	03/02/18	JP
	37. 	MX 50237 B	Pharmaceutical Capsule	12/18/15	07/19/17	MX
	38. 	30-2015-0065043	Pharmaceutical Capsule	12/18/15	03/06/17	KR
	39. 	101179	Pharmaceutical Capsule	12/21/15	01/10/17	RU
	40. 	A2015/01935	Pharmaceutical Capsule	12/21/15	05/16/17	ZA
	41. 	2015/00211	Natural Combination Hormone Replacement Therapies	06/18/13	07/27/16	ZA
	42. 	2015/00212	Progesterone Formulations	06/18/13	04/26/17	ZA
	43. 	6334519	Natural Combination Hormone Replacement Therapies	06/18/13	05/11/18	JP
	44. 	6342334	Transdermal Hormone Replacement Therapies	01/25/13	05/25/18	JP
	45. 	6342389	Transdermal Hormone Replacement Therapies	06/18/13	05/25/18	JP
	46. 	6397402	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	09/07/18	JP
	47. 	2013277235	Transdermal Hormone Replacement Therapies	06/18/13	08/02/18	AU
	48. 	2013277233	Progesterone Formulations	06/18/13	09/13/18	AU
	49. 	1624393	Pharmaceutical Capsule	12/21/15	01/18/19	JP
	50. 	2861234B	Progesterone Formulations	06/18/13	03/27/19	EP
	51. 	2806742B	Transdermal Hormone Replacement Therapies	01/25/13	03/27/19	EP

 

    SCHEDULE 4.7 - 3

     

    

 

Pending Patent Applications:

 

	 	Application Number	Title	Application Date (mm/dd/yy)	Country
	1. 	16/104,101	Natural Combination Hormone Replacement Formulations and Therapies	08/16/18	US
	2. 	BR1120140124442	Natural Combination Hormone Replacement Formulations and Therapies	11/21/12	BR
	3. 	2,856,520	Natural Combination Hormone Replacement Formulations and Therapies	11/21/12	CA
	4. 	12850845.4	Natural Combination Hormone Replacement Formulations and Therapies	11/21/12	EP
	5. 	2017-173842	Natural Combination Hormone Replacement Formulations and Therapies	11/21/12	JP
	6. 	MX/a/2014/006256	Natural Combination Hormone Replacement Formulations and Therapies	11/21/12	MX
	7. 	15/090,493	Natural Combination Hormone Replacement Formulations and Therapies	04/04/16	US
	8. 	20140101244	Natural Combination Hormone Replacement Formulations and Therapies	03/17/14	AR
	9. 	2017206262	Natural Combination Hormone Replacement Formulations and Therapies	07/20/17 	AU
	10. 	BR1120140319103	Natural Combination Hormone Replacement Formulations and Therapies	06/18/13	BR
	11. 	2,876,977	Natural Combination Hormone Replacement Formulations and Therapies	06/18/13	CA
	12. 	13806855.6	Natural Combination Hormone Replacement Formulations and Therapies	06/18/13	EP
	13. 	236358	Natural Combination Hormone Replacement Formulations and Therapies	06/18/13	IL
	14. 	2017-176379	Natural Combination Hormone Replacement Formulations and Therapies	06/18/13	JP
	15. 	10-2015-7001189	Natural Combination Hormone Replacement Formulations and Therapies	06/18/13	KR
	16. 	MX/a/2014/015898	Natural Combination Hormone Replacement Formulations and Therapies	06/18/13	MX
	17. 	2015100533	Natural Combination Hormone Replacement Formulations and Therapies	06/18/13	RU

 

    SCHEDULE 4.7 - 4

     

    

 

	 	Application Number	Title	Application Date (mm/dd/yy)	Country
	18. 	15/999,040	Natural Combination Hormone Replacement Formulations and Therapies	08/16/18	US
	19. 	14/512,046	Natural Combination Hormone Replacement Formulations and Therapies	10/10/14	US
	20. 	20150101608	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	AR
	21. 	2015264003	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	AU
	22. 	BR112016 027359 1	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	BR
	23. 	2,947,767	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	CA
	24. 	15727528.0	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	EP
	25. 	248985	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	IL
	26. 	2016-565647	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	JP
	27. 	10-2016-7032773	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	KR
	28. 	MX/a/2016/014281	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	MX
	29. 	2016143081	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	RU
	30. 	2016/07541	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	ZA
	31. 	15/832,757	Natural Combination Hormone Replacement Formulations and Therapies	12/05/17	US
	32. 	PCT/US2017/064788	Natural Combination Hormone Replacement Formulations and Therapies	12/05/17	PCT
	33. 	15/832,750	Natural Combination Hormone Replacement Formulations and Therapies	12/05/17	US
	34. 	16/244,020	Natural Combination Hormone Replacement Formulations and Therapies	01/09/19	US
	35. 	16/355,532	Natural Combination Hormone Replacement Formulations and Therapies	03/15/19	US

 

    SCHEDULE 4.7 - 5

     

    

 

	 	Application Number	Title	Application Date (mm/dd/yy)	Country
	36. 	62/822,609	Natural Combination Hormone Replacement Formulations and Therapies	03/22/19	US
	37. 	14/649,818	Soluble Estradiol Capsule for Vaginal Insertion	12/17/15	US
	38. 	2017208300	Soluble Estradiol Capsule for Vaginal Insertion 	06/18/13	AU
	39. 	BR1120140319146	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	BR
	40. 	2,876,968	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	CA
	41. 	13807188.1	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	EP
	42. 	236359	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	IL
	43. 	10-2015-7001193	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	KR
	44. 	MX/A/2018/009466	Soluble Estradiol Capsule for Vaginal Insertion	08/02/18	MX
	45. 	2015100531	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	RU
	46. 	2014/09278	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	ZA
	47. 	2018-162966	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	JP
	48. 	14/521,230	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	US
	49. 	20140103975	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	AR
	50. 	2014349132	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	AU
	51. 	BR1120160090080	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	BR
	52. 	2,926,342	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	CA
	53. 	14862905.8	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	EP
	54. 	245139	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	IL
	55. 	2016-516086	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	JP
	56. 	10-2016-7010901	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	KR
	57. 	MX/A/2016/005092	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	MX

 

    SCHEDULE 4.7 - 6

     

    

 

	 	Application Number	Title	Application Date (mm/dd/yy)	Country
	58. 	2016118396	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	RU
	59. 	2016/01933	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	ZA
	60. 	14/521,002	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	US
	61. 	15/372,385	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	US
	62. 	PCT/US2016/065466	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	PCT
	63. 	20160103768	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	AR
	64. 	2016366200	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	AU
	65. 	BR1120180114839	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	BR
	66. 	3,007,636	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	CA
	67. 	16873806.0	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	EP
	68. 	19122548.1	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	04/17/19	HK
	69. 	259884	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	IL
	70. 	2018-529574	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	JP
	71. 	10-2018-7019331	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	KR
	72. 	MX/A/2018/006882	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	MX
	73. 	743229	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	NZ
	74. 	2018121094	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	RU
	75. 	2018/03804	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	ZA

 

    SCHEDULE 4.7 - 7

     

    

 

	 	Application Number	Title	Application Date (mm/dd/yy)	Country
	76. 	62/680,715	Vaginal Inserted Estradiol Pharmaceutical Formulations and Methods	06/06/18	US
	77. 	15/893,542**4	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods 	02/09/18	US
	78. 	15/893,550**	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods 	02/09/18	US
	79. 	15/975,733	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	05/09/18	US
	80. 	15/975,723	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	05/09/18	US
	81. 	15/781,840	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	06/06/18	US
	82. 	16/004,338	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	06/08/18	US
	83. 	PCT/US2018/36790	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	06/08/18	PCT
	84. 	16/006,721	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	06/12/18	US
	85. 	16/037,452	Progesterone Formulations	07/17/18	US
	86. 	2018222947	Progesterone Formulations	06/18/13	AU
	87. 	BR1120140318379	Progesterone Formulations	06/18/13	BR
	88. 	2,876,964	Progesterone Formulations	06/18/13	CA
	89. 	MX/a/2014/015900	Progesterone Formulations	06/18/13	MX
	90. 	MX/a/2018/009467	Progesterone Formulations	08/02/18	MX
	91. 	15/454,898	Progesterone Formulations Having a Desirable PK Profile	03/09/17	US
	92. 	20150100920	Progesterone Compositions	03/27/15	AR
	93. 	2015237243	Progesterone Formulations	03/27/15	AU
	94. 	BR1120160225708	Progesterone Formulations	03/27/15	BR
	95. 	2,942,568	Progesterone Formulations	03/27/15	CA

 

 

** Application
contains allowable subject matter and a patent will issue in due course.

 

    SCHEDULE 4.7 - 8

     

    

 

	 	Application Number	Title	Application Date (mm/dd/yy)	Country
	96. 	15768772.4	Progesterone Formulations	03/27/15	EP
	97. 	247828	Progesterone Formulations	03/27/15	IL
	98. 	2016-557059	Progesterone Formulations	03/24/15	JP
	99. 	10-2016-7029519	Progesterone Formulations	03/27/15	KR
	100. 	MX/A/2016/011706	Progesterone Formulations	03/27/15	MX
	101. 	2016136666	Progesterone Formulations	03/27/15	RU
	102. 	2016/06309	Progesterone Formulations	03/27/15	ZA
	103. 	16/273,955	Progesterone Formulations Having a Desirable PK Profile	02/12/19	US
	104. 	16/125,201	Transdermal Cream	09/07/18	US
	105. 	P20150102431	Transdermal Cream	07/29/15	AR
	106. 	2015296609	Transdermal Cream	07/29/15	AU
	107. 	BR112016 029338 0	Transdermal Cream	07/29/15	BR
	108. 	2,951,284	Transdermal Cream	07/29/15	CA
	109. 	15827543.8	Transdermal Cream	07/29/15	EP
	110. 	248984	Transdermal Cream	07/29/15	IL
	111. 	2016-571728	Transdermal Cream	07/29/15	JP
	112. 	10-2017-7002451	Transdermal Cream	07/29/15	KR
	113. 	MX/a/2016/013693	Transdermal Cream	07/29/15	MX
	114. 	2016141135	Transdermal Cream	07/29/15	RU
	115. 	2016/07317	Transdermal Cream	07/29/15	ZA
	116. 	15/420,019	Transdermal Cream	01/30/17	US
	117. 	[***]	[***]	[***]	[***]
	118. 	[***]	[***]	[***]	[***]
	119. 	[***]	[***]	[***]	[***]
	120. 	15/217,301	Formulations for Solubilizing Hormones	07/22/16	US
	121. 	BR112014 018439 9	Transdermal Hormone Replacement Therapies	01/25/13	BR

 

    SCHEDULE 4.7 - 9

     

    

 

	 	Application Number	Title	Application Date (mm/dd/yy)	Country
	122. 	2,861,346	Transdermal Hormone Replacement Therapies	01/25/13	CA
	123. 	MX/A/2014/009093	Transdermal Hormone Replacement Therapies	01/25/13	MX
	124. 	13/843,362	Transdermal Hormone Replacement Therapies	03/15/13	US
	125. 	1120140318247	Transdermal Hormone Replacement Therapies	06/18/13	BR
	126. 	2,876,947	Transdermal Hormone Replacement Therapies	06/18/13	CA
	127. 	13807463.8	Transdermal Hormone Replacement Therapies	06/18/13	EP
	128. 	MX/A/2014/015897	Transdermal Hormone Replacement Therapies	06/18/13	MX
	129. 	2015/00210	Transdermal Hormone Replacement Therapies	06/18/13	ZA
	130. 	15/475,052	Steroid Hormone Pharmaceutical Composition	03/30/17	US
	131. 	PCT/US2017/025211	Steroid Hormone Pharmaceutical Composition	03/30/17	PCT
	132. 	20170100832	Steroid Hormone Pharmaceutical Composition	04/03/17	AR
	133. 	2017239679	Steroid Hormone Pharmaceutical Composition	03/30/17	AU
	134. 	BR1120180698776	Steroid Hormone Pharmaceutical Composition	03/30/17	BR
	135. 	3,019,375	Steroid Hormone Pharmaceutical Composition	03/30/17	CA
	136. 	17776724.1	Steroid Hormone Pharmaceutical Composition	03/30/17	EP
	137. 	261924	Steroid Hormone Pharmaceutical Composition	03/30/17	IL
	138. 	2018-550593	Steroid Hormone Pharmaceutical Composition	03/30/17	JP
	139. 	10-2018-7031666	Steroid Hormone Pharmaceutical Composition	03/30/17	KR
	140. 	MX/A/2018/011706	Steroid Hormone Pharmaceutical Composition	03/30/17	MX
	141. 	746686	Steroid Hormone Pharmaceutical Composition	03/30/17	NZ
	142. 	2018133921	Steroid Hormone Pharmaceutical Composition	03/30/17	RU
	143. 	2018/06413	Steroid Hormone Pharmaceutical Composition	03/30/17	ZA
	144. 	15/475,068	Steroid Hormone Pharmaceutical Composition in Medium Chain Oils	03/30/17	US
	145. 	20170100831	Steroid Hormone Compositions in Medium Chain Oils	04/03/17	AR
	146. 	PCT/US2017/025220	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	PCT

 

    SCHEDULE 4.7 - 10

     

    

 

	 	Application Number	Title	Application Date (mm/dd/yy)	Country
	147. 	15/473,742	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	US
	148. 	16/359,839	Steroid Hormone Compositions in Medium Chain Oils	03/20/19	US
	149. 	PCT/US2017/024955	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	PCT
	150. 	15/901,467	Steroid Hormone Compositions in Medium Chain Oils	02/21/18	US
	151. 	20170100830	Steroid Hormone Compositions in Medium Chain Oils	04/03/17	AR
	152. 	2017239645	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	AU
	153. 	BR1120180701998	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	BR
	154. 	3,020,153	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	CA
	155. 	17776645.8	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	EP
	156. 	261930	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	IL
	157. 	2018-550564	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	JP
	158. 	10-2018-7031878	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	KR
	159. 	MX/A/2018/011705	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	MX
	160. 	746682	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	NZ
	161. 	2018133932	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	RU
	162. 	2018/06414	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	ZA
	163. 	PCT/US2017/024994	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	PCT
	164. 	20170100829	Steroid Hormone Compositions in Medium Chain Oils	04/03/17	AR

 

    SCHEDULE 4.7 - 11

     

    

 

	 	Application Number	Title	Application Date (mm/dd/yy)	Country
	165. 	[***]	[***]	[***]	[***]
	166. 	[***]	[***]	[***]	[***]
	167. 	[***]	[***]	[***]	[***]
	168. 	[***]	[***]	[***]	[***]
	169. 	[***]*	[***]	[***]	[***]

 

		(D)	Patent Licenses

 

1. Borrower has licensed certain Product
Patents and is obligated to pay royalties and other payments pursuant to that certain License Agreement, dated July 30, 2018, between
Borrower and The Population Council, Inc.

 

2. Borrower has licensed certain Product
Patents pursuant to that certain License and Supply Agreement, dated July 30, 2018, as amended, between Borrower and Knight Pharmaceuticals,
Inc.

 

		(E)	Trademarks

 

Registered Trademarks:

 

	 	Registration Number	Trademark or Design	Registration Date 

(mm/dd/yy)	Country
	1. 	4430100	BOCAGREENMD	11/05/13	US
	2. 	4568945	BOCAGREENMD	07/15/14	US
	3. 	4607073	FEPLUS	09/16/14	US
	4. 	4581759	FOLMAX	08/05/14	US
	5. 	4271087	
         

        
	01/08/13	US
	6. 	5602058	IMVEXXY	11/06/18	US
	7. 	4444914	PRENA1	12/03/13	US
	8. 	4314431	REDICHEW	04/02/13	US
	9. 	4580454	THERAPEUTICSMD	08/05/14	US
	10. 	013048871	THERAPEUTICSMD	11/26/14	EU
	11. 	5714724	THERAPEUTICSMD	10/31/14	JP
	12. 	4580455	VITAMEDMD	08/05/14	US
	13. 	3842265	VITAMEDMD	10/31/10	US
	14. 	4271086	
        
	01/08/13	US
	15. 	5028550	VITATRUE	08/23/16	US

 

    SCHEDULE 4.7 - 12

     

    

 

Pending Trademark Applications or Pending
Designs:

 

	 	Serial Number	Pending Trademark or Design	Filing Date 

(mm/dd/yy)	Country
	1. 	88229031	
         

         

         

        
	12/13/18	US
	2. 	87744084	BIJUVA	10/10/14	US
	3. 	87916151	DUENTICA	05/10/18	US
	4. 	87327866	FLIRTAYIS	02/07/17	US
	5. 	87941900	
         

         

         

         

         
	05/30/18	US
	6. 	87941908	
         

         

         

         

        
	05/30/18	US
	7. 	88125885	
         

         

         

         

         
	09/20/18	US
	8. 	88125894	
         

         

         

         

        
	09/20/18	US

 

    SCHEDULE 4.7 - 13

     

    

 

	 	Serial Number	Pending Trademark or Design	Filing Date 

(mm/dd/yy)	Country
	9. 	87916153	OVANATA	05/10/18	US
	10. 	87498387	SYMBODA	06/20/17	US
	11. 	87916147	SYMEPTO	05/10/18	US
	12. 	87916140	VIEPA	05/10/18	US
	13. 	87916139	XUBIVVA	05/10/18	US
	14. 	87916136	YUTHENA	05/10/18	US
	15. 	88125949	YUVVEXY	09/20/18	US
	16. 	87126380	
        
	08/03/16	US
	17. 	87126398	
        

        
	08/03/16	US
	18. 	1947704	BIJUVA	02/22/19	CA
	19. 	1947721	JOYESTA	02/22/19	CA

 

    SCHEDULE 4.7 - 14

     

    

 

SERVICE MARKS

 

Registered Service Marks or Designs:

 

	 	Registration Number	Service Mark or Design	Registration Date 

(mm/dd/yy)	Country
	1. 	5051435	VITAMOM	09/27/16	US

 

Pending Service Mark Applications or Designs:

 

	 	Serial Number	Pending Service Mark or Design	Filing Date 

(mm/dd/yy)	Country
	1. 	87340782	BIO-IGNITE	02/17/17	US
	2. 	87398429	FOREVHER	04/04/17	US
	3. 	88346838	MENOCHOICE***	03/19/19	US

 

		(F)	Trademark Licenses

 

Borrower has licensed certain trademarks
under a June 13, 2014 Trademark License Agreement with Lang Pharma Nutrition, Inc.

 

		(G)	Trade Secret Licenses

 

None.

 

		(H)	Intellectual Property Exceptions

 

None.

 

 

*** Also in International Class 09.

 

    SCHEDULE 4.7 - 15

     

    

 

SCHEDULE 4.8

TO PLEDGE AND SECURITY AGREEMENT

 

COMMERCIAL TORT CLAIMS

 

	Name of Grantor	Commercial Tort Claims

 

None.

 

    SCHEDULE 4.8 - 1

     

    

 

EXHIBIT A

TO PLEDGE AND SECURITY AGREEMENT

 

PLEDGE SUPPLEMENT

 

This PLEDGE SUPPLEMENT,
dated as of ________, 20__, is delivered by [NAME OF GRANTOR] a [NAME OF STATE OF ORGANIZATION] [entity type] (a
“Additional Grantor”) pursuant to the Pledge and Security Agreement, dated as of April 24, 2019 (as amended,
restated, supplemented or otherwise modified from time to time, the “Security Agreement”), among the Grantors
party thereto from time to time, and TPG Specialty Lending, Inc., as the Administrative Agent. Capitalized terms used herein not
otherwise defined herein shall have the meanings ascribed thereto in the Security Agreement.

 

Additional Grantor
acknowledges and agrees that such Additional Grantor shall be a “Grantor” for all purposes under the Security Agreement
and to be bound by the terms thereof, and hereby confirms the grant to the Administrative Agent set forth in the Security Agreement
of, and does hereby grant to the Administrative Agent, a security interest in all of Additional Grantor’s right, title and
interest in and to all Collateral to secure the Secured Obligations. Additional Grantor represents and warrants that the attached
Supplements to Schedules accurately and completely set forth all additional information required pursuant to the Security Agreement
and hereby agrees that such Supplements to Schedules shall constitute part of the Schedules to the Security Agreement.

 

IN WITNESS WHEREOF,
Additional Grantor has caused this Pledge Supplement to be duly executed and delivered by its duly authorized officer as of the
date first set forth above.

 

	 	[NAME OF ADDITIONAL GRANTOR]
	 	 	 
	 	By:	 
	 	Name:
	 	Title

 

    EXHIBIT A - 1

     

    

 

EXHIBIT B

TO PLEDGE AND SECURITY AGREEMENT

 

TRADEMARK SECURITY AGREEMENT

 

This TRADEMARK SECURITY
AGREEMENT (this “Agreement”), dated as of ________, 20__, is entered into by and among ______________, a ___________
(the “Grantor”) and TPG Specialty Lending, Inc. (the “Assignee”), as Administrative Agent
pursuant to (i) that certain Pledge and Security Agreement, dated as of April 24, 2019, among the Assignee, the Grantor and the
other Grantors party thereto (as amended, restated, supplemented or otherwise modified from time to time, the “Security
Agreement”), and (ii) that certain Financing Agreement, dated as of April 24, 2019 (as amended, restated, supplemented
or otherwise modified from time to time, the “Financing Agreement”), between, among others, certain of the Grantor’s
affiliates, the Assignee, and certain Lenders party thereto.

 

Capitalized terms not
otherwise defined herein have the respective meanings ascribed to them in the Security Agreement or the Financing Agreement, as
applicable.

 

WHEREAS, pursuant to
the Security Agreement, the Grantor has granted in favor of the Assignee a security interest in certain Collateral, including the
federally registered Trademarks set forth on Schedule A hereto as of the date hereof.

 

NOW, THEREFORE, in
consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
the Grantor and the Assignee hereby agree as follows:

 

1.            Grant
of Security Interest

 

(a)       Subject
to the terms and conditions of the Security Agreement, to evidence further the security interest granted by the Grantor to the
Assignee pursuant to the Security Agreement, the Grantor hereby grants to the Assignee a security interest in all of the Grantor’s
right, title and interest in, to and under the Trademarks, whether now owned or existing or at any time hereafter acquired or arising
and wherever located, as collateral security for the prompt and complete payment and performance when due (whether at the stated
maturity, by acceleration or otherwise) of the Grantor’s Secured Obligations. For the purposes of this Agreement, “Trademarks”
means (i) all trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles,
service marks, logos, Internet domain names and other source or business identifiers, and all goodwill associated therewith, now
existing or hereafter adopted or acquired, all registrations and recordings thereof, and all applications in connection therewith,
in the United States Patent and Trademark Office or in any similar office or agency of the United States, and all common-law rights
related thereto, including, without limitation, any of the foregoing referred to on Schedule A hereto, and (ii) the right to obtain
all renewals thereof, provided that no United States intent-to-use trademark or service mark application shall be included
in the Trademarks to the extent that, and solely during the period in which, the grant of a security interest therein would impair
the validity or enforceability of such intent-to-use trademark or service mark application under Federal law.

 

(b)       Schedule
A hereto contains a true and accurate list of all of the Grantor’s federally registered United States registrations and
applications for registration for the Trademarks (excluding Internet domain names) existing as of the date hereof.

 

    EXHIBIT B - 1

     

    

 

(c)       The
security interest granted hereby is granted concurrently and in conjunction with the security interest granted to the Assignee
under the Security Agreement. In the event that any of the provisions of this Agreement are in conflict with the Security Agreement,
the provisions of the Security Agreement shall govern.

 

2.            Modifications

 

This Agreement or any
provision hereof may not be changed, waived, or terminated except in accordance with the amendment provisions of the Financing
Agreement. In connection with the foregoing, the Grantor authorizes the Assignee, upon notice to the Grantor, to modify this Agreement
without obtaining the Grantor’s signature to such modification, to the extent that such modification constitutes an amendment
of Schedule A hereto, to add any right, title or interest in any Trademarks owned or subsequently acquired by the Grantor or to
delete any reference to any right, title or interest in any Trademarks in which the Grantor no longer has or claims any right,
title or interest. The Grantor additionally agrees to execute any additional agreement or amendment hereto as may be reasonably
required by the Assignee from time to time, to subject any such owned or subsequently acquired right, title or interest in any
Trademark to the security interests and perfection created or contemplated hereby or by the Security Agreement.

 

3.            Applicable
Law

 

THIS AGREEMENT AND
THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND INTERPRETED IN ACCORDANCE
WITH, THE LAWS OF THE STATE OF NEW YORK.

 

4.            Counterparts

 

This Agreement may
be executed by one or more of the parties to this Agreement on any number of separate counterparts (including by telecopy), and
all of said counterparts taken together shall be deemed to constitute one and the same instrument.

 

IN WITNESS WHEREOF, each of the undersigned
has caused this Agreement to be duly executed and delivered as of the date first above written.

 

	 	ASSIGNEE:
	 	 	 
	 	TPG SPECIALTY LENDING, INC.
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 	 
	 	Address of Assignee:

 

    33

     

    

 

	 	GRANTOR:
	 	 	 	 
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 	 
	 	Address of Grantor:

 

    33

     

    

 

SCHEDULE A

TO TRADEMARK SECURITY AGREEMENT

 

Schedule A to TRADEMARK SECURITY AGREEMENT

 

U.S. Registered Trademarks

 

	Grantor	Trademark Name	Application Number	Filing Date	Status	Registration Number	Registration Date
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 

 

Applications of Registration of Trademarks

 

    Exhibit B - A - 1

     

    

 

EXHIBIT C

TO PLEDGE AND SECURITY AGREEMENT

 

COPYRIGHT SECURITY AGREEMENT

 

This COPYRIGHT SECURITY
AGREEMENT (this “Agreement”), dated as of ________, 20__, is entered into by and among ______________, a ___________
(the “Grantor”) and TPG Specialty Lending, Inc. (the “Assignee”), as Administrative Agent
pursuant to (i) that certain Pledge and Security Agreement, dated as of April 24, 2019, among the Assignee, the Grantor and the
other Grantors party thereto (as amended, restated, supplemented or otherwise modified from time to time, the “Security
Agreement”), and (ii) that certain Financing Agreement, dated as of April 24, 2019 (as amended, restated, supplemented
or otherwise modified from time to time, the “Financing Agreement”), between, among others, certain of the Grantor’s
affiliates, the Assignee, and certain Lenders party thereto.

 

Capitalized terms not
otherwise defined herein have the respective meanings ascribed to them in the Security Agreement or the Financing Agreement, as
applicable.

 

WHEREAS, pursuant to
the Security Agreement, the Grantor has granted in favor of the Assignee a security interest in certain Collateral, including the
Copyrights and the applications and registrations set forth on Schedule A hereto as of the date hereof, and all proceeds thereof,
including, without limitation, any and all causes of action which may exist by reason of infringement thereof and any and all damages
arising from past, present and future violations thereof.

 

NOW, THEREFORE, in
consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
the Grantor and the Assignee hereby agree as follows:

 

1.            Grant
of Security Interest

 

(a)       Subject
to the terms and conditions of the Security Agreement, to evidence further the security interest granted by the Grantor to the
Assignee pursuant to the Security Agreement, the Grantor hereby grants to the Assignee a security interest in all of the Grantor’s
right, title and interest in, to and under the Copyrights, whether now owned or existing or at any time hereafter acquired or arising
and wherever located, as collateral security for the prompt and complete payment and performance when due (whether at the stated
maturity, by acceleration or otherwise) of the Grantor’s Secured Obligations. For the purposes of this Agreement, “Copyrights”
means (i) all copyrights arising under the laws of the United States, any other country or any political subdivision thereof, whether
registered or unregistered and whether published or unpublished (including, without limitation, those listed on Schedule A), all
computer programs, computer databases, computer program flow diagrams, source codes, object codes and all tangible property embodying
or incorporating any copyrights, all registrations and recordings thereof, and all applications in connection therewith, including,
without limitation, all registrations, recordings and applications in the United States Copyright Office, and (ii) the right to
obtain all renewals thereof.

 

(b)       Schedule
A hereto contains a true and accurate list of all of the Grantor’s federally registered United States registrations and
applications for registration for the Copyrights existing as of the date hereof.

 

    Exhibit C - 1

     

    

 

(c)       The
security interest granted hereby is granted concurrently and in conjunction with the security interest granted to the Assignee
under the Security Agreement. In the event that any of the provisions of this Agreement are in conflict with the Security Agreement,
the provisions of the Security Agreement shall govern.

 

2.            Modifications

 

This Agreement or any
provision hereof may not be changed, waived, or terminated except in accordance with the amendment provisions of the Financing
Agreement. In connection with the foregoing, the Grantor authorizes the Assignee, upon notice to the Grantor, to modify this Agreement
without obtaining the Grantor’s signature to such modification, to the extent that such modification constitutes an amendment
of Schedule A hereto, to add any right, title or interest in any Copyrights owned or subsequently acquired by the Grantor or to
delete any reference to any right, title or interest in any Copyrights in which the Grantor no longer has or claims any right,
title or interest. The Grantor additionally agrees to execute any additional agreement or amendment hereto as may be reasonably
required by the Assignee from time to time, to subject any such owned or subsequently acquired right, title or interest in any
Copyright to the security interests and perfection created or contemplated hereby or by the Security Agreement.

 

3.            Applicable
Law

 

THIS AGREEMENT AND
THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND INTERPRETED IN ACCORDANCE
WITH, THE LAWS OF THE STATE OF NEW YORK.

 

4.            Counterparts

 

This Agreement may
be executed by one or more of the parties to this Agreement on any number of separate counterparts (including by telecopy), and
all of said counterparts taken together shall be deemed to constitute one and the same instrument.

 

IN WITNESS WHEREOF, each of the undersigned
has caused this Agreement to be duly executed and delivered as of the date first above written.

 

	 	ASSIGNEE:
	 	 	 
	 	TPG SPECIALTY LENDING, INC.
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 	 
	 	Address of Assignee:

 

    Exhibit C - 3

     

    

 

	 	GRANTOR:
	 	 	 	 
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 	 
	 	Address of Grantor:

 

    Exhibit C - 3

     

    

 

SCHEDULE A

TO COPYRIGHT SECURITY AGREEMENT

 

Schedule A to COPYRIGHT SECURITY AGREEMENT

 

U.S. Registered Copyrights

 

	Title	Application Number	Filing Date	Status	Registration Number	Registration Date
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 

 

Applications of Registration of Copyrights

 

	Owner	Application Number	Filing Date	Status	Registration Number	Registration Date
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 

 

    Exhibit C-A - 1

     

    

 

EXHIBIT D

TO PLEDGE AND SECURITY AGREEMENT

 

PATENT SECURITY AGREEMENT

 

This PATENT SECURITY
AGREEMENT (this “Agreement”), dated as of ________, 20__, is entered into by and among ______________, a ___________
(the “Grantor”) and TPG Specialty Lending, Inc. (the “Assignee”), as Administrative Agent
pursuant to (i) that certain Pledge and Security Agreement, dated as of April 24, 2019, among the Assignee, the Grantor and the
other Grantors party thereto (as amended, restated, supplemented or otherwise modified from time to time, the “Security
Agreement”), and (ii) that certain Financing Agreement, dated as of April 24, 2019 (as amended, restated, supplemented
or otherwise modified from time to time, the “Financing Agreement”), between, among others, certain of the Grantor’s
affiliates, the Assignee, and certain Lenders party thereto.

 

Capitalized terms not
otherwise defined herein have the respective meanings ascribed to them in the Security Agreement or the Financing Agreement, as
applicable.

 

WHEREAS, pursuant to
the Security Agreement, the Grantor has granted in favor of the Assignee a security interest in certain Collateral, including the
federally registered Patents set forth on Schedule A hereto as of the date hereof.

 

NOW, THEREFORE, in
consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
the Grantor and the Assignee hereby agree as follows:

 

1.            Grant
of Security Interest

 

(a)       Subject
to the terms and conditions of the Security Agreement, to evidence further the security interest granted by the Grantor to the
Assignee pursuant to the Security Agreement, the Grantor hereby grants to the Assignee a security interest in all of the Grantor’s
right, title and interest in, to and under the Patents, whether now owned or existing or at any time hereafter acquired or arising
and wherever located, as collateral security for the prompt and complete payment and performance when due (whether at the stated
maturity, by acceleration or otherwise) of the Grantor’s Secured Obligations. For the purposes of this Agreement, “Patents”
means (i) all letters patent of the United States, all reissues and extensions thereof and all goodwill associated therewith, including,
without limitation, any of the foregoing referred to on Schedule A hereto, (ii) all applications for letters patent of the United
States, continuations and continuations-in-part thereof, including, without limitation, any of the foregoing referred to on Schedule
A hereto, and (iii) all rights to obtain any reissues or extensions of the foregoing.

 

(b)       Schedule
A hereto contains a true and accurate list of all of the Grantor’s federally registered United States registrations and
applications for registration for the Patents existing as of the date hereof.

 

(c)       The
security interest granted hereby is granted concurrently and in conjunction with the security interest granted to the Assignee
under the Security Agreement. In the event that any of the provisions of this Agreement are in conflict with the Security Agreement,
the provisions of the Security Agreement shall govern.

 

    Exhibit D - 1

     

    

 

2.            Modifications

 

This Agreement or any
provision hereof may not be changed, waived, or terminated except in accordance with the amendment provisions of the Financing
Agreement. In connection with the foregoing, the Grantor authorizes the Assignee, upon notice to the Grantor, to modify this Agreement
without obtaining the Grantor’s signature to such modification, to the extent that such modification constitutes an amendment
of Schedule A hereto, to add any right, title or interest in any Patents owned or subsequently acquired by the Grantor or to delete
any reference to any right, title or interest in any Patents in which the Grantor no longer has or claims any right, title or interest.
The Grantor additionally agrees to execute any additional agreement or amendment hereto as may be reasonably required by the Assignee
from time to time, to subject any such owned or subsequently acquired right, title or interest in any Patent to the security interests
and perfection created or contemplated hereby or by the Security Agreement.

 

3.            Applicable
Law

 

THIS AGREEMENT AND
THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND INTERPRETED IN ACCORDANCE
WITH, THE LAWS OF THE STATE OF NEW YORK.

 

4.            Counterparts

 

This Agreement may
be executed by one or more of the parties to this Agreement on any number of separate counterparts (including by telecopy), and
all of said counterparts taken together shall be deemed to constitute one and the same instrument.

 

IN WITNESS WHEREOF, each of the undersigned
has caused this Agreement to be duly executed and delivered as of the date first above written.

 

	 	ASSIGNEE:
	 	 	 
	 	TPG SPECIALTY LENDING, INC.
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 	 
	 	Address of Assignee:

 

	 	GRANTOR:
	 	 	 	 

 

    Exhibit D -1

     

    

 

	 	By:	 	 
	 	 	Name:
	 	 	Title:
	 	 	 
	 	Address of Grantor:

 

    Exhibit D -2

     

    

 

SCHEDULE A

TO PATENT SECURITY AGREEMENT

 

Schedule A to PATENT SECURITY AGREEMENT

 

U.S. Registered Patents

 

	Title	Application Number	Filing Date	Status	Patent Number	Registration Date
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 

 

    Exhibit D-A - 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]